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Preface
Important recent discoveries in the field of medical sciences and related
disciplines have increased our understanding of cerebrovascular diseases.
Cerebrovascular diseases are called by a variety of medical conditions that affect
blood vessels in the brain and their hemodynamic state. The most common
presentations are stroke, transient ischemic attack, vascular malformations
(brain aneurysms), and arterial stenosis. Blood flows through the vessels
that supply oxygen and nutrients to the brain, which are usually damaged or
deformed in these disorders. If its flow is obstructed, by a blood clot that moves
to the brain or by a narrowing or rupturing of blood vessels, the brain loses
its energy supply, causing damage to brain tissues, causing sequelae of stroke.
This spectrum of conditions involving brain vessels is of immense importance
to public health, being the most common cause of disability and the second
most frequent cause of death in Western society. Annually, more than 15 million
people worldwide suffer a stroke, out of which five million die and another
five million are permanently disabled. Technological advances in new medical
therapies (calcium therapies in target vessels), advances in neurointerventionist
treatment (endovascular therapies and new surgical approaches), and innovative
approaches in the treatment of neurorehabilitation have strongly revolutionized
the neurobiological basis of neurovascular diseases by a measure of results. The
adequate correlation between central nervous system injuries and their clinical
characteristics with management and results directed at neurorehabilitation
represents the basis of personalized medicine, a promising perspective to
explain the different individual responses to treatment and improve the current
quality of care.
This book provides a comprehensive and up-to-date review of cerebrovascular
diseases, as well as new information on each important related topic. This
edition of the book was divided into seven sections, covering all the main
aspects of cerebrovascular diseases, including Introduction (stroke load),
Pathophysiology, Hemodynamics, Diagnosis, Management, Repair, and
Healing. These are distributed in 18 chapters designed to assist the reader
in self-examination to complete each topic. Each chapter simply represents
the opinion of the authors through a particular effort to identify and separate
the best of their knowledge. Although generally accepted concepts of new
or controversial material have been developed, this book has been designed
as a comprehensive review of cerebrovascular diseases, providing a reference
source for professionals or trainees, doctors, and clinicians, all interested in
cerebrovascular diseases.
Finally, I would very much like to acknowledge our achievements and to thank first
of all the authors without whom this edition would not be possible. Also, I would 
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Brain function is supported by the cerebrovascular system, and changes in vas-
cular phenotype and function through aging process make the brain more suscep-
tible to neurodegenerative diseases, particularly cognitive decline. Correspondingly, 
the incidence of dementia and the prevalence of neurodegenerative diseases have 
also increased. In aging, the vessels have been exposed to the inflammatory state 
by harmful factors referred to as the senescence-associated secretory phenotype 
(SASP). Aging is a complex process that is associated with accumulated cellular 
stresses and an increased stress response. The aging in the brain includes structural 
and functional changes, which cause brain pathologies in the elderly. Particularly, 
damaged neurovascular event can be a consequent trigger in the pathology of 
vascular cognitive impairment. This chapter introduces the current knowledge on 
cognitive decline according to cerebrovascular aging relevant to endothelial senes-
cence and the changes in the SASPs.
Keywords: aging, cerebrovascular, cognitive impairment, senescence-associated 
secretory phenotype, endothelial cells
1. Introduction
Aging is a complex process that is associated with an accumulation of the effects 
of cellular stresses and an increased stress response. The aging in the brain includes 
structural and functional changes, which together cause brain pathologies in the 
elderly. These changes are also thought to be critical risk factors in the develop-
ment of cognitive disorders [1, 2]. It is well known that the cerebrovascular system 
supports brain function [3]. Vascular phenotypic and functional changes caused by 
aging make the brain more susceptible to neurodegenerative diseases, particularly 
to cognitive decline [4]. Dysregulation of cerebral blood flow (CBF) is one factor in 
the pathogenesis of vascular cognitive impairment (VCI) [5]. However, definition, 
diagnostic criteria, and treatments for VCI have not been firmly established. Thus, 
strategies in translational medicine and the clinical approach to VCI patients and 
the current aged society need to be established. This is because according to the 
World Alzheimer Report 2015, it was estimated that 46.8 million people worldwide 
suffer from dementia, and this number is expected to increase to 74.7 million by 
2030 and 131.5 million by 2050 [6]. The report also stated that the incidence of 
dementia, including Alzheimer’s disease (AD) and vascular dementia (VaD), will 
increase by 45%. As a result of the increase in the size of the aging population, the 
incidence of dementia and the onset or prevalence of neurodegenerative diseases 
3
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are increasing. These diseases have become important social concerns and represent 
both a current and a future social and economic burden.
In the aging process, age-related cerebrovascular dysfunction results from 
multiple pathophysiological changes. The first of them is oxidative stress and 
inflammation. Excessive oxidative stress is well known to contribute to vascular 
aging in both animals [4, 7–10] and humans [11, 12]. It is an overproduction of 
reactive oxygen species (ROS) rather than accumulation of ROS. In cellular senes-
cence, inflammatory mediators such as chemokines and cytokines are secreted in an 
autocrine or paracrine manner. This is often referred to as the senescence-associated 
secretory phenotype (SASP) [13–15]. The second is the narrowing of the vascular 
lumen caused by atherosclerotic plaques, which is referred to as atherosclerosis in 
large vessels or arteriosclerosis in small vessels [16–18]. Technically a further factor 
is endothelial cell senescence induced by the SASP in the aging process. This arises 
as a result of the action of pro-inflammatory cytokines such as interleukin (IL)-1 
and IL-6 [19]. Under aging, atherosclerotic plaques are prone to arise in the human 
aorta and coronary arteries, which contain senescent endothelial cells [20]. The 
senescent phenotypes of endothelial cells can be physiologically classified as having 
either an anti-inflammatory phenotype or a pro-inflammatory senescent phenotype 
[21]. Recently, numerous studies have focused on the status of the immune system 
during aging [22–24]. This chapter introduces the current knowledge about cogni-
tive decline according to cerebrovascular aging relevant to cellular senescence and 
the changes in the SASPs. It also provides approaches on how senescent vessels 
exposed to the SASP enhance age-related cerebrovascular degeneration and vascu-
lar damage-derived cognitive impairment.
2. Aging and vessels
Cellular senescence is the state in which normal cells cease to divide. It can be 
thought of as a type of programmed cell cycle arrest. The senescent cells go through 
changes in gene expression and secretion of soluble factors in response to excessive 
stresses [25]. The secreted soluble factors from senescent cells are referred to as the 
SASP [26–28]. The SASP includes interleukins (IL) and chemokines such as IL-1, 
IL-6, IL-8, monocyte chemoattractant protein (MCP)-2, and macrophage inflam-
matory protein (MIP)-1 [29]. In addition, nitric oxide, growth factors, and several 
matrix metalloproteinases have also been identified in the SASP [14]. Several stud-
ies have reported that SASP factors have roles in inducing normal cells to acquire 
a senescent phenotype and can act in a paracrine manner to affect the activity of 
other nearby cells [30]. This might suggest that SASP factors do not merely arise as 
a result of cell senescence but could rather act to promote the senescence phenotype 
in normal cells.
Although it still remains equivocal whether neurodegenerative diseases arise as 
a result of, or from, aging-related changes, it is clear, however, that the prevalence 
of neurodegenerative diseases that show a cognitive decline is positively associated 
with aging. Increases in oxidative stress and inflammation in response to aging trig-
ger cellular senescence and the appropriate downstream responses. A series of these 
insults can aggravate age-related or neurodegenerative pathogenesis with several 
vascular diseases [31].
2.1 Endothelium
The endothelium is one of the vessel constituents and is important in vascular 
structure because of its high versatility. The endothelium has multifunctional 
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roles in maintaining blood fluidity and metabolic homeostasis. The features are 
important in regulating the delivery of water and nutrients through the whole body 
[32]. The endothelium also plays an important role in the resolution of inflam-
matory responses. Morphological and functional changes in the endothelium are 
also involved in the development of numerous pathological disorders [33, 34]. 
Endothelial cells are located in the inner layer of the vasculature and can come 
into contact with blood-containing macrophages. Therefore, endothelial cells are 
the first target of cytokines circulating in the blood. Simultaneously, endothelial 
cells also secrete pro-inflammatory cytokines, such as IL-1, IL-6, IL-8, IL-15, 
MCP-1, and tumor necrosis factor (TNF)-α [29]. In fact, endothelial cell-derived 
pro-inflammatory cytokines and chemokines are important in recruiting immune 
cells to the site and play a role in wound healing, angiogenesis, and inflammatory 
diseases. In addition to their inflammatory function, endothelial cells also produce 
pro-thrombotic mediators and cellular adhesion molecules (ICAM-1, intercellular 
adhesion molecule-1; PAI-1, plasminogen activator inhibitor-1) and enhance the 
adhesion and transmigration of immune cells into underlying tissues. It has also 
been reported that senescent endothelial cells have reduced expression levels of 
nitric oxide (NO) as well as reduced expression levels and phosphorylation of 
endothelial NO synthase (eNOS) [35, 36].
It is well accepted that senescence in vascular endothelial cells is a common 
factor in various age-related diseases. Associated with aging, endothelial cells 
dynamically change the inflammatory phenotype to SASP [21]. A recent study has 
demonstrated that alterations in toll-like receptor (TLR) and TLR ligands during 
aging might determine the state of the inflammatory process [29]. Since endothelial 
cells are not immune cells, they cannot recognize foreign antigens via TLRs or pres-
ent antigens through MHC II molecules to T and B cells [37]. On the other hand, 
endothelial cells have been shown to upregulate the mRNA levels of TLR-2, TLR-4, 
TLR-7, TLR-8, TLR-9, and TLR-10 during aging [38]. Since aging is a chronic 
inflammatory condition in the lower level, nonimmune endothelial cells could play 
a role in controlling and maintaining immune homeostasis. Taken these reasons, 
endothelial cells could be a therapeutic target to allow for recovery of a disruption 
in immune homeostasis.
Endothelial cells derived from patients with severe coronary artery disease have 
also been shown to be mostly senescent endothelial cells with reduced levels of telo-
meric DNA-binding factor 1 (TRF1) and increased telomere oxidation [20]. When 
TRF1 was overexpressed in a cellular aging model, namely, human umbilical vein 
endothelial cells’ (HUVECs) passage for a long period of time, the telomere-associ-
ated DNA damage foci and the SASP were decreased [39, 40]. These results suggest 
that telomere dysfunction and the SASP occur prior to cellular senescence and 
induce vascular dysfunction following cardiovascular disease (CVD) development.
2.2 Atherosclerosis
Atherosclerosis and its associated clinical outcomes such as vascular stiffness 
are initiated and progressed through dysfunction in senescent endothelial cells 
[29]. During oxidation in the vessel, there are changes in its physicochemical 
properties including lipid charge, size, and content. Oxidized low-density lipid 
(oxLDL) becomes different from natural LDL. The oxLDL stimulates endothelial 
cells to induce the expression of adhesion molecules such as E-selectin and vascular 
cell adhesion molecule-1 (VCAM-1) on the surface of the artery [41]. Numerous 
senescent endothelial cells are detected in the aorta of the human with athero-
sclerotic plaques [42, 43]. The formation of atherosclerotic plaques is initiated by 
macrophages that infiltrate into the arterial intima in response to oxLDL present in 
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a result of cell senescence but could rather act to promote the senescence phenotype 
in normal cells.
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a result of, or from, aging-related changes, it is clear, however, that the prevalence 
of neurodegenerative diseases that show a cognitive decline is positively associated 
with aging. Increases in oxidative stress and inflammation in response to aging trig-
ger cellular senescence and the appropriate downstream responses. A series of these 
insults can aggravate age-related or neurodegenerative pathogenesis with several 
vascular diseases [31].
2.1 Endothelium
The endothelium is one of the vessel constituents and is important in vascular 
structure because of its high versatility. The endothelium has multifunctional 
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roles in maintaining blood fluidity and metabolic homeostasis. The features are 
important in regulating the delivery of water and nutrients through the whole body 
[32]. The endothelium also plays an important role in the resolution of inflam-
matory responses. Morphological and functional changes in the endothelium are 
also involved in the development of numerous pathological disorders [33, 34]. 
Endothelial cells are located in the inner layer of the vasculature and can come 
into contact with blood-containing macrophages. Therefore, endothelial cells are 
the first target of cytokines circulating in the blood. Simultaneously, endothelial 
cells also secrete pro-inflammatory cytokines, such as IL-1, IL-6, IL-8, IL-15, 
MCP-1, and tumor necrosis factor (TNF)-α [29]. In fact, endothelial cell-derived 
pro-inflammatory cytokines and chemokines are important in recruiting immune 
cells to the site and play a role in wound healing, angiogenesis, and inflammatory 
diseases. In addition to their inflammatory function, endothelial cells also produce 
pro-thrombotic mediators and cellular adhesion molecules (ICAM-1, intercellular 
adhesion molecule-1; PAI-1, plasminogen activator inhibitor-1) and enhance the 
adhesion and transmigration of immune cells into underlying tissues. It has also 
been reported that senescent endothelial cells have reduced expression levels of 
nitric oxide (NO) as well as reduced expression levels and phosphorylation of 
endothelial NO synthase (eNOS) [35, 36].
It is well accepted that senescence in vascular endothelial cells is a common 
factor in various age-related diseases. Associated with aging, endothelial cells 
dynamically change the inflammatory phenotype to SASP [21]. A recent study has 
demonstrated that alterations in toll-like receptor (TLR) and TLR ligands during 
aging might determine the state of the inflammatory process [29]. Since endothelial 
cells are not immune cells, they cannot recognize foreign antigens via TLRs or pres-
ent antigens through MHC II molecules to T and B cells [37]. On the other hand, 
endothelial cells have been shown to upregulate the mRNA levels of TLR-2, TLR-4, 
TLR-7, TLR-8, TLR-9, and TLR-10 during aging [38]. Since aging is a chronic 
inflammatory condition in the lower level, nonimmune endothelial cells could play 
a role in controlling and maintaining immune homeostasis. Taken these reasons, 
endothelial cells could be a therapeutic target to allow for recovery of a disruption 
in immune homeostasis.
Endothelial cells derived from patients with severe coronary artery disease have 
also been shown to be mostly senescent endothelial cells with reduced levels of telo-
meric DNA-binding factor 1 (TRF1) and increased telomere oxidation [20]. When 
TRF1 was overexpressed in a cellular aging model, namely, human umbilical vein 
endothelial cells’ (HUVECs) passage for a long period of time, the telomere-associ-
ated DNA damage foci and the SASP were decreased [39, 40]. These results suggest 
that telomere dysfunction and the SASP occur prior to cellular senescence and 
induce vascular dysfunction following cardiovascular disease (CVD) development.
2.2 Atherosclerosis
Atherosclerosis and its associated clinical outcomes such as vascular stiffness 
are initiated and progressed through dysfunction in senescent endothelial cells 
[29]. During oxidation in the vessel, there are changes in its physicochemical 
properties including lipid charge, size, and content. Oxidized low-density lipid 
(oxLDL) becomes different from natural LDL. The oxLDL stimulates endothelial 
cells to induce the expression of adhesion molecules such as E-selectin and vascular 
cell adhesion molecule-1 (VCAM-1) on the surface of the artery [41]. Numerous 
senescent endothelial cells are detected in the aorta of the human with athero-
sclerotic plaques [42, 43]. The formation of atherosclerotic plaques is initiated by 
macrophages that infiltrate into the arterial intima in response to oxLDL present in 
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the vessel [69]. Lipid-laden foam cells become pro-inflammatory, and macrophages 
secrete pro-inflammatory cytokines. The recruited macrophages move into the 
artery, and consequently, the atherosclerotic plaque size and complexity are getting 
larger [44].
Atherosclerosis occurs following chronic exposure to cellular stressors. It has 
been reported that SASP can be restrained simply by inhibiting TNF-α without 
any transmission of senescence signals in an autocrine or paracrine manner [45]. 
Anti-TNF-α treatment has been demonstrated to physiologically reduce the non-
cell autonomous effects of SASP. In patients treated with adalimumab (Humira, 
a human monoclonal antibody against TNF-α), epigenetic modifications were 
triggered. The molecular mechanisms are identified as TNF-α signaling in senescent 
endothelial cells, which raises the possibility of therapeutic approaches for age-
associated diseases. In senescent human umbilical vein endothelial cells (HUVECs), 
the levels of miR-146a-5p and miR-126-3p show higher than younger HUVECs. 
Additionally, the levels of miR-146a-5p are increased in both senescent and young 
HUVECs following lipopolysaccharide (LPS) exposure, whereas the level of miR-
126-3p is decreased only in senescent HUVECs and is unchanged in young HUVECs 
[45]. This study also showed that changes in the levels of several microRNAs (miR-
NAs) do not arise as a result of just treatment with LPS or an anti-TNF-α antibody. 
These data suggest that some miRNAs work in an age-dependent manner in vessels 
and endothelial cells.
2.3 Vascular aging
From a classical perspective, the aged vasculature is viewed as having worsened 
vasodilation, arterial stiffness, remodeling of the extracellular matrix, intimal 
thickening, and endothelial cell dysfunction [46]. The effects of vascular aging 
have been explored extensively and have been attributed to the number of different 
causes with genome instability and mTOR being two of the major causes. Studies 
with mTOR-inhibiting drugs in vessels have shown that such drugs have a deleteri-
ous effect on endothelial function in patients who have advanced arterial aging and 
inserted coronary stents [47–49]. Compared to human studies, cultured endothelial 
cells have augmented anti-inflammatory effects to mTOR inhibitors with a dose-
dependent manner and have increased cytostatic effect [50]. It also showed that 
rapamycin, an mTOR inhibitor, induces the expression of PAI-1 in mice as well as 
in cultured endothelial cells [51]. When the Atg7 gene, one of the mediators of the 
autophagic process, is deleted in mice, vascular aging is accelerated [52]. In a mouse 
model of Hutchinson-Gilford progeria, autophagy is activated by AMPK activation 
and inhibition of mTOR [53]. These results showed that the mTOR–AMPK signal-
ing pathway might be a link to the regulation of autophagy in age-related diseases. 
Based on the results described above, it is hard to firmly establish that rapamycin 
plays a preventive role on cellular senescence.
Telomere shortening is known to be a hallmark of cellular senescence. Telomeres 
are significantly shorter in several endothelial cells and vascular smooth muscle 
cells (VSMCs), which is a clear marker of SASP in aged vasculature. The shortened 
telomeres in mouse vascular tissue have been shown to be sufficient to induce 
endothelial dysfunction [54], whereas human VSMCs still have a normal phenotype 
sustaining plaque stability regardless of telomere length [55]. Although telomere 
shortening is common in vascular aging and CVD, it remains unclear whether 
telomere shortening is sufficient to lead to cellular senescence and vascular degen-
eration in aged vessels [56].
In the patients with severe coronary artery disease, most of endothelial cells 
demonstrated the features of senescent endothelial cells that reduced levels of 
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telomeric DNA-binding factor 1 (TRF1) and increased telomere oxidation as men-
tioned above [20, 39, 40]. These results suggest that telomere dysfunction and the 
SASP occur prior to cellular senescence and induce vascular dysfunction following 
CVD development.
The causes of vascular aging and vascular aging-related phenotypes can be sum-
marized as follows:
i. Oxidative DNA damage: during aging, the onset of CVD led by changes 
in vascular endothelial cells results in an impairment of endothelium-
dependent vasodilation, an overproduction of pro-inflammatory and pro-
thrombotic factors, and an increase in oxidative stress [57]. In the human 
population, age is an important and independent risk factor for CVD [58].
ii. Telomere shortening: an association between telomere shortening and CVD 
risk factors has been found in atherosclerosis, arterial stiffness, type 1 and 
type 2 diabetes, and obesity [59–62].
iii. Genome instability: a failure in DNA damage repair occurs in cells and tis-
sues during the aging process [63].
3. Aging and cerebrovascular function
As aging progresses, cerebrovascular function declines which can increase the 
possibility for ischemic stroke, intracerebral hemorrhages (ICHs), microbleeds, and 
cognitive decline [64]. Healthy functional cerebral vessels can coordinate with CBF 
and appropriately supply blood to the brain [65]. However, cerebrovascular aging 
has the following features, which can lead to age-related cerebrovascular diseases: 
(i) endothelial senescence, (ii) oxidative stress and inflammation, (iii) microvascu-
lar rarefaction, (iv) arterial stiffness, (v) vascular lumen narrowness, and (vi) CBF 
reduction. Each feature according to cerebrovascular aging is described in detail in 
the following subsections.
3.1 Cerebral vasculature
Cerebral vessels play a critical role in mediating between the whole body and 
the brain by transporting molecules between the blood and brain [5]. The brain 
vasculature that supplies blood to the brain tissue consists of two blood supply 
systems. One is the internal carotid artery system. This system is responsible for 
approximately 70% of the total CBF. The other system is the vertebral artery sys-
tem, which is responsible for approximately 30% of the total CBF. These two major 
blood systems converge at Willis’ circle, which allows communication between 
the left and right brain hemispheres, and branch out into the whole brain through 
cerebral arteries [66]. The most common structural feature of cerebral vessels is the 
blood–brain barrier (BBB), which comprises tight junctions and adherens junctions 
[5]. These tight junctions exist between endothelial cells, the basal membrane, 
pericytes, and the astrocyte end feet [67].
The BBB is important because it prevents harmful molecules from entering 
the brain tissue from the systemic circulation. Accordingly, a malfunction in BBB 
permeability has been reported in neurodegenerative disorders and cognitive 
decline that leads to dementia [68–70]. CBF is regulated in response to blood pres-
sure through cerebral autoregulation. It was demonstrated that there were minor 
differences between CBF and blood pressure (within 10 mmHg of blood pressure) 
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[45]. This study also showed that changes in the levels of several microRNAs (miR-
NAs) do not arise as a result of just treatment with LPS or an anti-TNF-α antibody. 
These data suggest that some miRNAs work in an age-dependent manner in vessels 
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vasodilation, arterial stiffness, remodeling of the extracellular matrix, intimal 
thickening, and endothelial cell dysfunction [46]. The effects of vascular aging 
have been explored extensively and have been attributed to the number of different 
causes with genome instability and mTOR being two of the major causes. Studies 
with mTOR-inhibiting drugs in vessels have shown that such drugs have a deleteri-
ous effect on endothelial function in patients who have advanced arterial aging and 
inserted coronary stents [47–49]. Compared to human studies, cultured endothelial 
cells have augmented anti-inflammatory effects to mTOR inhibitors with a dose-
dependent manner and have increased cytostatic effect [50]. It also showed that 
rapamycin, an mTOR inhibitor, induces the expression of PAI-1 in mice as well as 
in cultured endothelial cells [51]. When the Atg7 gene, one of the mediators of the 
autophagic process, is deleted in mice, vascular aging is accelerated [52]. In a mouse 
model of Hutchinson-Gilford progeria, autophagy is activated by AMPK activation 
and inhibition of mTOR [53]. These results showed that the mTOR–AMPK signal-
ing pathway might be a link to the regulation of autophagy in age-related diseases. 
Based on the results described above, it is hard to firmly establish that rapamycin 
plays a preventive role on cellular senescence.
Telomere shortening is known to be a hallmark of cellular senescence. Telomeres 
are significantly shorter in several endothelial cells and vascular smooth muscle 
cells (VSMCs), which is a clear marker of SASP in aged vasculature. The shortened 
telomeres in mouse vascular tissue have been shown to be sufficient to induce 
endothelial dysfunction [54], whereas human VSMCs still have a normal phenotype 
sustaining plaque stability regardless of telomere length [55]. Although telomere 
shortening is common in vascular aging and CVD, it remains unclear whether 
telomere shortening is sufficient to lead to cellular senescence and vascular degen-
eration in aged vessels [56].
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telomeric DNA-binding factor 1 (TRF1) and increased telomere oxidation as men-
tioned above [20, 39, 40]. These results suggest that telomere dysfunction and the 
SASP occur prior to cellular senescence and induce vascular dysfunction following 
CVD development.
The causes of vascular aging and vascular aging-related phenotypes can be sum-
marized as follows:
i. Oxidative DNA damage: during aging, the onset of CVD led by changes 
in vascular endothelial cells results in an impairment of endothelium-
dependent vasodilation, an overproduction of pro-inflammatory and pro-
thrombotic factors, and an increase in oxidative stress [57]. In the human 
population, age is an important and independent risk factor for CVD [58].
ii. Telomere shortening: an association between telomere shortening and CVD 
risk factors has been found in atherosclerosis, arterial stiffness, type 1 and 
type 2 diabetes, and obesity [59–62].
iii. Genome instability: a failure in DNA damage repair occurs in cells and tis-
sues during the aging process [63].
3. Aging and cerebrovascular function
As aging progresses, cerebrovascular function declines which can increase the 
possibility for ischemic stroke, intracerebral hemorrhages (ICHs), microbleeds, and 
cognitive decline [64]. Healthy functional cerebral vessels can coordinate with CBF 
and appropriately supply blood to the brain [65]. However, cerebrovascular aging 
has the following features, which can lead to age-related cerebrovascular diseases: 
(i) endothelial senescence, (ii) oxidative stress and inflammation, (iii) microvascu-
lar rarefaction, (iv) arterial stiffness, (v) vascular lumen narrowness, and (vi) CBF 
reduction. Each feature according to cerebrovascular aging is described in detail in 
the following subsections.
3.1 Cerebral vasculature
Cerebral vessels play a critical role in mediating between the whole body and 
the brain by transporting molecules between the blood and brain [5]. The brain 
vasculature that supplies blood to the brain tissue consists of two blood supply 
systems. One is the internal carotid artery system. This system is responsible for 
approximately 70% of the total CBF. The other system is the vertebral artery sys-
tem, which is responsible for approximately 30% of the total CBF. These two major 
blood systems converge at Willis’ circle, which allows communication between 
the left and right brain hemispheres, and branch out into the whole brain through 
cerebral arteries [66]. The most common structural feature of cerebral vessels is the 
blood–brain barrier (BBB), which comprises tight junctions and adherens junctions 
[5]. These tight junctions exist between endothelial cells, the basal membrane, 
pericytes, and the astrocyte end feet [67].
The BBB is important because it prevents harmful molecules from entering 
the brain tissue from the systemic circulation. Accordingly, a malfunction in BBB 
permeability has been reported in neurodegenerative disorders and cognitive 
decline that leads to dementia [68–70]. CBF is regulated in response to blood pres-
sure through cerebral autoregulation. It was demonstrated that there were minor 
differences between CBF and blood pressure (within 10 mmHg of blood pressure) 
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among healthy humans in the plateau region [71]. The report also suggested that 
hypertension and a higher pulsatile rate might disrupt cerebral autoregulation, 
which make subjects prone to neurodegenerative diseases because the aging brain is 
subject to hypoperfusion [71].
3.2 Cerebral vascular aging
Healthy functional cerebral vessels can coordinate with CBF and appropriately 
supply blood to the brain [65]. As aging progresses, however, cerebrovascular func-
tion declines, which can increase the possibility of ischemic stroke, intracerebral 
hemorrhages (ICHs), microbleeds, and cognitive decline [64]. Cerebrovascular 
aging has the following features, which can lead to age-related cerebrovascular 
diseases:
i. Endothelial senescence: many studies have shown the presence of senescent 
endothelial cells in aged cerebrovascular lesions, which is triggered by 
the accumulation of ROS [31] and modulated by inflammatory factors, as 
described above.
ii. Oxidative stress and inflammation: in vessels’ walls, ROS increase nicotina-
mide adenine dinucleotide phosphate (NADPH) oxidase activity associated 
with aging [7, 72, 73]. These findings have been reported in both nonclinical 
and clinical studies. It is also well known that the vasculature can be easily 
damaged by vasculopathy, including atherosclerosis [74–76].
iii. Microvascular rarefaction: this is a condition where the microvascular 
network and its density are reduced. Rarefaction has been detected in some 
brain subregions, particularly in the hippocampus. Since the hippocampus 
is involved in memory, it could lead to memory loss [77, 78]. Circulating 
endothelial progenitor cells have been shown to be diminished by aging, 
which is linked to white matter changes and a decline in cognitive function 
[79, 80].
iv. Arterial stiffness: this is a major characteristic of vascular aging. Vascular 
stiffness increases blood flow velocity and blood pressure. Arterial stiffness 
results in an increase in systolic pressure and a decrease in diastolic pressure.
v. Vascular lumen narrowness: the accumulation of toxic molecules in the ves-
sel walls makes the vascular lumen narrow. There have been clinical studies 
such as cerebral autosomal dominant arteriopathy with subcortical infarcts 
and leukoencephalopathy (CADASIL) that have examined Notch3 molecules 
in cerebral autosomal dominant arteriopathy with subcortical infarcts and 
leukoencephalopathy. The high-temperature requirement A serine peptidase 
1 (HTRA1) is also explored in cerebral autosomal recessive arteriopathy and 
leukoencephalopathy [81–83].
vi. CBF reduction: generally, hypoperfusion in the cerebral circulation is sug-
gested to lead to cognitive impairment [84]. In cases of mild hypoperfusion, 
synaptic plasticity is impaired by a reduction in protein synthesis during 
learning and memory consolidation [2]. Under severe hypoperfusion, there 
is failure in the formation of the action potential, disruption in the acid–base 
balance, occurrence of neuronal edema, and accumulation of neurotic 
molecules [85].
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With respect to neural activity, cerebrovascular reactivity (CVR) can be used 
to measure the response levels of brain blood vessels to various stimuli. Very recent 
evidence has shown that cerebral vessel contractility and dilation decrease as aging 
progresses and have effects on the neurovascular damage mediated by NO [86]. In 
addition, there is an induction of vasoconstrictive factors in the cerebral endothelium 
[87]. Since the vessel wall undergoes structural changes through the normal aging pro-
cess, it is a natural and frequently found phenomenon that the basement membrane 
becomes thicker but smooth muscle cells and elastin layer are thinner [88]. These dif-
ferent responses between young and old adults have been demonstrated using blood-
oxygen-level-dependent functional MRI (BOLD fMRI) data [89]. As a result of these 
collective findings, it is now considered that the vasculature plays a critical secondary 
cause in many neurodegenerative diseases, particularly in neurovascular dysfunction. 
Therefore, there needs to be an increase in recognition and a focus on cognitive decline 
after vascular damage to develop newer therapeutic approaches.
4. Aging and vessel-related cognitive decline
Dementia is an irreversible cognitive condition. According to a statistical report, 
7.7 million people are newly diagnosed with dementia every year [90]. Among 
these, patients with vascular cognitive impairment and dementia (VCID) compose 
over 20% of the total dementia patient population [91]. By 2030, the number of 
older people (>60 years of age) is predicted to increase by 56% compared to the 
number in 2015, and it will continue to grow year by year. Finally, by 2050, our 
society will become a superaged society, and it is evident that the prevalence of 
neurodegenerative diseases will increase. Cognitive-related diseases, such as AD or 
VaD, will increase by 45% in 2050 compared to 2015 [92].
Mild cognitive impairment (MCI) is included as a cognitive-related disease in 
the older population. Although MCI is also considered as a pre-step proceeding to 
dementia, patients with MCI still fortunately have a chance of recovery or at least 
have a chance to delay the progression of the disease. Therefore, new strategies are 
urgently needed to diagnose and treat patients with MCI. Some blood factors such 
as MCP-1 or IL-6 have been suggested to be biomarkers for estimating the progres-
sion in cognitive decline because the vascular blood factors are modified in patients 
with MCI [93]. Some clinical studies have shown that VCID occurs in 25–30% of 
aged people who have had a previous stroke [94, 95]. Stroke is known to be the 
second leading cause of cognitive dysfunction. Furthermore, a clinical history of 
stroke increases the risk of cognitive dysfunction up to fivefold [96, 97]. Therefore, 
the symptoms of poststroke dementia could be related to the occlusion site, occlu-
sion type, occlusion numbers, and lesion volume in the brain. There are studies that 
have shown that poststroke cognitive decline is related to the pathology of cerebro-
vascular disease and dementia, although the mechanisms involved in poststroke 
dementia are complex [90, 98].
Aging is complex and vulnerable to cognitive decline as well as brain disorders 
[99]. A recent study concluded that cognitive impairment in aged adults with 
depression is correlated with the SASP profile [100]. This study showed that the 
levels of the SASP were highest in participants with both late-life depression (LLD) 
and MCI (Figure 1). This study suggests that cognitive impairment in LLD is linked 
to an aging-specific molecular profile, which might be an indicator for aging people 
with LLD who develop dementia [100]. Recent clinical studies have reported that 
depression and cognitive impairment in aging are associated with the regulation of 
the SASP: immune-inflammatory response [101], proteostasis [102], signal trans-
duction, and oxidative stress [103].
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aged people who have had a previous stroke [94, 95]. Stroke is known to be the 
second leading cause of cognitive dysfunction. Furthermore, a clinical history of 
stroke increases the risk of cognitive dysfunction up to fivefold [96, 97]. Therefore, 
the symptoms of poststroke dementia could be related to the occlusion site, occlu-
sion type, occlusion numbers, and lesion volume in the brain. There are studies that 
have shown that poststroke cognitive decline is related to the pathology of cerebro-
vascular disease and dementia, although the mechanisms involved in poststroke 
dementia are complex [90, 98].
Aging is complex and vulnerable to cognitive decline as well as brain disorders 
[99]. A recent study concluded that cognitive impairment in aged adults with 
depression is correlated with the SASP profile [100]. This study showed that the 
levels of the SASP were highest in participants with both late-life depression (LLD) 
and MCI (Figure 1). This study suggests that cognitive impairment in LLD is linked 
to an aging-specific molecular profile, which might be an indicator for aging people 
with LLD who develop dementia [100]. Recent clinical studies have reported that 
depression and cognitive impairment in aging are associated with the regulation of 
the SASP: immune-inflammatory response [101], proteostasis [102], signal trans-
duction, and oxidative stress [103].
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5. Conclusions
Clinically and pathologically, vessel diseases including atherosclerosis are 
important diseases in a rapidly aging world. Age-related cerebrovascular dysfunc-
tions result from multiple pathophysiological alterations. The clear one thing is 
that vascular aging and the aged brain vessels are vulnerable to damages and harm-
ful factors such as the SASPs. Once the cerebral vessels have experienced insults, 
cognitive decline is eventually followed. The source of insults can be SASP particu-
larly in the aging process. Despite efforts to develop therapeutic targets, it is not 
possible to identify the processes contributing to the onset of vascular disease and 
its progression of cognitive decline. Our aging society needed more fundamental 
approaches for treating aging-related neurodegenerative diseases containing 
dementia. Preferential treatment might be a preventive chance to neurodegenera-
tive diseases. In the present time when dementia becomes an important issue in 
public heath, economics, social aspects, as well as the political fields, it should be 
possible to develop preventing and also therapeutic strategies against progressive 
dementia with a careful focus on treating vascular health by modulating the SASP.
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Figure 1. 
Aging, cerebrovascular burden, and developing cognitive decline to vascular dementia. With aging, the number 
of resident senescent cells displaying SASP increases. The familial genetic backgrounds and vascular risk factors 
acquired through individual lifestyle or harmful habits, such as smoking, increase vulnerability to vascular 
damage and neuronal dysfunction. Combined with aging factors, such as SASP, during the aging process, 
vascular damage and neuronal diseases could lead to susceptibility to cognitive decline, which consequently 
contributes to the progression of vascular dementia. Abbreviations: SASP, senescence-associated secretory 
phenotype; APOE4, apolipoprotein E4; PSEN1, presenilin 1; VSMC, vascular smooth muscle cell; EC, 
endothelial cell.
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Abstract
Incidental detection of unruptured intracranial aneurysms (UIA) has increased 
in the recent years. There is a need in the clinical community to identify those that 
are prone to rupture and would require preventive treatment. Hemodynamics in 
cerebral blood vessels plays a key role in the lifetime cycle of intracranial aneurysms 
(IA). Understanding their initiation, growth, and rupture or stabilization may 
identify those hemodynamic features that lead to aneurysm instability and rupture. 
Modeling hemodynamics using computational fluid dynamics (CFD) could aid in 
understanding the processes in the development of IA. The neurosurgical approach 
during operation of IA allows direct visualization of the aneurysm sac and its sam-
pling in many cases. Detailed analysis of the quality of the aneurysm wall under the 
microscope, together with histological assessment of the aneurysm wall and CFD 
modeling, can help in building complex knowledge on the relationship between the 
biology of the wall and hemodynamics. Detailed CFD analysis of the rupture point 
can further strengthen the association between hemodynamics and rupture. In this 
chapter we summarize current knowledge on CFD and intracranial aneurysms.
Keywords: intracranial aneurysm, hemodynamics, rupture, cerebral blood flow, 
computational fluid dynamics
1. Introduction
Intracranial aneurysm (IA), a pathological dilation of the vessel wall, is the 
result of hemodynamic forces on the wall of the intracranial artery. It is character-
ized by mild to moderate structural changes of the vessel wall, which may result in 
aneurysm rupture, leading to a severe form of hemorrhagic stroke [1].
In the last 15 years, there has been increasing incidental detection of unruptured 
intracranial aneurysms (UIA) due to an increasing use of noninvasive radiological 
examinations, such as computed tomography angiography (CTA) and magnetic 
resonance angiography (MRA) [2]. The increasing use of these noninvasive 
techniques for various non-specific complaints results in higher detection and 
increasing treatment of UIA. While 20% of individuals operated on for an IA in 
1998 were carrying a UIA, in more recent years, the number has increased to more 
than 50% of all patients operated on for IA in the Department of Neurosurgery of 
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than 50% of all patients operated on for IA in the Department of Neurosurgery of 
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the Jan Evangelista Purkyně, Masaryk Hospital in Ústí nad Labem, Czech Republic. 
Concurrently, there have been an increasing number of patients that we monitor for 
UIA who do not receive treatment. Should the aneurysm not rupture, which occurs 
in the majority of IA cases, very few become symptomatic in other ways. If it does 
rupture, it results in severe consequences including death, various levels of neuro-
logical disabilities, and cognitive or social difficulties.
The decision on whether to treat an individual with a UIA is based on the balance 
between the risk of treatment and the risk of the natural history of the aneurysm. If 
the aneurysm does not rupture, the risk of other clinical symptoms is quite low. These 
symptoms may appear as compression of the nervous structures (the optic nerve may 
be compressed by an ophthalmic aneurysm, the oculomotor nerve by a posterior com-
municating artery aneurysm, or the brain stem may be compressed by a large basilar 
aneurysm). Other symptoms may result from embolization of thrombi from the sac 
of an aneurysm; this is, however, very rare [3]. The worst outcome is that patients may 
experience aneurysm rupture. Overall, this risk is low in most patients and therefore 
does not occur in the vast majority of them in their lifetime [4]. The risk of rupture 
is associated with many factors; some of them are inherent (higher risk of rupture in 
females, some nations, such as Japanese); other factors are modifiable (higher risks are 
associated with hypertension or smoking). The rupture leads to a severe form of hem-
orrhagic stroke or even death. The risk of death after rupture is somewhere between 26 
and 36% of patients [5]. The improved care of patients with SAH in specialized neu-
rovascular centers improves survival rates [6]. Alternatively, about 15% of patients die 
immediately after rupture or before they are transported to hospital. Approximately 
20% of those that survive develop a global cognitive deficit [7].
Contrarily the treatment, even in selected UIA, may carry the risk of severe 
complications may be as high as 16% of patients; the risk of mortality being 0–3.2% 
and the chance of not being discharged home almost 20% [8]. All the scoring sys-
tems used for analyzing the risk of rupture are based on data from large population 
studies. These factors include the size of the aneurysm, its location within the circle 
of Willis, its shape, etc. However, the size or the shape of the aneurysm is a result of 
forces that themselves lead to aneurysm initiation, its growth, and eventual rupture 
(or stability with no rupture). This is the result of the balance between hemody-
namic forces and the quality of the blood vessel wall at the site of the aneurysm. 
Immediately when the hemodynamic forces overcome the strength of the aneurysm 
wall, it will rupture. Consequently an understanding of the hemodynamics within 
the cerebral blood vessels and the aneurysm itself may help with understanding its 
initiation, growth, and eventual rupture. The ability to model the hemodynamics 
within the aneurysm could also possibly assist with predicting their risk element 
and the direction to preventive treatment. It may also be possible to securely moni-
tor aneurysms with a non-risky hemodynamic profile.
In this chapter we aim to provide current information on aneurysm hemody-
namic modeling, using CFD. We will focus on ruptured and unruptured aneurysms, 
the hemodynamic characteristics at the point of rupture and the difference between 
ruptured and unruptured IA. We will discuss the issue from the perspective of 
neurosurgery and its possible contribution to clinical practice. We will summarize 
our 8 years of experience with CFD modeling in intracranial aneurysms, as well as 
the current literature.
2. The pathophysiology of the life cycle of intracranial aneurysms
During physiological conditions, the cerebral blood vessels consist of three 
layers: (1) tunica intima with a basal membrane, endothelial cells, and the internal 
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elastic lamina; (2) tunica media, which consists of circumferentially oriented 
smooth muscle cells inside a dense network of collagen and elastin fibers; and 
(3) tunica adventitia, which consists mostly of collagen providing strength for 
the vessel wall. Tunica intima and tunica media are separated by a layer of lamina 
elastica interna, which is the key structure and has to degrade for the intracranial 
aneurysm to develop [9]. Cerebral blood vessels differ from extracranial blood 
vessels in that they have a thicker internal elastic lamina, less elastin, and smooth 
muscle cells in the media; in addition, they have no lamina elastica externa and a 
thinner layer of adventitia. There is minimum perivascular tissue in the subarach-
noid space. The bifurcations of cerebral blood vessels contain irregularities in the 
vessel wall. The bifurcations are the typical areas of aneurysm development [10, 
11]. Due to the small diameter of intracranial blood vessels, the wall shear stress 
plays a significant role in the degeneration of blood vessels and development of 
IA. The small diameter of cerebral blood vessels is also influenced by pathological 
forces induced, for example, by hypertension, and these lead to the development 
of IA. On the other hand, it is not quite clear what is the character of hemodynamic 
forces that lead to the development and rupture of IA. Some hypotheses describe 
the pathological influence of low wall shear stress leading to blood flow stagnation 
and the accumulation of blood elements (erythrocytes, leukocytes, thrombocytes), 
causing degeneration of the vessel wall together with inflammatory changes [12]. 
Another theory is based on high wall shear stress (WSS) causing damage of the 
endothelium, remodeling of the blood vessel wall, and its eventual degradation. It 
seems that possibly both scenarios could play a role [13].
3. Computational fluid dynamics (CFD) of intracranial aneurysms
The actual process of modeling hemodynamic parameters consists of several 
steps. Creating a 3D model is done by manual or semiautomatic segmentation 
(Figure 1). Angiographic examinations (3D angiography, CT angiography, or MR 
angiography) are used as the source data. Each radiological method has its own 
limitations (calcifications, flow artifacts, etc.). Several studies have tried to assess 
the relationship between different imaging examinations [14, 15]. In one such 
study, the authors compared the results of CFD obtained from CTA or DSA [14]. 
In conclusion, the authors state that, despite the quantitative differences in the 
individual hemodynamic parameters between the CTA and the DSA segmented 
group, the basic flow characteristics of both groups were identical.
In the next step, a calculation is performed using the Navier-Stokes equations, 
which describe the flow of incompressible fluid with constant viscosity. The use of 
the numerical solution of the Navier-Stokes equations calculates with assumption of 
blood having laminar flow. Possible influences of phenomena not captured by this 
model are further investigated, such as the influence of turbulent flow or viscosity 
change depending on the shear stress [16–19].
Figure 1. 
The process of obtaining patient-specific geometry from the CT or MR scan with high resolution includes 
accurate voxel segmentation of the vessel, generating surface mesh, and finally smoothing, generating volumetric 
mesh, and prescribing inlets and outlets with possible shortening and elongating of the outputs.
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These calculations characterize the flow, i.e., they provide information about 
fluid velocity and pressure on the vessel wall and the quantities derived there from 
such a stress tensor. Due to the uncertainty in the description of the area, as well 
as the specified boundary conditions, the inconsistency of these variables may be 
significant, but certain global-derived quantities—wall shear stress and oscillatory 
shear index (OSI)—are identical for a certain variation in the accuracy of numerical 
solutions [20]. WSS is defined as the pressure that acts in parallel with the blood 
vessel lumen. The OSI then describes the difference between the WSS vector and 
the blood flow during the cardiac cycle. When interpreting the data, we always need 
to bear in mind the approximations and assumptions during the process of CFD 
modeling.
The development of intracranial aneurysm can be divided into three phases: 
initiation, growth, and stabilization. Only a small percentage of aneurysms are 
unstable, progressing, and eventually resulting in rupture. The growth, shape 
change, and rupture of the aneurysm are the situations that we try to understand 
by mathematical modeling and to estimate the risk of these critical phases of 
development.
3.1 CFD in ruptured vs. unruptured intracranial aneurysms
One way to determine the risk of intracranial aneurysms is to compare the 
hemodynamic characteristics between ruptured and unruptured aneurysms. We 
can either compare non-specific aneurysms based on the status of rupture or only 
compare ruptured and unruptured aneurysms either at specific locations (MCA, 
PCom, etc.) or the so-called “mirror” aneurysms (right and left PCom or MCA 
aneurysms) [21, 22].
To date, several studies have been conducted to compare ruptured and unrup-
tured aneurysms [22, 23]. Some of them were performed on a large number of 
aneurysms; others were focused on a small number of aneurysms at a specific loca-
tion [22, 24–26]. The aim of these studies was to find differences between morpho-
logical and hemodynamic parameters, which would distinguish both groups. The 
characteristics of ruptured aneurysms could then help to identify the risky ones.
In one of the largest studies on 119 aneurysms, the authors found differences in 
4 morphological and 6 hemodynamic parameters between ruptured and unrup-
tured intracranial aneurysms [27]. The multivariate logistic regression analysis 
revealed that the morphological factor of size ratio and two hemodynamic factors, 
WSS and OSI, were independent factors of rupture risk. In 2017, a meta-analysis 
was published which, based on 1257 aneurysms from 22 studies, evaluated differ-
ences in hemodynamic parameters between ruptured and unruptured aneurysms. It 
showed that in ruptured aneurysms, WSS is significantly lower than in unruptured 
ones [28]. The same result was shown on 106 ACM aneurysms [22]. Alternatively, 
the largest ever study comparing ruptured and unruptured aneurysms has shown 
that wall shear stress is higher than those in unruptured aneurysms [29].
Previous results must therefore be given careful consideration as many factors 
have a significant influence on WSS. The meta-analysis itself shows, for example, 
the difference in WSS in aneurysms at different locations (the lowest is in the 
aneurysms of the apex of the basilar artery). One way to eliminate the influence of 
different localizations is to compare either the so-called mirror aneurysms (right 
and left IA MCA or PCom) or aneurysms of one localization in general (ACom, 
ICA, MCA, PCom, etc.).
Another important factor affecting IA hemodynamics is their size [13, 30]. We 
compared hemodynamic factors in small and large aneurysms based on the largest 
diameter of 10 mm (small <10 mm, large >10 mm) as this is commonly used to 
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differentiate between small and large aneurysms in clinical practice (publication in 
preparation). We have found that size significantly influences the WSS within the 
aneurysm, independent of its rupture status. WSS in small aneurysms was signifi-
cantly smaller. The only similar study used a volume of the sac to differentiate small 
and large aneurysms [30]. However, in clinical practice, the volume of the sac is not 
assessed on a regular basis, and its use is less practical in clinics. Nonetheless the 
results of both studies emphasize the importance of aneurysm size assessment with 
respect to evaluation of hemodynamic factors; generally it is necessary to compare 
hemodynamic parameters in equally sized aneurysms. One possible way to circum-
vent this effect is to use the so-called WSS statistical maps to convert the results to 
the surface of the aneurysm sac [31].
Specific limitations of studies comparing ruptured and unruptured aneurysms 
result from the fact that we already assess the condition given by rupture, not the 
aneurysm at risk, before rupture. Therefore, altered morphology of the aneurysm 
after rupture can lead to erroneous results or misinterpretations [32]. Another 
limitation in these studies is that we usually do not possess the individual boundary 
conditions for each aneurysm and need to use literature-based information.
3.2 CFD in ruptured intracranial aneurysms
The study of hemodynamics in ruptured aneurysms provides a chance to link the 
hemodynamic parameters with rupture (Figure 2A–D). Most studies have focused 
on the aneurysm sac as a whole. However, the aneurysm sac in ruptured aneurysms 
may be divided into the site of the rupture and the surrounding part of the sac. In 
these rare cases when we are able to differentiate those two parts of the aneurysm 
sac, we can combine our knowledge with local hemodynamic parameters. There are 
two types of studies in which the authors were able to identify the point of rupture. 
Firstly, there are surgical series when the neurosurgeon perioperatively identifies the 
site of rupture (perioperative rupture, apparent wall rupture during inspection of 
the sac usually before clip deployment, etc.) [33, 34]. Secondly, there are mostly case 
reports when the rupture in the angiographic room occurs, and the leakage of blood 
from the sac is thus identifiable during the interventional procedure [35, 36].
The site of rupture may show specific hemodynamic features (Figure 2D). So 
far there have been few studies with altogether a low number of patients (around 
40 in total). The results are rather contradictory as it is apparent from the table; 
thus, it is difficult to make any straightforward general conclusions (Table 1).
It seems that the site of rupture is associated either with concentrated jet flow 
and high WSS (Figure 2D) or, on the other hand, a slow flow and low WSS. Both 
types of flow can lead to degeneration of the blood vessel wall but via a different 
mechanism [13]. Whereas low WSS and high OSI may lead to the activation of 
inflammatory cells and impairment of vessel wall structure, high WSS leads to the 
activation of cells in the vessel wall, leading to the growth of aneurysm sacs and 
rupture in small sacs or blebs. Reaching a certain size of the aneurysm sac during its 
growth leads to slowing the flow and recirculations, resulting in WSS decrease. In 
the IA itself, the highest WSS is usually around the neck and it decreases toward the 
apex. The low WSS can lead to degradation of the internal structure of the vessel 
wall and a further increase in the size of the sac. Most ruptures take place just in the 
apex of the aneurysm sac.
The disadvantage of all studies evaluating local hemodynamic parameters rela-
tive to the rupture site is the same as in all studies evaluating ruptured aneurysms. 
As mentioned above ruptured aneurysms may have a different shape after rupture, 
which can influence the results of hemodynamic modeling parameters as compared 
to the pre-rupture situation [32, 37]. Studies in which a hemodynamic analysis was 
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vent this effect is to use the so-called WSS statistical maps to convert the results to 
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3.2 CFD in ruptured intracranial aneurysms
The study of hemodynamics in ruptured aneurysms provides a chance to link the 
hemodynamic parameters with rupture (Figure 2A–D). Most studies have focused 
on the aneurysm sac as a whole. However, the aneurysm sac in ruptured aneurysms 
may be divided into the site of the rupture and the surrounding part of the sac. In 
these rare cases when we are able to differentiate those two parts of the aneurysm 
sac, we can combine our knowledge with local hemodynamic parameters. There are 
two types of studies in which the authors were able to identify the point of rupture. 
Firstly, there are surgical series when the neurosurgeon perioperatively identifies the 
site of rupture (perioperative rupture, apparent wall rupture during inspection of 
the sac usually before clip deployment, etc.) [33, 34]. Secondly, there are mostly case 
reports when the rupture in the angiographic room occurs, and the leakage of blood 
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The site of rupture may show specific hemodynamic features (Figure 2D). So 
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tive to the rupture site is the same as in all studies evaluating ruptured aneurysms. 
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which can influence the results of hemodynamic modeling parameters as compared 
to the pre-rupture situation [32, 37]. Studies in which a hemodynamic analysis was 
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performed shortly before rupture avoid this limitation and may be helpful [35, 38]. 
These studies are rare, but their results are important, as they provide a hemody-
namic characteristic within an extremely vulnerable aneurysm (which will soon 
rupture). Zhang et al. described three cases of large carotid aneurysms just before 
their rupture (2–5 days before SAK from aneurysm) and compared them with the 
same large eight unruptured ones [35]. They found that all ruptured aneurysms had 
an irregular shape and a higher aspect ratio (AR), and the WSS was lower than in 
the parent artery, as opposed to ruptured aneurysms. Additionally, in another study 
where the hemodynamic study of the basilar artery apex was performed 2 hours 
before the aneurysm rupture, the authors also found that in this aneurysm, WSS 
was lower than the parent artery [38]. However, the actual rupture site was associ-
ated with high WSS at the point of the blood jet into the sac. We found a similar 
flow characteristic in our case report where the site of rupture correlated with 
concentrated jet flow accompanied with high WSS and high normal pressure [39].
Understanding the changes in hemodynamics in ruptured aneurysms over time 
before the moment of rupture is of great importance; such studies are obviously quite 
Figure 2. 
(A–C) Development of WSS over time in an IA that eventually ruptured. The WSS gradually decreased 
between the years 2007 and 2011. (D) A ruptured ACom aneurysm. The point of rupture (*) was confirmed 
during surgery. It was associated with increased WSS. (E) A perioperative image showing a ruptured MCA 
aneurysm. The point of rupture is in the weak part of the aneurysm wall. (F) A perioperative image showing 
an unruptured MCA aneurysm with heterogenous wall, an atherosclerotic part with a thrombus inside (black 
asterisk) and a red thin wall (white asterisk). (G) A histological image showing in detail the vessel wall of the 
Willis’s circle without an aneurysm: the structure consists of the tunica intima with endothelial cells, which is 
separated from the tunica media by the internal elastic lamina (IEL), the tunica media with linear layer of 
smooth muscle cells, and the tunica adventitia, the outermost layer, which comprise mainly of collagen. (H) An 
UIA: moderate structural changes of the vessel wall, mainly fibrosis across the vessel wall without layers and 
the internal elastic lamina. (I) A ruptured IA: severe structural changes of the vessel wall. The wall is thinner, 
without tunica intima, and linear layer of smooth muscle cells, with the presence of organized thrombus 
(Masson trichrome staining in all three histological images).
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rare [32, 40]. Our own study showed that a secondary aneurysm, a frequent rupture 
site, was observed in the aneurysm that subsequently ruptured (Figure 2A-C) [40]. 
WSS was reduced and the flow was slow at the rupture point. Over time, the area 
of low WSS increases in aneurysms that rupture (Sejkorová et al., in preparation). 
Such studies are vital for identifying the hemodynamic factors associated with the 
increased risk of rupture and may possibly be used in the future as an indicator for the 
active treatment of monitored UIA.
3.3  Correlating hemodynamics with the histology of the wall of intracranial 
aneurysms
One of the shortcomings of mathematical modeling is that we still know little 
about the relationship between hemodynamics and its influence of the biology of 
the vessel wall [41]. Understanding the balance between the flow and the biology 
of the aneurysm wall is the key factor in the life cycle intracranial aneurysms. The 
aneurysm wall ruptures when there is an imbalance between the aneurysm wall 
thickness and hemodynamic forces; both reciprocities are influenced. Modeling the 
relationship between histological changes and hemodynamic parameters is a logical 
way of research development (Figure 2E–I). The correlation of histological changes 
with mathematical models can help to verify the accuracy of mathematical models of 
hemodynamics, to improve understanding of the acquired data, and to transfer this 
methodology closer to practice in clinical neurosurgery. The correlation of histologi-
cal changes and hemodynamics avoids errors related to CFD parameter evaluation in 
relation to, for example, aneurysm rupture; while the ruptured one was not ruptured 
prior to the event, the unruptured one could be ruptured in a few hours.
Frösen et al. classified four types of histological wall structures of aneurysms, 
based on disorganization of the vessel wall structure, myointimal hyperplasia or 
hypocellularity of the vessel wall, smooth muscle cell (SMC) proliferation, and the 
presence of organized thrombus [42]. The ruptured aneurysm wall is more often 
characterized by being disorganized, thinner, hypocellular, with an organized 
thrombus present (Figure 2I). Different types of wall structures can be found 
within one aneurysm sac. One of the first studies to correlate hemodynamic param-
eters with the pattern of the vessel wall has recently been published [43]. Quite 
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6 Periop finding Low WSS and high OSI




12 Periop finding Low WSS and slow flow
Cebral et al., 2015 [57] 9 3DRA and CT High WSS
Hejčl et al., 2017 [39] 1 Periop finding Jet flow and high WSS
Wang et al., 2018 [58] 1 Periop finding Low WSS and high OSI
Suzuki et al. 2019 [59] 7 Periop finding Max pressure areas, then decreased 
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CFD studies evaluating hemodynamic parameters at the known site of rupture.
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rare [32, 40]. Our own study showed that a secondary aneurysm, a frequent rupture 
site, was observed in the aneurysm that subsequently ruptured (Figure 2A-C) [40]. 
WSS was reduced and the flow was slow at the rupture point. Over time, the area 
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Such studies are vital for identifying the hemodynamic factors associated with the 
increased risk of rupture and may possibly be used in the future as an indicator for the 
active treatment of monitored UIA.
3.3  Correlating hemodynamics with the histology of the wall of intracranial 
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One of the shortcomings of mathematical modeling is that we still know little 
about the relationship between hemodynamics and its influence of the biology of 
the vessel wall [41]. Understanding the balance between the flow and the biology 
of the aneurysm wall is the key factor in the life cycle intracranial aneurysms. The 
aneurysm wall ruptures when there is an imbalance between the aneurysm wall 
thickness and hemodynamic forces; both reciprocities are influenced. Modeling the 
relationship between histological changes and hemodynamic parameters is a logical 
way of research development (Figure 2E–I). The correlation of histological changes 
with mathematical models can help to verify the accuracy of mathematical models of 
hemodynamics, to improve understanding of the acquired data, and to transfer this 
methodology closer to practice in clinical neurosurgery. The correlation of histologi-
cal changes and hemodynamics avoids errors related to CFD parameter evaluation in 
relation to, for example, aneurysm rupture; while the ruptured one was not ruptured 
prior to the event, the unruptured one could be ruptured in a few hours.
Frösen et al. classified four types of histological wall structures of aneurysms, 
based on disorganization of the vessel wall structure, myointimal hyperplasia or 
hypocellularity of the vessel wall, smooth muscle cell (SMC) proliferation, and the 
presence of organized thrombus [42]. The ruptured aneurysm wall is more often 
characterized by being disorganized, thinner, hypocellular, with an organized 
thrombus present (Figure 2I). Different types of wall structures can be found 
within one aneurysm sac. One of the first studies to correlate hemodynamic param-
eters with the pattern of the vessel wall has recently been published [43]. Quite 
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surprisingly, the authors found that the high WSS and high-velocity flow were asso-
ciated with the appearance of inflammatory changes in the aneurysm wall, while 
low flow areas were associated with degenerative changes in the aneurysm wall and 
loss of smooth muscle and pericytes. This finding is quite different from the previ-
ous studies, which did not correlate hemodynamics and histological characteristics. 
The correlation of histological changes and hemodynamics avoids the risk of error 
in comparing ruptured and unruptured aneurysms. There will most likely be a dif-
ference between an aneurysm that never ruptures and an aneurysm whose rupture 
is imminent. However it is not known which aneurysms we are analyzing.
In a less elaborative way, CFD modeling can be correlated simply with the periop-
erative findings during surgery (Figures 2E, F and 3). The wall of many aneurysms 
can be heterogenous including thin red areas, calcifications, and the thick yellow 
atherosclerotic wall part. In one such study, red, thin aneurysm wall areas were more 
often associated with low WSS (Figure 3A1–3) [44]. A total of 39 areas were identi-
fied and directly visually inspected on the aneurysms walls. The study showed that 
red, thin aneurysm wall areas were more often associated with low WSS, high pres-
sure, parallel WSS vectors, and curved streamlines (75%) [40]. On the other hand, 
the association of low WSS with high pressure, diverging WSS vectors, direct impact 
of streamlines, and high-velocity flow more frequently matched with yellow, athero-
sclerotic aneurysm walls (79%) (Figure 3B1–3). Although routinely used imaging 
techniques can provide information about morphology and anatomical relationships 
of the aneurysm with the surrounding structures, there is currently no way to predict 
the thickness of the aneurysm wall. CFD can potentially provide this kind of informa-
tion, which would be valuable not only to assess rupture risk but also to improve the 
surgical strategy during clipping or coiling. The authors of this study hypothesize that 
direct, high-velocity impact of blood flow on a specific area of the aneurysm could 
trigger a remodeling of the wall, ultimately leading to a reactive thickening.
In our recent project, we evaluated histological changes in ruptured and 
unruptured intracranial aneurysms. According to our preliminary data on the first 
30 samples of individuals with ruptured and unruptured IA together with some 
control samples from similar locations of the cadaver’s Willis’s circle, the wall was 
Figure 3. 
(Left panel) Red, thin areas on aneurysm wall are more often associated with low WSS. (A1) Right ICA 
aneurysm. (A2) Intraoperative microscopical view. (A3) CFD analysis. (Right panel) Yellow, atherosclerotic 
areas on aneurysm wall are more often associated with low WSS, high pressure, diverging WSS vectors, direct 
impact of streamlines with high-velocity flow (labeled with “1” in the figure). (B1) Anterior communicating 
artery aneurysm. (B2) Intraoperative endoscopic view. (B3) CFD analysis.
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damaged by scarring, with the disappearance of the tunica intima and the internal 
elastic membrane, in patients with both ruptured and unruptured aneurysms 
(Figure 2G–I). In the classification according to Frösen et al., categories A to C 
were demonstrated for unruptured IA, i.e., minor to moderate structural changes, 
such as fibrosis and disorganization of SMC (Figure 2H). However, the wall of 
ruptured aneurysms was thin, hypocellular, and fibrotized, often with the presence 
of an organized thrombus (Figure 2I). In the classification according to Frösen, it 
corresponded to categories C and D, i.e., a significantly damaged wall.
The correlation of vessel wall biology in intracranial aneurysms also has 
limitations:
1. Resection of only a part of the aneurysm sac. The entire aneurysm cannot be 
taken for histological evaluation. Due to the need to close at least the neck, 
but often also significant parts of the dome with an aneurysm clip, it is often 
possible to remove only the apex bag, even for larger aneurysms. Often small 
aneurysms are all hidden within a clip. On the other hand, large aneurysms 
often have a wall that is altered by atherosclerosis, weakened or calcified, and 
thus requires the application of, for example, several parallel clips and often a 
minimal residue of free sac to allow for sampling. A possible, at least partial, 
solution is the correlation of hemodynamics with the perioperative description 
of the aneurysm wall character (thinned wall, calcification, thickened athero-
sclerotic wall, etc.) by a neurosurgeon.
2. 3D orientation of the histological sample against angiographic imaging. The 
problem is the orientation of the cut bag in 3D space or 3D neuroradiological 
mapping. The hemodynamic parameters are processed in a 3D image based on 
CTA or 3D DSA. However, after cutting off the tip of the bag, it is necessary 
to orient the specimen and mark it properly so that the histology of the vessel 
wall with hemodynamic results can be ideally correlated. So far, a methodo-
logical study has been published to address this topic. However, it is currently 
quite complicated to be applied in clinical practice.
Another disease that is also used to investigate the relationship between athero-
sclerosis and hemodynamics is the carotid plaque in the bifurcation of the common 
carotid artery (Figure 4) [45]. This model is more advantageous for several reasons. 
It can be removed completely without disturbing its structure and then prepared 
for histological examination in one piece. Due to the size of the plaque and a simple 
orientation in the 3D geometry of the carotid arteries, the spatial correlation of the 
plaque model relative to the 3D image of hemodynamic calculations is simple. Also 
mathematical calculations on the carotid arteries are significantly simpler due to the 
relatively flat shape of the vessels and the larger cross-sectional size of the arteries, 
which are thus less affected by minor inequalities and errors given by the neurora-
diological images. Therefore, the histological studies of carotid plaques in correla-
tion with hemodynamic characteristics in the common carotid bifurcation can be 
performed with fewer approximations and thus can contribute to the understand-
ing of atherosclerosis and degenerative changes in the vascular wall.
3.4 Hemodynamics and the risk of intracranial aneurysm rupture
The degeneration of the aneurysm wall progresses from the neck toward the 
dome. Aneurysm rupture usually occurs at the apex, which is also often a low shear 
stress region. According to a large meta-analysis by Zhou et al., the low shear stress 
(0–1.5 Pa) in the aneurysm sac is a characteristic of ruptured aneurysms [28]. It 
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sure, parallel WSS vectors, and curved streamlines (75%) [40]. On the other hand, 
the association of low WSS with high pressure, diverging WSS vectors, direct impact 
of streamlines, and high-velocity flow more frequently matched with yellow, athero-
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techniques can provide information about morphology and anatomical relationships 
of the aneurysm with the surrounding structures, there is currently no way to predict 
the thickness of the aneurysm wall. CFD can potentially provide this kind of informa-
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surgical strategy during clipping or coiling. The authors of this study hypothesize that 
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damaged by scarring, with the disappearance of the tunica intima and the internal 
elastic membrane, in patients with both ruptured and unruptured aneurysms 
(Figure 2G–I). In the classification according to Frösen et al., categories A to C 
were demonstrated for unruptured IA, i.e., minor to moderate structural changes, 
such as fibrosis and disorganization of SMC (Figure 2H). However, the wall of 
ruptured aneurysms was thin, hypocellular, and fibrotized, often with the presence 
of an organized thrombus (Figure 2I). In the classification according to Frösen, it 
corresponded to categories C and D, i.e., a significantly damaged wall.
The correlation of vessel wall biology in intracranial aneurysms also has 
limitations:
1. Resection of only a part of the aneurysm sac. The entire aneurysm cannot be 
taken for histological evaluation. Due to the need to close at least the neck, 
but often also significant parts of the dome with an aneurysm clip, it is often 
possible to remove only the apex bag, even for larger aneurysms. Often small 
aneurysms are all hidden within a clip. On the other hand, large aneurysms 
often have a wall that is altered by atherosclerosis, weakened or calcified, and 
thus requires the application of, for example, several parallel clips and often a 
minimal residue of free sac to allow for sampling. A possible, at least partial, 
solution is the correlation of hemodynamics with the perioperative description 
of the aneurysm wall character (thinned wall, calcification, thickened athero-
sclerotic wall, etc.) by a neurosurgeon.
2. 3D orientation of the histological sample against angiographic imaging. The 
problem is the orientation of the cut bag in 3D space or 3D neuroradiological 
mapping. The hemodynamic parameters are processed in a 3D image based on 
CTA or 3D DSA. However, after cutting off the tip of the bag, it is necessary 
to orient the specimen and mark it properly so that the histology of the vessel 
wall with hemodynamic results can be ideally correlated. So far, a methodo-
logical study has been published to address this topic. However, it is currently 
quite complicated to be applied in clinical practice.
Another disease that is also used to investigate the relationship between athero-
sclerosis and hemodynamics is the carotid plaque in the bifurcation of the common 
carotid artery (Figure 4) [45]. This model is more advantageous for several reasons. 
It can be removed completely without disturbing its structure and then prepared 
for histological examination in one piece. Due to the size of the plaque and a simple 
orientation in the 3D geometry of the carotid arteries, the spatial correlation of the 
plaque model relative to the 3D image of hemodynamic calculations is simple. Also 
mathematical calculations on the carotid arteries are significantly simpler due to the 
relatively flat shape of the vessels and the larger cross-sectional size of the arteries, 
which are thus less affected by minor inequalities and errors given by the neurora-
diological images. Therefore, the histological studies of carotid plaques in correla-
tion with hemodynamic characteristics in the common carotid bifurcation can be 
performed with fewer approximations and thus can contribute to the understand-
ing of atherosclerosis and degenerative changes in the vascular wall.
3.4 Hemodynamics and the risk of intracranial aneurysm rupture
The degeneration of the aneurysm wall progresses from the neck toward the 
dome. Aneurysm rupture usually occurs at the apex, which is also often a low shear 
stress region. According to a large meta-analysis by Zhou et al., the low shear stress 
(0–1.5 Pa) in the aneurysm sac is a characteristic of ruptured aneurysms [28]. It 
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is assumed that wall shear stress of approximately 2.0 N/m2 (Pa) is most suitable 
for maintaining the integrity of the vessel wall. A shear stress of less than 1.5 N/m2 
results in endothelial cell apoptosis [46]. Takao et al. found that the minimum WSS 
value for ruptured aneurysms was half that of ruptured aneurysms [26]. Thus, low 
WSS may be an indicator of an increased risk of intracranial aneurysm rupture. 
Furthermore, several authors have demonstrated that in ruptured aneurysms, the 
low WSS region is greater than in unruptured aneurysms [21, 25, 47]. Similar results 
were found in our study (Sejkorová et al., in preparation), in which we have shown 
that the area of low wall shear stress (LSA) grows over time in those aneurysms that 
eventually ruptured. The nature of the flow and its properties are influenced by the 
shape of the sac. Inside the narrow neck aneurysms, there may be a slow flow with 
recirculations, resulting in low shear stress leading to increased vascular degenera-
tion. Hemodynamic changes within the aneurysm lead to the production of biologi-
cal signals in endothelial cells and may result in microscopic changes in the vessel 
wall [48]. Nitric oxide is a key mediator of low WSS and shear stress oscillation. 
The low shear stress further promotes the expression of adhesion molecules such as 
VCAM-1 and ICAM-1. These promote adhesion of leukocytes leading to inflamma-
tion and vascular changes. Therefore low WSS seems to be associated with degen-
eration of cerebral aneurysm vessel wall resulting in rupture. But the situation is 
probably more complex as in another study in a large number of aneurysms, the 
authors found that ruptured aneurysms were characterized by concentrated blood 
stream and a higher shear stress compared to unruptured ones [29].
3.5 Limitations of mathematical modeling of IA
Mathematical modeling performed in IA extends our knowledge on the 
pathophysiology of their initiation, growth, development, and rupture [13, 49]. 
At the same time, it is necessary to note that CFD modeling is usually based on 
many approximations and carries several limitations. In most studies, individual 
patient data are not available. This is particularly difficult to obtain in patients 
with ruptured aneurysms that require acute treatment, and there is usually no 
time for additional diagnostic examinations (TCD or PC-MR). The method that 
can partially reduce the disadvantage of missing individual data is to relate values 
Figure 4. 
CFD in a model of carotid stenosis. WSS (A) and streamlines (B).
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in the aneurysm to the parent artery. Such value normalization reduces the impact 
of missing input data. Another limitation is that CFD represents mathematical 
models that are currently not able to describe all aspects of the biology of the 
cerebral aneurysms and cerebral blood vessels, their histology, atherosclerotic 
changes, pulsations, etc. Also during modeling, blood vessels are simplified as 
rigid tubes. The rheological properties of blood are simplified as incompressible 
Newtonian fluid.
Another aspect associated with limitations in CFD modeling is the use of 
different mathematical modeling algorithms among various groups working on 
CFD. This has been clearly shown in the CFD rupture challenge—phase I and phase 
II [50, 51]. In the rupture challenge, two MCA aneurysms, one ruptured and one 
unruptured IA, were evaluated using CFD analysis, and the status of the aneurysm 
was supposed to be identified by the research groups. In the second phase, several 
research groups were supposed to describe the hemodynamic parameters in one 
IA. The vast differences among the research groups confirmed the fact that various 
algorithms may lead to significant differences in the hemodynamic analysis [52]. In 
future it will be necessary to somehow unify the methodology in order to get more 
universally applicable results.
Another disadvantage of CFD modeling is the relatively complicated protocol 
with the need to include sophisticated and laborious calculations requiring super-
computers. Nonetheless, technological advances in imaging may provide hemo-
dynamic modeling during regular MRI examinations [53]. If MRI allows precise 
evaluation of hemodynamic parameters in the future, it can be used even during 
initial MRI evaluation and during follow-ups without radiation burden.
4. Final remarks and future directions
The rationale for studying hemodynamics of IA is the increasing detection of UIA 
with the need to decide whether to treat or watch the aneurysm. Studying and model-
ing hemodynamics within an aneurysm provides more information on the patho-
physiology of IA. We can evaluate the hemodynamic parameter at one time point or 
follow the aneurysm with CFD assessments over time [40, 54]. The method has been 
mostly developed by endovascular surgeons with the goal to assess the effect of various 
treatment modalities, such as flow diverters, stents, scarification of the parent vessel, 
etc. The neurosurgeons would mostly need information on aneurysm hemodynamics 
with respect to the rupture risk in the assessment of UIA [40]. The neurosurgeons 
themselves may provide unique information on aneurysm wall quality: direction 
visualization of the aneurysm sac under the operating microscope (calcifications, wall 
weakening, atherosclerotic changes, thrombosis), identification of the site of rupture, 
aneurysm sac harvesting after clipping, etc. The aneurysm sac wall may then be 
assessed histologically. Some pilot studies have already been published [43]. Despite an 
increasing number of CFD studies, there are, to date, still no conclusions with respect 
to hemodynamics and growth or rupture that would be universally accepted.
From a clinical point of view, the CFD data need to be clinically useful and 
relevant, such as in a study that points out the relationship between the hemody-
namic factors and the risk of endovascular treatment failure in patients treated 
for a basilar apex aneurysm [55]. The CFD parameters more often mentioned 
with respect to clinical use are WSS and character of flow. Many studies show that 
aneurysms with low WSS and complex flow tend to be associated with a higher risk 
of rupture [27, 28]. Further developments are still required in CFD research before 
it may be considered clinically relevant in providing useful information on UIA and 
its assessment, with respect to the risk of rupture.
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is assumed that wall shear stress of approximately 2.0 N/m2 (Pa) is most suitable 
for maintaining the integrity of the vessel wall. A shear stress of less than 1.5 N/m2 
results in endothelial cell apoptosis [46]. Takao et al. found that the minimum WSS 
value for ruptured aneurysms was half that of ruptured aneurysms [26]. Thus, low 
WSS may be an indicator of an increased risk of intracranial aneurysm rupture. 
Furthermore, several authors have demonstrated that in ruptured aneurysms, the 
low WSS region is greater than in unruptured aneurysms [21, 25, 47]. Similar results 
were found in our study (Sejkorová et al., in preparation), in which we have shown 
that the area of low wall shear stress (LSA) grows over time in those aneurysms that 
eventually ruptured. The nature of the flow and its properties are influenced by the 
shape of the sac. Inside the narrow neck aneurysms, there may be a slow flow with 
recirculations, resulting in low shear stress leading to increased vascular degenera-
tion. Hemodynamic changes within the aneurysm lead to the production of biologi-
cal signals in endothelial cells and may result in microscopic changes in the vessel 
wall [48]. Nitric oxide is a key mediator of low WSS and shear stress oscillation. 
The low shear stress further promotes the expression of adhesion molecules such as 
VCAM-1 and ICAM-1. These promote adhesion of leukocytes leading to inflamma-
tion and vascular changes. Therefore low WSS seems to be associated with degen-
eration of cerebral aneurysm vessel wall resulting in rupture. But the situation is 
probably more complex as in another study in a large number of aneurysms, the 
authors found that ruptured aneurysms were characterized by concentrated blood 
stream and a higher shear stress compared to unruptured ones [29].
3.5 Limitations of mathematical modeling of IA
Mathematical modeling performed in IA extends our knowledge on the 
pathophysiology of their initiation, growth, development, and rupture [13, 49]. 
At the same time, it is necessary to note that CFD modeling is usually based on 
many approximations and carries several limitations. In most studies, individual 
patient data are not available. This is particularly difficult to obtain in patients 
with ruptured aneurysms that require acute treatment, and there is usually no 
time for additional diagnostic examinations (TCD or PC-MR). The method that 
can partially reduce the disadvantage of missing individual data is to relate values 
Figure 4. 
CFD in a model of carotid stenosis. WSS (A) and streamlines (B).
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in the aneurysm to the parent artery. Such value normalization reduces the impact 
of missing input data. Another limitation is that CFD represents mathematical 
models that are currently not able to describe all aspects of the biology of the 
cerebral aneurysms and cerebral blood vessels, their histology, atherosclerotic 
changes, pulsations, etc. Also during modeling, blood vessels are simplified as 
rigid tubes. The rheological properties of blood are simplified as incompressible 
Newtonian fluid.
Another aspect associated with limitations in CFD modeling is the use of 
different mathematical modeling algorithms among various groups working on 
CFD. This has been clearly shown in the CFD rupture challenge—phase I and phase 
II [50, 51]. In the rupture challenge, two MCA aneurysms, one ruptured and one 
unruptured IA, were evaluated using CFD analysis, and the status of the aneurysm 
was supposed to be identified by the research groups. In the second phase, several 
research groups were supposed to describe the hemodynamic parameters in one 
IA. The vast differences among the research groups confirmed the fact that various 
algorithms may lead to significant differences in the hemodynamic analysis [52]. In 
future it will be necessary to somehow unify the methodology in order to get more 
universally applicable results.
Another disadvantage of CFD modeling is the relatively complicated protocol 
with the need to include sophisticated and laborious calculations requiring super-
computers. Nonetheless, technological advances in imaging may provide hemo-
dynamic modeling during regular MRI examinations [53]. If MRI allows precise 
evaluation of hemodynamic parameters in the future, it can be used even during 
initial MRI evaluation and during follow-ups without radiation burden.
4. Final remarks and future directions
The rationale for studying hemodynamics of IA is the increasing detection of UIA 
with the need to decide whether to treat or watch the aneurysm. Studying and model-
ing hemodynamics within an aneurysm provides more information on the patho-
physiology of IA. We can evaluate the hemodynamic parameter at one time point or 
follow the aneurysm with CFD assessments over time [40, 54]. The method has been 
mostly developed by endovascular surgeons with the goal to assess the effect of various 
treatment modalities, such as flow diverters, stents, scarification of the parent vessel, 
etc. The neurosurgeons would mostly need information on aneurysm hemodynamics 
with respect to the rupture risk in the assessment of UIA [40]. The neurosurgeons 
themselves may provide unique information on aneurysm wall quality: direction 
visualization of the aneurysm sac under the operating microscope (calcifications, wall 
weakening, atherosclerotic changes, thrombosis), identification of the site of rupture, 
aneurysm sac harvesting after clipping, etc. The aneurysm sac wall may then be 
assessed histologically. Some pilot studies have already been published [43]. Despite an 
increasing number of CFD studies, there are, to date, still no conclusions with respect 
to hemodynamics and growth or rupture that would be universally accepted.
From a clinical point of view, the CFD data need to be clinically useful and 
relevant, such as in a study that points out the relationship between the hemody-
namic factors and the risk of endovascular treatment failure in patients treated 
for a basilar apex aneurysm [55]. The CFD parameters more often mentioned 
with respect to clinical use are WSS and character of flow. Many studies show that 
aneurysms with low WSS and complex flow tend to be associated with a higher risk 
of rupture [27, 28]. Further developments are still required in CFD research before 
it may be considered clinically relevant in providing useful information on UIA and 
its assessment, with respect to the risk of rupture.
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Abstract
Subarachnoid haemorrhage (SAH) occurs as a result of rupture of intracra-
nial aneurysms. SAH causes significant morbidity and mortality. In addition, 
SAH leads to significant financial burden. In this chapter, we will look into the 
association between raised serum homocysteine and intracranial aneurysms. 
In a study on the Han Chinese patients with intracranial aneurysm who were 
admitted to the hospital, the mean serum total homocysteine level in the patient 
group with intracranial aneurysm was significantly higher than those in the 
control group. In the same study, the patients with raised serum homocysteine 
had 2.196 higher risk of developing intracranial aneurysms. Ren et al. proposed 
that homocysteine should be seen as an indicator of the risk of intracranial 
aneurysm and not a direct cause of intracranial aneurysm. In another study, 
homocysteine increases the development of intracranial aneurysms in rats. 
Endothelial damage is an early change in the walls of intracranial aneurysms. 
Polymorphisms of the genes coding for the various components of the vessel 
walls may be associated with the formation of intracranial aneurysms. In a pre-
vious animal study, the size of intracranial aneurysms is significantly smaller in 
the mice with inducible nitric oxide synthase (iNOS) compared with the mice 
without iNOS.
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1. Introduction
1.1 Subarachnoid haemorrhage
Subarachnoid haemorrhage (SAH) is caused by rupture of intracranial aneu-
rysms [1, 2]. Approximately 5–15% of the stroke patients have ruptured intracranial 
aneurysms [3, 4].
Aneurysmal SAH leads to a prolonged hospital stay [1]. Therefore, aneurysmal 
subarachnoid haemorrhage results in a significant financial burden in the USA [1]. In 
addition, aneurysmal SAH causes approximately 45% mortality in 30 days [3, 5]. As 
many as 30% of the patients who survived the SAH had moderate to severe neuro-
logical deficit and disability [3, 5].
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1. Introduction
1.1 Subarachnoid haemorrhage
Subarachnoid haemorrhage (SAH) is caused by rupture of intracranial aneu-
rysms [1, 2]. Approximately 5–15% of the stroke patients have ruptured intracranial 
aneurysms [3, 4].
Aneurysmal SAH leads to a prolonged hospital stay [1]. Therefore, aneurysmal 
subarachnoid haemorrhage results in a significant financial burden in the USA [1]. In 
addition, aneurysmal SAH causes approximately 45% mortality in 30 days [3, 5]. As 
many as 30% of the patients who survived the SAH had moderate to severe neuro-
logical deficit and disability [3, 5].
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1.2 Intracranial aneurysms
Saccular intracranial aneurysms are abnormal focal outpouchings of cerebral 
arteries [3]. The prevalence of intracranial aneurysms in the adult population in the 
USA is 1–5% [3, 6]. Most of the intracranial aneurysms are small [3]. Approximately 
50–80% of all the intracranial aneurysms do not rupture [3, 7].
Intracranial aneurysms are usually sporadically acquired lesions [3]. A rare 
familial form is present, and this is associated with conditions such as cerebral 
arteriovenous malformations (AVMs), autosomal dominant polycystic kidney 
disease (ADPKD), fibromuscular dysplasia, Marfan syndrome and Ehlers-Danlos 
syndrome [3, 5]. Multiple genetic susceptibilities may be acting synergistically in 
the development of SAH [5, 8]. The increase in the familial risk of developing SAH 
is nearly four times higher among first-degree relatives [5, 9, 10].
Unruptured aneurysms can potentially result in cranial nerve palsies such as 
third cranial nerve palsy and rarely brainstem compression [3, 7, 11]. These patients 
have a higher risk of rupture of intracranial aneurysm [3, 7]. They have an annual 
risk of aneurysmal rupture of about 6% [3, 12].
1.3 Homocysteine
Homocysteine is an endogenous, nonstructural protein which contains sulphur 
[13]. Homocysteine is involved in the metabolism pathway of methionine and 
cysteine [13, 14]. Homocysteine can be irreversibly degraded to cysteine via the 
trans-sulphuration pathway or remethylated back to methionine [15]. The bio-
chemistry of methionine is regulated by the enzymes controlling homocysteine 
concentration [15]. An elevated level of serum homocysteine is the intermediate 
product of methionine metabolism [16].
In addition, the metabolism of homocysteine is dependent on nutritional 
factors comprising of vitamin B12 and folic acid [16, 17]. A reduction in the levels 
of vitamin B12 and folic acid causes an increase in serum homocysteine levels [16]. 
Homocysteine also plays an important role in the metabolism of folic acid and 
catabolism of choline which are both vital for the regulation of methionine [15]. 
Homocysteine is very important for the cellular homeostasis [15].
Normal level of total concentration of homocysteine in plasma of healthy people 
is between 5.0 and 15.0 mmol/l. [13] Raised serum homocysteine is an independent 
risk factor for cardiovascular diseases [13, 15, 18]. Elevated serum homocysteine is 
associated with a rise in morbidity and mortality [18, 19].
An increase in serum homocysteine results in oxidative stress and systemic 
inflammation which in turn leads to an accelerated telomere shortening [13, 19]. 
Furthermore, elevated serum homocysteine damages endothelial cells [13]. As a 
result, the blood vessels are less flexible and the process of haemostasis is disturbed 
[13]. An increase in serum homocysteine can be treated by folic acid, vitamin 
B12 and vitamin B6 supplements [13, 15].
2. Homocysteine and intracranial aneurysm
Ren et al. conducted a study on the Han Chinese patients with intracranial aneu-
rysm who were admitted to the hospital [17]. In this study, the mean serum total 
homocysteine level in the patient group with intracranial aneurysm was significantly 
higher than those in the control group [17]. In addition, homocysteine had an adjusted 
odds ratio of 2.196 (P = 0.012) for the development of intracranial aneurysm [17].
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Furthermore, raised serum homocysteine was reported to be an independent 
risk factor for development of intracranial aneurysms [17]. Ren et al. proposed that 
homocysteine should be seen as an indicator of the risk of intracranial aneurysm 
and not a direct cause of intracranial aneurysm [17].
In the same study, an association between serum total homocysteine and folate 
and vitamin B12 in the patients with intracranial aneurysm was present [17]. The 
serum total homocysteine level was negatively correlated with folate and vitamin 
B12 levels in the study by Ren et al. [17] Folic acid and vitamin B12 are therefore 
found to be protective against formation of intracranial aneurysms [17]. This is 
due to the roles of vitamin B12 and folic acid in the regulation of the metabolism of 
homocysteine [17]. In a previous study, insufficient plasma level of one or more B 
vitamins may potentially result in high levels of serum homocysteine [16].
In the study conducted by Xu et al., homocysteine increases the development of 
intracranial aneurysms in rats, possibly by the different effects on the expression 
of molecules which are essential for vascular wall modeling [20]. The formation of 
intracranial aneurysms is associated with chronic inflammation [20].
Endothelial damage is one of the early changes in the walls of intracranial 
aneurysms resulting from inflammation [20]. An increase in serum homocysteine 
has been reported to damage the vascular endothelium [20]. This in turn leads to 
the development of atherosclerosis [20].
3. Polymorphism
Interestingly, polymorphism of the genes coding for the various components of 
the vessel walls has been proposed to be associated with the development of intra-
cranial aneurysms [5, 8].
Polymorphisms involving homocysteine metabolism can also promote formation 
of abdominal aortic aneurysms, dissection of the cervical arteries and atherosclero-
sis [5, 21, 22].
Moreover, the expression of matrix metalloproteinase-2 (MMP-2), endothelial 
nitric oxide synthase (eNOS), vascular endothelial growth factor (VEGF) and 
MMP-2 in the walls of intracranial aneurysm was increased by methionine treat-
ment in Xu et al.’s study [20].
Furthermore, autosomal recessive deficiency in cystathionine-synthase is 
involved in homocysteine metabolism [5, 23]. This deficiency in cystathionine-
synthase presents together with the development of intracranial aneurysms [5, 23].
In the study by Semmler et al., polymorphisms of homocysteine metabolism are 
possible risk factors for the formation of intracranial aneurysms [5]. The G-allele of 
RFC1c.80G→A and the insertion allele of DHFRc.594 + 59del19bp polymorphisms 
may result in intracranial aneurysm formation [5]. The G-allele of the missense 
polymorphism Tc2c.777C→G may protect from the development of intracranial 
aneurysm [5]. This G-allele of the Tc2c.777C→G polymorphism has been reported 
to affect the vitamin B12 binding affinity and the ability to transport vitamin B12 
into tissues [5, 24–26]. This causes a decrease in remethylation of homocysteine to 
methionine by vitamin B12-dependent MTR [5, 24–26].
4. Role of nitric oxide in homocysteine metabolism
Impairment of homocysteine metabolism may lead to an accumulation of 
asymmetric dimethylarginine [27, 28]. Asymmetric dimethylarginine.is a major 
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endogenous inhibitor of nitric oxide (NO) and is a good predictor of early car-
diovascular diseases and mortality [27–30]. In addition, the availability of NO is a 
major requirement for the development of intracranial aneurysms [5, 31].
In an animal study conducted in rodents, the development of intracranial aneu-
rysm was prevented by inhibition of nitric oxide synthase (NOS) [5, 31]. Inducible 
nitric oxide synthase (iNOS) is expressed in human and rat cerebral aneurysms [2]. 
In another animal study, the size of intracranial aneurysms is significantly smaller 
in the mice with iNOS compared to the mice without iNOS [2, 5].
Aminoguanidine is a relatively selective inhibitor of iNOS [2]. Aminoguanidine 
reduces the number of the aneurysms in rats [2]. In the study by Sadamasa et al., 
iNOS possibly has management potential in the prevention of the progression of 
cerebral aneurysms, though it is not necessary for the initiation of cerebral aneu-
rysm [2].
However, in another study, there was no association between homocysteine and 
intracranial aneurysms. Notably, this study was conducted comparing a case group 
(patients with intracranial aneurysms) with a control group consisting of patients 
with arteriovenous malformation (AVM) as well as no aneurysms [14].
5. Management
Raised serum homocysteine can be properly managed with dietary changes 
[17]. An increase in serum homocysteine can be treated by folic acid, vitamin B12 
and vitamin B6 supplements [13, 15]. Folic acid and vitamin B12 supplements can 
prevent the development and progression of intracranial aneurysm [17].
6. Conclusion
In conclusion, we believe that there is association between raised serum 
homocysteine and development or progression of intracranial aneurysms. In 
the future, more case-control research studies can be conducted to compare the 
patients with intracranial aneurysms and patients without intracranial aneu-
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Abstract
Calcium-phosphate levels have an effect on the vascular wall. Calcium is a cation 
in human body. It is has a crucial effect on intracellular and extracellular mecha-
nisms. Extracellular calcium levels are more than intracellular levels. In total serum, 
the calcium level is approximately 8.8–10.4. Parathormone and vitamin D regulate 
blood calcium levels. Phosphorus is more common than calcium in the human 
body. Most of the phosphorus is present in the skeletal system. Phosphorus level is 
approximately 2.5–4.5 mg/dl in blood. It is often observed calcification in cardiovas-
cular system in some diseases such as chronic renal failure due to increased calcium-
phosphate levels. While the calcification seems in tunica intima layer of the vessel 
in atherosclerotic disease, it seems in tunica media layer of vessel in chronic renal 
failure with high uremic level. Vascular calcification is due to arterial stiffness, ste-
nosis, and occlusion. Vascular and valvular calcifications are irreversible. Increased 
arterial stiffness destroys vascular compliance, causes left ventricular hypertrophy, 
and disrupts coronary perfusion. As a result, increased vascular calcification is 
associated with cardiovascular mortality.
Keywords: cardiovascular calcification, arterial stiffness, vascular compliance, 
hyperparathyroidism, hyperphosphatemia
1. Introduction
Cardiovascular pathologies are still one of the most serious diseases in the 
world and are also known to be an important reason of mortality and morbidity. 
Furthermore, they cause a significant burden on the health costs. The understand-
ing of pathophysiology of cardiovascular diseases has an important role for the 
treatment success. In this chapter, vascular calcification mechanism and its results 
will be discussed.
There are several reasons leading to vascular calcifications (Table 1). Vascular 
calcifications often occur in the advanced stage of the atherosclerosis [1]. In addi-
tion to this, these calcifications may also occur as a complication of metabolic 
disorders in the end stage of chronic renal failure. Calcium deposits accumulate in 
vascular tissues as a result of secondary hyperparathyroidism that occurs in chronic 
renal failure [2, 3]. Another cause of vascular calcifications is familial hypercho-
lesterolemia. Particularly severe aortic calcifications are seen in these patients [4]. 
Vascular calcifications associated with diabetes mellitus also affect the media and 
intima layer of vessels [5]. Hypertension is associated with calcifications in the 
abdominal aorta [6]. The other causes of vascular calcification include smoking 
[7], male gender [6], and older age [7]. Recently, it has been observed thanks to 
intravascular invasive images that the use of statins increases vascular calcifica-
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1. Introduction
Cardiovascular pathologies are still one of the most serious diseases in the 
world and are also known to be an important reason of mortality and morbidity. 
Furthermore, they cause a significant burden on the health costs. The understand-
ing of pathophysiology of cardiovascular diseases has an important role for the 
treatment success. In this chapter, vascular calcification mechanism and its results 
will be discussed.
There are several reasons leading to vascular calcifications (Table 1). Vascular 
calcifications often occur in the advanced stage of the atherosclerosis [1]. In addi-
tion to this, these calcifications may also occur as a complication of metabolic 
disorders in the end stage of chronic renal failure. Calcium deposits accumulate in 
vascular tissues as a result of secondary hyperparathyroidism that occurs in chronic 
renal failure [2, 3]. Another cause of vascular calcifications is familial hypercho-
lesterolemia. Particularly severe aortic calcifications are seen in these patients [4]. 
Vascular calcifications associated with diabetes mellitus also affect the media and 
intima layer of vessels [5]. Hypertension is associated with calcifications in the 
abdominal aorta [6]. The other causes of vascular calcification include smoking 
[7], male gender [6], and older age [7]. Recently, it has been observed thanks to 
intravascular invasive images that the use of statins increases vascular calcifica-
tion. Despite the antilipidemic and anti-inflammatory effects of it, statins cause an 
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increased calcification in vascular tissue with an unknown mechanism. This effect 
is defined as the statin paradox [8].
2. Pathophysiology
Vascular smooth muscle cells (VSMCs) play an important role in the pathology 
of vascular calcifications. Vascular smooth muscle cells are of mesenchymal origin. 
These cells may turn into osteoblasts and chondrocytes under stress. Osteoblast-like 
cells that contain hydroxyapatite crystals appear in the extracellular matrix during 
vascular smooth muscle calcification. Subsequently, the number of osteochon-
drogenic cells increases, and calcification inhibitors are suppressed; an increased 
regulation of bone mineralization regulating genes and the release of calcified 
membrane-dependent carriers from smooth muscle cells in these calcifications are 
observed. In addition, intracellular phosphate concentration increases in osteoblast-
like cells due to developing hyperphosphatemia in chronic renal failure. Apoptosis 
in smooth muscle cells, oxidative stress, remodeling in extracellular matrix, and 
high levels of metalloproteinases increase vascular calcification, resulting in endo-
thelial dysfunction [9].
Vascular smooth muscle cells are the predominant cell type in the arterial wall. 
VSMCs are mainly composed of the medial layer of the blood vessels, which are 
subjected to mechanical stress and pressure of blood flow, and maintain vascular 
tone and resistance [10]. Calcium functions as a stimulator, and under physiological 
conditions, intracellular calcium is present in VSCMs to regulate many biophysical 
and biochemical processes [11]. Although the agents responsible for production of 
vasospasm have not yet been clearly identified, recently the molecular mechanisms 
involved in the development of vasospasm mainly based on experimental data in 
canine two-hemorrhage model are reviewed. The blood products after subarach-
noid hemorrhage most likely stimulate many cell membrane receptors to activate 
the tyrosine kinase pathway of WSCMs. The activation of the tyrosine kinase 
pathway is associated with continuous elevation of intracellular Ca++ levels and 
activation of mu-calpain. The increased intracellular Ca++ concentration stimulates 
Ca++/calmodulin and depends on myosin light-chain kinase to phosphorylate 
myosin light-chain continuously during vasospasms [12]. Cerebral vasospasm is the 
most frequent and troublesome complication after aneurysmal subarachnoid hem-
orrhage. Cerebral vasospasm is considered a treatable clinicopathological entity; it 
is still responsible for many deaths and serious disabilities among patients suffering 
from intracranial aneurysm rupture [13].
Causes of vascular calcification
• Atherosclerosis













Vascular calcifications are divided into two subtypes (Figure 1). These are called 
intima and media calcifications according to the localization of calcification.
Intimal calcifications or the so-called atherosclerotic calcifications begin to 
occur in the presence of chronic inflammations and/or lipid accumulations. Lipid-
loaded calcifications in the intima cause intimal thickening and subsequent narrow-
ing of the lumen diameter.
Medial calcifications are characterized by concentric calcium deposits in the 
tunica media layer. Here, elastin lamellae occur between the smooth muscle cells 
and the elastin fibers. Medial calcifications cause loss of elasticity in the arteries, 
resulting in arterial stiffness [9].
4. Imaging methods
Various methods are used to visualize calcifications. Macrocalcifications can be 
seen in three ways:
1. Speckled: spotty calcification flecks, up to 50 μm diameters
2. Sheetlike fragments: linear or wide single focus of calcium, >2 mm in diameter
3. Diffuse: segments of continuous calcification, ≥5 mm in diameter
Imaging methods can be performed as noninvasive and invasive (Table 2).
4.1 Noninvasive methods
Computerized tomography (CT) is the gold standard for imaging calcifications. 
400 μm of calcification can be shown as 2D and 3D with the help of CT. However, 
the calcifications sometimes can be seen as more exaggerated than usual because 
of the absorption of high X-rays by neighboring tissues in CT imaging. This exag-
gerated image (artifact) may mask parts of calcification in the proximal region of 
the lesions. In this case, the artifact can be distinguished from the surrounding soft 
tissue with the help of magnetic resonance imaging (MRI). MRI is also superior 
to CT in differentiating multiple components including the coexistence of lipid 
accumulation, fibrotic tissue, and calcifications.
Microcalcifications can be detected by the use of positron emission tomography 
(PET) which is one of the other noninvasive methods. Early microcalcifications are 
shown using indirect gamma rays with the aid of 18F-sodium fluoride. With the use 
Figure 1. 
The classification of vascular calcification.
New Insight into Cerebrovascular Diseases - An Updated Comprehensive Review
46
increased calcification in vascular tissue with an unknown mechanism. This effect 
is defined as the statin paradox [8].
2. Pathophysiology
Vascular smooth muscle cells (VSMCs) play an important role in the pathology 
of vascular calcifications. Vascular smooth muscle cells are of mesenchymal origin. 
These cells may turn into osteoblasts and chondrocytes under stress. Osteoblast-like 
cells that contain hydroxyapatite crystals appear in the extracellular matrix during 
vascular smooth muscle calcification. Subsequently, the number of osteochon-
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observed. In addition, intracellular phosphate concentration increases in osteoblast-
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high levels of metalloproteinases increase vascular calcification, resulting in endo-
thelial dysfunction [9].
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activation of mu-calpain. The increased intracellular Ca++ concentration stimulates 
Ca++/calmodulin and depends on myosin light-chain kinase to phosphorylate 
myosin light-chain continuously during vasospasms [12]. Cerebral vasospasm is the 
most frequent and troublesome complication after aneurysmal subarachnoid hem-
orrhage. Cerebral vasospasm is considered a treatable clinicopathological entity; it 
is still responsible for many deaths and serious disabilities among patients suffering 
from intracranial aneurysm rupture [13].
Causes of vascular calcification
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Vascular calcifications are divided into two subtypes (Figure 1). These are called 
intima and media calcifications according to the localization of calcification.
Intimal calcifications or the so-called atherosclerotic calcifications begin to 
occur in the presence of chronic inflammations and/or lipid accumulations. Lipid-
loaded calcifications in the intima cause intimal thickening and subsequent narrow-
ing of the lumen diameter.
Medial calcifications are characterized by concentric calcium deposits in the 
tunica media layer. Here, elastin lamellae occur between the smooth muscle cells 
and the elastin fibers. Medial calcifications cause loss of elasticity in the arteries, 
resulting in arterial stiffness [9].
4. Imaging methods
Various methods are used to visualize calcifications. Macrocalcifications can be 
seen in three ways:
1. Speckled: spotty calcification flecks, up to 50 μm diameters
2. Sheetlike fragments: linear or wide single focus of calcium, >2 mm in diameter
3. Diffuse: segments of continuous calcification, ≥5 mm in diameter
Imaging methods can be performed as noninvasive and invasive (Table 2).
4.1 Noninvasive methods
Computerized tomography (CT) is the gold standard for imaging calcifications. 
400 μm of calcification can be shown as 2D and 3D with the help of CT. However, 
the calcifications sometimes can be seen as more exaggerated than usual because 
of the absorption of high X-rays by neighboring tissues in CT imaging. This exag-
gerated image (artifact) may mask parts of calcification in the proximal region of 
the lesions. In this case, the artifact can be distinguished from the surrounding soft 
tissue with the help of magnetic resonance imaging (MRI). MRI is also superior 
to CT in differentiating multiple components including the coexistence of lipid 
accumulation, fibrotic tissue, and calcifications.
Microcalcifications can be detected by the use of positron emission tomography 
(PET) which is one of the other noninvasive methods. Early microcalcifications are 
shown using indirect gamma rays with the aid of 18F-sodium fluoride. With the use 
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of MRI or CT combined with PET, we can obtain more detailed information about 
the effects of calcifications, interactions with fibrotic tissue, and plaque geometry.
4.2 Invasive methods
In recent years, intravascular ultrasound (IVUS) has been widely used in the 
detection of vascular calcifications, and its success is 50% higher than CT imag-
ing. However, in the vessels with severe calcifications, they may not be able to 
adequately measure volume and wall thickness due to acoustic shadowing and 
insufficient penetration into macrocalcific deposits.
Optical coherence tomography (OCT) is an alternative modality using infrared 
ray. The specificity and sensitivity of this method is higher than other methods. 
OCT also identifies superficial calcifications in the vessels. In addition, in the case 
of acute plaque rupture, OCT detects spot calcifications in the areas of plaque near 
the lumen and the thinning of the vessel wall [14].
5. Clinical properties
The calcifications may occur in all anatomic structures of the cardiovascular 
system. Pericardial calcifications occur secondary to inflammation. Calcification of 
this type is usually asymptomatic; however, the clinical findings are observed when 
it causes constrictive pericarditis [15].
Myocardial calcifications are metastatic or dystrophic calcifications. Metastatic 
calcifications develop after impaired calcium metabolism due to chronic renal fail-
ure or hyperparathyroidism. Dystrophic calcifications develop as a result of myo-
cardial fibrosis, infections, sarcoidosis, and hemorrhagic events in the myocardium. 
The cell necrosis occurs in this pathology, resulting in myocardial damage. This type 
of calcification leads to local myocardial contraction disorder, diastolic dysfunction, 
arrhythmia, and eventually congestive heart failure [16].
Epidemiological studies have found a strong association between calcification 
and coronary artery-related event and mortality using coronary artery calcification 
scores. Cardiovascular prognosis and mortality can be predicted with these scoring. 
Calcifications have an important role in thrombotic complications of atherosclerosis. 
Progression in coronary artery calcification shows active atherosclerosis and high 
rupture risk in unstable plaques. On the other hand, calcifications in the coronary artery 
cause some problems in the invasive treatments. During percutaneous transluminal 
coronary angioplasty (PTCA), a high dilatation pressure is required due to calcific 
coronary artery structure. Technical difficulties also arise when adjusting the position 
The imaging methods for vascular calcification
Noninvasive methods
• Computerized tomography (CT)
• Magnetic resonance imaging (MRI)
• Positron emission tomography (PET)
Invasive methods
• Intravascular ultrasound (IVUS)
• Optical coherence tomography (OCT)
Table 2. 




of the stent. As a result, coronary artery calcifications cause dissection, thrombosis, and 
restenosis during PTCA [17]. Another issue is that long-term prognosis of patients who 
underwent PTCA for moderate and severe coronary artery calcification is also poor [18].
Calcifications also affect heart valves. The annulus of the mitral valve is affected 
from this calcification, especially in female, elder patients and in case of chronic 
renal failure, radiotherapy applications. The pathophysiology of mitral annular 
calcification (MAC) is similar to that of atherosclerosis. Excessive MAC makes it 
difficult to perform balloon valvuloplasty and valve-sparing surgical procedures. 
On the other hand, in patients with MAC who underwent valve replacement, para-
valvular leakage, the circumflex coronary artery injury, arrhythmia, and patient 
artificial valve mismatch (because of the condition of small-size valve usage) may 
be observed [19]. During transcatheter mitral valve replacements, calcifications 
may lead to left ventricle outflow obstruction and paravalvular leakage [20].
Calcific aortic valve disease is the most common form of calcific valvular pathol-
ogy. When we look at the pathogenesis of this disease, the ectopic calcium nodules 
are located on the aortic surface of the aortic valve and in the aortic annulus. The 
incidence of calcific aortic valve increases with age. However, calcification of bicus-
pid valves may be seen at an early age. Risk factors are similar to other cardiovascu-
lar diseases. Calcifications can reduce the success of prosthetic aortic valve surgery 
[21]. In the late stages of valve replacement for calcific aortic valve stenosis, fistulas 
may develop between the left ventricle and the right atrium [22]. In transcatheter 
aortic valve implantations (TAVI), the degree of valve calcification is routinely 
evaluated by preoperative multi-slice CT. In this way, the information about the 
presence of asymmetric calcification is obtained before the procedure [23]. As a 
complication, cerebral emboli originating from calcific aortic valve stenosis may 
occur [24]. In addition, valve degeneration may occur secondary to calcification in 
patients undergoing valve replacement with bioprosthetic valve [25].
Excessive aortic valve calcification and metastatic calcifications due to chronic 
renal failure and hyperparathyroidism may affect the conduction system of the 
heart. Many arrhythmia types, from nodal rhythm to branch blocks, may be 
observed due to these calcifications [26–28].
Calcifications in the arcus and thoracic aorta cause aneurysm development, 
aortic occlusions, and distal embolization. These calcifications in the aortic wall 
also affect the success of endovascular stenting and surgical interventions [29]. It 
has been observed that the possibility of developing intermittent claudication is 
increased in the follow-up of patients with abdominal aortic calcification [30].
İntracranial artery calcification has been demonstrated to be correlated with isch-
emic stroke, cognitive decline, and other vascular events by accumulating evidence 
from both Western and Asian populations [31]. As atherosclerotic vasculopathy is a 
systemic process, vascular calcification may play a role in cerebrovascular events in 
both qualitative and quantitative calcium scoring with intracranial atherosclerosis 
and ischemic events [32]. On the other hand, some studies showed that ruptured 
intracranial aneurysms had a lower calcification fraction and lacked macrocalcifica-
tions than unruptured intracranial aneurysms [33]. Another study showed that 
arterial calcification correlated with white matter hyperintensities and lacunes [34].
Calcification is rarely seen in the venous system. Venous calcifications in the 
literature are mostly associated with the portal vein [35].
6. Treatment
Treatment of vascular calcifications is distributed over a wide range. Developing 
new medications and technical devices reconstruct our treatment modalities with 
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cardial fibrosis, infections, sarcoidosis, and hemorrhagic events in the myocardium. 
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and coronary artery-related event and mortality using coronary artery calcification 
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Calcifications also affect heart valves. The annulus of the mitral valve is affected 
from this calcification, especially in female, elder patients and in case of chronic 
renal failure, radiotherapy applications. The pathophysiology of mitral annular 
calcification (MAC) is similar to that of atherosclerosis. Excessive MAC makes it 
difficult to perform balloon valvuloplasty and valve-sparing surgical procedures. 
On the other hand, in patients with MAC who underwent valve replacement, para-
valvular leakage, the circumflex coronary artery injury, arrhythmia, and patient 
artificial valve mismatch (because of the condition of small-size valve usage) may 
be observed [19]. During transcatheter mitral valve replacements, calcifications 
may lead to left ventricle outflow obstruction and paravalvular leakage [20].
Calcific aortic valve disease is the most common form of calcific valvular pathol-
ogy. When we look at the pathogenesis of this disease, the ectopic calcium nodules 
are located on the aortic surface of the aortic valve and in the aortic annulus. The 
incidence of calcific aortic valve increases with age. However, calcification of bicus-
pid valves may be seen at an early age. Risk factors are similar to other cardiovascu-
lar diseases. Calcifications can reduce the success of prosthetic aortic valve surgery 
[21]. In the late stages of valve replacement for calcific aortic valve stenosis, fistulas 
may develop between the left ventricle and the right atrium [22]. In transcatheter 
aortic valve implantations (TAVI), the degree of valve calcification is routinely 
evaluated by preoperative multi-slice CT. In this way, the information about the 
presence of asymmetric calcification is obtained before the procedure [23]. As a 
complication, cerebral emboli originating from calcific aortic valve stenosis may 
occur [24]. In addition, valve degeneration may occur secondary to calcification in 
patients undergoing valve replacement with bioprosthetic valve [25].
Excessive aortic valve calcification and metastatic calcifications due to chronic 
renal failure and hyperparathyroidism may affect the conduction system of the 
heart. Many arrhythmia types, from nodal rhythm to branch blocks, may be 
observed due to these calcifications [26–28].
Calcifications in the arcus and thoracic aorta cause aneurysm development, 
aortic occlusions, and distal embolization. These calcifications in the aortic wall 
also affect the success of endovascular stenting and surgical interventions [29]. It 
has been observed that the possibility of developing intermittent claudication is 
increased in the follow-up of patients with abdominal aortic calcification [30].
İntracranial artery calcification has been demonstrated to be correlated with isch-
emic stroke, cognitive decline, and other vascular events by accumulating evidence 
from both Western and Asian populations [31]. As atherosclerotic vasculopathy is a 
systemic process, vascular calcification may play a role in cerebrovascular events in 
both qualitative and quantitative calcium scoring with intracranial atherosclerosis 
and ischemic events [32]. On the other hand, some studies showed that ruptured 
intracranial aneurysms had a lower calcification fraction and lacked macrocalcifica-
tions than unruptured intracranial aneurysms [33]. Another study showed that 
arterial calcification correlated with white matter hyperintensities and lacunes [34].
Calcification is rarely seen in the venous system. Venous calcifications in the 
literature are mostly associated with the portal vein [35].
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Treatment of vascular calcifications is distributed over a wide range. Developing 
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that disease. As is known, vascular calcifications are the major factor limiting 
endovascular treatment methods. One of the methods developed to overcome this 
problem is the peripheral intravascular lithotripsy (IVL) system. With this method, 
calcific lesions can be eliminated by applying pulsatile mechanical energy under 
fluoroscopy [36].
Obstructive disease of infra-inguinal arteries is treated with atherectomy 
methods. Various atherectomy devices have been developed for this method. Some 
of these are rotational, phoenix, directional, orbital, etc. The B-Laser atherectomy 
system is one of the new generation devices. This device is equipped with an 
optical fiber and circumferential designed blades for transmitting laser energy. 
Calcifications, fibrotic atherosclerotic plaques, and re-stenotic tissues are removed 
with the aspiration catheter added to the system [37].
There are several studies to improve medical treatment. Experimental animal 
studies have shown that angiotensin II receptor inhibitors prevent the vascular 
calcification due to hyperphosphatemia [38]. In another experimental animal study, 
the use of teniposide which inhibits DNA topoisomerase II in the treatment of 
cancer has been shown to prevent the development of vascular calcification [39]. 
Vitamin K II, added to the diet in chronic renal failure, acts on calcium hemostasis 
by preventing bone loss. Thus, it is shown that vitamin K II can prevent vascular 
calcification by adding it to the treatment regimen [40]. Another treatment modal-
ity is parathyroidectomy which is applied especially in vascular calcifications as a 
result of calcium and phosphate metabolism-related disorders [41].
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
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Abstract
Normal pressure hydrocephalus (NPH) is characterized by dilated ventricles 
and a combination of gait impairment, cognition impairment, and loss of urinary 
control (urgency and incontinence). The only effective treatment for NPH is a CSF 
shunt; however, only a small percentage of patients ever receive it. The features 
of gait impairment in patients with NPH are difficult to distinguish from patients 
of neurodegenerative disorders with motor involvement, such as parkinsonism or 
dementia with Lewy bodies. CT or MRI imaging is required for the diagnosis of 
idiopathic normal pressure hydrocephalus. An Evans ratio of more than 0.3 indicates 
large ventricles, and a ratio of more than 0.33 indicates very large ventricles, but is not 
specific for idiopathic normal pressure hydrocephalus. The international and Japanese 
guidelines support shunt surgery as effective treatment of idiopathic normal pressure 
hydrocephalus, as does the American Academy of Neurology practice guideline. There 
is a need to provide longitudinal care of patients with idiopathic normal pressure 
hydrocephalus after shunt surgery as all symptoms respond well to shunt surgery.
Keywords: normal pressure hydrocephalus, shunts surgery
1. Introduction
Normal-pressure hydrocephalus (NPH) is the earliest identified cause of demen-
tia which can be potentially treated [1, 2]. NPH was described by Hakim and Adams 
in 1965, and the entity was characterized by gait disturbances, impaired cognition, 
and urinary incontinence that is associated with ventricular enlargement without 
rise in cerebrospinal fluid (CSF) pressure [3, 4]. NPH may be primary or idiopathic 
NPH (without known precipitating factors) or secondary (due to trauma, hemor-
rhage, infection, mass lesions, or delayed aqueductal stenosis) [5–7].
2. Epidemiology
The exact incidence and prevalence of INPH is difficult to determine; however, 
the incidence of INPH is between 1.8 and 2.2 cases per 1,000,000 individuals [8, 9]. 
In a door to door survey from two German villages, the 0.41% prevalence of NPH 
was reported [10]. In patients with dementia, the reported incidence of NPH ranges 
between 1.6 and 5.4% [11, 12].
3. Pathophysiology
There are two main mechanisms involved in the pathogenesis of NPH [13, 14], that 
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in 1965, and the entity was characterized by gait disturbances, impaired cognition, 
and urinary incontinence that is associated with ventricular enlargement without 
rise in cerebrospinal fluid (CSF) pressure [3, 4]. NPH may be primary or idiopathic 
NPH (without known precipitating factors) or secondary (due to trauma, hemor-
rhage, infection, mass lesions, or delayed aqueductal stenosis) [5–7].
2. Epidemiology
The exact incidence and prevalence of INPH is difficult to determine; however, 
the incidence of INPH is between 1.8 and 2.2 cases per 1,000,000 individuals [8, 9]. 
In a door to door survey from two German villages, the 0.41% prevalence of NPH 
was reported [10]. In patients with dementia, the reported incidence of NPH ranges 
between 1.6 and 5.4% [11, 12].
3. Pathophysiology
There are two main mechanisms involved in the pathogenesis of NPH [13, 14], that 
is, increased venous resistance and altered production and absorption of CSF. Studies 
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have found that in patients with NPH, there is reduction in vascular compliance 
particularly involving superior sagittal sinus. Hakim and Adam’s hypothesized [4] 
that in NPH reduced CSF absorption leads to raised intracranial pressure and over 
a period leading to compensatory ventricular enlargement. This new intracranial 
pressure state directs more CSF flow toward the Virchow-Robin spaces and thus into 
the brain parenchyma [15]. These metabolic and mechanical changes further leads 
to periventricular damage and raised myelin basic protein (a possible biomarker) 
elevated in these patients [16]. This leads to tissue compression, white matter ischemia 
and parenchymal changes characterized by myelin pallor. These changes further lead 
to periventricular damage, reduced cellular metabolism, clearance of toxins, and their 
sequel [15, 17]. Studies have shown that following CSF diversion, there is normaliza-
tion in global brain stiffness and elasticity on magnetic resonance studies [18].
4. Clinical features
The classical clinical triad of INPH includes gait disturbance, dementia, and 
urinary incontinence [3–6, 8]. These symptoms are typically insidious in onset, and 
the patients are in their sixth and eighth decades. These changes occur in presence of 
ventriculomegaly without much evidence of cortical atrophy on brain imaging [2].
5. Gait disturbances
Gait disturbances are the most common initial symptom (present in 90% of the 
patients) and initially characterized by unsteadiness, frequent falls, slowness of 
gait, with difficulty initiating and turning, as the disease advances, these transform 
into magnetic, slow, broad based, and short steps (with preserved arm swing). 
These gait disturbances are not usually associated with increase in tone, exaggerated 
reflexes or weakness and usually there is absence of primary sensorimotor deficits, 
cerebellar dysfunction, or involuntary movements, involving difficulty integrating 
sensory information about the position of the body in relation to its environment. 
The impairment should be symmetric unless coexisting musculoskeletal disorders 
(e.g., knees, hips, and spine) cause asymmetry.
6. Dementia
INPH patients have subcortical frontal dysexecutive syndrome, manifesting as 
memory impairment, decreased attention, impaired planning, slowness of thought, 
and apathy. The cognitive findings of NPH reflect involvement of the prefrontal 
brain structures, similar to a subcortical dementia, with executive dysfunction (e.g., 
slow processing, and difficulty with problem solving) and memory deficits with 
poor retrieval and relatively intact recognition memory. Delirium is not typical in 
NPH and implies the presence of a concomitant disorder or medication side effect.
7. Urinary incontinence
The urological manifestations include frequency, urgency, and urge inconti-
nence. In a series of 41 patients with possible iNPH, 95% patients had urodynamic 
evidence of detrusor overactivity [12]. Bladder manifestations in NPH have been 




are usually aware of the urinary urge and are concerned about their incontinence. 
Incontinence without awareness of urinary urge or that one’s clothes are wet is not 
a feature of NPH. Patients or family should be asked about the use of incontinence 
pads or undergarments, as occasionally they do not consider the patient to be incon-
tinent if the urine is contained by the pads or undergarments. As bladder symptoms 
are common in elderly patients, other causes are frequently present in patients with 
suspected NPH.
8. Imaging
The differential diagnosis of NPH other non-treatable causes of dementias and 
degenerative disorders is extremely for proper selection of potential candidates for 
CSF diversion. No brain imaging studies are sufficient to diagnose INPH; however 
ventricular enlargement with appropriate symptoms is necessary to establish a 
diagnosis of NPH. Combination of imaging modalities and correlation with clinical 
findings shall help to make a diagnosis of NPH [2]. Evans’ index 0.3 or greater suggests 
significant ventriculomegaly (Figures 1 and 2) [19]. Other imaging features include:
Figure 1. 
CT brain of a patient with INPH showing ventriculomegaly without significant cortical atrophy (Evan’s  
index > 0.3).
Figure 2. 
CT brain of a patient with INPH showing increased bicaudate ratio > 0.25.
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• Bicaudate ratio > 0.25
• Enlargement of temporal horn
• Periventricular abnormal signals
• Flow void in aqueduct or fourth ventricle
9. Supportive radiological investigations include
• Radionuclide cisternogram may show delayed clearance.
• Cine MRI can show increased ventricular flow rate
• SPECT-acetazolamide will demonstrate decreased periventricular perfusion 
which is not reversed with acetazolamide
Distinguishing dilated ventricles due to cerebral atrophy from NPH is difficult 
[19–22]. Focal atrophy is often indicative of a degenerative dementia, particularly 
if it is asymmetric (e.g., frontotemporal dementia) or is stereotypical, such as 
hippocampal atrophy in Alzheimer dementia. In NPH, the Sylvain fissures are 
disproportionately widened in comparison to the cortical sulci, which are flattened 
(“high tight” convexity). The appearance of a pulsation artifact in the cerebral 
aqueduct, or measurements of CSF stroke volume or velocity in the aqueduct using 
phase – contrast methods cannot be used alone to recommend shunt surgery, but 
can support the diagnosis of NPH and the need for further testing.
10. Classification of INPH
Based on clinical and radiological features, INPH can be classified into probable, 
possible, and unlikely categories [19]. Probable criteria include age > 40, symptoms 
> 3 months, gait disorder, urinary incontinence or dementia, Evan’s index > 0.3, 
temporal horn enlargement, aqueductal/Fourth ventricle flow void, and callosal 
angle > 40 [19]. If there is papilloedema, or absence of triad or no ventriculomegaly, 
the diagnosis of NPH is unlikely [19].
11. Prognostic tests
The tests which are done to ascertain the benefit of surgical intervention in 
INPH include: lumbar puncture which has a sensitivity of 26%, and specificity of 
100%, extended lumbar drainage (sensitivity of 50–80% and specificity of 80%), 
measurement of CSF outflow resistance measurement (if >18 mm Hg/ml/min than 
46% sensitive and 87% specific) and cine phase-contrast MRI (has insufficient 
evidence).
12. Tap test
In this, 40-50 ml of CSF is removed, and pre- and post-tap with the Gait Scale 




number of steps required for the patient to walk 10 m. Similarly, pre- and post-tap 
cognitive function assessed Folstein Mini Mental State Exam and within 2–4 hours 
after the CSF tap post-tap assessments are conducted. A significant response to the 
tap test indicates responsiveness to shunt surgery [23]. However, lack of significant 
response does not exclude shunt responsiveness because the tap test is specific, 
rather than sensitive. External lumbar drainage can be considered if iNPH is still 
clinically suspected after a patient has failed to improve after the tap test.
13. External lumbar drainage
In this test, CSF is drained (10 to 15 cc per hour) for 72 hours and patient is 
assessed before and after the drainage (positive predictive value 90% and negative 
predictive value 78%). Positive ELD indicates good benefit with shunt. Negative 
ELD indicates low risk-benefit ratio. Neuropsychological testing before and after 
external lumbar drainage may also be helpful. Most publications have cited 72 hours 
of CSF drainage, although some centers drain CSF for shorter periods [19, 20]. This 
test has the risk of headache, lumbar radiculopathy, and risk of meningitis.
14. CSF infusion testing
Infusion testing for assessment of CSF hydrodynamics is commonly used in 
Europe to diagnose NPH, but is rarely used in the United States or Canada. In CSF 
infusion test, Ringer lactate is infused via one spinal needle and a second needle 
simultaneously records CSF pressure. One of the most consistent findings in NPH 
research is that patients have an increased resistance to outflow.
15. ICP monitoring
The recordings in NPH reveal wave-form abnormalities similar to those originally 
described for brain tumor or acute injury, (i.e., B waves and A waves). The presence 
of unstable ICP (predominantly B waves) in NPH is well known, and the correlation 
with NPH shunt responsiveness ranges from 50 to 90%. Recently, analysis of the 
amplitudes of the ICP pulse pressure has been pro-posed as a predictive test in NPH.
16. Practice guidelines
If the CSF pressure is high, the patient should be investigated for other causes 
of obstructive hydrocephalus. If there is improvement of the patient after a 40 to 
50-mL (high-volume) lumbar tap that the patient will likely respond well to shunt-
ing. An external ventricular drainage may be used in patients who fail to respond to 
a high-volume tap. Currently, there is no substantial evidence to support predictive-
ness to MRI CSF flow studies [19, 20].
17. Treatment
Treatment includes conservative measures and surgery for patients with 
favorable risk benefit ratio. Temporizing measures include acetazolamide and 
high volume tap. As per practice guidelines, surgery is considered for patients 
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after the CSF tap post-tap assessments are conducted. A significant response to the 
tap test indicates responsiveness to shunt surgery [23]. However, lack of significant 
response does not exclude shunt responsiveness because the tap test is specific, 
rather than sensitive. External lumbar drainage can be considered if iNPH is still 
clinically suspected after a patient has failed to improve after the tap test.
13. External lumbar drainage
In this test, CSF is drained (10 to 15 cc per hour) for 72 hours and patient is 
assessed before and after the drainage (positive predictive value 90% and negative 
predictive value 78%). Positive ELD indicates good benefit with shunt. Negative 
ELD indicates low risk-benefit ratio. Neuropsychological testing before and after 
external lumbar drainage may also be helpful. Most publications have cited 72 hours 
of CSF drainage, although some centers drain CSF for shorter periods [19, 20]. This 
test has the risk of headache, lumbar radiculopathy, and risk of meningitis.
14. CSF infusion testing
Infusion testing for assessment of CSF hydrodynamics is commonly used in 
Europe to diagnose NPH, but is rarely used in the United States or Canada. In CSF 
infusion test, Ringer lactate is infused via one spinal needle and a second needle 
simultaneously records CSF pressure. One of the most consistent findings in NPH 
research is that patients have an increased resistance to outflow.
15. ICP monitoring
The recordings in NPH reveal wave-form abnormalities similar to those originally 
described for brain tumor or acute injury, (i.e., B waves and A waves). The presence 
of unstable ICP (predominantly B waves) in NPH is well known, and the correlation 
with NPH shunt responsiveness ranges from 50 to 90%. Recently, analysis of the 
amplitudes of the ICP pulse pressure has been pro-posed as a predictive test in NPH.
16. Practice guidelines
If the CSF pressure is high, the patient should be investigated for other causes 
of obstructive hydrocephalus. If there is improvement of the patient after a 40 to 
50-mL (high-volume) lumbar tap that the patient will likely respond well to shunt-
ing. An external ventricular drainage may be used in patients who fail to respond to 
a high-volume tap. Currently, there is no substantial evidence to support predictive-
ness to MRI CSF flow studies [19, 20].
17. Treatment
Treatment includes conservative measures and surgery for patients with 
favorable risk benefit ratio. Temporizing measures include acetazolamide and 
high volume tap. As per practice guidelines, surgery is considered for patients 
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with favorable risk benefit ratio. Age alone is not an exclusionary criterion unless 
there are other surgical risk factors. Surgical options for the management of 
INPH include ventriculoperitoneal shunt and endoscopic third ventriculostomy. 
Literature favors low pressure programmable ventriculo peritoneal shunt as both 
over and under drainage can be managed in non-invasive manner. Endoscopic third 
ventriculostomy is indicated in patients with relative aqueduct stenosis and when 
there is triventricular hydrocephalus. Gangemi et al. reported 72% improvement 
with 4% complications rate [24].
18. Follow up after shunt surgery
Patients who have had shunt surgery should have periodic follow-up visits. 
The follow-up of patients with a shunt is similar to the follow-up of patients with 
parkinsonism or other chronic neurologic disorders. The interval history should 
cover all three NPH symptoms of gait impairment, incontinence, and dementia. 
The neurologic examination should include cognitive screening (e.g., MMSE), gait 
evaluation, and a general neurologic examination. Imaging may be done to rule out 
over-drainage, such as subdural effusion or hematoma, particularly in the first 6–12 
months after shunt surgery until it is determined that the patient’s condition and 
the appearance of the scan are stable. In most instances, a CT scan without contrast 
suffices. The setting of adjustable shunts should be confirmed during the follow-up 
visit, provided the neurologist has the device appropriate for the patient’s shunt. 
Depending on the degree of symptomatic recovery and presence or absence of low-
pressure signs and symptoms, the shunt setting can be raised or lowered in incre-
ments [25]. If there is suspicion regarding patency of the shunt radionucleotide, 
shunt patency test can determine the flow of radionuclide in the peritoneal cavity or 
the venous system (for ventriculoatrial shunts) [25].
19. Conclusion
NPH common, treatable disorder can be reliably diagnosed with an organized 
approach by most neurosurgeons and neurologists. Evidence supports the use of 
shunt surgery to treat patients with NPH, and when patients are properly selected, 
the benefit-to-risk ratio is favorable. Neurologists have a role in the longitudinal 
care of patients with NPH who have undergone shunt surgery, particularly in 
considering the differential diagnosis of any symptoms that may worsen after shunt 
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Abstract
Hydrocephalus is an abnormal accumulation of excess cerebrospinal fluid 
(CSF) in the brain causing increased intracranial pressure, which can arise from 
a variety of causes, including congenital, acquired, or idiopathic pathologies. 
Ventriculoperitoneal (VP) shunting is most commonly used to treat hydrocephalic 
patients, relieving the increased intracranial pressure by draining excess CSF from 
the ventricles to the peritoneal cavity. VP shunts are primarily completed using 
either an open or a more minimally invasive neuronavigated laparoscopic-assisted 
surgical technique. There is a high level of surgical complications, shunt failures 
and revision rates following VP shunting. It is suggested that different surgical 
techniques are associated with varying degrees of patient outcomes, surgical com-
plications, and revision rates, with the less invasive laparoscopic-assisted approach 
producing improved results. We present our results on 14 consecutive hydrocephalic 
patients, analyzed retrospectively between 2017 and 2019, investigating the ben-
efits offered by the neuronavigated laparoscopic-assisted insertion of VP shunts. 
Additionally, we explain our workflow and procedural technique. By investigating 
these differences, changes can be implemented in current routine procedures to 
ameliorate patient safety, surgical complications, and revision rates.
Keywords: hydrocephalus, ventriculoperitoneal shunt, laparoscopy, 
neuronavigation, complications, shunt failure, revision rates
1. Introduction
Hydrocephalus is a pathological accumulation of cerebrospinal fluid (CSF) in 
the ventricular system due to abnormal production, flow, or absorption of CSF [1]. 
The buildup of CSF increases the intracranial pressure (ICP), producing a variety of 
neurological defects concurrent with ventriculomegaly [2]. Arising from multiple 
congenital, acquired and idiopathic pathologies, hydrocephalus can ultimately lead 
to brain damage in the compressed tissues if left untreated [3, 4].
Hydrocephalus is primarily treated using a shunt system, draining the excess 
CSF from the cerebral ventricles into another region of the body where it can be 
absorbed. The peritoneal cavity remains the preferred drainage site in both pedi-
atric and adult populations, accessed using a ventriculoperitoneal (VP) shunt [5]. 
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the ventricular system due to abnormal production, flow, or absorption of CSF [1]. 
The buildup of CSF increases the intracranial pressure (ICP), producing a variety of 
neurological defects concurrent with ventriculomegaly [2]. Arising from multiple 
congenital, acquired and idiopathic pathologies, hydrocephalus can ultimately lead 
to brain damage in the compressed tissues if left untreated [3, 4].
Hydrocephalus is primarily treated using a shunt system, draining the excess 
CSF from the cerebral ventricles into another region of the body where it can be 
absorbed. The peritoneal cavity remains the preferred drainage site in both pedi-
atric and adult populations, accessed using a ventriculoperitoneal (VP) shunt [5]. 
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Other surgical treatment options include third ventriculostomies and alternative 
shunt types [6] such as ventriculoatrial (VA), ventriculopleural, ventriculocister-
nal, and lumboperitoneal [7].
2. Ventriculoperitoneal shunt
VP shunts are comprised of a proximal inflow catheter, reservoir, valve mecha-
nism, and a distal outflow catheter. The proximal catheter generally lies in the trigone 
of the lateral ventricle; however it can be inserted in the frontal horn if it follows an 
internalization of an external ventricular drain. The proximal catheter leads into the 
reservoir, which contains a small collection of CSF used for samples or to obtain pres-
sure measurements. A retro-auricular unidirectional valve follows the reservoir and is 
responsible for controlling the flow of CSF into the distal catheter. The distal catheter 
then travels subcutaneously from the valve into the right upper abdominal quadrant 
where the excess CSF can freely drain into the peritoneal cavity [4, 8].
Although a commonly relied upon procedure to treat hydrocephalus, VP shunts 
are not without complications and failures. VP shunts are subject to a variety of 
complications of mechanical, functional, and infectious nature [6]. Mechanical 
complications consist of complications inhibiting the shunt from functioning, 
including shunt migration, obstruction, malpositioning, disconnection, and 
fracture. Contrarily, functional complications involve improperly functioning 
shunts such as overdrainage or underdrainage [6]. Finally, shunts are subject to 
various infections, the majority arising from normal skin flora and occurring 
within 30 days of surgery [3]. Current studies suggest an overall infection rate of 
8.4% and a shunt failure rate, defined as a catheter-related problem necessitating 
surgical intervention [9], of 51.4% [10]. It has been shown that patients require 2–3 
surgical revisions on average due to shunt failures in the 20 years after the original 
shunt placement [8], with the majority of shunt revisions occurring in the first 
6–12 months [4, 8]. Specifically, 25–30% of all shunt revisions result from distal 
peritoneal catheter failure [5, 11, 12], such as preperitoneal placement, obstruction 
due to adhesions or pseudocysts, and malabsorption with secondary ascites [12].
3. Ventriculoperitoneal shunt: challenges
With time, the frequent revision rates and complications have provoked 
multiple changes and advancements in both VP shunt equipment, including the 
catheters and valve mechanisms [9, 13], as well as the surgical procedure itself 
[9]. Traditionally, VP shunts have been inserted using mini-laparotomy, although 
recently, a neuronavigated laparoscopically assisted approach has become a more 
commonly accepted surgical technique [9, 14]. Multiple studies have demonstrated 
that relative to the mini-laparotomy technique, a laparoscopically assisted approach 
has a shorter operative time and length of stay in the hospital, a decreased distal 
shunt failure rate [4, 9, 14], and a decreased risk of visceral injury [10]. Laparoscopy 
has also been shown to offer favorable outcomes with smaller incisions leading 
to reduced post-operative pain [11], faster mobilization and a preferred cosmetic 
appearance [5]. Many of the proposed benefits associated with laparoscopic-
assisted VP shunts are a direct result of the increased visualization offered by lapa-
roscopy. Laparoscopy allows for the verification of accurate peritoneal placement 
of the distal catheter as well as the proper functioning of the shunt by observing 
CSF outflow [5]. Laparoscopy can also be used to perform adhesiolysis, useful in the 
presence of excess adhesions, often found in patients who have undergone previous 
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abdominal surgeries [11]. As shunt obstruction can commonly result from the distal 
catheter becoming lodged in a collection of adhesions, adhesiolysis offers a poten-
tial solution to prevent this from occurring, reducing complications and future 
shunts failures. Additionally, the mini-laparotomy approach has been associated 
with increased risks of post-operative hernia formation and adhesion formation [4]. 
Neuronavigation has also been shown to increase the accuracy of ventricular place-
ment of the proximal catheter resulting in a decrease in proximal shunt revisions 
[15, 16]. However, as most neurosurgeons do not possess the necessary laparoscopy 
skill, collaboration with a general surgeon is required for the laparoscopic-assisted 
approach [4]. Incorporating a second surgeon may elicit difficulties in scheduling, 
requiring that both surgeons be available at given times [17].
Due to the high revision rates for VP shunts as well as the personal and medical 
burden of the complications and associated revisions, current practices must be 
assessed for alterations to improve these outcomes. Neuronavigated laparoscopic-
assisted VP shunt placement is being regarded as a minimally invasive alternative to 
an open technique to improve surgical complications and patient outcomes.
4. Surgical technique
The procedure is done under general anesthesia, in the supine position with the 
head turned 30–45° toward the left, as right trigone is favored for the insertion of 
the ventricular catheter. The left upper limb is in abduction with the shoulder at 90°, 
and the right upper limb is tucked against the body. First generation cephalosporin is 
administered 30–60 minutes before incision. The neuronavigation magnetic system 
(Axiem, on Stealth by Medtronic) is used with 3D reconstruction of preoperative 
brain CT scan. Entry point, trajectory and length of insertion are defined on the 
navigation system. A Foley catheter is not used, as the risk of bladder injury is lowered 
by laparoscopic approach, which in turn reduces the post-operative UTI risk. A 
retro-auricular shaving for horizontal 2 cm incision or question mark incision is done. 
Scrubbing with chlorhexedine 2% is done at the cranial level and over the neck, chest 
and abdomen. Draping from the scalp to the pubic level is done in sterile fashion.
4.1 Tunneling of the peritoneal catheter
Starting at the scalp, an incision is made, dissection of the galea until reaching 
the entry point. Dissection of the subcutaneous cranio-cervical tissue is done.
A 60–90 cm passer is used from the scalp to the right upper quadrant (RUQ ). 
The peritoneal catheter is tunneled through the passer and 5 mm incision is done 
at the RUQ. An anti-siphon programmable or pre-fixed pressure valve is con-
nected to the peritoneal catheter.
4.2 Placement of ventricular catheter
The ventricular catheter is inserted using the navigation stylet until reaching the 
body of the right lateral ventricle. CSF is drained and a sample for culture is routinely 
sent. Ventricular catheter is connected to the valve and CSF flow through the valve to 
the peritoneal catheter is observed before peritoneal insertion of the catheter.
4.3 Placement of abdominal catheter
Laparoscopic approach to the peritoneum is done by the general surgeon. A 
supra-umbilical, longitudinal incision is incised through skin with the scalpel blade. 
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Other surgical treatment options include third ventriculostomies and alternative 
shunt types [6] such as ventriculoatrial (VA), ventriculopleural, ventriculocister-
nal, and lumboperitoneal [7].
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reservoir, which contains a small collection of CSF used for samples or to obtain pres-
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where the excess CSF can freely drain into the peritoneal cavity [4, 8].
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has a shorter operative time and length of stay in the hospital, a decreased distal 
shunt failure rate [4, 9, 14], and a decreased risk of visceral injury [10]. Laparoscopy 
has also been shown to offer favorable outcomes with smaller incisions leading 
to reduced post-operative pain [11], faster mobilization and a preferred cosmetic 
appearance [5]. Many of the proposed benefits associated with laparoscopic-
assisted VP shunts are a direct result of the increased visualization offered by lapa-
roscopy. Laparoscopy allows for the verification of accurate peritoneal placement 
of the distal catheter as well as the proper functioning of the shunt by observing 
CSF outflow [5]. Laparoscopy can also be used to perform adhesiolysis, useful in the 
presence of excess adhesions, often found in patients who have undergone previous 
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abdominal surgeries [11]. As shunt obstruction can commonly result from the distal 
catheter becoming lodged in a collection of adhesions, adhesiolysis offers a poten-
tial solution to prevent this from occurring, reducing complications and future 
shunts failures. Additionally, the mini-laparotomy approach has been associated 
with increased risks of post-operative hernia formation and adhesion formation [4]. 
Neuronavigation has also been shown to increase the accuracy of ventricular place-
ment of the proximal catheter resulting in a decrease in proximal shunt revisions 
[15, 16]. However, as most neurosurgeons do not possess the necessary laparoscopy 
skill, collaboration with a general surgeon is required for the laparoscopic-assisted 
approach [4]. Incorporating a second surgeon may elicit difficulties in scheduling, 
requiring that both surgeons be available at given times [17].
Due to the high revision rates for VP shunts as well as the personal and medical 
burden of the complications and associated revisions, current practices must be 
assessed for alterations to improve these outcomes. Neuronavigated laparoscopic-
assisted VP shunt placement is being regarded as a minimally invasive alternative to 
an open technique to improve surgical complications and patient outcomes.
4. Surgical technique
The procedure is done under general anesthesia, in the supine position with the 
head turned 30–45° toward the left, as right trigone is favored for the insertion of 
the ventricular catheter. The left upper limb is in abduction with the shoulder at 90°, 
and the right upper limb is tucked against the body. First generation cephalosporin is 
administered 30–60 minutes before incision. The neuronavigation magnetic system 
(Axiem, on Stealth by Medtronic) is used with 3D reconstruction of preoperative 
brain CT scan. Entry point, trajectory and length of insertion are defined on the 
navigation system. A Foley catheter is not used, as the risk of bladder injury is lowered 
by laparoscopic approach, which in turn reduces the post-operative UTI risk. A 
retro-auricular shaving for horizontal 2 cm incision or question mark incision is done. 
Scrubbing with chlorhexedine 2% is done at the cranial level and over the neck, chest 
and abdomen. Draping from the scalp to the pubic level is done in sterile fashion.
4.1 Tunneling of the peritoneal catheter
Starting at the scalp, an incision is made, dissection of the galea until reaching 
the entry point. Dissection of the subcutaneous cranio-cervical tissue is done.
A 60–90 cm passer is used from the scalp to the right upper quadrant (RUQ ). 
The peritoneal catheter is tunneled through the passer and 5 mm incision is done 
at the RUQ. An anti-siphon programmable or pre-fixed pressure valve is con-
nected to the peritoneal catheter.
4.2 Placement of ventricular catheter
The ventricular catheter is inserted using the navigation stylet until reaching the 
body of the right lateral ventricle. CSF is drained and a sample for culture is routinely 
sent. Ventricular catheter is connected to the valve and CSF flow through the valve to 
the peritoneal catheter is observed before peritoneal insertion of the catheter.
4.3 Placement of abdominal catheter
Laparoscopic approach to the peritoneum is done by the general surgeon. A 
supra-umbilical, longitudinal incision is incised through skin with the scalpel blade. 
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The incision may be altered due to previous surgery and concern for adhesions. 
Generally, we will go through old incisions using the supra-umbilical technique, 
but an infra-umbilical or epigastric open technique can be used as well. The fascia 
is elevated between two Kocher instruments and divided with scalpel blade. The 
peritoneum is divided between two snap instruments with scalpel blade. A finger is 
inserted into the abdomen to ensure adhesions are clear of the undersurface of the 
abdominal wall. Previous surgery and/or adhesions are not a contra-indication to 
this technique. Adhesions may be taken down carefully from the undersurface of 
the abdominal wall to allow placement of the laparoscopic balloon port. A 5–10 mm 
laparoscopic balloon port is placed intra-abdominally and the abdomen insufflated.
We maintain medium flow (20–30 L/min) and pressures (15 mmHg) for all 
cases. A 5 mm, 30-degree camera is inserted into the abdomen and used to visualize 
the undersurface of the abdominal wall. Placement of the catheter was generally in 
the RUQ but was also placed in left upper quadrant (LUQ ) depending on adhesions 
from previous surgeries or due to the presence of previously placed shunts. At times 
we did navigate through heavy adhesions to guide the catheter placement but did 
not ever need to take down adhesions laparoscopically or add additional trocars for 
the catheter placement.
After the laparoscopic approach to the peritoneum is done, we approach the 
abdomen by a puncture using an introducer sheath and dilator (Arrow®). The 
catheter and CSF flow is observed in the peritoneal cavity. Once the shunt is placed 
the sheath is removed and skin closed with 4-0 subcuticular monocryl stitch.
After final satisfactory inspection of the abdomen is desufflated and the cam-
era and laparoscopic balloon port removed. Fascia is closed with a purse-string 
0-PDS suture. Skin is closed with a 4-0 subcuticular monocryl stitch. Incisions are 
infiltrated with 0.5% Marcaine with epinephrine. Steristrips and dry dressings are 
applied.
Following the completion of the laparoscopic portion of the procedure, the scalp 
closure is done in 2 layers and the entry point to the abdomen is closed in 1 layer.
Patient is awakened extubated and transferred to recovery room. Once fully 
awake, patient is transferred to the floor; diet is started at 6 hours post operatively 
in addition to increasing activity.
5. Methods
Fourteen consecutive hydrocephalic patients were treated with neuronavigated 
laparoscopically assisted VP shunts to explore the benefits offered by this surgical 
technique. Patient charts were collected retrospectively from February 2017 to 
March 2019. Collected charts were analyzed to obtain sex, age, BMI, indication for 
surgery, and whether the patient had a prior shunt placement or previous abdomi-
nal surgeries. Additionally, to assess the advantages of the neuronavigated laparo-
scopically assisted technique the variables collected were length of stay in hospital 
after surgery, operative time, intra- and post-operative complications, infection, 
and whether the shunt failed. No patients were excluded from this study. All surger-
ies were performed at the same institution by the same neurosurgeon and general 
surgeon. Clinical and radiological follow-up is done at 6-weeks post-operatively. 
The shunt series is used to evaluate the position of the shunt system and a brain CT 
is done to rule out over drainage (Figure 1).
The shunt series X-rays includes skull with an antero-posterior and lateral view, 
an antero-posterior chest x-ray and an antero-posterior abdominal x-ray.
The abdominal x-ray is repeated at 60 minutes to evaluate the peritoneal part of 
the shunt and its mobility (Figure 2).
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Figure 1. 
Pre (left) and post (right) operative brain Ct scan with ventricular catheter in the body of the right lateral 
ventricule.
Figure 2. 
Top Abdominal X-ray at day 1 (left) and at 3 months follow up (right) showing good peritoneal catheter 
mobility. Bottom Lateral skull X-ray (left) and Antero-posterior view (right) showing the ventricular catheter 
and programmable valve.
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Figure 1. 
Pre (left) and post (right) operative brain Ct scan with ventricular catheter in the body of the right lateral 
ventricule.
Figure 2. 
Top Abdominal X-ray at day 1 (left) and at 3 months follow up (right) showing good peritoneal catheter 
mobility. Bottom Lateral skull X-ray (left) and Antero-posterior view (right) showing the ventricular catheter 
and programmable valve.
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6. Results
There were 14 patients in total who received a ventriculoperitoneal shunt 
placement using a neuronavigated laparoscopic-assisted approach. The mean age 
of patients at the time of surgery was 56.8 years, although ranged from 31 to 78. 
There were 11 females and three males in the group. Eleven patients received a new 
VP shunt placement, whereas three patients were undergoing shunt revision. All 
patients except for one had undergone at least one previous abdominal surgery, 
with many of the patients having experienced multiple abdominal surgeries. Of 
note is the average BMI of the group being 31.2. Only one patient was within the 
normal range with a BMI of 24.6, one patient was classified as underweight at 14.6, 
four patients were considered overweight, and the remaining eight patients were 
obese with a BMI above 30.
Patients required a VP shunt for a variety of indications, with idiopathic normal 
pressure hydrocephalus (NPH) being the most common, occurring in half of the 
patients. Other indications included obstructive hydrocephalus secondary to a 
ventricular tumor, NPH secondary to subarachnoid hemorrhage (SAH), idiopathic 
intracranial hypertension, and a revision of the shunt for subependymal hemor-
rhage at birth. Average operative time for the VP shunt placements was approxi-
mately 45 minutes but ranged from 35 to 90 minutes. Patients on average stayed 
in the hospital for 2.25 days after the surgery, however, over 40% of patients were 
discharged after a single day in the hospital, 2/3 had left by 2 days, and all but one 
patient had left the hospital at 3 days. Two patients were not discharged from the 
hospital due to other medical conditions unrelated to the VP shunt placement and 
were therefore excluded from this calculation. There were no intraoperative com-
plications that occurred, however it is worth noting that there were many patients 
with extensive abdominal adhesions due to previous abdominal surgeries, as well as 
the extra difficulty presented by the increased rate of obesity in the patient group.
Three patients experienced post-operative complications. One patient’s shunt 
became infected with Staph epidermis, another patient experienced a functional 
complication of overdrainage with symptomatic bilateral subdural hematomas, 
requiring the removal of the shunt and drainage of the subdural hematomas. The 
remaining patient experienced mechanical dysfunction of the shunt. Each patient 
with a post-operative complication led to a shunt failure necessitating a shunt 
revision. The latter patient first underwent a proximal revision to replace both the 
ventricular catheter and the valve, due to valve malfunction. This same patient 
eventually experienced peritoneal complications requiring two distal shunt revi-
sions on separate occasions. Following the second peritoneal complication, the 
patient decided to obtain a VA shunt insertion, which continues to offer successful 
treatment.
7. Discussion
VP shunts are one of the most common neurosurgical procedures performed [3]. 
Despite its widespread use and successes in the treatment of hydrocephalus, there 
are often complications and failures. This has encouraged the ongoing develop-
ment of alternative procedural techniques producing better outcomes [5]. The cost 
associated with VP shunts produces a significant medical burden, which is only 
furthered by the numerous complications and shunts revisions following the initial 
surgery. Shunt revisions account for approximately 50% of all shunt-related costs 
and admissions [5, 12]. By decreasing the amount of shunt revisions and complica-
tions, both the medical and personal burden of VP shunts will greatly improve. The 
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neuronavigated laparoscopic-assisted VP shunt placement performed in this study 
offers a safe and effective technique, bringing numerous benefits not seen with the 
traditional mini-laparotomy method.
The length of stay in the hospital followed a similar trend to other studies with 
most patients being discharged in the first 24 hours [18]. The more minimally inva-
sive technique decreases the length of stay in the hospital as well as prompts a faster 
recovery rate [9, 14]. This allows for less resource use by individual patients and 
increased patient satisfaction by leaving the hospital soon after surgery and return-
ing to regular activities faster than with the mini-laparotomy technique [9, 11, 14].
Of the most noteworthy benefits of a laparoscopic-assisted neuronavigated 
technique is the decreased proximal and distal revision rates. The decreased revi-
sion rates are largely due to the avoidance of catheter malposition during placement. 
The accuracy of ventricular [16, 17] and peritoneal [4, 14, 17] catheter placement 
has increased as a result of clear visualization of the placement in the proper 
anatomical locations. Once properly positioned, the laparoscopic approach helps 
prevent migration of the distal catheter because of the fewer abdominal incisions 
and the smaller peritoneal wall defect [10]. The decreased revision rates can be seen 
in our patient population, as only a single patient required a distal revision for shunt 
malposition as a result of peritoneal adhesions, as well as a ventricular repositioning 
due to a valve dysfunction. Additionally, the increased visualization offered by this 
technique can be used to confirm CSF outflow through the VP shunt, indicating a 
properly functioning shunt, before finishing surgery.
This technique should also be heavily considered for obese individuals as well 
as those who have undergone previous abdominal surgeries [12], the two patient 
populations demonstrating the highest number of distal complications with 
VP shunt placements [5]. Both obesity and peritoneal adhesions resulting from 
abdominal surgeries pose difficulties with visualization during surgery, which leads 
to improper placement of shunts and increased complications and shunt failures. 
Further advantages come with adhesiolysis that can be performed during laparos-
copy, creating a clearer visualization for those with previous abdominal surgeries as 
well as preventing obstruction of the distal catheter by placing it within the perito-
neal adhesions [4, 9].
There have been concerns over the laparoscopic-assisted approach to VP shunts 
in that they require two surgical teams and specific instrumentation, increasing 
the cost of the surgery [5, 9] as well as the difficulty of scheduling, especially for 
emergent cases [17]. However, with the countless benefits being demonstrated 
by laparoscopy and neuronavigation, it should be considered that the mentioned 
concerns are outweighed.
Our study has limitations, specifically in the small sample size and the surgeries 
all being performed by the same surgeons. It is possible that results could differ 
based on the level of expertise of a surgeon. General surgeons performing laparos-
copy often will have more experience with adhesions and distorted anatomy as well 
as neurosurgeons using neuronavigation more often will gain more expertise. It has 
been suggested that neurosurgeons should be trained on laparoscopy in the future 
to both avoid the influence of the general surgeon’s expertise and to prevent poten-
tial scheduling conflicts when organizing two surgical teams [9].
Advancements are continuing to be made in VP shunts technology and proce-
dures. All advancements are aimed at continuing the improvement of patient out-
comes and lifting the imposed medical and personal burden of VP shunts. Recently, 
there have been some new advancements in techniques including a percutaneous 
minimal access insertion without the use of laparoscopy, as well as a single-port 
laparoscopic surgery that show further promise in optimizing patient care and 
routine practices [19, 20].
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8. Conclusion
Surgical management of hydrocephalus using neuronavigated laparoscopic-
assisted VP shunt placements is becoming a widely accepted alternative to the 
traditional mini-laparotomy approach. This technique offers a safe, effective, and 
minimally invasive approach for VP placements in hydrocephalic patients. It pro-
vides accurate insertion of both the ventricular and peritoneal catheter, resulting in 
decreased complications of mechanical, functional, and infectious origin, as well as 
revision rates. As much of VP shunt-related costs result from shunt revisions, any 
technical advancements made to reduce revision rates will help alleviate the medical 
and financial burden associated with this common neurosurgical procedure. This 
technique should also be considered in more difficult patient cases involving obesity 
and extensive peritoneal adhesions from previous abdominal surgeries. The benefits 
offered by the neuronavigated laparoscopic-assisted approach are numerous and 
seem to outweigh any concerns surrounding this technique. This particular surgical 
approach should be considered in adjusting current routine practices, resulting in 
optimal care for hydrocephalic patients and decreasing VP shunt-related medical costs.
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8. Conclusion
Surgical management of hydrocephalus using neuronavigated laparoscopic-
assisted VP shunt placements is becoming a widely accepted alternative to the 
traditional mini-laparotomy approach. This technique offers a safe, effective, and 
minimally invasive approach for VP placements in hydrocephalic patients. It pro-
vides accurate insertion of both the ventricular and peritoneal catheter, resulting in 
decreased complications of mechanical, functional, and infectious origin, as well as 
revision rates. As much of VP shunt-related costs result from shunt revisions, any 
technical advancements made to reduce revision rates will help alleviate the medical 
and financial burden associated with this common neurosurgical procedure. This 
technique should also be considered in more difficult patient cases involving obesity 
and extensive peritoneal adhesions from previous abdominal surgeries. The benefits 
offered by the neuronavigated laparoscopic-assisted approach are numerous and 
seem to outweigh any concerns surrounding this technique. This particular surgical 
approach should be considered in adjusting current routine practices, resulting in 
optimal care for hydrocephalic patients and decreasing VP shunt-related medical costs.
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Abstract
Intracranial atherosclerotic stroke differs from extracranial atherosclerotic 
stroke in many aspects, including risk factors and stroke patterns. It occurs in 
association with in situ thrombotic occlusion, artery-to-artery embolism, branch 
occlusion, and hemodynamic insufficiency. Intracranial atherosclerotic stenosis 
(ICAS) could have only been diagnosed by transcranial Doppler (TCD) and tran-
scranial color-coded sonography (TCCS), which are burdened by a risk of bias, or 
catheter angiography (DSA), which, on the contrary, is very precise, but rarely it is 
done in clinical practice due to its invasiveness. Computed tomography angiography 
(CT-A) and magnetic resonance imaging angiography (MR-A) have increased the 
identification of ICAS in a wider stroke population.
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1.  Epidemiology, natural history, and risk factors of intracranial 
atherosclerotic disease
1.1 The incidence of intracranial atherosclerotic disease (ICAD)
Intracranial atherosclerosis is one of the most important causes of stroke 
worldwide [1]. All major intracranial arteries are affected by atherosclerotic disease, 
and between 6 and 50% of all world ischemic strokes are the result of ICAD [2]. 
Intracranial arterial atherosclerotic stenosis (ICAS) represents the most advanced 
stage of ICAD, and thus nonstenotic ICAD is much more common than stenotic 
ICAD [3].
Regarding the incidence of ICAD, it varies especially by ethnicity. Population 
groups which are at high risk for ICAS include: Asians (30–50% of all new ischemic 
strokes) [4], Hispanics, and population of African descent; conversely, the risk is 
lower in Caucasians (8–10% of all new ischemic strokes) [5]. The reason for racial 
differences is still unclear. The main hypotheses include: low lipid levels and high 
blood pressure (susceptibility to intracranial and intracerebral vascular disease); 
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stage of ICAD, and thus nonstenotic ICAD is much more common than stenotic 
ICAD [3].
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differences is still unclear. The main hypotheses include: low lipid levels and high 
blood pressure (susceptibility to intracranial and intracerebral vascular disease); 
New Insight into Cerebrovascular Diseases - An Updated Comprehensive Review
80
high lipids and high blood pressure (susceptibility to extracranial occlusive 
vascular lesions); and diabetes mellitus and metabolic syndrome (for ICAS) [2, 6, 
7]. Other studies include inherited susceptibility of intracranial vessels to athero-
sclerosis [8], acquired differences in the prevalence of risk factors [5], differential 
responses to the same risk factors [9], and different genetic susceptibility [7]. It 
is also possible that misclassifying patients with adult-onset Moya-Moya disease 
(MMD) as having ICAD may partly explain the high prevalence of ICAD in Asians 
[10]. A genome-wide linkage analysis and an exome analysis identified the stron-
gest susceptibility gene for MMD in East Asian people: ring finger 213 (RNF213) 
[10]. An important role in the emergence of these ethnic differences can be repre-
sented by the lifestyle: the pattern of ischemic stroke is changing in Asian patients; 
due to the westernized lifestyle, the number of extracranial cervical disease is 
rising [11].
1.2 Prognosis of asymptomatic intracranial atherosclerotic disease (ICAD)
Regarding the prevalence of asymptomatic ICAD in general population, 
information is still limited, in the absence of large clinical trials [12]. The 
atherosclerotic process develops silently over years, until its lesions suddenly 
become symptomatic. Accordingly, early diagnosis of ICAD may improve 
the therapeutic strategy, while the disease is still asymptomatic. However, 
the natural history of asymptomatic ICAD is not fully known, especially in 
Caucasians [3].
The natural history of asymptomatic versus symptomatic ICAD differs from 
that of extracranial carotid disease (ECAD). Patients with symptomatic ICAD 
have a low risk of stroke in the stenotic arterial territory, compared to patients 
with asymptomatic ECAD, while patients with symptomatic ICAD have a higher 
risk, especially those with clinically significant hemodynamic stenosis, early 
after stroke [13]. Therefore, recent studies suggest that the annual risk of stroke 
in asymptomatic patients with at least 50% stenosis of a major intracranial artery 
is less than 10% [14]. Furthermore, patients with severe intracranial stenosis 
(70–99%) have a higher risk of stroke than do patients with moderate intracranial 
stenosis (50–69%) [14].
Arenillas designed a population-based study [3], which comes to clarify the 
natural history and the prevalence of asymptomatic ICAD in Caucasians. Study 
subjects (1503) were randomly selected from a population of 600 000 inhabit-
ants, from March 2007 until June 2010. The primary enrollment criteria were: age 
over 50 years, no past history of cerebrovascular or ischemic heart disease, and 
moderate-to-high vascular risk. Presence and severity of ICAS were determined 
through the medium of transcranial color-coded duplex (TCCS) and subsequent 
MR angiography (MRA) confirmation. Preliminary results showed a prevalence of 
asymptomatic ICAD of 9% in the first 157 studied subjects [3].
Several transcranial Doppler (TCD) studies in an asymptomatic Asian popula-
tion have also been conducted. They have come to the conclusion that the preva-
lence of asymptomatic ICAS ranged from 5.9 to 24.5% [15].
1.3 Risk factors for intracranial atherosclerotic disease (ICAD)
Oh Young Bang reported various conditions and risk factors for ICAD, from risk 
factors associated with asymptomatic ICAD to risk factors for stroke recurrence 
[16]. ICAD risk could not be fully related to conventional risk factors for stroke; 
therefore, specialists are still investigating specific risk factors for ICAD [3].
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2.  The mechanisms of ischemia in intracranial atherosclerotic disease 
(ICAD)
According to Arenillas [3], our traditional understanding of ICAD is based on 
the detection of hemodynamically relevant intracranial arterial stenosis (ICAS).
The main limitations of this classical approach are as follows:
1. It may be restricted to the most advanced stage of ICAD alone [3].
2. It is unable to differentiate atherosclerosis from stenosis caused by other enti-
ties. The etiological differential diagnosis of the arterial stenosis includes ath-
erosclerotic disease, embolus with partial recanalization, arterial dissection, 
vasculitis, and vasospasm. Thus, it is important to note that while anatomic 
diagnosis of arterial narrowing can be made with appropriate accuracy using 
conventional imaging techniques, identifying the cause of stenosis involves 
iterative or multimodal imaging [3].
3. It may not be able to provide information about the histopathologic composi-
tion and activity of the intracranial atherosclerotic plaque. The importance of 
this last point is based on the fact that symptomatic intracranial atherosclerotic 
plaques are characterized not only by a higher degree of luminal stenosis but 
also by a richer content in lipid, intraplaque hemorrhage, and inflammatory 
cell infiltration, all of which are well-known determinants of plaque instability 
in the extracranial vasculature [3, 17].
Stroke associated with ICAD occurs in association with four mechanisms:
a. In situ thrombotic occlusion (with impaired anterograde flow). Plaque rupture 
reveals its thrombogenic core to clotting factors resulting a thrombus that can 
locally occlude the artery or even embolize distally. The term of “vulnerable 
plaques” refers to those ones with a large lipid core, the presence of intraplaque 
hemorrhage, or a thin or ruptured fibrous cap; this kind of plaques are liable to 
suffer anytime a rupture. Patients with unstable intracranial plaques may show 
large territorial lesions via sudden thrombotic occlusion [16].
b. Artery-to-artery embolism. This mechanism commonly causes multiple 
cortico-subcortical infarcts [16].
c. Hemodynamic insufficiency/failure (with impaired collateral flow and cer-
ebrovascular reserve). Severe narrowing or occlusion of the lumen may lead to 
hypoperfusion of the distal brain territory, especially in patients with inad-
equate collateral flow. The hypoperfusion through a stenotic intracranial artery 
causes watershed or border-zone strokes [16].
d. Branch occlusion disease (BOD) is one of the main stroke mechanisms of 
ICAD. This mechanism, specific to ICAD, consists in growing of the plaque 
over the ostia of penetrating arteries. It is defined by a milder degree of stenosis 
and comma-shaped infarcts extending to the basal surface of the parent artery. 
BOD has been related to cryptogenic strokes [16, 18].
Thus, even mild stenosis of intracranial atherosclerotic arteries (<50%) may 
be clinically relevant, and high-resolution magnetic resonance imaging (HR-MRI) 
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MR angiography (MRA) confirmation. Preliminary results showed a prevalence of 
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tion have also been conducted. They have come to the conclusion that the preva-
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studies are needed to identify and determine the degree and location of stenosis in 
this patient group [19]. Oh Young Bang and others asserted that these mechanisms 
can coexist and interact in the same patient [16, 18, 20, 21].
2.1 Clinical recurrence rate
As we mentioned before, the annual recurrence rates for any ischemic stroke 
reported in the WASID trial were as high as 15 and 14% in the aspirin and warfarin 
arms, respectively [16].
It has been shown that symptomatic ICAD is particularly burdened with a high 
clinical recurrence rate [3]. Moreover, Famakin and coworkers reported that most 
subsequent strokes in patients with symptomatic ICAS occurred in the same arte-
rial territory were nonlacunar, and nearly half of them were disabling [19]. Their 
results were similar to the findings in NASCET, which showed that 95% of strokes 
were ipsilateral in patients with 70–99% carotid stenosis, and 71% of strokes were 
ipsilateral in patients with 50–69% carotid stenosis [22].
It is also important to mention that Famakin and coworkers observed that 
patients with ICAS have a propensity for atherosclerotic stenosis at different sites 
within the intracranial circulation [19]. Supporting this idea, they reported that 
among the 27% of the strokes occurring outside the territory of the symptomatic 
intracranial artery, almost half (48%) could have been caused by previously 
asymptomatic or newly developed ICAS in a different vascular territory. However, 
in the same study, it was suggested that it is also possible that some of these strokes 
may have been caused by an embolus which partially recanalized leaving a residual 
stenosis [19]. Supporting this theory is data from another WASID analysis, which 
showed that asymptomatic ICAS that was present at study entry (coexistent with 
the symptomatic stenosis) was associated with a low rate of stroke (3.5% after 1 
year of follow-up) [23].
Identifying whether ICAS is actually the cause of the present stroke (determin-
ing whether the stenosis is symptomatic or asymptomatic), it is however still a 
challenge, knowing that, according to Famakin, in up to 20% of the patients with 
stroke and IACS, there is another cause for its occurrence (extracranial large artery 
stenosis, cardiac embolism, and small artery occlusion can co-exist with ICAS) 
[19]. Nowadays, different noninvasive imaging techniques can provide physiologi-
cal data on the mechanisms associated with ICAD-linked stroke and their forms of 
coexistence, including markers of anterograde and collateral flow, dynamic cerebro-
vascular reserve, static tissue perfusion, characteristics and morphological details 
of plaques with embolic potential, etc. [16, 18, 24].
All these data may improve stroke risk stratification, adding to clinical and 
anatomic (i.e., percent stenosis) predictors of stroke risk, developing mechanism-
specific prevention and treatment strategies, and also serve in patients’ selection for 
endovascular therapies [16, 18, 24].
3.  Catheter-based digital substraction angiography (DSA)—diagnostic 
test for intracranial arterial stenosis (ICAS)
Catheter-based digital subtraction angiography (DSA) is the gold standard in 
the diagnosis of ICAS. ICAS is considered as symptomatic, if there are obvious 
radiological signs of acute ischemia in the supplying vascular area and if no other 
obvious cause (e.g., acute occlusion) is present.
Regarding the advantages of DSA, it allows [12]: the visualization of vessel 
contour—at a high resolution (microns); the localization of stenosis; and the 
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estimation of degree and length of stenosis (DSA measures stenosis precisely); 3D 
reconstruction provides even greater detail, highlighting of collateral circulation 
(measure anterograde and collateral flow). Prabhakaran and coworkers suggested 
that DSA can identify the mechanisms of stroke in symptomatic ICAS by using sur-
rogate imaging markers of stroke risk [12]: for the mechanism of decreased antegrade 
flow—the surrogate imaging marker of TICI (thrombolysis in cerebral infarction) 
flow grade; for the mechanism of progression of stenosis—the surrogate imaging 
marker of TICI (thrombolysis in cerebral infarction) flow grade; and for the mecha-
nism of poor collateral flow—the surrogate imaging marker of collateral flow grade. 
However, being an invasive method that can generate periprocedural complications 
(periprocedural neurologic injury, access site injury, radiation risks, contrast risks, 
low availability, and great costs), DSA cannot be used in everyday routine clinical 
practice, in all patients [25].
3.1  DSA allows an excellent visualization of intracranial arterial contour, at a 
high resolution (microns)
Monitoring the natural history of stenosis due to ICAD may be a useful method 
in finding new possible treatments. Long-term angiographic progress of ICAS has 
not received much attention before WASID trial; Bauer et al. [26] reported the 
progression of atherosclerotic stenoses by location, including extracranial and 
intracranial sites. Overall, 35.3% of intracranial sites progressed. Craig et al. [27] 
noted that intracranial ICA stenoses progressed in 5 of 5 patients on follow-up 
angiography. Akins and coworkers retrospectively reviewed records over a 7-year 
period to identify patients with ICAS and serial angiograms. The most common 
location for an ICAS of 50% or greater was the intracranial portion of the ICA (49% 
of lesions), followed by the MCA (20%), PCA (11%), distal VA and BA (11%), and 
ACA (9%) [28].
Angiography is an excellent method for monitoring intracranial atherosclero-
sis, but this method defines the vessel lumen only; the disease process leading to 
luminal narrowing being inferred [28]. If the patient has widespread atheroscle-
rosis, the stenosis is usually ascribed to this. The arterial narrowing is generally 
caused by local atherosclerosis, but associated thrombus may also contribute. 
Emboli also cause luminal narrowing. In this situation, the follow-up study may 
show the complete resolution of the stenosis due to spontaneous clot lysis. This 
pattern was encountered in 3 of the 45 sites studied by Akins. He noted that 
there are also other pathological conditions that can cause vessel narrowing, such 
as vasculitis, vasospasm, or malignancies. He concluded that ICAS is dynamic 
lesions [28].
3.2  DSA allows an excellent localization and evaluation of the degree and length 
of intracranial arterial stenosis (ICAS)
Angiographic measurement methods are routinely used nowadays in clinical 
practice to identify patients who may benefit from carotid endarterectomy [29]. 
Samuels affirmed that the established methods for measuring extracranial ICA 
stenosis are unsuitable for measuring the stenosis of a major intracranial artery 
because the intracranial arteries are often tortuous, have several branches, and are 
narrowing gradually in their distal portions [29].
If the prognosis of ICAS and the choice of therapy for these patients was clearly 
shown by WASID trial [2] to be based on the severity of ICAS, a repeatable method 
for measuring percent stenosis of the major intracranial arteries was required: 
standard WASID criteria for grading of ICAS [29].
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reconstruction provides even greater detail, highlighting of collateral circulation 
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flow—the surrogate imaging marker of TICI (thrombolysis in cerebral infarction) 
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marker of TICI (thrombolysis in cerebral infarction) flow grade; and for the mecha-
nism of poor collateral flow—the surrogate imaging marker of collateral flow grade. 
However, being an invasive method that can generate periprocedural complications 
(periprocedural neurologic injury, access site injury, radiation risks, contrast risks, 
low availability, and great costs), DSA cannot be used in everyday routine clinical 
practice, in all patients [25].
3.1  DSA allows an excellent visualization of intracranial arterial contour, at a 
high resolution (microns)
Monitoring the natural history of stenosis due to ICAD may be a useful method 
in finding new possible treatments. Long-term angiographic progress of ICAS has 
not received much attention before WASID trial; Bauer et al. [26] reported the 
progression of atherosclerotic stenoses by location, including extracranial and 
intracranial sites. Overall, 35.3% of intracranial sites progressed. Craig et al. [27] 
noted that intracranial ICA stenoses progressed in 5 of 5 patients on follow-up 
angiography. Akins and coworkers retrospectively reviewed records over a 7-year 
period to identify patients with ICAS and serial angiograms. The most common 
location for an ICAS of 50% or greater was the intracranial portion of the ICA (49% 
of lesions), followed by the MCA (20%), PCA (11%), distal VA and BA (11%), and 
ACA (9%) [28].
Angiography is an excellent method for monitoring intracranial atherosclero-
sis, but this method defines the vessel lumen only; the disease process leading to 
luminal narrowing being inferred [28]. If the patient has widespread atheroscle-
rosis, the stenosis is usually ascribed to this. The arterial narrowing is generally 
caused by local atherosclerosis, but associated thrombus may also contribute. 
Emboli also cause luminal narrowing. In this situation, the follow-up study may 
show the complete resolution of the stenosis due to spontaneous clot lysis. This 
pattern was encountered in 3 of the 45 sites studied by Akins. He noted that 
there are also other pathological conditions that can cause vessel narrowing, such 
as vasculitis, vasospasm, or malignancies. He concluded that ICAS is dynamic 
lesions [28].
3.2  DSA allows an excellent localization and evaluation of the degree and length 
of intracranial arterial stenosis (ICAS)
Angiographic measurement methods are routinely used nowadays in clinical 
practice to identify patients who may benefit from carotid endarterectomy [29]. 
Samuels affirmed that the established methods for measuring extracranial ICA 
stenosis are unsuitable for measuring the stenosis of a major intracranial artery 
because the intracranial arteries are often tortuous, have several branches, and are 
narrowing gradually in their distal portions [29].
If the prognosis of ICAS and the choice of therapy for these patients was clearly 
shown by WASID trial [2] to be based on the severity of ICAS, a repeatable method 
for measuring percent stenosis of the major intracranial arteries was required: 
standard WASID criteria for grading of ICAS [29].
New Insight into Cerebrovascular Diseases - An Updated Comprehensive Review
84
All patients enrolled in the WASID trial have been subjected to DSA, to confirm 
a symptomatic ICAS (50–99%) of the ICA, MCA, VA, or BA. All major intracranial 
vessels were screened for stenosis stratified into three categories of lumen reduction 
(30–50, 50–70, and >70%). The percentage of stenosis of an intracranial artery was 
defined by Samuels [29].
  WASID method [1 − (Dstenosis/Dnormal)] × 100 = % Stenosis . (1)
Rules applied for measuring a stenosis of the carotid siphon and basilar artery.
Dstenosis is the residual diameter of the artery at the site of the most severe steno-
sis, and Dnormal is the diameter of the proximal normal artery.
• If the proximal segment is diseased, contingency sites are chosen to measure D 
normal: distal artery (second choice) or feeding artery (third choice).
• If tandem intracranial lesions are present (e.g., distal vertebral and mid-
basilar), percent stenosis of both sites is measured and the more severe stenosis 
is selected.
When a “gap sign” is present (i.e., the lumen of the vessel cannot be visualized 
at the site of severe stenosis), D stenosis cannot be measured with calipers. In these 
cases, percent stenosis is defined as 99% luminal stenosis [29].
3.3 DSA is an excellent assessor of collateral intracranial arterial circulation
Cerebral collateral circulation is a supplementary vascular channels network 
that plays an important role in stabilizing the cerebral blood flow when the main 
arterial supplying systems fail (Liebeskind and coworkers) [30, 31]. Arterial insuf-
ficiency due to thromboembolism, hemodynamic compromise, or a combination of 
these factors may lead to the recruitment of collaterals [30, 31].
Impaired cerebral hemodynamics is a well-established predictor in large artery 
stroke [32]. Cerebral perfusion pressure distal to a high-grade stenosis or occlusion 
depends on collateral sources of blood flow. The anterior and posterior communi-
cating arteries (ACoA, PCoA) provide most collateral flow in ICA and BA stenosis 
(primary collaterals), while distal pial and leptomeningeal anastomoses (secondary 
collaterals) are important in MCA stenosis [32]. DSA is the most valuable inves-
tigation that provides the assessment of collateral cerebral flow; Liebeskind and 
coworkers reporting that collateral flow on DSA was found to be absent in 69% of 
patients with symptomatic ICAS and it was also considered an independent predic-
tor of recurrent ipsilateral stroke [30, 31].
Stroke risk, due to ICAD, increases with the arterial stenosis degree. Liebeskind 
and coworkers conducted a retrospective analysis of the baseline DSA acquired in 
the WASID trial, and they provided the first comprehensive evaluation of collater-
als in modifying stroke risk in patients diagnosed with ICAD and its impact on 
subsequent stroke characteristics. They observed that the collateral circulation was 
adequately available for analysis in 287/569 patients from WASID (50%) subjects 
with proximal arterial stenoses ranging from 50 to 99% [30, 31].
According to Liebeskind, collateral brain circulation is one of the most signifi-
cant factors that mediates the potentially devastating effects of cerebral ischemia. 
He asserted that patho-physiological recruitment of these collateral vessels (poten-
tial anastomotic connections) depends on the temporal course of numerous com-
pensatory (hemodynamic, metabolic, and neural) mechanisms and on the caliber 
and patency of primary pathways that may rapidly compensate for decreased 
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blood flow and the adequacy of secondary collateral routes [30, 31]. He asserted 
that collaterals maintain perfusion downstream from arterial occlusions in acute 
stroke, determining the hemodynamic characteristics of the ischemic penumbra, 
the evolution of infarct, and susceptibility for hemorrhagic transformation [30]. 
He suggested that focal neurologic symptoms manifest only when collaterals fail. 
Regarding the therapeutic point of view, robust collaterals are an effective predictor 
of arterial recanalization and good clinical outcomes in acute stroke [31]. It is also 
well known that arterial occlusion secondary to progressive atherosclerotic stenosis 
of an intracranial segment allows the development of robust collaterals over time, 
unlike the cardioembolic or abrupt thrombotic occlusion. Collaterals and functional 
demonstration of flow impairment may be more informative than isolated anatomic 
measures of maximal stenosis or length [30].
Liebeskind concluded that collateral circulation is a powerful determinant 
of stroke risk in ICAD, demonstrating a protective role with severe stenoses and 
perhaps distinguishing milder stenoses that are relatively unstable [30, 31].
4.  Transcranian Doppler (TCD) and transcranian color—coded 
sonography (TCCS)—diagnostic tests for intracranial arterial 
stenosis (ICAS)
Intracranial circulation can be examined by transcranial Doppler ultrasonog-
raphy (TCD) or transcranial color-coded duplex sonography (TCCS) through 
different bone windows (transtemporal, transforaminal, and transorbital). The 
signal can be enhanced by using ultrasound contrast agents [33–38]. TCD com-
bines in real-time intracranial blood flow patterns and velocities modifications 
with arterial diameter in the stenotic vessels. The most important data are: depth, 
blood flow direction, different velocities (peak systolic-PSV, end diastolic-EDV, 
and mean blood flow velocity-MFV), pulsatility index-PI, and resistance index-
RI. The physiological data assessed from TCD are complementary to the anatomi-
cal data analyzed from other neuroimaging techniques (DSA, CTA, and MRA) 
[33–38].
TCD has some advantages: inexpensive, noninvasive, portable test than can be 
performed bedside, serial examination, emboli detection, and vasomotor reactivity 
testing. TCD has high specificity, sensitivity, and negative predictive value (NPV) 
[33–38]. In the same time, TCD has some disadvantages: low reliability, technical 
limits (inadequate or absent windows, the tortuous course of the basilar artery, 
etc.), and operator-dependent results. TCD presents a modest positive predic-
tive value (PPV) (36–75%). Therefore, it is useful to exclude significant ICAS 
with high certainty but requires confirmation by other imaging methods when 
stenosis is suggested [33–41]. The circle of Willis is complete in only 20% of cases; 
in other cases, one or several vascular segments may be hypoplastic or aplastic. 
Visualization of the intracranial vessels and assessment of cerebral hemodynamics 
are only possible with TCCS, but this technique still requires further certification 
in larger studies [33–41].
Prabhakaran and coworkers suggested that TCD can specify the mechanisms 
of stroke in symptomatic ICAS by using surrogate imaging markers of stroke risk: 
for the mechanism of decreased antegrade flow—the surrogate imaging marker of 
flow velocity; for the progression of stenosis—the flow velocity; for the poor col-
lateral flow—the circle of Willis collaterals; for the artery-to-artery embolism—the 
microembolic signal; and for the impaired vasomotor reactivity—the cerebrovas-
cular reactivity [33–41]. Serial monitoring of flow velocities by TCD can detect the 
evolution of ICAS and therapeutic effects [22, 41].
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that collaterals maintain perfusion downstream from arterial occlusions in acute 
stroke, determining the hemodynamic characteristics of the ischemic penumbra, 
the evolution of infarct, and susceptibility for hemorrhagic transformation [30]. 
He suggested that focal neurologic symptoms manifest only when collaterals fail. 
Regarding the therapeutic point of view, robust collaterals are an effective predictor 
of arterial recanalization and good clinical outcomes in acute stroke [31]. It is also 
well known that arterial occlusion secondary to progressive atherosclerotic stenosis 
of an intracranial segment allows the development of robust collaterals over time, 
unlike the cardioembolic or abrupt thrombotic occlusion. Collaterals and functional 
demonstration of flow impairment may be more informative than isolated anatomic 
measures of maximal stenosis or length [30].
Liebeskind concluded that collateral circulation is a powerful determinant 
of stroke risk in ICAD, demonstrating a protective role with severe stenoses and 
perhaps distinguishing milder stenoses that are relatively unstable [30, 31].
4.  Transcranian Doppler (TCD) and transcranian color—coded 
sonography (TCCS)—diagnostic tests for intracranial arterial 
stenosis (ICAS)
Intracranial circulation can be examined by transcranial Doppler ultrasonog-
raphy (TCD) or transcranial color-coded duplex sonography (TCCS) through 
different bone windows (transtemporal, transforaminal, and transorbital). The 
signal can be enhanced by using ultrasound contrast agents [33–38]. TCD com-
bines in real-time intracranial blood flow patterns and velocities modifications 
with arterial diameter in the stenotic vessels. The most important data are: depth, 
blood flow direction, different velocities (peak systolic-PSV, end diastolic-EDV, 
and mean blood flow velocity-MFV), pulsatility index-PI, and resistance index-
RI. The physiological data assessed from TCD are complementary to the anatomi-
cal data analyzed from other neuroimaging techniques (DSA, CTA, and MRA) 
[33–38].
TCD has some advantages: inexpensive, noninvasive, portable test than can be 
performed bedside, serial examination, emboli detection, and vasomotor reactivity 
testing. TCD has high specificity, sensitivity, and negative predictive value (NPV) 
[33–38]. In the same time, TCD has some disadvantages: low reliability, technical 
limits (inadequate or absent windows, the tortuous course of the basilar artery, 
etc.), and operator-dependent results. TCD presents a modest positive predic-
tive value (PPV) (36–75%). Therefore, it is useful to exclude significant ICAS 
with high certainty but requires confirmation by other imaging methods when 
stenosis is suggested [33–41]. The circle of Willis is complete in only 20% of cases; 
in other cases, one or several vascular segments may be hypoplastic or aplastic. 
Visualization of the intracranial vessels and assessment of cerebral hemodynamics 
are only possible with TCCS, but this technique still requires further certification 
in larger studies [33–41].
Prabhakaran and coworkers suggested that TCD can specify the mechanisms 
of stroke in symptomatic ICAS by using surrogate imaging markers of stroke risk: 
for the mechanism of decreased antegrade flow—the surrogate imaging marker of 
flow velocity; for the progression of stenosis—the flow velocity; for the poor col-
lateral flow—the circle of Willis collaterals; for the artery-to-artery embolism—the 
microembolic signal; and for the impaired vasomotor reactivity—the cerebrovas-
cular reactivity [33–41]. Serial monitoring of flow velocities by TCD can detect the 
evolution of ICAS and therapeutic effects [22, 41].
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Transcranial ultrasound is used for multiple aims: TCD/TCCS can detect, 
localize, and grade the severity of ICAS; can detect and localize the intracranial 
arterial occlusion; can realize the real-time monitoring of recanalization in 
patients treated with systemic thrombolysis and of rescue reperfusion techniques 
(identification of reocclusion, hyper-perfusion syndrome, etc.); can detect 
clinically silent emboli: microembolic signals (MES), which recognizes patients 
at higher risk of embolic stroke; can recognize patients with extracranial internal 
carotid artery (ICA) stenosis at a higher stroke risk; can assess both collateral 
pathways and the vasomotor reactivity (VMR), which detects the risk stratifica-
tion of hemodynamic stroke [22, 33, 37, 41]; and can identify intracranial arterial 
blood flow steals.
4.1 TCD/TCCS can detect, localize, and grade the severity of ICAS
In clinical practice, interpretation of TCD data should be individualized, with 
various parameters (velocities values, spectrum, waveform patterns, flow pulsatil-
ity, collateral flows, status of extracranial arteries, systemic conditions: anemia, 
etc.) (Tables 1 and 2) [35]. TCD presents higher precision for identification of 
ICAS in the MCA and BA than in other intracranial arteries, due to the tortuosity in 
the latter [33].
ICAS criteria are direct and indirect.
Artery Stenosis >50% (MFV, 
SPR)
Stenosis >70% (MFV, 
SPR)
Diffuse disease or near occlusion 
(MFV, SPR)
MCA >100 cm/s, >2 >120 cm/s, >3 <30 cm/s, <1
ACA >80 cm/s, >2 n.a., >3 <30 cm/s, <1
PCA >80 cm/s, >2 n.a., >3 <30 cm/s, <1
BA >90 cm/s, >2 >110 cm/s, >3 <20 cm/s, <1
VA >90 cm/s, >2 >110 cm/s, >3 <20 cm/s, <1
MCA, middle cerebral artery; ACA, anterior cerebral artery; PCA, posterior cerebral artery; BA, basilar artery; VA, 
vertebral artery; MFV, mean flow velocity; n.a., not available; and SPR, stenotic/prestenotic MFV ratio.
Table 1. 
TCD criteria for intracranial stenosis (ICAS) [33].
Artery Mild stenosis Moderate stenosis Severe stenosis
Stenosis <50% (PSV) Stenosis >50% (PSV) Stenosis >80%
MCA >155 cm/s >220 cm/s +Indirect signs
ACA >120 cm/s >155 cm/s +Indirect signs
PCA >100 cm/s >145 cm/s +Indirect signs
BA >100 cm/s >140 cm/s +Indirect signs
VA >90 cm/s >120 cm/s +Indirect signs
MCA, middle cerebral artery; ACA, anterior cerebral artery; PCA, posterior cerebral artery; BA, basilar artery; VA, 
vertebral artery; and PSV, peak systolic velocity.
Table 2. 
TCCS criteria for intracranial stenosis (ICAS) [42].
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A. Direct criteria (modifications observed at the stenosis level) include:
a. A color aliasing phenomenon (only in TCCS exam), which may indicate 
augmented flow velocities, caused by a stenosis or other etiologies (tortuos-
ity, etc.) [35].
b. A progressive focal increase of blood flow velocities in ≥50% stenosis or 
paradoxical velocity decrease with very severe stenosis, near-occlusion or 
diffuse intracranial disease (Figures 1, 2).
Figure 2. 
TCDS transtemporal approach, axial, midbrain plane, color mode (left C1 stenosis).
Figure 1. 
TCDS, transtemporal approach, axial midbrain plane, color mode (left M1 higher grade stenosis).
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various parameters (velocities values, spectrum, waveform patterns, flow pulsatil-
ity, collateral flows, status of extracranial arteries, systemic conditions: anemia, 
etc.) (Tables 1 and 2) [35]. TCD presents higher precision for identification of 
ICAS in the MCA and BA than in other intracranial arteries, due to the tortuosity in 
the latter [33].
ICAS criteria are direct and indirect.
Artery Stenosis >50% (MFV, 
SPR)
Stenosis >70% (MFV, 
SPR)
Diffuse disease or near occlusion 
(MFV, SPR)
MCA >100 cm/s, >2 >120 cm/s, >3 <30 cm/s, <1
ACA >80 cm/s, >2 n.a., >3 <30 cm/s, <1
PCA >80 cm/s, >2 n.a., >3 <30 cm/s, <1
BA >90 cm/s, >2 >110 cm/s, >3 <20 cm/s, <1
VA >90 cm/s, >2 >110 cm/s, >3 <20 cm/s, <1
MCA, middle cerebral artery; ACA, anterior cerebral artery; PCA, posterior cerebral artery; BA, basilar artery; VA, 
vertebral artery; MFV, mean flow velocity; n.a., not available; and SPR, stenotic/prestenotic MFV ratio.
Table 1. 
TCD criteria for intracranial stenosis (ICAS) [33].
Artery Mild stenosis Moderate stenosis Severe stenosis
Stenosis <50% (PSV) Stenosis >50% (PSV) Stenosis >80%
MCA >155 cm/s >220 cm/s +Indirect signs
ACA >120 cm/s >155 cm/s +Indirect signs
PCA >100 cm/s >145 cm/s +Indirect signs
BA >100 cm/s >140 cm/s +Indirect signs
VA >90 cm/s >120 cm/s +Indirect signs
MCA, middle cerebral artery; ACA, anterior cerebral artery; PCA, posterior cerebral artery; BA, basilar artery; VA, 
vertebral artery; and PSV, peak systolic velocity.
Table 2. 
TCCS criteria for intracranial stenosis (ICAS) [42].
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A. Direct criteria (modifications observed at the stenosis level) include:
a. A color aliasing phenomenon (only in TCCS exam), which may indicate 
augmented flow velocities, caused by a stenosis or other etiologies (tortuos-
ity, etc.) [35].
b. A progressive focal increase of blood flow velocities in ≥50% stenosis or 
paradoxical velocity decrease with very severe stenosis, near-occlusion or 
diffuse intracranial disease (Figures 1, 2).
Figure 2. 
TCDS transtemporal approach, axial, midbrain plane, color mode (left C1 stenosis).
Figure 1. 
TCDS, transtemporal approach, axial midbrain plane, color mode (left M1 higher grade stenosis).
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Baracchini noted that, as a rule for a vessel with straight walls, a 50% diameter 
reduction double the velocity, and a 70% stenosis may triple the velocity at the end 
of the stenosis compared with a prestenotic segment or with the contralateral no 
affected side. The velocity values detected by TCCS are higher than those by TCD 
(due to angle correction) [35].
c. A significant (>30%) side-to-side difference of velocity (for symmetrical 
vessel segments after angle correction) [35].
B. Indirect criteria (changes observed in other arteries):
a. Only observed in very severe stenosis (>80%).
b. Are the same as for occlusion—proximal or distal flow alterations: a diastolic 
velocity drop; high RI in the feeding vessel or in the proximal segment of 
the stenotic vessel; a delayed systolic flow augmentation and velocity drop 
downstream; and flow diversion and signs of collateralization [35, 41–43].
TCD criteria for ICAS in anterior as well as posterior circulation have been 
validated against DSA, MRA, and CTA, and serve as reliable tools for their diagno-
sis (Table 1) [33].
The velocity criteria for ≥50% ICAS were detected by Feldmann and cowork-
ers in (SONIA) trial [39], which standardized the data of TCD, MRA, and 
DSA. The cut points were the measures of continuous variables such as the 
percentage of stenosis on MRA or velocity on TCD for each intracranial arterial 
vessel:
a. MRA ≥50% stenosis, without occlusion, or the presence of a flow gap defined a 
positive test. Stenosis ≥50% on TCD was identified using an MFV >100 cm/s in 
MCA, >90 cm/s in the intracranial ICA, or >80 cm/s in the BA or VAs [39].
b. For 80% stenosis on MRA, the SONIA TCD-MFV (cm/s) cut points for 
70–99% DSA stenosis of different arteries were: MCA 240, ICA 130, BA 130, 
and VA 130 [39].
SONIA trial established that both TCD and MRA could reliably exclude the 
presence of ICAS, rather than identifying them; abnormal findings on TCD or MRA 
requiring a confirmatory test such as DSA to diagnose ICAS [39].
The correlation between TCD and DSA for the identification of ≥50% ICAS at 
laboratories with (SONIA) TCD scanning protocol was established by Limin Zhao and 
coworkers [40]. Stenosis ≥50% on TCD was detected using an MFV >100 cm/s in the 
MCA, >90 cm/s in the intracranial ICA, or >80 cm/s in the VAs/BA. For ≥70% ICAS, 
they used expanded criteria (MFV-MCA >120 cm/s, MFV-VAs/BA >110 cm/s, stenotic/
prestenotic velocity/ratio-SPR ≥3, and low velocity). These criteria demonstrated 
excellent-to-good sensitivity of TCD and indicated good agreement with DSA [40].
Baumgartner and coworkers conducted a TCCS study that evaluated PSV cutoff 
values for the assessment of >50 and <50% stenosis of the intracranial arteries 
(Table 2) [42].
4.2 TCD/TCCS can detect and localize the intracranial arterial occlusion
Intracranial occlusion can be directly or indirectly detected by ultrasound 
examination.
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a. Direct criteria for intracranial arterial proximal occlusion are diagnosed using 
the thrombolysis in brain ischemia (TIBI) flow-grading system. They include: 
no flow signal (TIBI 0) and minimal flow signal (TIBI 1), while blunted flow 
signal (TIBI 2) and dampened flow signal (TIBI 3) are criteria for distal occlu-
sion (Figure 3). A missing flow signal could be occlusion or hypoplasia/aplasia 
(it is essential to use ultrasound contrast agents and to verify for indirect 
criteria of intracranial arterial occlusion) [35, 36, 43, 44].
b. Indirect criteria for intracranial arterial occlusion comprise proximal or distal 
flow alterations: a diastolic velocity drop; high RI in the feeding vessel or in the 
proximal segment of the stenotic vessel; a delayed systolic flow augmentation 
and velocity drop downstream; and flow diversion and signs of collateraliza-
tion (Figure 4) [33–38].
4.3  TCD/TCCS can realize the real-time monitoring of recanalization in acute 
ischemic stroke patients treated with systemic thrombolysis and of rescue 
reperfusion techniques (identification of reocclusion, hyperperfusion 
syndrome, etc.)
TCD/TCCS can detect the residual flow at thrombus-blood interface.
The TIBI flow grading system, TIBI: 0–5, was elaborated to identify residual 
flow and to monitor thrombus dissolution in real time [37, 43–45].
Absent flow (TIBI 0): no flow signals; or lack of regular pulsatile flow signals 
(using lowest pulse repetition frequency-PRF and increased color-gain settings).
Minimal (TIBI I): systolic spikes of variable velocity and duration; and absent 
diastolic flow during all cardiac cycles.
Blunted (TIBI II): flattened or delayed systolic flow acceleration compared 
with control side; positive end-diastolic velocity (EDV); and pulsatility index 
(PI) <1.2.
Dampened (TIBI III): normal systolic flow acceleration; positive EDV; and 
>30% decrease in mean flow volume (MFV) compared with control side.
Figure 3. 
Thrombolysis in brain ischemia (TIBI) flow-grading system.
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excellent-to-good sensitivity of TCD and indicated good agreement with DSA [40].
Baumgartner and coworkers conducted a TCCS study that evaluated PSV cutoff 
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the thrombolysis in brain ischemia (TIBI) flow-grading system. They include: 
no flow signal (TIBI 0) and minimal flow signal (TIBI 1), while blunted flow 
signal (TIBI 2) and dampened flow signal (TIBI 3) are criteria for distal occlu-
sion (Figure 3). A missing flow signal could be occlusion or hypoplasia/aplasia 
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Minimal (TIBI I): systolic spikes of variable velocity and duration; and absent 
diastolic flow during all cardiac cycles.
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with control side; positive end-diastolic velocity (EDV); and pulsatility index 
(PI) <1.2.
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>30% decrease in mean flow volume (MFV) compared with control side.
Figure 3. 
Thrombolysis in brain ischemia (TIBI) flow-grading system.
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Stenotic (TIBI IV): MFV >80 cm/s and velocity difference >30% compared with 
control side; if the velocity difference is <30%, look for additional signs of stenosis; 
and affected and comparison sides have MFV <80cm/s.
Normal (TIBI V): <30% MFV difference compared with control side; and 
similar wave form shapes compared with control side [37, 43–45].
TIBI flow grades I–III correspond to acute proximal intracranial artery occlu-
sion, while a TIBI flow grade of IV is an indicative of proximal artery hemodynami-
cally significant (>50%) stenosis.
The assessment of the diagnostic value of transcranial power motion-mode 
Doppler (PMD-TCD) against computed tomography angiography (CTA) in 
patients with acute ischemic stroke was evaluated by Tsivgoulis and coworkers. 
They asserted that PMD-TCD detected a substantial proportion of ICAS or occlu-
sions, in concordance with CTA in patients with acute ischemic stroke. PMD-TCD 
identified data supplementary to the CTA: collateralization of flow with extracra-
nial ICA stenosis/occlusion; real-time embolization-MES; and arterial blood flow 
steal [45].
The evaluation of the diagnostic value of PMD-TCD against DSA in the detec-
tion of acute posterior circulation steno-occlusive disease was realized by Tsivgoulis 
and coworkers. They showed that the higher value of PMD-TCD compared with 
single-gate TCD may be associated with its ability to observe flow on the PMD dis-
play along tortuous and long arterial segments that may not be readily identified by 
sonographers during a single-gate TCD exam. In conclusion, PMD-TCD can exclude 
vertebro-basilar artery occlusion and can select patients for DSA and endovascular 
interventions if the sonographers are confirmed by DSA [46].
An acute arterial occlusion differs from chronic as it is often partial and 
incomplete and exhibits dynamic processes (partial obstruction to flow, thrombus 
propagation, reocclusion, and sometimes spontaneous recanalization). TCD can 
rapidly identify patients with these lesions and detect not only the flow-limiting 
lesion but also the ongoing embolization, the collateralization, and the failure of the 
vasomotor reserve [37].
Figure 4. 
TCDS, transtemporal approach, axial midbrain plane, color mode (right proximal ICA occlusion, with right 
M1-MCA poststenotic flow pattern).
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4.4  TCD can identify clinically silent emboli: microembolic signals (MES), 
which recognizes patients at higher risk of embolic stroke
MES detection in different interventional procedures (cerebral and coronary 
angiography, angioplasty, carotid endarterectomy, etc.) and in patients with extra 
and intracranial large artery atherosclerotic stenosis is useful in risk stratification, 
thus enabling to select those patients who could benefit from a more aggressive 
treatment [33, 41, 47]. MES detection requires continuous monitoring (at least 1 
hour) of the major intracranial arteries. Most MES can be detected several days 
after the embolic event. The origin of emboli is important; the detection of an 
embolic signal in the distal MCA might represent an atherosclerotic plaque in the 
ipsilateral MCA or ICA. On the other hand, the identification of MES in multiple 
bilateral arteries indicates a cardiac origin [33, 41, 47].
4.5  TCD can recognize patients with extracranial ICA stenosis at a higher stroke 
risk, can assess both collateral pathways, and the vasomotor reactivity 
(VMR), which detects patients at higher risk of hemodynamic stroke
Severe extracranial ICA stenosis may produce embolic or hemodynamic hemi-
spheric infarct [48]. While the risk of an embolic ischemic stroke increases with the 
severity of ICA’s stenosis, the hemodynamic risk correlates less well with the degree 
of stenosis because of the functional capacity of the collateral pathways [48]. A 
complete circle of Willis and the possibility to activate primary collaterals (anterior 
communicating artery-ACoA, posterior communicating artery-PCoA) or second-
ary collaterals (ophthalmic artery-OA, lepto-meningeal arteries) reduce the risk 
of hemodynamic infarct ipsilateral to the extracranial ICA disease [33, 36, 38]. In 
patients with collateral flow signals (reversed OA, anterior cross-filling, and PCoA 
flow) identified by TCD, proximal ICA occlusion is confirmed by subsequent neck 
CTA, MRA, or DSA [33, 36, 38].
Vasomotor reactivity (VMR) defines the autoregulatory vasodilation of cerebral 
vessels in response to a vasodilatory challenge, such as hypercapnia or acetazolamide 
(apnea test, breath-holding test, and Diamox test). VMR represents a measure of 
dynamic cerebrovascular reserve capacity. Its study recognizes patients at higher 
risk of hemodynamic stroke, in both intra and extracranial large vessel disease, thus 
allowing to select those patients who could benefit from a more aggressive treatment 
[38, 48]. According to Prabhakaran, the presence of MES, poor collateral flow, and 
impaired VMR predict the high risk of recurrence in intracranial atherosclerosis [41].
TCD can identify intracranial arterial blood flow steals (reversed Robin Hood 
syndrome).
Intracranial arterial blood flow steals can be detected in chronic disease (e.g., 
subclavian artery stenoses, arterio-venous malformations, and fistulas) but also in 
patients with acute ischemic stroke. Flow diversion is the hallmark of a steal and 
can appear at any level of the intracranial arteries (large proximal vessels and small 
distal vessels) [33–35].
5.  Magnetic resonance angiography (MRA) and high-resolution 
magnetic resonance imaging (HR-MRI) for the diagnosis of 
intracranial atherosclerotic disease (ICAD)
ICAD includes two major features: (a) atherosis caused by lipid deposits in the 
intima of the arteries and inflammation; and (b) sclerosis, as a result of endothelial 
dysfunction, leading to arterial stiffness [49].
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Strokes associated with ICAD occur in association with four major stroke 
mechanisms: in situ thrombotic occlusion; branch occlusion; artery-to-artery 
embolism; and hemodynamic insufficiency [50, 51]. Unstable intracranial plaques 
can suddenly lead to thrombotic occlusion. Using transcranial duplex monitoring, 
artery-to-artery embolism can be discovered, which commonly causes multiple 
cortico-subcortical infarcts. Branch occlusive disease (BOD) is one of the main 
stroke mechanisms of ICAD, which can be characterized by a milder degree of 
stenosis [19] and comma-shaped infarcts extending to the basal surface of the par-
ent artery [52].
The first two mechanisms are the consequences of plaque rupture, which reveals 
the thrombogenic core to clotting factors, resulting a thrombus that occludes the 
artery locally or embolizes distally [50].
The third mechanism, specific to ICAD, is the growth of plaque over the ostia 
of penetrating arteries resulting in occlusion, which was described by Caplan [53] 
as branch atheromatous disease. Lastly, high-grade narrowing or occlusion of the 
lumen may lead to the fourth mechanism: hypoperfusion of the distal brain terri-
tory, particularly in cases with inadequate collateral flow [31, 50].
MRA, CTA, DSA, TCD, and TCCS can detect ICAS of different histopathologi-
cal nature (including partially recanalized emboli) and can assess ICAS progression 
and in-stent restenosis. Unfortunately, these methods are unable to directly exam 
plaque instability, with the exception of microembolic signals (MES) detection by 
TCD as a surrogate marker [3].
Arenillas suggested that for the detection of intracranial plaque morphology, the 
imaging techniques used include high-resolution MRI (HR-MRI), high magnetic 
field (3T) preferable, and intravascular ultrasound. This new concept allows the 
detection and characterization of nonstenotic intracranial atheroma, establishing 
its role in stroke of undetermined origin, and may have the power to confirm the 
atherosclerotic nature of ICAS [3].
5.1 Magnetic resonance angiography (MRA)
Degnana noted that 3D time-of-flight (TOF)-MRA is a imaging technique 
that noninvasively explores the intracranial arteries. It takes the advantage of the 
contrast between nonsaturated spins in the blood entering the imaging plane and 
the stationary adjacent tissue, which remains saturated. 3D TOF-MRA allows the 
visualization of any variation in blood flow. It provides detailed information about 
the lumen status of the intracranial vessels (Figure 5) [54].
The following arterial segments are assessed: bilateral intracranial ICA, ACA-A1/
A2, MCA-M1/M2, PCA-P1/P2, BA, and VA. According to the severity of stenosis, 
there are four groups in which patients are classified: <50% or no stenosis, 50–69% 
stenosis, 70–99% stenosis, and occlusion groups. Focal flow void found on MRA 
with distal filling is considered as severe stenosis (70–99%) [55].
Other MR sequences, such as T2-/T1-weighted imaging, fluid-attenuated 
inversion recovery sequences, and diffusion-weighted imaging (DWI), are also 
performed on a conventional MRI on a 3.0 or 1.5T MR scanner [56].
Degnana asserted that MRA offers good equivalency with DSA for the detection 
of >50% stenosis with the reported sensitivity, specificity, and accuracy of 92, 91, 
and 91%, respectively [54].
Higher field strength scanners may carry additional benefits in improving signal 
intensity-to-noise ratio and background suppression; other sequences, such as novel 
sensitivity encoding (SENSE) TOF-MRA protocols, also have substantially abbrevi-
ated acquisition times [57].
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MRA has some advantages: noninvasive, no radiation, low cost, and widely 
available, but for the detection of ICAS requires confirmation by another imaging 
modality [51, 54]. The main disadvantage is that it overestimates stenosis. MRA can 
render ambiguous or erroneous results. The inability to distinguish between high-
grade stenosis and occlusion is another major disadvantage [58].
In addition, MRA has magnet contraindications: limited to no use in morbidly 
obese and claustrophobic patients and those with implanted metallic objects [51]. 
Although CTA performs better overall compared with MRA for the purpose of 
determining the degree of stenosis (CTA can better visualize high-grade stenoses 
than MRA since the latter tends to overestimate the degree of stenosis), MRA is bet-
ter than CTA at evaluating the petrous and cavernous ICA as bony artifacts affect 
CTA [51, 54].
Degnana noted that MRA can be superior in the evaluation of MCA stenosis 
compared with DSA but still only provides information about vessel patency alone. 
MRA can be an effective screening technique for patients with suspected MCA 
syndromes to detect stenosis within the intracranial vessels and to indicate the need 
for HR-MRI to accurately image the stenotic region [54, 59].
5.2 Contrast-enhanced (CE) MRA
It provides better anatomic visualization, particularly in the regions of changing 
blood flow directions; however, the visualization of smaller arteries remains limited 
[54, 60].
5.3 Quantitative MRA (QMRA)
Prabhakaran noted that QMRA, utilizing phase-contrast techniques, quantifies 
anterograde blood flow at distal site of stenosis; it exploits the phase shift in the 
signal of flowing blood, which is proportional to flow velocity, to quantify flow rate 
in medium and large vessels [51].
5.4 High-resolution MRI (HR-MRI)
The conventional imaging such as DSA, MRA, CTA, and TCD fall short in char-
acterizing the presence of no occlusive atherosclerotic disease, because it focuses on 
the vessel lumen estimate luminal stenosis by measuring blood flow velocity [2, 54].
Figure 5. 
Comprehensive imaging of a patient with recent stroke depicting left MCA stenosis. A−C, DSA (A) confirms 
stenosis, but contrast – enhanced MRA (B) and volume-reduced TOF MRA (C) overestimate the degree of 
stenosis in this particular case [54].
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Strokes associated with ICAD occur in association with four major stroke 
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MRA has some advantages: noninvasive, no radiation, low cost, and widely 
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determining the degree of stenosis (CTA can better visualize high-grade stenoses 
than MRA since the latter tends to overestimate the degree of stenosis), MRA is bet-
ter than CTA at evaluating the petrous and cavernous ICA as bony artifacts affect 
CTA [51, 54].
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anterograde blood flow at distal site of stenosis; it exploits the phase shift in the 
signal of flowing blood, which is proportional to flow velocity, to quantify flow rate 
in medium and large vessels [51].
5.4 High-resolution MRI (HR-MRI)
The conventional imaging such as DSA, MRA, CTA, and TCD fall short in char-
acterizing the presence of no occlusive atherosclerotic disease, because it focuses on 
the vessel lumen estimate luminal stenosis by measuring blood flow velocity [2, 54].
Figure 5. 
Comprehensive imaging of a patient with recent stroke depicting left MCA stenosis. A−C, DSA (A) confirms 
stenosis, but contrast – enhanced MRA (B) and volume-reduced TOF MRA (C) overestimate the degree of 
stenosis in this particular case [54].
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HR-MRI can be used to assess intracranial arterial disease, both atherosclerotic 
and nonatherosclerotic [50].
According to Bodle, HR-MRI represents MR acquisitions using clinically avail-
able 1.5–3.0 Tesla magnetic field strength targeted to intracranial arterial pathology 
that are of sufficient quality to visualize the arterial wall, separate from the lumen 
of the proximal circle of Willis vessels. HR-MRI can be accomplished at 1.5 T by lim-
iting the field of view to focus on a single vessel or point of interest, but higher field 
strength at 3 T has many advantages over conventional MRI (1.5 T). Image quality 
in MRI depends on several factors (e.g., slice thickness, field of view, signal-to-noise 
ratio, matrix size, and magnetic field strength) [50, 61]. Image acquisition is faster 
and there are increased signal-to-noise and contrast-to-noise ratios, with better 
image quality for black-blood imaging. The increased signal and contrast that 3 T 
provides improves the detection of complex atherosclerotic plaque and can identify 
plaque components in larger arteries [50, 62].
HR-MRI allows the direct assessment of intracranial atherosclerotic plaques; it is 
capable of characterizing plaque location, severity, and morphology, and discrimi-
nating from other nonatherosclerotic etiologies [3, 50, 51].
Bodle also suggested that an intracranial plaque with HR-MRI features of 
intraplaque hemorrhage and a ruptured fibrous cap in a patient with downstream 
ischemia is likely associated with artery-to-artery embolism, whereas a stable 
plaque with a large amount of fibrous tissue and small lipid core resulting in 
high-grade stenosis may cause hypoperfusion [50]. Thus, HR-MRI may directly 
determine stroke mechanism and play a role in selecting secondary prevention 
therapies (e.g., patients with hypoperfusion may benefit from intracranial revas-
cularization procedures that patients with artery-to-artery embolism may not 
benefit) [50].
The simplest use of HR-MRI of the MCA is the calculation of the degree of MCA 
stenosis, which may be stated as:
  %Stenosis =  (1 − Lumen area / Reference lumen area) × 100, (2)
where the reference lumen area is the area of the nonoccluded lumen, preferably 
at a proximal segment [2].
Bodle mentioned that ICAS can be caused by diverse pathologies (e.g., athero-
sclerosis, inflammation, and vasospasm), with diverse treatment implications. 
HR-MRI may noninvasively differentiate between the etiologies of ICAS by identi-
fying plaque components or unique enhancement patterns [50].
Patients with symptomatic (versus asymptomatic) and non-BOD type (versus 
BOD) ICAD had characteristic changes in: (a) the wall area (larger plaques); (b) 
plaque signals (eco-centric enhancement and heterogeneous signal intensity sug-
gesting unstable plaque); and (c) remodeling patterns (positive remodeling sug-
gesting outward expansion of the vessel wall) [63].
On the contrary, superiorly located MCA plaques (near to the orifices of pen-
etrating arteries) are associated with BOD-type ICAD [64].
Bodle asserted that, in other vascular beds, the determination of atherosclerotic 
plaque constituents has helped in risk-stratify patients and select treatments. Using 
clinical, imaging, and pathological correlations, studies of coronary and carotid 
artery disease have detected characteristics that indicate plaque vulnerability: lipid 
core size, intraplaque hemorrhage, and fibrous cap thickness. These vulnerable 
plaque characteristics are also present in ICAD [50, 65] but are less well studied 
(Table 3). Bodle also noted that intraplaque hemorrhage (IPH) from rupture of 
plaque microvessels causing the accumulation of erythrocyte membranes, deposi-
tion of cholesterol, macrophage infiltration and enlargement of the necrotic core 
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results in atheroma growth, and plaque destabilization. A large amount of lipid 
within the necrotic core of a plaque is another sign of plaque vulnerability HR-MRI 
measurement of lipid-necrotic core area in extracranial ICA plaques correlates well 
with pathology [50].
HR-MRI can identify fibrous cap characteristics (thin, thick, or ruptured) in 
extracranial ICAs. The fibrous cap is a layer of connective tissue covering the lipid-
necrotic core. Thick fibrous caps are less prone to rupture [50].
HR-MRI is noninvasive, but less available, still with limited clinical value, 
requiring extensive postprocessing. Bodle asserted that imaging characteristics in 
ICAD have not yet been correlated with pathological specimens because, while the 
HR-MRI of the extracranial ICAs can be correlated with endarterectomy speci-
mens, intracranial vessels are not accessible to pathology sampling in live patients. 
Therefore, the signal characteristics of intracranial plaque components can only be 
extrapolated from extracranial ICAs HR-MRI [50].
Another disadvantage is the small size (2.0–5.0 mm) and the depth of the 
intracranial vessels, which require relatively long acquisition times, making 
HR-MRI imaging difficult because of patient motion artifact and limitations in 
resolution.
According to Bodle, HR-MRI can help to identify stroke mechanisms, determine 
the degree and etiology of stenoses, identify nonstenotic plaques, and identify 
potentially high-risk plaque components. These plaque characteristics are not 
visualized with conventional luminal imaging and may be important predictors of 
stroke [50].
6.  Multidetector computed tomography and multidetector computed 
tomography angiography for the diagnosis of intracranial 
atherosclerotic disease (ICAS)
6.1 Nonenhanced multidetector computed tomography (MDCT)
The study of the prevalence, and of the risk factors for intracranial internal 
carotid artery calcification (ICAC), as a marker of intracranial atherosclero-
sis was determined by Bos and coworkers. They assessed a white population 
(2495 persons) from the population-based Rotterdam Study with a no enhanced 
multidetector (16-slice or 64-slice) computed tomography (MDCT) of the 
intracranial ICAs. A calcified plaque had >130 Hounsfield units. They con-






















Calcification Hypointense Hypointense Hypointense Hypointense
Table 3. 
Plaque characteristics on multiple contrast weightings based on carotid imaging literature [50, 65]
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ischemia is likely associated with artery-to-artery embolism, whereas a stable 
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cularization procedures that patients with artery-to-artery embolism may not 
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stenosis, which may be stated as:
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Bodle mentioned that ICAS can be caused by diverse pathologies (e.g., athero-
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HR-MRI may noninvasively differentiate between the etiologies of ICAS by identi-
fying plaque components or unique enhancement patterns [50].
Patients with symptomatic (versus asymptomatic) and non-BOD type (versus 
BOD) ICAD had characteristic changes in: (a) the wall area (larger plaques); (b) 
plaque signals (eco-centric enhancement and heterogeneous signal intensity sug-
gesting unstable plaque); and (c) remodeling patterns (positive remodeling sug-
gesting outward expansion of the vessel wall) [63].
On the contrary, superiorly located MCA plaques (near to the orifices of pen-
etrating arteries) are associated with BOD-type ICAD [64].
Bodle asserted that, in other vascular beds, the determination of atherosclerotic 
plaque constituents has helped in risk-stratify patients and select treatments. Using 
clinical, imaging, and pathological correlations, studies of coronary and carotid 
artery disease have detected characteristics that indicate plaque vulnerability: lipid 
core size, intraplaque hemorrhage, and fibrous cap thickness. These vulnerable 
plaque characteristics are also present in ICAD [50, 65] but are less well studied 
(Table 3). Bodle also noted that intraplaque hemorrhage (IPH) from rupture of 
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mens, intracranial vessels are not accessible to pathology sampling in live patients. 
Therefore, the signal characteristics of intracranial plaque components can only be 
extrapolated from extracranial ICAs HR-MRI [50].
Another disadvantage is the small size (2.0–5.0 mm) and the depth of the 
intracranial vessels, which require relatively long acquisition times, making 
HR-MRI imaging difficult because of patient motion artifact and limitations in 
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According to Bodle, HR-MRI can help to identify stroke mechanisms, determine 
the degree and etiology of stenoses, identify nonstenotic plaques, and identify 
potentially high-risk plaque components. These plaque characteristics are not 
visualized with conventional luminal imaging and may be important predictors of 
stroke [50].
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tomography angiography for the diagnosis of intracranial 
atherosclerotic disease (ICAS)
6.1 Nonenhanced multidetector computed tomography (MDCT)
The study of the prevalence, and of the risk factors for intracranial internal 
carotid artery calcification (ICAC), as a marker of intracranial atherosclero-
sis was determined by Bos and coworkers. They assessed a white population 
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6.2 Multidetector computed tomography angiography (MCTA)
A comprehensive high-resolution intracranial vessel assessment is possible by 
the introducing of multislice CT (MSCT: multiple row scanning: 4, 16, 64, up to 
320 rows, associated with an increased rotational speed: 0.5 s/rotation). MSCT 
represents the first-line imaging modality in stroke patients [67]. CTA calculates 
the degree of stenosis using the published method for the Warfarin-Aspirin 
Symptomatic Intracranial Disease Study (WASID) (vide supra) [2].
According to Arenillas, CTA detects the degree of stenosis for each of 15 large 
intracranial arterial segments assessed: bilateral supraclinoid ICAs, A1-ACA, 
M1-ACM, M2-ACM, P1-PCA, proximal, mid, and distal BA, and intracranial 
VA. CTA identifies and characterizes the ICAS of different histopathological nature 
(including partially recanalized emboli), being unable to directly assess plaque 
instability. It allows the examination of ICAS progression and in-stent restenosis 
[3, 68]. The stenotic lesions are considered to be atherosclerotic in nature, if no 
cases with subarachnoid hemorrhage or intracerebral hemorrhage are detected by 
CT head (in consequence, vasospasm is unlikely the cause of these ICAS). Arterial 
segments are excluded from the analyses of stenosis, if they are identified to be 
congenitally hypoplastic or seen only through collaterals or cross-filling [69].
The prevalence, distribution, calcification, and the risk factors predisposing 
ICAS in a white stroke population were investigated by Homburg and coworkers. All 
patients underwent MDCT of the brain and MDCTA (with a 16-slice MDCT scanner 
or a 64-slice MDCT scanner with a standardized protocol) of the extracranial and 
intracranial arteries in a single session [70]. They concluded that the majority of 
ICAS was observed in the posterior circulation. ICAS in the proximal intracranial 
arteries was mainly classified, but in distal arteries, it was frequently nonclassified, 
indicating a different pathophysiology of atherosclerotic disease in the two segments. 
The absence of calcification on CT of the brain does not exclude the presence of 
ICAS in the distal arteries. Association of nonclassified ICAS and ESR may indicate a 
prominent role for inflammatory factors in intracranial arteries disease (ICAD) [71].
6.3 CTA versus DSA
CTA was compared with DSA for the detection and measurement of stenosis/
occlusions in large intracranial arteries by Nguyen and coworkers [69]. They 
reported high sensitivity and a high PPV for CTA for the detection of occlusion 
and stenosis of greater than 50%. CTA has relatively fewer risks, costs less, is more 
readily available, and appears to have the same accuracy as DSA, to identify the 
exact site of arterial occlusion in acute ischemic stroke. Maximum intensity projec-
tions and volume rendering can help to quickly identify the occlusion. On the other 
hand, CTA does not appear to be as reliable as DSA for determining the presence of 
stenosis in small arteries distal to the first 1 cm of the artery [72].
6.4 CTA versus MRA
CTA has several advantages compared with MRA: better anatomic visualization 
of the circle of Willis and of the state of the arteries [73] and quite accurate in the 
evaluation of stenosis, since the latter tends to overestimate high-grade stenosis 
attributable to turbulent flow; CTA is more accurate for identifying occlusion (sen-
sitivity, 100%; specificity, 99.4–100%) than for measuring the degree of stenosis 
[68]. CTA is minimally invasive, performed quickly, modest cost, scanner availabil-
ity 24/7, operator-independent, less susceptible to motion artifacts than MRA, and 
less dependent on hemodynamic effects compared with MRA [68, 69, 74, 75].
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Its disadvantages, besides radiation risk exposure, are patient movement, 
contrast risk reactions (allergy to iodine contrast agents), different contra-
indications (nephron-toxicity-serum creatinine levels >1.2 mg/dL, etc.), and 
difficult evaluation of arteries within bone canals (particularly of the carotid 
siphon) due to bone artifacts. However, intracranial, with the proper examina-
tion and postprocessing techniques, is possible to use CTA to assess the petrous 
and cavernous portions of the ICA. Multiplanar reformation (MPR) can display 
2D images in various planes without any loss of information. Maximum inten-
sity projection (MIP) enhances high attenuation contrast tissues, including 
bone, wall calcification, or blood vessels. Since calcifications can interfere with 
the evaluation of the degree of stenosis, bone elimination is done during post-
processing [68, 69].
6.5 CTA versus 3D-TOF-MRA and DSA
Bash et al. [76] retrospectively examined 28 subjects with ischemic stroke or 
TIA comparing CTA and MRA using DSA as the gold standard, among intracranial 
arteries with stenosis >30% (anterior circulation vessels 42 versus 58% posterior 
circulation arteries). They concluded that CTA demonstrated a higher sensitivity, 
specificity, and PPV than those of MRA for the evaluation of stenotic and occluded 
intracranial vessel segments. CTA has a high interoperator reliability for the quan-
titation of stenotic lesions when expert readers are used. Helical CTA is superior to 
DSA in the demonstration of arterial patency in posterior circulation arteries when 
very low- or balanced flow states are present due to a severe stenosis [76]. In the era 
of the mechanical thrombectomy with stent-retriever, when faster puncture time 
to endovascular therapy became very important, CTA became essential due to its 
shorter scan time and the evaluations of collaterals on multiphase imaging, which 
can contribute to faster recanalization and better evolution [68].
6.6 CTA versus DSA versus TCCS
Roubec and coworkers compared ICAS in 67 patients with stroke using three 
different methods: TCCS, CTA, and DSA in a common clinical practice. They found 
substantial agreement between CTA and DSA, and moderate agreement between 
TCCS and DSA as well as CTA and TCCS, for the evaluation of ICAS [77].
6.7 Intracranial nonocclusive thrombosis (iNOT)
The frequency and clinical course of patients with acute ischemic stroke or TIA 
who had intracranial nonocclusive thrombus (iNOT) on CTA of the circle of Willis 
were assessed by Puez and coworkers [78]. Before CTA, a noncontrast CT (NCCT) 
was accomplished in all cases. iNOT has been described first on DSA or MRA [79, 
80]. Criteria to diagnose iNOT rather than occlusive thrombus or atherosclerotic 
stenosis were: (1) residual lumen present and eccentric; (2) nontapering thrombus; 
(3) smooth and well-defined thrombus margins; and (4) absence of vessel wall 
calcification [78]. Puez concluded that iNOT was relatively uncommon. Probably, 
iNOT may be more frequently diagnosed when performing early CTA in such 
patients. The majority of patients had a good clinical outcome. Clinical deteriora-
tion was associated with unchanged or enlarged iNOT in repeated vascular studies, 
whereas diminished or resolved iNOT was associated with a benign clinical course. 
Particularly, in patients with minor symptoms, iNOT may indicate increased risk 
for clinical deterioration. Puez’s study supported the importance of urgent vascular 
imaging in these patients [78].
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substantial agreement between CTA and DSA, and moderate agreement between 
TCCS and DSA as well as CTA and TCCS, for the evaluation of ICAS [77].
6.7 Intracranial nonocclusive thrombosis (iNOT)
The frequency and clinical course of patients with acute ischemic stroke or TIA 
who had intracranial nonocclusive thrombus (iNOT) on CTA of the circle of Willis 
were assessed by Puez and coworkers [78]. Before CTA, a noncontrast CT (NCCT) 
was accomplished in all cases. iNOT has been described first on DSA or MRA [79, 
80]. Criteria to diagnose iNOT rather than occlusive thrombus or atherosclerotic 
stenosis were: (1) residual lumen present and eccentric; (2) nontapering thrombus; 
(3) smooth and well-defined thrombus margins; and (4) absence of vessel wall 
calcification [78]. Puez concluded that iNOT was relatively uncommon. Probably, 
iNOT may be more frequently diagnosed when performing early CTA in such 
patients. The majority of patients had a good clinical outcome. Clinical deteriora-
tion was associated with unchanged or enlarged iNOT in repeated vascular studies, 
whereas diminished or resolved iNOT was associated with a benign clinical course. 
Particularly, in patients with minor symptoms, iNOT may indicate increased risk 
for clinical deterioration. Puez’s study supported the importance of urgent vascular 
imaging in these patients [78].
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Clot length can be examined by thin-sliced noncontrast CT and CTA. A better 
visualization of collateral circulation (which is an important prognostic factor for 
favorable outcome) can be realized with multiphase CTA [81, 82].
7. Conclusions
This chapter focuses on key findings and recent approaches in diagnosis of 
intracranial arterial atherosclerotic stenosis (ICAS), with an emphasis on novel 
procedures to define the underlying mechanisms of stroke in intracranial athero-
sclerotic disease (ICAD). The importance of ICAS as a principal cause of ischemic 
stroke in Caucasians is undervalued as compared to that of extracranial athero-
sclerotic stenosis (ECAS) and nonvalvular atrial fibrillation (NVAF). On the other 
hand, intracranial arterial calcifications, stenosis, and occlusions represent the 
most frequent disturbance observed in intracranial arteries [83].
Intracranial arterial stenosis is caused by an atherosclerotic plaque in more than 
90% of cases (ICAS). Intracranial atherosclerotic stroke differs from extracranial 
atherosclerotic stroke in many aspects, including risk factors and stroke patterns. 
Unlike in patients with ECAS or NVAF, stroke correlated to ICAD occurs in associa-
tion with various stroke mechanisms such as in situ thrombotic occlusion, artery-
to-artery embolism, branch occlusion, and hemodynamic insufficiency [83].
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Abstract
Aneurysmal subarachnoid hemorrhage (aSAH) is a devastating neurological 
condition and these patients often have unfavorable outcomes at the long-term 
follow-up. Poor-grade aSAH is a severe subtype of aSAH and is defined as World 
Federation of Neurosurgical Surgeon (WFNS) grade IV or V. All patients should be 
treated by a multidisciplinary team that consists of vascular neurosurgeons, inter-
ventional neuroradiologists, neurologists, and anesthetists. Aneurysm rebleeding 
occurs in the poor-grade aSAH within the first 72 h after ictus. Timing of treatment 
for aSAH has shifted from delayed to early treatment of ruptured aneurysms, 
and there will be a trend toward early or ultra-early treatment for poor-grade 
aSAH. However, there is no consensus regarding the optimal timing of treatment 
for poor-grade aSAH. Endovascular coiling has provided a viable alternative to sur-
gical clipping. An increasing number of patients have received endovascular treat-
ment. There are limited data on high-level clinical trials focused on the treatment 
of poor-grade aSAH. An accurate prediction model remains challenging. Predicting 
long-term outcome is essential to support treatment decision-making. We reviewed 
the current therapeutical management and prognosis of poor-grade aSAH.
Keywords: intracranial aneurysms, subarachnoid hemorrhage, poor-grade, 
treatment, prognosis
1. Introduction
Aneurysmal subarachnoid hemorrhage (aSAH) is a devastating neurological con-
dition and is associated with high morbidity and mortality. Poor-grade aSAH accounts 
for approximately 30% of all aSAH, and it is a severe subtype of aSAH. These patients 
more often present with acute hydrocephalus, severe intraventricular hemorrhage, 
microcirculatory disturbances, and even multi-organ failure after ictus [1, 2] . 
Traditionally, these patients are managed conservatively, and only those who show 
clinical improvement were selected for aggressive treatment [1, 3, 4]. However, aneu-
rysm rebleeding occurs in patients with poor-grade aSAH, and about 50% of rebleed-
ing is at the early stage after the hemorrhage [5]. Nowadays endovascular coiling, 
surgical clipping, and intensive neurocritical care have improved outcomes in patients 
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1. Introduction
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dition and is associated with high morbidity and mortality. Poor-grade aSAH accounts 
for approximately 30% of all aSAH, and it is a severe subtype of aSAH. These patients 
more often present with acute hydrocephalus, severe intraventricular hemorrhage, 
microcirculatory disturbances, and even multi-organ failure after ictus [1, 2] . 
Traditionally, these patients are managed conservatively, and only those who show 
clinical improvement were selected for aggressive treatment [1, 3, 4]. However, aneu-
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ing is at the early stage after the hemorrhage [5]. Nowadays endovascular coiling, 
surgical clipping, and intensive neurocritical care have improved outcomes in patients 
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with poor-grade aSAH [6–11]. However, more than 60% of patients have unfavorable 
outcomes with severe disability [12]. The treatment decision-making is still challeng-
ing. There are limited data on high-level clinical trials focusing on the treatment of 
poor-grade aSAH. Therefore, we review the current therapeutical management and 
prognosis of poor-grade aSAH.
2. Diagnosis
Several grading systems, including Glasgow coma score (GCS), WFNS grade 
(World Federation of Neurological Societies), Hunt & Hess scale, or modified 
Hunt & Hess scale, have been used for initial clinical assessment of aSAH. Patients 
with poor-grade aSAH often present with stupor or coma because of the primary 
brain injury. WFNS grade has better inter- and intraobserver reliability than Hunt 
& Hess scale and makes it more appropriate [13]. Poor-grade aSAH is defined as 
WFNS grade IV or V (a GCS score of 7–12 for grade IV and 3–6 for grade V) [14]. It 
is important to detect ruptured aneurysms in the setting of poor-grade aSAH. These 
patients are often unstable and require sedation or anesthesia during examination.
Traditionally, digital subtraction angiography (DSA) is the gold standard 
technique for detecting ruptured aneurysms [15–19]. CT angiography (CTA) is less 
invasive and less time-consuming in providing information on ruptured intra-
cranial aneurysms as a primary examination tool for aSAH. Current studies have 
reported the sensitivity and specificity of CTA for detecting intracranial aneurysms 
[20]. Matsumoto et al. [21] reported that 27 patients underwent successful surgi-
cal clipping based on CTA alone. Our previous study reported that more than a 
third of patients underwent successful surgical treatment on the basis of CTA 
alone [22]. All ruptured aneurysms were detected and clipped. Complications and 
clinical outcomes did not significantly differ between CTA alone and DSA group. 
Therefore, CTA can provide fast and accurate diagnostic and anatomic informa-
tion on ruptured aneurysms and it can be safely and effectively used in most 
patients with poor-grade aSAH requiring surgical treatment. Patients with smaller 
ruptured aneurysms or multiple aneurysms may be considered for additional DSA 
examination.
3. Aneurysm rebleeding and predictor of the rebleeding
Rebleeding more often occurs in patients with poor-grade aSAH [23–27]. Van 
Donkelaar et al. [28] reported that 41 (11.0%) of 374 patients experienced rebleed-
ing. Of the 297 patients included in our previous study, 30 (10.1%) patients expe-
rienced rebleeding; 14 (46.7%) cases occurred within 24 h after ictus, 11 (36.7%) 
occurred between 1 and 7 days, and 5 (16.6%) occurred after 7 days [5]. High blood 
pressure, poor-grade clinical condition, modified Fisher grade, posterior circulation 
aneurysms, larger aneurysms (>10 mm), intracerebral or intraventricular hemor-
rhage are reported to be important predictors of rebleeding after aSAH [24, 28–30]. 
Van Donkelaar et al. [28] reported that a higher modified Fisher grade was a strong 
risk factor associated with a rebleeding probably because the amount of blood was a 
marker of stability of the ruptured aneurysm wall.
Many neurosurgeons use preoperative ventricular drainage in all patients with 
poor-grade aSAH to maintain adequate cerebral perfusion [15, 24, 31–33]; however, 
there is no guideline for the drainage after poor-grade aSAH. Laidlaw and Siu 
reported that 2 of 133 patients treated with surgery underwent ventricular drain-
age because of the concern of rebleeding [34]. On the other hand, several studies 
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found no increased risk of rebleeding after the drainage [35, 36]. Our previous study 
showed that a lower Fisher grade, ruptured anterior cerebral artery aneurysms, 
and preoperative external ventricular drainage were independently associated with 
rebleeding after poor-grade aSAH [5]. Therefore, these patients may have increased 
risk of rebleeding after ventricle drainage without aneurysm repair, and early aneu-
rysm treatment may be considered for patients who required emergency ventricle 
drainage.
4. Therapeutical management
Poor-grade aSAH should be treated with a multidisciplinary team that consists 
of neurologists, neurosurgeons, interventional neuroradiologists, and anesthetists. 
Emergency treatment should include aggressive resuscitation to keep the basic life 
support. Central venous catheters are first inserted for fluid and medicine admin-
istration and hemodynamic monitoring. Systolic blood pressure should be main-
tained below 160 mmHg to prevent the rebleeding. Oral or nasotracheal intubation 
should be performed if the patients require respiratory support.
4.1 Timing of treatment
There is no consensus regarding the optimal timing of treatment for poor-grade 
aSAH. Traditionally, these patients have been managed medically and only undergo 
the treatment of the ruptured aneurysm when clinically stabilized and improved. In 
the past decades, several studies have shown that early surgery (within 72 h of ictus) 
improved the outcome in selected patients with poor-grade aneurysms [15–17, 33, 
37–39]. At more than 6 months of follow-up, 46% of patients had a good outcome 
after early surgical clipping [40]. Zentner et al. [41] reported that early surgery 
resulted in a good outcome of 22% of patients with the worst grade. A study of 103 
patients with grade V showed a good outcome in 26% of patients at follow-up [42]. 
Despite the rates of morbidity and death remaining high in patients with WFNS 
grade V, these findings suggest that early aneurysm repair is feasible and safe for 
poor-grade aSAH. Early treatment for ruptured aneurysm may help reduce the risk 
of rebleeding and manage cerebral vasospasm and delayed ischemia. Patients with 
younger age, WFNS IV after emergency resuscitation, and middle cerebral artery 
aneurysms are more likely to have a favorable outcome after early surgery [43].
Aneurysm treatment as early as possible is recommended to prevent rebleed-
ing after initial aSAH [44, 45]. Ultra-early treatment (within 24 h) reduces the 
risk of rebleeding and improves outcomes in most patients with good-grade aSAH 
[46–48]. However, there is no evidence to support ultra-early treatment of poor-
grade aSAH because these patients experience more severe brain swelling than 
good-grade patients [42, 49]. With development in microsurgical techniques, there 
has been growing interest in ultra-early treatment of aSAH. A current series of 78 
patients with poor-grade treated with surgical treatment showed 44 patients (56%) 
had a good outcome, including 26% of patients presenting with WFNS grade V, 
and surgery was performed within 24 h after admission [33]. In a multicenter and 
contemporary cohort of poor-grade aSAH, 47 (40%) of 118 patients underwent 
ultra-early surgery, 16 (34%) patients in ultra-early surgery group and 42 (59%) 
patients in delayed group had a good outcome [50]. Laidlaw et al. [17, 34]reported 
40% of patients were independent after 3 months and 45% died. With coiling, there 
are few technical limitations to ultra-early treatment of aSAH as the limitations 
related to inflammation and brain swelling do not affect the technical aspects of the 
procedure [51].
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with poor-grade aSAH [6–11]. However, more than 60% of patients have unfavorable 
outcomes with severe disability [12]. The treatment decision-making is still challeng-
ing. There are limited data on high-level clinical trials focusing on the treatment of 
poor-grade aSAH. Therefore, we review the current therapeutical management and 
prognosis of poor-grade aSAH.
2. Diagnosis
Several grading systems, including Glasgow coma score (GCS), WFNS grade 
(World Federation of Neurological Societies), Hunt & Hess scale, or modified 
Hunt & Hess scale, have been used for initial clinical assessment of aSAH. Patients 
with poor-grade aSAH often present with stupor or coma because of the primary 
brain injury. WFNS grade has better inter- and intraobserver reliability than Hunt 
& Hess scale and makes it more appropriate [13]. Poor-grade aSAH is defined as 
WFNS grade IV or V (a GCS score of 7–12 for grade IV and 3–6 for grade V) [14]. It 
is important to detect ruptured aneurysms in the setting of poor-grade aSAH. These 
patients are often unstable and require sedation or anesthesia during examination.
Traditionally, digital subtraction angiography (DSA) is the gold standard 
technique for detecting ruptured aneurysms [15–19]. CT angiography (CTA) is less 
invasive and less time-consuming in providing information on ruptured intra-
cranial aneurysms as a primary examination tool for aSAH. Current studies have 
reported the sensitivity and specificity of CTA for detecting intracranial aneurysms 
[20]. Matsumoto et al. [21] reported that 27 patients underwent successful surgi-
cal clipping based on CTA alone. Our previous study reported that more than a 
third of patients underwent successful surgical treatment on the basis of CTA 
alone [22]. All ruptured aneurysms were detected and clipped. Complications and 
clinical outcomes did not significantly differ between CTA alone and DSA group. 
Therefore, CTA can provide fast and accurate diagnostic and anatomic informa-
tion on ruptured aneurysms and it can be safely and effectively used in most 
patients with poor-grade aSAH requiring surgical treatment. Patients with smaller 
ruptured aneurysms or multiple aneurysms may be considered for additional DSA 
examination.
3. Aneurysm rebleeding and predictor of the rebleeding
Rebleeding more often occurs in patients with poor-grade aSAH [23–27]. Van 
Donkelaar et al. [28] reported that 41 (11.0%) of 374 patients experienced rebleed-
ing. Of the 297 patients included in our previous study, 30 (10.1%) patients expe-
rienced rebleeding; 14 (46.7%) cases occurred within 24 h after ictus, 11 (36.7%) 
occurred between 1 and 7 days, and 5 (16.6%) occurred after 7 days [5]. High blood 
pressure, poor-grade clinical condition, modified Fisher grade, posterior circulation 
aneurysms, larger aneurysms (>10 mm), intracerebral or intraventricular hemor-
rhage are reported to be important predictors of rebleeding after aSAH [24, 28–30]. 
Van Donkelaar et al. [28] reported that a higher modified Fisher grade was a strong 
risk factor associated with a rebleeding probably because the amount of blood was a 
marker of stability of the ruptured aneurysm wall.
Many neurosurgeons use preoperative ventricular drainage in all patients with 
poor-grade aSAH to maintain adequate cerebral perfusion [15, 24, 31–33]; however, 
there is no guideline for the drainage after poor-grade aSAH. Laidlaw and Siu 
reported that 2 of 133 patients treated with surgery underwent ventricular drain-
age because of the concern of rebleeding [34]. On the other hand, several studies 
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found no increased risk of rebleeding after the drainage [35, 36]. Our previous study 
showed that a lower Fisher grade, ruptured anterior cerebral artery aneurysms, 
and preoperative external ventricular drainage were independently associated with 
rebleeding after poor-grade aSAH [5]. Therefore, these patients may have increased 
risk of rebleeding after ventricle drainage without aneurysm repair, and early aneu-
rysm treatment may be considered for patients who required emergency ventricle 
drainage.
4. Therapeutical management
Poor-grade aSAH should be treated with a multidisciplinary team that consists 
of neurologists, neurosurgeons, interventional neuroradiologists, and anesthetists. 
Emergency treatment should include aggressive resuscitation to keep the basic life 
support. Central venous catheters are first inserted for fluid and medicine admin-
istration and hemodynamic monitoring. Systolic blood pressure should be main-
tained below 160 mmHg to prevent the rebleeding. Oral or nasotracheal intubation 
should be performed if the patients require respiratory support.
4.1 Timing of treatment
There is no consensus regarding the optimal timing of treatment for poor-grade 
aSAH. Traditionally, these patients have been managed medically and only undergo 
the treatment of the ruptured aneurysm when clinically stabilized and improved. In 
the past decades, several studies have shown that early surgery (within 72 h of ictus) 
improved the outcome in selected patients with poor-grade aneurysms [15–17, 33, 
37–39]. At more than 6 months of follow-up, 46% of patients had a good outcome 
after early surgical clipping [40]. Zentner et al. [41] reported that early surgery 
resulted in a good outcome of 22% of patients with the worst grade. A study of 103 
patients with grade V showed a good outcome in 26% of patients at follow-up [42]. 
Despite the rates of morbidity and death remaining high in patients with WFNS 
grade V, these findings suggest that early aneurysm repair is feasible and safe for 
poor-grade aSAH. Early treatment for ruptured aneurysm may help reduce the risk 
of rebleeding and manage cerebral vasospasm and delayed ischemia. Patients with 
younger age, WFNS IV after emergency resuscitation, and middle cerebral artery 
aneurysms are more likely to have a favorable outcome after early surgery [43].
Aneurysm treatment as early as possible is recommended to prevent rebleed-
ing after initial aSAH [44, 45]. Ultra-early treatment (within 24 h) reduces the 
risk of rebleeding and improves outcomes in most patients with good-grade aSAH 
[46–48]. However, there is no evidence to support ultra-early treatment of poor-
grade aSAH because these patients experience more severe brain swelling than 
good-grade patients [42, 49]. With development in microsurgical techniques, there 
has been growing interest in ultra-early treatment of aSAH. A current series of 78 
patients with poor-grade treated with surgical treatment showed 44 patients (56%) 
had a good outcome, including 26% of patients presenting with WFNS grade V, 
and surgery was performed within 24 h after admission [33]. In a multicenter and 
contemporary cohort of poor-grade aSAH, 47 (40%) of 118 patients underwent 
ultra-early surgery, 16 (34%) patients in ultra-early surgery group and 42 (59%) 
patients in delayed group had a good outcome [50]. Laidlaw et al. [17, 34]reported 
40% of patients were independent after 3 months and 45% died. With coiling, there 
are few technical limitations to ultra-early treatment of aSAH as the limitations 
related to inflammation and brain swelling do not affect the technical aspects of the 
procedure [51].
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A current meta-analysis and systemic review of poor-grade aSAH evaluated out-
comes by timing of treatment modality and found that patients receiving ultra-early 
treatment (within 48 h of aSAH) had the highest rates of good neurological outcome 
(61% compared to 40% for early and 47% for delayed) [12]. Park et al. [47] reported 
that ultra-early surgery did not significantly decrease the incidence of rebleeding 
of poor-grade aSAH and also that it was not associated with outcomes [18, 47, 48]. 
Ultra-early aneurysm treatment of poor-grade aSAH still remains controversial.
4.2 Surgical treatment
Surgical treatment includes external ventricular drainage for hydrocephalus 
or intraventricular hemorrhage, surgical clipping of ruptured aneurysms, and 
decompressive craniectomy. Surgical selections are based on aneurysm morphology, 
patient’s neurological condition, and treatment relative risk following multidisci-
plinary consultation. Patients with associated large intracerebral hemorrhage (more 
than 30 ml) are more often considered for surgical clipping. After surgery, patients 
are transferred to the intensive care unit, and they are treated with standard manage-
ment for vasospasm. Illustrative case receiving surgical clipping is shown in Figure 1.
The international subarachnoid aneurysm trial (ISAT) demonstrated that for 
aSAH amenable to both treatments, patients treated with endovascular coiling had 
better outcomes than patients treated with surgical clipping [52]. Although endo-
vascular treatment has been used as an available alternative to surgery for aSAH, 
surgical treatment is still an important treatment modality for poor-grade aSAH. In 
the contemporary multicenter cohorts of poor-grade aSAH, patients receiving clip-
ping more often had a lower GCS score, a WFNS grade of V, a higher Fisher grade 
and modified Fisher grade, and a ruptured anterior circulation aneurysm than those 
receiving coiling [53]. Patients with WFNS grade V after emergency resuscitation, 
a better Fisher grade, brain herniation, the presence of ICH, or the absence of IVH 
more often underwent early surgical clipping [43]. Patients with brain herniation 
more commonly are treated with surgery. There are no significant differences in 
rebleeding, cerebral infarction, symptomatic vasospasm, seizure, pneumonia 
between coiling and clipping groups. There is also no significant difference in 
outcomes at 6 and 12 months between the two treatments [53].
Figure 1. 
A 45-year-old male presented with unconsciousness for 2 h and had a Glasgow coma score of 6 and World 
Federation of Neurosurgical Surgeon grade of V at admission. He was treated with emergency surgical clipping 
of ruptured aneurysm and hematoma evacuation. He recovered well and had a modified Rankin scale of 1 at 
12 months of follow-up. (A) Emergency CT scan shows a large frontotemporal parietal lobe hematoma and 
midline shift to left side. (B) CT angiography shows a right middle cerebral artery bifurcation aneurysm.  
(C) CT shows a slight edema of surgical field after 10 days of surgery.
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Decompressive craniectomy has been reported in the treatment for severe 
traumatic brain injury, massive ischemic stroke, and aSAH [54–60]. This procedure 
can reduce increased intracranial pressure and improve cerebral perfusion and out-
comes in selected patients with ruptured aneurysms with associated intracerebral 
hemorrhage [61]. However, there are no studies focusing on the safety and efficacy 
of decompressive craniectomy for poor-grade aSAH compared with conventional 
craniotomy. Our previous study has shown that primary decompressive craniec-
tomy does not increase postoperative complications and can be performed safely in 
poor-grade sSAH. More than one-half of patients benefit from primary decompres-
sive craniectomy.
4.3 Endovascular treatment
Since the ISAT study, endovascular treatment is more commonly used than clip-
ping for ruptured aneurysm. Aneurysms can be coiled though the minimally inva-
sive endovascular approach to reduce the rate of rebleeding and avoid brain swelling 
and high intracranial pressure. Endovascular treatment is performed in continuity 
with the initial angiography and requires less treatment time. The current results at 
the 3- and 6-year follow-up in the ruptured aneurysm treatment study showed that 
there was no significant difference in outcome between the two treatments for rup-
tured aneurysms [62, 63]. A current systematic review of surgical and endovascular 
treatment of poor-grade aSAH has also shown that the proportion of patients with 
endovascular coiling increased from 10.0 to 62.0% between 1990 and 2000 and 2010 
and 2014 [12]. Therefore, endovascular coiling is a feasible and reasonable option for 
poor-grade aSAH. Illustrative case receiving coiling is shown in Figure 2.
Mocco et al. [31] reported that 35 (35.7%) of 98 patients received coiling, and 
there was also similar outcome between coiling and clipping for poor-grade aSAH. In 
our prospective and multicenter registry of 262 patients with poor-grade ruptured 
aneurysm, 133 (50.8%) patients received endovascular coiling within 21 days after 
poor-grade aSAH [53]. An unadjusted analysis showed that the rate of outcome 
(mRS 0–2 or mRS 0–3) at discharge at 6 and 12 months in the coiled patients 
was higher than that in the clipped patients probably because of selection bias. In 
our exploratory analysis, there was no significant difference in clinical outcomes 
between the two groups. Patients receiving coiling had a higher risk of radiological 
Figure 2. 
A 53-year-old male presented with unconsciousness for 1 h and had a Glasgow coma score of 5 and World 
Federation of Neurosurgical Surgeon grade of V at admission. He was treated with emergency coiling of 
ruptured aneurysm and external ventricle drainage. He had a modified Rankin scale of 3 at 12 months of 
follow-up. (A) Emergency CT scan shows severe subarachnoid hemorrhage and frontal lobe hematoma. 
(B) Preoperative angiography shows a very small anterior communicating artery aneurysm. (C) Immediate 
angiography shows complete occlusion of aneurysms using coils.
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A current meta-analysis and systemic review of poor-grade aSAH evaluated out-
comes by timing of treatment modality and found that patients receiving ultra-early 
treatment (within 48 h of aSAH) had the highest rates of good neurological outcome 
(61% compared to 40% for early and 47% for delayed) [12]. Park et al. [47] reported 
that ultra-early surgery did not significantly decrease the incidence of rebleeding 
of poor-grade aSAH and also that it was not associated with outcomes [18, 47, 48]. 
Ultra-early aneurysm treatment of poor-grade aSAH still remains controversial.
4.2 Surgical treatment
Surgical treatment includes external ventricular drainage for hydrocephalus 
or intraventricular hemorrhage, surgical clipping of ruptured aneurysms, and 
decompressive craniectomy. Surgical selections are based on aneurysm morphology, 
patient’s neurological condition, and treatment relative risk following multidisci-
plinary consultation. Patients with associated large intracerebral hemorrhage (more 
than 30 ml) are more often considered for surgical clipping. After surgery, patients 
are transferred to the intensive care unit, and they are treated with standard manage-
ment for vasospasm. Illustrative case receiving surgical clipping is shown in Figure 1.
The international subarachnoid aneurysm trial (ISAT) demonstrated that for 
aSAH amenable to both treatments, patients treated with endovascular coiling had 
better outcomes than patients treated with surgical clipping [52]. Although endo-
vascular treatment has been used as an available alternative to surgery for aSAH, 
surgical treatment is still an important treatment modality for poor-grade aSAH. In 
the contemporary multicenter cohorts of poor-grade aSAH, patients receiving clip-
ping more often had a lower GCS score, a WFNS grade of V, a higher Fisher grade 
and modified Fisher grade, and a ruptured anterior circulation aneurysm than those 
receiving coiling [53]. Patients with WFNS grade V after emergency resuscitation, 
a better Fisher grade, brain herniation, the presence of ICH, or the absence of IVH 
more often underwent early surgical clipping [43]. Patients with brain herniation 
more commonly are treated with surgery. There are no significant differences in 
rebleeding, cerebral infarction, symptomatic vasospasm, seizure, pneumonia 
between coiling and clipping groups. There is also no significant difference in 
outcomes at 6 and 12 months between the two treatments [53].
Figure 1. 
A 45-year-old male presented with unconsciousness for 2 h and had a Glasgow coma score of 6 and World 
Federation of Neurosurgical Surgeon grade of V at admission. He was treated with emergency surgical clipping 
of ruptured aneurysm and hematoma evacuation. He recovered well and had a modified Rankin scale of 1 at 
12 months of follow-up. (A) Emergency CT scan shows a large frontotemporal parietal lobe hematoma and 
midline shift to left side. (B) CT angiography shows a right middle cerebral artery bifurcation aneurysm.  
(C) CT shows a slight edema of surgical field after 10 days of surgery.
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Decompressive craniectomy has been reported in the treatment for severe 
traumatic brain injury, massive ischemic stroke, and aSAH [54–60]. This procedure 
can reduce increased intracranial pressure and improve cerebral perfusion and out-
comes in selected patients with ruptured aneurysms with associated intracerebral 
hemorrhage [61]. However, there are no studies focusing on the safety and efficacy 
of decompressive craniectomy for poor-grade aSAH compared with conventional 
craniotomy. Our previous study has shown that primary decompressive craniec-
tomy does not increase postoperative complications and can be performed safely in 
poor-grade sSAH. More than one-half of patients benefit from primary decompres-
sive craniectomy.
4.3 Endovascular treatment
Since the ISAT study, endovascular treatment is more commonly used than clip-
ping for ruptured aneurysm. Aneurysms can be coiled though the minimally inva-
sive endovascular approach to reduce the rate of rebleeding and avoid brain swelling 
and high intracranial pressure. Endovascular treatment is performed in continuity 
with the initial angiography and requires less treatment time. The current results at 
the 3- and 6-year follow-up in the ruptured aneurysm treatment study showed that 
there was no significant difference in outcome between the two treatments for rup-
tured aneurysms [62, 63]. A current systematic review of surgical and endovascular 
treatment of poor-grade aSAH has also shown that the proportion of patients with 
endovascular coiling increased from 10.0 to 62.0% between 1990 and 2000 and 2010 
and 2014 [12]. Therefore, endovascular coiling is a feasible and reasonable option for 
poor-grade aSAH. Illustrative case receiving coiling is shown in Figure 2.
Mocco et al. [31] reported that 35 (35.7%) of 98 patients received coiling, and 
there was also similar outcome between coiling and clipping for poor-grade aSAH. In 
our prospective and multicenter registry of 262 patients with poor-grade ruptured 
aneurysm, 133 (50.8%) patients received endovascular coiling within 21 days after 
poor-grade aSAH [53]. An unadjusted analysis showed that the rate of outcome 
(mRS 0–2 or mRS 0–3) at discharge at 6 and 12 months in the coiled patients 
was higher than that in the clipped patients probably because of selection bias. In 
our exploratory analysis, there was no significant difference in clinical outcomes 
between the two groups. Patients receiving coiling had a higher risk of radiological 
Figure 2. 
A 53-year-old male presented with unconsciousness for 1 h and had a Glasgow coma score of 5 and World 
Federation of Neurosurgical Surgeon grade of V at admission. He was treated with emergency coiling of 
ruptured aneurysm and external ventricle drainage. He had a modified Rankin scale of 3 at 12 months of 
follow-up. (A) Emergency CT scan shows severe subarachnoid hemorrhage and frontal lobe hematoma. 
(B) Preoperative angiography shows a very small anterior communicating artery aneurysm. (C) Immediate 
angiography shows complete occlusion of aneurysms using coils.
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hydrocephalus than clipped patients, and there was a trend toward clinical hydro-
cephalus after coiling. However, Zaidi et al. [64] found that there was no difference 
in hydrocephalus among patients treated by coiling or clipping.
With advances of endovascular technology, stent-assisted coiling has been used 
in the treatment of ruptured aneurysms. There is a main concern about the safety of 
stent-assisted coiling for poor-grade ruptured aneurysms. A review reported clinical 
outcomes in the stent-assisted coiling were worse than those in the coiling alone of 
acutely ruptured aneurysms [65]. Several studies showed that hemorrhagic complica-
tions often occurred in patients with acutely ruptured aneurysms after stent-assisted 
coiling and external ventricular drainage probably because of dual-antiplatelet 
therapy [66–68]. Using a multicenter poor-grade aneurysm study, we compared 
perioperative complications, and clinical outcomes between the stent-assisted coiling 
and the coiling-alone groups [69]. Twenty-three (17.6%) patients were treated with 
stent-assisted coiling compared with 108 (82.4%) patients treated with coiling 
alone. There were no statistically significant differences in intraprocedural rupture, 
procedure-related ischemic complication, ventricle drainage-related hemorrhagic 
complication, and symptomatic vasospasm between the stent-assisted coiling group 
and the coiling-alone group. However, there was a trend toward rebleeding after 
stent-assisted coiling. The hemorrhagic complication should be considered before 
the treatment decision-making. Therefore, treatment of wide-necked ruptured 
aneurysms remains challenging and we still require improvement of endovascular 
treatment of wide-neck ruptured aneurysms. A clinical trial focused on poor-grade 
ruptured aneurysms may be necessary to assess the efficacy of the treatment.
5. Outcomes and prognosis
The clinical outcomes of patients with aneurysm rebleeding remain very poor 
probably because of a severe secondary brain injury caused by a large cerebral 
hematoma or severe intraventricular hemorrhage. The rebleeding is independently 
associated with poor outcome (odds ratio [OR] 36.37, p < 0.001) and associated 
with mortality (OR 25.03, p < 0.001) at 12 months [5]. Tanno et al. [70] reported 
that 152 (84%) of 181 patients presented with semicoma to coma after rebleeding. 
Of the 30 patients with rebleeding in our previous study, 22 (73.3%) patients died at 
discharge. At 12 months, 2 (6.7%) patients had a modified Rankin Score (mRS) of 
1, 1 (3.3%) had a mRS of 4, and 26 (86.7%) died [5]. A higher modified Fisher grade 
before rebleeding, larger aneurysms, and a lower GCS score after rebleeding were 
independently associated with increased mortality. A lower WFNS grade treated 
with aggressive treatment is more likely to have a good outcome [71].
Aggressive treatment and successful aneurysm repair can reduce the rebleeding 
and improve clinical outcomes in selected patients. In a current review of poor-
grade aSAH, the rate of good outcome increased from 37.0 to 44.0% over the years. 
Good outcome was 38% (95% CI = 33–43%) in the endovascular group and 39% 
(95% CI = 34–44%) in the surgical group at the over 6 months of follow-up [12]. 
In our multicenter poor-grade aneurysm study [53], 52 (19.8%) patients had a mRS 
score of 0 or 1, 98 (29.8%) had a mRS score of 0–2, 112 (32.4%) had a mRS score 
of 0–3, and 51 (19.5%) had died at discharge. Ninety-five (36.3%) patients had a 
mRS score of 0 or 1, 115 (43.9%) had a mRS of 0–2, 126 (48.1%) had a mRS of 0–3, 
and 103 (39.3%) had died at 12 months. The outcome is improved after endovas-
cular coiling or clipping over time of the follow-up [53]. In a prospective database 
of poor-grade aSAH patients, 40% of the 98 patients had a favorable outcome at 
12 months [31]. In the 136 patients receiving endovascular coiling, 59 (43.3%) 
patients had a mRS of 0 or 1, and 64 (47.0%) had a poor outcome (mRS4-6) [72].
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About one-half of patients achieve a good outcome after the treatment, 
therefore predicting outcome after poor-grade aSAH is essential to support early 
treatment [73]. A few prognostic prediction models have been reported [3, 31, 74]. 
However, these studies are from a single center or have a limited sample size. Older 
age, lower GCS score, absence of pupil reactivity, higher modified Fisher grade, 
and conservative treatment are associated with poor outcome in most studies 
[3, 31, 74, 75]. These predictors of poor outcome are summarized in Table 1. We 
developed an integer-based outcome risk score (WAP) to predict the long-term 
outcomes [76]. The WAP score consists of three variables: WFNS grade, Age (three 
categories), and Pupillary reactivity. The sum of the weighted scores was used 
to assess the overall score and was ranged from 0 to 4. The predicted risk of poor 
outcome ranged from 25.5% for a WAP score of 0 to 96.2% for a score of 4. The risk 
score is easily measured and may complement treatment decision-making [76].
6. Conclusions
Poor-grade aSAH is a severe subtype of subarachnoid hemorrhage caused by 
ruptured aneurysms. Timing of treatment for the aSAH has shifted from delayed to 
early surgery, and there will be a trend toward ultra-early treatment for poor-grade 
aSAH. However, there is no consensus regarding the optimal timing of treatment for 
poor-grade aSAH. Although endovascular treatment has been used as an available 
alternative to surgical clipping for aSAH, surgical treatment is still an important 
treatment modality for poor-grade aSAH. Despite advancements in aneurysm 
Authors Study design Mean time 
of follow-up
Treatments Predictors of poor outcome
Le Roux 
et al.
Retrospective 6 months Clipping Hunt & Hess Grade V, blood 
glucose, fibrin degradation 
products, severity of ventricular 




Retrospective 6 months Clipping Hunt-Hess grade, aneurysm size, 




Prospective 12 months Clipping and 
coiling
Older than 65 years, 
hyperglycernia preoperative Hunt 
& Hess Grade V, and aneurysm 
size of at least 13 mm
Zhao et al. Prospective 12 months Clipping Older age, WFNS grade V, brain 
herniation, intraventricular 
hemorrhage, non-middle cerebral 
artery aneurysms
Zhao et al. Prospective 12 months Coiling Older age, WFNS grade of V, 




Prospective 12 months Clipping, coiling, 
and conservative 
treatment
Older age, lower Glasgow coma 
scale score (GCS), the absence 
of pupillary reactivity, higher 
modified Fisher grade, and 
conservative treatment
Table 1. 
Summary of predictors of poor outcome at the long-term follow-up.
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hydrocephalus than clipped patients, and there was a trend toward clinical hydro-
cephalus after coiling. However, Zaidi et al. [64] found that there was no difference 
in hydrocephalus among patients treated by coiling or clipping.
With advances of endovascular technology, stent-assisted coiling has been used 
in the treatment of ruptured aneurysms. There is a main concern about the safety of 
stent-assisted coiling for poor-grade ruptured aneurysms. A review reported clinical 
outcomes in the stent-assisted coiling were worse than those in the coiling alone of 
acutely ruptured aneurysms [65]. Several studies showed that hemorrhagic complica-
tions often occurred in patients with acutely ruptured aneurysms after stent-assisted 
coiling and external ventricular drainage probably because of dual-antiplatelet 
therapy [66–68]. Using a multicenter poor-grade aneurysm study, we compared 
perioperative complications, and clinical outcomes between the stent-assisted coiling 
and the coiling-alone groups [69]. Twenty-three (17.6%) patients were treated with 
stent-assisted coiling compared with 108 (82.4%) patients treated with coiling 
alone. There were no statistically significant differences in intraprocedural rupture, 
procedure-related ischemic complication, ventricle drainage-related hemorrhagic 
complication, and symptomatic vasospasm between the stent-assisted coiling group 
and the coiling-alone group. However, there was a trend toward rebleeding after 
stent-assisted coiling. The hemorrhagic complication should be considered before 
the treatment decision-making. Therefore, treatment of wide-necked ruptured 
aneurysms remains challenging and we still require improvement of endovascular 
treatment of wide-neck ruptured aneurysms. A clinical trial focused on poor-grade 
ruptured aneurysms may be necessary to assess the efficacy of the treatment.
5. Outcomes and prognosis
The clinical outcomes of patients with aneurysm rebleeding remain very poor 
probably because of a severe secondary brain injury caused by a large cerebral 
hematoma or severe intraventricular hemorrhage. The rebleeding is independently 
associated with poor outcome (odds ratio [OR] 36.37, p < 0.001) and associated 
with mortality (OR 25.03, p < 0.001) at 12 months [5]. Tanno et al. [70] reported 
that 152 (84%) of 181 patients presented with semicoma to coma after rebleeding. 
Of the 30 patients with rebleeding in our previous study, 22 (73.3%) patients died at 
discharge. At 12 months, 2 (6.7%) patients had a modified Rankin Score (mRS) of 
1, 1 (3.3%) had a mRS of 4, and 26 (86.7%) died [5]. A higher modified Fisher grade 
before rebleeding, larger aneurysms, and a lower GCS score after rebleeding were 
independently associated with increased mortality. A lower WFNS grade treated 
with aggressive treatment is more likely to have a good outcome [71].
Aggressive treatment and successful aneurysm repair can reduce the rebleeding 
and improve clinical outcomes in selected patients. In a current review of poor-
grade aSAH, the rate of good outcome increased from 37.0 to 44.0% over the years. 
Good outcome was 38% (95% CI = 33–43%) in the endovascular group and 39% 
(95% CI = 34–44%) in the surgical group at the over 6 months of follow-up [12]. 
In our multicenter poor-grade aneurysm study [53], 52 (19.8%) patients had a mRS 
score of 0 or 1, 98 (29.8%) had a mRS score of 0–2, 112 (32.4%) had a mRS score 
of 0–3, and 51 (19.5%) had died at discharge. Ninety-five (36.3%) patients had a 
mRS score of 0 or 1, 115 (43.9%) had a mRS of 0–2, 126 (48.1%) had a mRS of 0–3, 
and 103 (39.3%) had died at 12 months. The outcome is improved after endovas-
cular coiling or clipping over time of the follow-up [53]. In a prospective database 
of poor-grade aSAH patients, 40% of the 98 patients had a favorable outcome at 
12 months [31]. In the 136 patients receiving endovascular coiling, 59 (43.3%) 
patients had a mRS of 0 or 1, and 64 (47.0%) had a poor outcome (mRS4-6) [72].
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About one-half of patients achieve a good outcome after the treatment, 
therefore predicting outcome after poor-grade aSAH is essential to support early 
treatment [73]. A few prognostic prediction models have been reported [3, 31, 74]. 
However, these studies are from a single center or have a limited sample size. Older 
age, lower GCS score, absence of pupil reactivity, higher modified Fisher grade, 
and conservative treatment are associated with poor outcome in most studies 
[3, 31, 74, 75]. These predictors of poor outcome are summarized in Table 1. We 
developed an integer-based outcome risk score (WAP) to predict the long-term 
outcomes [76]. The WAP score consists of three variables: WFNS grade, Age (three 
categories), and Pupillary reactivity. The sum of the weighted scores was used 
to assess the overall score and was ranged from 0 to 4. The predicted risk of poor 
outcome ranged from 25.5% for a WAP score of 0 to 96.2% for a score of 4. The risk 
score is easily measured and may complement treatment decision-making [76].
6. Conclusions
Poor-grade aSAH is a severe subtype of subarachnoid hemorrhage caused by 
ruptured aneurysms. Timing of treatment for the aSAH has shifted from delayed to 
early surgery, and there will be a trend toward ultra-early treatment for poor-grade 
aSAH. However, there is no consensus regarding the optimal timing of treatment for 
poor-grade aSAH. Although endovascular treatment has been used as an available 
alternative to surgical clipping for aSAH, surgical treatment is still an important 
treatment modality for poor-grade aSAH. Despite advancements in aneurysm 
Authors Study design Mean time 
of follow-up
Treatments Predictors of poor outcome
Le Roux 
et al.
Retrospective 6 months Clipping Hunt & Hess Grade V, blood 
glucose, fibrin degradation 
products, severity of ventricular 




Retrospective 6 months Clipping Hunt-Hess grade, aneurysm size, 




Prospective 12 months Clipping and 
coiling
Older than 65 years, 
hyperglycernia preoperative Hunt 
& Hess Grade V, and aneurysm 
size of at least 13 mm
Zhao et al. Prospective 12 months Clipping Older age, WFNS grade V, brain 
herniation, intraventricular 
hemorrhage, non-middle cerebral 
artery aneurysms
Zhao et al. Prospective 12 months Coiling Older age, WFNS grade of V, 




Prospective 12 months Clipping, coiling, 
and conservative 
treatment
Older age, lower Glasgow coma 
scale score (GCS), the absence 
of pupillary reactivity, higher 
modified Fisher grade, and 
conservative treatment
Table 1. 
Summary of predictors of poor outcome at the long-term follow-up.
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treatment, the morbidity and mortality of poor-grade aSAH remain high. Many 
retrospective studies have reported the predictors of outcomes, but there is not 
appropriate prediction model for poor-grade aSAH. The treatment decision-making 
is still challenging. Further prospective cohort study or clinical trials focused on 
poor-grade aSAH are required to help guide treatment decisions for this devastating 
condition.
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Abstract
With the worldwide increase in the incidence of atherosclerotic coronary artery 
disease, the rate of coronary interventions has increased. One of the serious compli-
cations of this procedure is contrast-induced nephropathy (CIN). This complication 
can lead to poor outcomes, with an increase in morbidity and mortality of patients. 
The pathophysiology and risk factors for the occurrence of contrast-induced 
nephropathy are several and interconnected. The most proposed management of 
this entity is prophylaxis and thus avoidance of its occurrence. We will take a deeper 
look on the pathophysiology, the mechanisms by which this complication is aggra-
vated, and how to expect and manage such a problem.
Keywords: coronary intervention, contrast, nephropathy
1. Introduction
Contrast-induced nephropathy (CIN) is a grave complication of angiographic 
procedures and arises from administration of iodinated contrast media (CM) 
[1]. CIN is the third most common cause of hospital acquired acute renal injury 
representing about 12% of the cases. The incidence of CIN varies from 0 to 24% 
depending on the patient’s risk factors [2]. It is generally a transient and reversible 
state of acute renal failure [3]. However, the development of CIN is linked to a more 
prolonged hospital stay, an increased morbidity and mortality, and a high health-
care cost. Treatment of CIN is predominantly of supportive nature, consisting of 
calculated fluid and electrolyte management; however, dialysis may be required in 
some cases [3].
2. Definition
Clinical and experimental studies have used different laboratory parameters 
to define CIN [4, 5]. Currently, CIN is most commonly defined when either of the 
following occur within 48 h after contrast administration and persisting for 2–5 
days [6, 7]:
• A 25% increase in serum creatinine (SCr) concentration from baseline value
• An absolute increase in SCr of at least 0.5 mg/dL (44.2 μmol/L)
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3. Epidemiology
CIN is one of the most significant causes of hospital-acquired acute kidney 
injury (AKI) [8] and presents about 12% of the cases [9]. It represents the third 
most common cause after renal hypoperfusion (42%) and postoperative renal 
injury (18%). The reported incidence of CIN following percutaneous coronary 
intervention (PCI) lies between 0 and 24%. This depends on the associated risk 
factors, with the greatest incidence being reported after emergency PCI [10, 11]. 
A meta-analysis which included 40 studies showed a 6% incidence of CIN follow-
ing contrast-enhanced computed tomography (CT) [12], 9% following peripheral 
angiography [3], and 4% following intravenous pyelography [13]. The incidence 
of CIN is low in patients with normal renal function (0–5%) [14]. However, there 
is an incidence of 12–27% in patients having preexisting renal impairment [15]. 
Moreover, in one study, an incidence as high as 50% was found in patients with dia-
betic nephropathy undergoing coronary angiography despite the use of low-osmolar 
CM (LOCM) and adequate hydration. Also, up to 15% of them needed dialysis [16]. 
Development of CIN is associated with a longer duration of hospital stay and an 
increased morbidity and mortality, in addition to more costs [1, 17]. Elevation of 
post-PCI serum creatinine may have prognostic significance regardless of the initial 
kidney functions. In fact, a slight elevation in serum creatinine (25–35 μmol/l) is 
associated with an increase in 30-day mortality [18]. Furthermore, post-PCI serum 
creatinine elevation has been reported to be linked to higher 1-year mortality than 
periprocedural myocardial necrosis [19].
4. Risk factors
Mild, transient decreases in GFR occur after contrast administration in nearly all 
patients. The development of clinically significant acute renal failure depends very 
much upon the presence or absence of certain risk factors (Table 1); factors that 
increase the incidence of development of CIN are linked to the patient’s comorbid 
conditions, the procedure to be performed, and the nature of the contrast agents [21].
4.1 Preexisting renal disease
Preexisting renal disease with an elevated basal level of serum creatinine is 
the most important risk factor for the occurrence of CIN. The incidence of CIN in 
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14.8 to 55% [20]. As depicted in a study, despite pre-procedure adequate hydra-
tion and the use of nonionic CM, CIN happened in one-third of the 439 patients 
who underwent PCI and had basal creatinine level more than or equal to 1.8 mg/dl 
[22]. The higher the basal serum creatinine level, the greater the risk of developing 
CIN. As seen in a study, if basal serum creatinine level is estimated to be ≤1.2 mg/dl, 
the risk of development of CIN is just 2% [23]. In patients with values of creatinine 
in the range of 1.4–1.9 mg/dl, the risk of CIN in comparison with that in the previous 
group increases fivefold (10.4%) [23]. Regarding patients with baseline serum cre-
atinine more than or equal to 2.0 mg/dl, 62% of them developed CIN [24]. However, 
baseline creatinine is not reliable enough for the determination of patients who are 
at risk for CIN. This arises due to the variation on the basis of gender, age, and mus-
cular mass. For instance, a normal serum creatinine value probably correlates with 
a moderate decrease in renal function. In order to properly evaluate renal function, 
assessment of creatinine clearance should be done. The direct measurement of the 
creatinine clearance is not practical to be done; however, its estimation based on the 
Cockcroft-Gault formula or Modification of Diet in Renal Disease equation can be 
easily performed. Multiple studies have proven that an estimated glomerular filtra-
tion rate (eGFR) of 60 mL/min/1.73 m2 is a cutoff value for considering patients at 
high risk for the development of CIN. Thus, the estimation of GFR is crucial for CIN 
risk assessment [25].
4.2 Diabetes mellitus
Diabetic patients represent a very important proportion of those undergo-
ing contrast exposures due not only to the prevalence of diabetes in the general 
population but also the ability of the disease to cause a wide spectrum of diseases 
which require radiological procedures using contrast media. The incidence of CIN 
in diabetic patients varies from 5.7 to 29.4% [26]. Importantly, in diabetic patients 
with preserved renal function and without other risk factors, the rates of CIN are 
approximately equal to those of a nondiabetic population [27], while clinically 
important CIN mostly happens in a group of diabetics with preexisting renal 
impairment [27].
4.3 Age
Several studies showed that older age is an independent predictor of CIN [28]. 
The reasons for higher risk are multifactorial, which encompasses age-related 
changes in renal function including decreased glomerular filtration rate, renal 
concentration ability, and tubular secretion. The presence of multi-vessel coronary 
artery disease, mandating complex more prolonged PCI, combined with more dif-
ficult vascular access that results from tortuosity and calcification of the vessels that 
frequently requires a greater amount of contrast, and therefore represent additional 
factors of elevated CIN risk in elderly.
4.4 Gender
Ovarian hormones can have an influence upon the renin-angiotensin system 
as well as the renal blood flow. In a retrospective study of 8628 patients who 
underwent PCI, female sex presented an independent risk predictor of CIN (OR = 
1.4, p < 0.0001). One-year analyses of outcomes by gender demonstrated a higher 
mortality rate when compared to males in a cohort of CIN patients (14 vs 10%, p = 
0.05) [29].
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4.5 Heart failure
Advanced congestive heart failure (New York Heart Association class III or IV), 
reduced left ventricular ejection fraction, or any history of congestive heart failure 
are independent predictors of CIN and contribute to a greater risk in patients who 
have diabetes or renal disease. The risk arises as a result of decreased renal blood 
flow due to low cardiac output in those patients. Moreover, the risk is enhanced by 
this population’s use of specific medications such as aspirin, diuretics, and angio-
tensin converting enzyme (ACE) inhibitors [30].
4.6 Anemia
Anemia can cause deterioration of renal ischemia which can be an acceptable 
explanation for the higher incidence of contrast-induced nephropathy in patients 
with a lower hematocrit level. A baseline hematocrit value of less than 39% for men 
and less than 36% for women is considered a risk that leads to a higher incidence 
of CIN. This relation was investigated in a prospective study of 6773 patients who 
underwent PCI [31]. A lower basal hematocrit value was an independent risk 
predictor of CIN; and every 3% decline in basal hematocrit resulted in a significant 
increase in the occurrence of CIN in patients with and without chronic kidney 
disease (11 and 23%, respectively). Dangas et al. showed that the basal hematocrit 
level is an independent risk factor for the occurrence of CIN among patients with 
chronic kidney disease (OR = 0.95, p < 0.00001) [17].
4.7 Hyperuricemia
Contrast media have a uricosuric effect, which is caused by increased renal 
tubular secretion of uric acid. Moreover, hyperuricemia is accompanied by an acti-
vated renin-angiotensin-aldosterone system, enhanced synthesis of reactive oxygen 
species, increased endothelin-1, tubular obstruction by uric acid, and an inhibited 
nitric oxide synthesis that provokes the development of CIN [32].
4.8 Hypercholesterolemia
Altered nitric oxide-dependent renal vasodilatation is common in hypercho-
lesterolemia. Hypercholesterolemia enhanced the occurrence of CIN through the 
reduced production of nitric oxide [24].
4.9 Hypovolemia
Hypovolemia leads to active sodium reabsorption, which is an oxygen-depen-
dent process, and increases neurohumoral vasoconstrictive stimuli that can dimin-
ish medullary oxygenation. The toxic actions of contrast media on the renal tubular 
lumen can be exaggerated in hypovolemia. Decreased circulatory volume and renal 
perfusion augment vasoconstriction of renal vasculature after administration of 
CM. Volume expansion decreases the activity of the renin-angiotensin system, 
increases the perfusion of the medulla, and minimizes the elevation in blood viscos-
ity and osmolality. Currently, the most effective preventive measure against the 
development of CIN is proper hydration [33].
4.10 Hypertension
The alteration in intrarenal expression of vasoactive mediators, mainly renin-




an important risk factor for CIN. Impaired nitric oxide-dependent renal vasodi-
latation is common in individuals who are hypertensive. In addition, a decreased 
nephron count could predispose hypertensive patients to CIN.
4.11 Nephrotoxic drugs
Nephrotoxic drugs that inhibit the vasodilatory effects of prostaglandins 
make the kidneys extremely vulnerable to the toxic effect of contrast media. 
Aminoglycosides, sulfonamides, and their combinations with furosemide are very 
risky. Cyclosporin A may intensify medullary hypoxia, and cisplatin can bind 
to sulfhydryl groups. Mannitol can increase the metabolic load and the oxygen 
consumption of the kidney, and amphotericin B can cause the combined effect of 
mannitol and cyclosporine A. It has been demonstrated that nonselective NSAIDs 
and selective COX-2 inhibitors decrease the availability of vasodilatory prostaglan-
dins in the kidneys and enhance the vasoconstrictive effect of CM [34].
4.12 ACE inhibitors and angiotensin receptor blockers
ACE inhibitors have been identified as a risk factor for CIN because of their 
ability to reduce renal function. On the contrary, some small studies have shown 
that the inhibition of angiotensin II can decrease renal vasoconstriction follow-
ing the injection of contrast media. In a randomized controlled study including 
71 patients with diabetes who underwent coronary angiography and randomized 
to captopril (25 mg thrice daily) or control, there was a significant decrease in 
CIN in the patients who received captopril compared with the control group (6 vs 
29%, respectively, p < 0.02) [35]. A randomized controlled study was performed 
on 80 patients with serum creatinine less than 2 mg/dl who underwent coronary 
angiography where captopril was administered in 48 patients preceding coronary 
angiography. CIN occurred in five patients (10.4%) in the captopril group, com-
pared with only one patient (3.1%) in the control group (p = 0.02) [36]. We can 
say that holding ACE inhibitor or ARB use before coronary angiography is to be 
considered.
4.13 Acute myocardial infarction
A study by Rihal and his colleagues pointed that acute myocardial infarction 
occurring within 24 h before administration of the CM is a risk predictor to CIN 
(OR = 1.85, p = 0.0006). This study showed that CIN represents a frequent com-
plication in acute myocardial infarction. This can occur, as well, in patients with a 
normal baseline renal function [30]. In 2082 percutaneous interventions for acute 
myocardial infarction, a more than sevenfold (3.2 vs 23.3%) elevation in 1-year 
mortality in patients who acquired CIN was acknowledged [37].
4.14 Contrast medium-related risk factors
4.14.1 Increased dose of contrast medium
Based upon multiple sources, the relatively unhazardous cutoff point of contrast 
amount ranges from 70 mL up to 220 mL. However, very small doses as much as 
20–30 mL are capable of inducing CIN. In a study that included patients performing 
coro¬nary angiography, each 100 mL of contrast medium administered was linked 
to a significant increase of 12% in the risk of CIN (OR = 1.12, p = 0.02) [32]. A clear 
accepted dose is four times the creatinine clearance.
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4.14.2 High-osmolar and ionic CM
Most side effects attributable to contrast media are linked to its hypertonicity. 
Currently, four main types of contrast media are used in practice today, includ-
ing nonionic low-osmolar, ionic low-osmolar, nonionic iso-osmolar, and ionic 
high-osmolar contrast media. In a large study which compared the nonionic low-
osmolality agent iohexol to the ionic high-osmolality agent meglumine/sodium 
diatrizoate in patients with preexisting renal impairment undergoing angiography, 
patients with renal impairment who received diatrizoate were 3.3 times more liable 
to develop CIN in comparison with those receiving iohexol [38]. NEPHRIC trial 
is a randomized, prospective study that made a comparison between the nonionic 
iso-osmolar CM iodixanol with the nonionic low-osmolar CM iohexol in 129 
patients with renal impairment and diabetes undergoing coronary or aortofemoral 
angiography. The incidence of CIN was 3% in the iodixanol group and 26% in the 
iohexol group (p = 0.002) [39]. In one other randomized study, the incidence of 
CIN provoked by iodixanol and iohexol was compared in 124 patients with basal 
creatinine level >1.7 mg/dl. The incidence of CIN was 3.7% in iodixanol group and 
10% in iohexol group (p > 0.05) [17]. In addition, CM are classified as ionic and 
nonionic. A randomized trial of 1196 patients performing coronary angiography 
showed that nonionic CM lowered the incidence of CIN in patients with preexisting 
renal impairment [38]. In high-risk patients, it is better to avoid the use the high-
osmolar and ionic CM to lower the risk of CIN.
5. Pathophysiology
No definitive causative has been defined as regards the pathogenesis of CIN 
in the literature. The most accepted theory for the development of CIN following 
contrast administration relies upon the vasoconstriction of the vessels in the renal 
medulla leading to reduced oxygen delivery [40]. Reduced oxygen delivery and 
prolonged vasoconstriction leads to enhanced production of oxygen-free radicals 
like hydrogen peroxide and superoxide leading to increased damage [41]. Other 
suggested causes of this condition are elevated blood viscosity, reperfusion injury, 
direct toxic damage to the cells, and the release of dopamine, angiotensin II, and 
vasopressin. These factors induce further vasoconstriction and damage the renal 
function [42]. The use of supportive therapy in critically ill patients, for instance, 
the mechanical ventilation and inotropic drugs, and the variable health risks this 
group of patients have as anemia and sepsis have been shown to increase additional 
kidney damage resulting from vasoconstriction and hypoxia [43].
5.1 Regional hypoxia as a cause of contrast-induced nephropathy (CIN)
Renal perfusion is very high in the cortex. The medullary portions are main-
tained at the border of hypoxia such that pO2 levels can be as low as 20 mmHg 
[44]. This is the price for maintaining the countercurrent mechanism used for the 
control of urine excretion. A vulnerable kidney region is the deeper part of the 
outer medulla, an area far from the vasa recta which supply the renal medulla with 
blood. It is there where the thick ascending limbs of the loop of Henle encounter 
hypoxic damage [45]. The cause for the vulnerability of the outer medullary 
portion of the nephron is the relatively higher oxygen needs due to salt reabsorp-
tion. The addition of contrast media to the medium augments the hypoxic injury 
imposed upon this region by increasing the renal vascular resistance, as seen in 




an elevated oxygen demand due to an enhanced workload in the tubular cells. 
First, there is a temporary increase in GFR that follows giving contrast media 
[47], and second, osmotic diuresis may reduce the para-cellular absorption of 
the proximal tubular cells, causing a greater load of NaCl that has to be absorbed 
in the distal tubules. Liss et al. [48] have shown that contrast media can enhance 
medullary blood flow to the kidney, although pO2 decreases, which is supported 
also by a study of Heyman et al. [49]. These two studies suggest that an increased 
oxygen demand has taken place following contrast media injection. Local kidney 
hypoxia can be augmented by the systemic effects of some contrast media, such as 
transiently diminished cardiac output [50] and abnormal pulmonary ventilation-
perfusion relationship [51]. Also, the amount of oxygen delivered to the peripheral 
tissues might be impaired, since contrast media can increase oxygen affinity of 
hemoglobin [52]. If renal outer medullary hypoxia causes CIN, the blockade of the 
transporters in this portion of the nephron must have helpful effects on its preven-
tion. The major part of the transport that occurs in the medullary thick ascending 
limb is the Na-K+-2Cl− cotransporter, which, as mentioned above, is blocked by 
furosemide. Blocking this transport would significantly decrease the local oxygen 
consumption.
5.2 Radiocontrast-mediated changes in renal blood supply
Renal blood flow and intrarenal microcirculation are markedly altered by 
contrast medium (CM) [53]. The extent and distribution of renal hemodynamic 
changes depends on the species investigated as well as on the type, volume, and 
rate of contrast administration. Moreover, renal hemodynamic effects of CM 
gravely depend on the hydration state and on additional predisposing factors that 
may have an effect on the renal circulation and the tone of the renal vasculature, 
such as chronic renal disease, diabetes mellitus, senility, and inflammation. In an 
early study in dogs subjected to a high-osmolar CM, total renal blood flow was 
transiently enhanced for 5–15 min, followed by a decline by 25% below baseline, 
reaching beyond a couple of hours [54]. In healthy humans, renal blood flow fell 
8% over 30 min after the intravenous administration of conventional doses of CM 
[53]. On the contrary, in patients with chronic kidney disease undergoing coronary 
angiography, a transient short augmentation of renal blood flow was followed by a 
dramatic 40% decline, lasting for more than 3 h [54].
5.3 Cytotoxic effects on renal tubular cells
Investigations performed in vitro on cell lines are used to assess the renal tubular 
cell function or damage. A porcine cell line of renal proximal tubules, LLC-PK1, 
was used by Hardiek et al. [55] to investigate the occurrence of CIN. An effect on 
apoptosis was not elucidated, even though proliferation was impaired. Diminished 
proliferation will have a hazardous effect on renal function with a delay of hours 
to days, which may help in explaining the course of CIN. Independent of the 
contrast media used, tubular cell damage can occur. A more specific distortion of 
proximal tubular function seems to be a perturbation of mitochondrial enzymatic 
activity and mitochondrial membrane potential [56]. The degree of mitochondrial 
enzymatic activity impairment depends mainly on two features of the contrast 
media: the ionic nature as well as the molecular structure. Remarkably, low-osmolar 
contrast media had the least observed effects, followed by the iso-osmolar contrast 
media. Ionic compounds showed the most deleterious effects [56]. In the distal 
tubule, contrast media may trigger apoptotic effects in the cells, as depicted in the 
Madin-Darby canine kidney (MDCK) cell line model [57].
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an elevated oxygen demand due to an enhanced workload in the tubular cells. 
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5.4 Generation of oxygen-free radicals
Among the often-discussed mechanisms, superoxide and other reactive oxygen 
species (ROS) have been discussed to be an aggravating factor for CIN. Oxygen free 
radicals are endogenously produced, and levels can increase during oxidative stress. 
The commonest oxygen radicals are superoxide (O2−), hydrogen peroxide (H2O2), 
and hydroxyl radical (OH−) [58]. O2− and OH− are more reactive in comparison 
with H2O2, which is not a radical but shows greater membrane permeability. O2− 
rapidly scavenges nitric oxide (NO) and could diminish NO activity in the renal 
vessels. Since NO decreases oxygen consumption, it is considerable to speculate 
that decreased (scavenged) NO levels in diabetes increases oxygen consumption, 
thus leading to reduced partial oxygen pressure values with consequences for 
endothelial-epithelial structure and function. ROS can play a role in the effects 
of various vasoconstrictors that are considered necessary for the development of 
CIN. Because ROS are extracellular signaling molecules, they can have a crucial role 
in mediating the effects of vasoconstrictors, such as thromboxane A2, angiotensin 
II, adenosine, endothelin (ET)-1, and norepinephrine. The adverse effects of CM 
on kidney function can therefore involve the generation of ROS, for example, via 
adenosine formation. This idea is supported by experiments in which the  generation 
of ROS was inhibited by allopurinol or the amount of ROS was decreased by O2− 
dismutase. In these models, CM-induced reductions in glomerular filtration rate are 
attenuated [59].
6. Preventive measures against contrast-induced nephropathy
6.1 Adequate hydration
6.1.1 Intravenous hydration
Adequate hydration for patients performing CM-enhanced imaging studies was 
suggested approximately 40 years ago [30]. The beneficial effects of hydration were 
initially reported in the early 1980s by studies that compared outcomes of hydrated 
patients with historical controls [60, 61]. These reports were supported by the first 
RCT in 1994, concluding that patients with chronic renal impairment benefit better 
from intravenous (0.45%) saline administration (for 12 h before and 12 h after 
angiography) in comparison with saline plus mannitol or furosemide [62]. Since 
then, multiple RCTs have assured the benefit of intravenous normal saline (0.9%) 
hydration that is started 12 h preceding to 12 h after CM injection [63–65] in the 
prevention against CIN over 0.45% saline [65] or a fluid bolus (300 mL) during CM 
administration only [66]. The rate of infusion was reported as 1 mL/kg/h [67]. CM 
safety committee endorse a regime of intravenous infusion of 1.0–1.5 mL/kg/h for at 
least 6 h before and after CM administration [68].
6.1.2 Oral hydration
In order to overcome the limitations of outpatient intravenous hydration, inves-
tigators have assessed the use of pre-procedure oral hydration followed by post-
procedure intravenous hydration in patients who are admitted for catheterization 
on the day of procedure. In an RCT on patients with mild-to-moderate renal insuf-
ficiency, Taylor et al. reported an effective protocol which includes pre-angiography 
oral hydration (1000 mL clear fluids over 10 h) that is followed by 6 h of intravenous 




exposure [69]. The results were comparative with overnight intravenous hydration 
(0.45% normal saline solution at 75 mL/h for both 12 h before and after angiogra-
phy). A limitation of this protocol can be high infusion rate (300 mL/h) post-proce-
dure for the patients having left ventricular impairment. Trivedi and his colleagues 
demonstrated different results as they observed that patients with unrestricted oral 
hydration had more opportunities of acute renal impairment compared to those 
receiving normal saline for 24 h (at a rate of 1 mL/kg/h) beginning 12 h before the 
scheduled catheterization (p = 0.005) [68]. In this study, however, there was no set 
protocol for oral hydration for patients to follow that probably could have contrib-
uted to its ineffectiveness. Later, Dussol et al. randomized 312 patients with chronic 
kidney disease (CKD) to receive either per oral sodium chloride (NaCl) (dose: 
1 g/10 kg bodyweight/day for 2 days before the procedure), intravenous normal 
saline 15 mL/kg for the 6 h preceding the procedure (control arm), theophylline, or 
furosemide in addition to the treatment given to patients in the control arm [70]. 
Oral saline hydration was found to have comparative effectiveness as intravenous 
saline hydration as regards preventing CI-AKI.
6.1.3 Sodium bicarbonate-based hydration
The acidic PH promotes free radical production (which is found in tubular 
urine) [71], while elevated pH of normal extracellular fluid inhibits it [72, 73]. 
Since CM administration escalates the oxidative stress and increases the generation 
of free radicals and reactive oxygen species (ROS), alkalinizing renal tubular fluid 
with bicarbonate appears to be a logical strategy to protect against renal injury 
[74]. As a result of active reabsorption, bicarbonate concentration in the renal 
tubules lowers (to about 6 mEq/L), and the tubular fluid pH is approximately 6.5 
near the end of the proximal tubule in the renal medulla [75]. In the descending 
loop of Henle, water and chloride are passively reabsorbed. This elevates urine pH 
to ~7.4 at the tip of the papilla, and this part is spared from contrast nephropathy 
[76], which suggests that higher pH is protective. Also important is the observation 
that outer medulla is the most susceptible to CIN [62] and has acidic pH [72] that 
promotes activity of ROS. Superoxide, a ROS generated by ischemia, might react 
with medullary NO to produce the potent oxidant peroxynitrite [73]. At physiologic 
concentrations, bicarbonate scavenges peroxynitrite and other ROSs produced from 
NO [74]. Thus, several oxidant mechanisms of renal injury might be avoided using 
sodium bicarbonate. The useful effect of higher proximal tubular pH is approved by 
a report that acetazolamide, a carbonic-anhydrase inhibitor which blocks proximal 
tubular bicarbonate reabsorption, is protective in contrast-induced renal failure 
[77]. Merten et al. reported first study on the use of sodium bicarbonate in humans 
as a nephron-protective agent [78]. Patients received 154 mEq/l of either NaCl (in 
5% dextrose H2O) or sodium bicarbonate (in dextrose H2O), as a bolus of 3 mL/kg/h 
for 1 h before iopamidol contrast, followed by an infusion of 1 mL/kg/h for 6 h after 
the procedure. CIN occurred in 8 patients (13.6%) infused with NaCl but in only 1 
(1.7%) of those receiving sodium bicarbonate (p = 0.02). Afterwards, many RCTs 
have compared the efficacy of sodium bicarbonate with saline hydration regarding 
the prophylaxis against CIN. These have been reviewed in multiple meta-analysis 
[79–82], which concluded that sodium bicarbonate-based saline hydration is more 
efficacious to saline hydration only.
6.1.4 Pharmacological prophylaxis
Various drugs have been assessed as prophylactic nephroprotective agents 
against contrast-induced acute kidney injury (CI-AKI) such as N-acetylcysteine 
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(NAC) [36, 83], statins [84, 85], ascorbic acid [76, 86], and theophylline [87]. 
However, only statins have been approved for the prevention against the occur-
rence of CIN. Currently, the CM safety committee recommends the withdrawal of 
nephrotoxic drugs before CM administration [85].
6.1.5 N-Acetylcysteine (NAC)
NAC gives protection against CIN by improving the body’s antioxidant abilities 
[88]. In vitro, NAC does this efficiently by scavenging hypochlorous acid as well 
as reacting with hydroxyl radicals [89]. In vivo due to its extensive degradation, it 
is likely that any antioxidant effect it exerts would be indirect, most probably by 
inducing glutathione synthesis. Different studies have suggested that NAC guards 
against glutathione depletion [90, 91] and elevates renal glutathione levels [92]; the 
latter has been demonstrated to result in the reduction of renal injury in ischemia 
reperfusion models [93, 94] and recently in CIN [95, 96]. Glutathione cannot enter 
the cell; instead, it must be formed inside the cell from glycine, glutamate, and 
cysteine [97]. Cysteine offers the active HS group which is crucial for the glutathi-
one synthesis and thus is the rate-limiting factor in this process. NAC after deacyla-
tion produces cysteine that passes to the renal cells and serves as a precursor for 
glutathione synthesis. It can also produce vasodilator effects [98]. By ameliorating 
contrast-induced vasoconstriction, NAC can produce its nephron-protective role 
[99]. Increase in the medullary blood flow with NAC has also been demonstrated 
[100, 101]. The first clinical use of NAC for CIN was reported by Tepel et al. [83]. 
Eighty-three patients who had chronic renal impairment were randomly planned 
either to take oral NAC (600 mg twice daily) and 0.45% saline intravenously, before 
and after administration of the CM, or to receive placebo and saline. NAC-receiving 
patients had lower incidence of CIN. Since then numerous studies have assessed the 
role of NAC against CIN. Those studies have been done mainly in patients undergo-
ing coronary angiography [102]. Some 17 meta-analyses have been published as 
regards this subject [76, 86, 87, 103–116], 10 that approve its use (most of which 
were published early on). Most of these meta-analyses reported vast heterogeneity 
that makes it difficult to make clinical treatment recommendations relying on the 
provided data. Recently, results of the largest multicenter RCT of 2308 patients 
called “Acetylcysteine for Contrast-Induced Nephropathy Trial” (ACT) have been 
published [36]. It randomized patients in 46 centers in Brazil, to take 1200 mg 
of oral NAC or placebo twice daily for 2 doses before and after the procedure. 
Intravenous hydration with normal saline, 1 mL/kg/h, from 6–12 h before to 6–12 h 
after angiography, was strongly recommended. NAC was not able to significantly 
reduce the incidence of CIN (12.7% in the NAC group and 12.7% in the control 
group, p = 0.97) [117].
6.1.6 Ascorbic acid
Ascorbic acid serves as an antioxidant [118]. It does this via reacting with most 
biologically relevant free radicals and oxidants such as superoxide ions and hydroxyl 
ion [119]. It donates an electron to devastating oxidizing radicals [120]; this one-
electron oxidation leads to the formation of AHˉ the ascorbyl radical also called 
semidehydroascorbic acid [121]. Consequently, the reactive free radical is reduced 
[122]. Ascorbic acid has been reported to result in vasodilatation in coronary [123] 
and brachial arteries [124]. Thus, vitamin C can have favorable effects on vascular 
dilatation, through its antioxidant actions on nitric oxide, but these findings are 
not consistent [125]. Through which pathway vitamin C may offer nephron protec-




acid for CIN prevention was reported by Spargias and his colleagues [116]. Two 
hundred and thirty-one patients were summoned and randomized to obtain either 
3 g of ascorbic acid supplied in chewable tablets or placebo at least 2 h prior to the 
beginning of the required procedure. This was followed by 2 g of ascorbic acid or 
placebo the night and the morning post-procedure. Intravenous hydration with 
normal saline at a rate of 50–125 mL/h was started in every patient till at least 6 h 
post-procedure. Incidence of CIN was less in ascorbic acid group (9%) and 20% in 
control group (p = 0.02). A considerable change in the antioxidant state was noticed 
in the group treated with ascorbic acid. Since then various RCTs have been per-
formed [126, 127]. Pooled analysis of these trials assumed that patients who receive 
ascorbic acid have 33% less risk of CIN in comparison with patients receiving 
placebo or alternative pharmacological therapy (RR: 0.67 (95% CI: 0.46–0.96), p = 
0.03) [100]. This indicates that ascorbic acid provides effective nephron protection 
in the face of CIN and may form a part of efficient prophylactic pharmacological 
regimens. However, the utilization of ascorbic acid has not yet been recommended 
by the contrast media safety committee.
6.2 Statins
Statins maintain nitric oxide formation, lower oxidative stress, and beneficially 
affect the endothelial function [101]. In one retrospective study of more than 1,000 
patients with renal impairment undergoing coronary angiography, the risk of CIN 
was markedly decreased in patients who are receiving a statin before the procedure 
[128]. Another study of more than 29,000 patient recorded in a percutaneous 
cardiac intervention registry demonstrated that patients who received statins before 
the procedure had both a lower CIN incidence (p < 0.0001) and nephropathy that 
required dialysis (p < 0.03) [181]. Further studies looking into the benefit from 
statins are warranted [129].
6.2.1 High-dose versus low-dose statins
High-dose statin therapy may be theoretically more efficacious regarding CIN 
prevention as a result of acute suppression of inflammatory chemokines [130]. 
Xie and his colleagues investigated the potency of high-dose statins (simvastatin 
80mg, atorvastatin 40 and 80 mg) compared with low-dose statins (simvastatin 
20 mg, atorvastatin 10 and 20mg) and revealed that high-dose statins lowered the 
incidence of CIN [131]. These results were backed up by a recent meta-analysis 
which showed that high-dose statins (atorvastatin 80 mg, simvastatin 80 mg) in 
comparison with low-dose statins (atorvastatin 10 and 20 mg, simvastatin 20 mg) 
in patients having acute coronary syndromes resulted in a relative risk ratio for CIN 
of 0.46 (4.5 vs 10.2%, p = 0.004); however, it was not of considerable significance 
among patients performing elective procedures [132]. However, high-dose statins 
are guideline recommended medications to lower the risk of CIN.
6.2.2 Theophylline
Adenosine has been implicated to be a responsible factor for mediating 
CM-enhanced renal vasoconstriction [133–135]: hence the use of adenosine antago-
nists appears logical [136]. Theophylline and aminophylline have been often used 
to measure their efficacy as adenosine receptor antagonists in guarding against 
contrast-induced acute kidney injury (CI-AKI). Various randomized trials have 
used theophylline [20, 137, 138]. A meta-analysis of those studies guided to the fact 
that theophylline considerably lowers the risk of CIN (RR: 0.48; 95% CI: 0.26–0.89; 
New Insight into Cerebrovascular Diseases - An Updated Comprehensive Review
128
(NAC) [36, 83], statins [84, 85], ascorbic acid [76, 86], and theophylline [87]. 
However, only statins have been approved for the prevention against the occur-
rence of CIN. Currently, the CM safety committee recommends the withdrawal of 
nephrotoxic drugs before CM administration [85].
6.1.5 N-Acetylcysteine (NAC)
NAC gives protection against CIN by improving the body’s antioxidant abilities 
[88]. In vitro, NAC does this efficiently by scavenging hypochlorous acid as well 
as reacting with hydroxyl radicals [89]. In vivo due to its extensive degradation, it 
is likely that any antioxidant effect it exerts would be indirect, most probably by 
inducing glutathione synthesis. Different studies have suggested that NAC guards 
against glutathione depletion [90, 91] and elevates renal glutathione levels [92]; the 
latter has been demonstrated to result in the reduction of renal injury in ischemia 
reperfusion models [93, 94] and recently in CIN [95, 96]. Glutathione cannot enter 
the cell; instead, it must be formed inside the cell from glycine, glutamate, and 
cysteine [97]. Cysteine offers the active HS group which is crucial for the glutathi-
one synthesis and thus is the rate-limiting factor in this process. NAC after deacyla-
tion produces cysteine that passes to the renal cells and serves as a precursor for 
glutathione synthesis. It can also produce vasodilator effects [98]. By ameliorating 
contrast-induced vasoconstriction, NAC can produce its nephron-protective role 
[99]. Increase in the medullary blood flow with NAC has also been demonstrated 
[100, 101]. The first clinical use of NAC for CIN was reported by Tepel et al. [83]. 
Eighty-three patients who had chronic renal impairment were randomly planned 
either to take oral NAC (600 mg twice daily) and 0.45% saline intravenously, before 
and after administration of the CM, or to receive placebo and saline. NAC-receiving 
patients had lower incidence of CIN. Since then numerous studies have assessed the 
role of NAC against CIN. Those studies have been done mainly in patients undergo-
ing coronary angiography [102]. Some 17 meta-analyses have been published as 
regards this subject [76, 86, 87, 103–116], 10 that approve its use (most of which 
were published early on). Most of these meta-analyses reported vast heterogeneity 
that makes it difficult to make clinical treatment recommendations relying on the 
provided data. Recently, results of the largest multicenter RCT of 2308 patients 
called “Acetylcysteine for Contrast-Induced Nephropathy Trial” (ACT) have been 
published [36]. It randomized patients in 46 centers in Brazil, to take 1200 mg 
of oral NAC or placebo twice daily for 2 doses before and after the procedure. 
Intravenous hydration with normal saline, 1 mL/kg/h, from 6–12 h before to 6–12 h 
after angiography, was strongly recommended. NAC was not able to significantly 
reduce the incidence of CIN (12.7% in the NAC group and 12.7% in the control 
group, p = 0.97) [117].
6.1.6 Ascorbic acid
Ascorbic acid serves as an antioxidant [118]. It does this via reacting with most 
biologically relevant free radicals and oxidants such as superoxide ions and hydroxyl 
ion [119]. It donates an electron to devastating oxidizing radicals [120]; this one-
electron oxidation leads to the formation of AHˉ the ascorbyl radical also called 
semidehydroascorbic acid [121]. Consequently, the reactive free radical is reduced 
[122]. Ascorbic acid has been reported to result in vasodilatation in coronary [123] 
and brachial arteries [124]. Thus, vitamin C can have favorable effects on vascular 
dilatation, through its antioxidant actions on nitric oxide, but these findings are 
not consistent [125]. Through which pathway vitamin C may offer nephron protec-




acid for CIN prevention was reported by Spargias and his colleagues [116]. Two 
hundred and thirty-one patients were summoned and randomized to obtain either 
3 g of ascorbic acid supplied in chewable tablets or placebo at least 2 h prior to the 
beginning of the required procedure. This was followed by 2 g of ascorbic acid or 
placebo the night and the morning post-procedure. Intravenous hydration with 
normal saline at a rate of 50–125 mL/h was started in every patient till at least 6 h 
post-procedure. Incidence of CIN was less in ascorbic acid group (9%) and 20% in 
control group (p = 0.02). A considerable change in the antioxidant state was noticed 
in the group treated with ascorbic acid. Since then various RCTs have been per-
formed [126, 127]. Pooled analysis of these trials assumed that patients who receive 
ascorbic acid have 33% less risk of CIN in comparison with patients receiving 
placebo or alternative pharmacological therapy (RR: 0.67 (95% CI: 0.46–0.96), p = 
0.03) [100]. This indicates that ascorbic acid provides effective nephron protection 
in the face of CIN and may form a part of efficient prophylactic pharmacological 
regimens. However, the utilization of ascorbic acid has not yet been recommended 
by the contrast media safety committee.
6.2 Statins
Statins maintain nitric oxide formation, lower oxidative stress, and beneficially 
affect the endothelial function [101]. In one retrospective study of more than 1,000 
patients with renal impairment undergoing coronary angiography, the risk of CIN 
was markedly decreased in patients who are receiving a statin before the procedure 
[128]. Another study of more than 29,000 patient recorded in a percutaneous 
cardiac intervention registry demonstrated that patients who received statins before 
the procedure had both a lower CIN incidence (p < 0.0001) and nephropathy that 
required dialysis (p < 0.03) [181]. Further studies looking into the benefit from 
statins are warranted [129].
6.2.1 High-dose versus low-dose statins
High-dose statin therapy may be theoretically more efficacious regarding CIN 
prevention as a result of acute suppression of inflammatory chemokines [130]. 
Xie and his colleagues investigated the potency of high-dose statins (simvastatin 
80mg, atorvastatin 40 and 80 mg) compared with low-dose statins (simvastatin 
20 mg, atorvastatin 10 and 20mg) and revealed that high-dose statins lowered the 
incidence of CIN [131]. These results were backed up by a recent meta-analysis 
which showed that high-dose statins (atorvastatin 80 mg, simvastatin 80 mg) in 
comparison with low-dose statins (atorvastatin 10 and 20 mg, simvastatin 20 mg) 
in patients having acute coronary syndromes resulted in a relative risk ratio for CIN 
of 0.46 (4.5 vs 10.2%, p = 0.004); however, it was not of considerable significance 
among patients performing elective procedures [132]. However, high-dose statins 
are guideline recommended medications to lower the risk of CIN.
6.2.2 Theophylline
Adenosine has been implicated to be a responsible factor for mediating 
CM-enhanced renal vasoconstriction [133–135]: hence the use of adenosine antago-
nists appears logical [136]. Theophylline and aminophylline have been often used 
to measure their efficacy as adenosine receptor antagonists in guarding against 
contrast-induced acute kidney injury (CI-AKI). Various randomized trials have 
used theophylline [20, 137, 138]. A meta-analysis of those studies guided to the fact 
that theophylline considerably lowers the risk of CIN (RR: 0.48; 95% CI: 0.26–0.89; 
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p = 0.02). There was moderate heterogeneity that suggests cautious interpretation 
of these results. Furthermore, patients with baseline renal insufficiency did not 
show any benefit from theophylline.
6.2.3 Allopurinol
This drug is a xanthine oxidase inhibitor which may hamper the fall in the GFR 
following CM exposure by limiting oxygen free radical production, inhibiting 
adenine nucleotide degradation, and limiting the vasodilator reaction to intrarenal 
adenosine. A trial that included 159 patients randomized patients performing 
coronary angiography procedures to allopurinol (300 mg orally) with hydration 
or hydration alone, showed that allopurinol can guard against CIN in high-risk 
patients receiving CM [139]. However, these effects of allopurinol in the prevention 
of CIN need further larger studies.
6.2.4 Dopamine
Dopamine (in a renal dose 0.5–2.5 μg/kg/min) has a vasodilator action on the 
renal vasculature and has an ability to increase renal blood flow and GFR with a 
potential benefit in the prevention of CIN. Trials with positive results were small, 
not randomized and with questionable endpoints [140]. On the contrary, negative 
trials were large, randomized, controlled, and with adequate statistical power [141]. 
Thus, the usage of dopamine in guarding against CIN is no longer recommended.
6.2.5 Targeted renal therapy
A suggested theory for failure of various drugs used for kidney protection is that 
systemically administered drugs may not achieve adequate drug level in the renal 
vasculature in order to be successful regarding the prevention of CIN. This has led 
to the technique of direct infusion of a drug in a selective manner into the kidneys 
via the renal arteries, which is known as targeted renal therapy (TRT). This should 
have the ability of decreasing the systemic side effects of that drug. Fenoldopam is 
a dopamine-1 agonist that acts as a vasodilator and thus has a potential to attenu-
ate the vasoconstriction induced by CM in the renal vessels. Although it was not 
possible to demonstrate its benefit in reducing the incidence of CIN [142], it was 
observed that a large number of patients could not tolerate low doses of fenoldo-
pam as a result of drug-induced hypotension, which is itself a risk predictor of 
CIN. Employing TRT, selective bilateral renal artery catheterization may be per-
formed for localized drug delivery. In a pilot study on patients undergoing endovas-
cular aneurysm repair, Benephit PV Infusion System (Flow Medica, Inc., Fremont, 
CA, USA) was used for selective catheterization of both renal arteries through 
brachial artery puncture. There was no episode of hypotension, thus every patient 
received fenoldopam at a rate of 0.4 μg/kg/min for the duration of the aneurysm 
repair [143]. If the pigtail catheter is inserted in the aorta just over the level of the 
renal artery avoiding selective catheterization, this appears to be a simple way but 
would lead to considerable systemic drug effects as a result of infusion of the drug 
into the systemic circulation [143]. The safety and performance of TRT were also 
assessed by retrospective analysis of 285 patients who received fenoldopam via 
TRT, as a part of “The Benephit System Renal Infusion Therapy (Be-RITe)” registry 
[144]. Benephit Infusion System (Flow Medica, Inc., Fremont, CA, USA) was used. 
Bilateral renal artery cannulation achieved success in 94.2%, with a mean cannula-




benefit in patients with highest risk of CIN. Prospective studies and RCTs are 
therefore required in order to assess real ability of this technique.
6.2.6 Ischemic preconditioning
Ischemic preconditioning includes exposure to short episodes of ischemia fol-
lowed by reperfusion to make the target organ prepared against the main ischemic 
insult. If the site of generation of these short episodes of ischemic reperfusion is 
remote from the site of target organ, it is called remote ischemic preconditioning. 
This technique has been used with only variable success in offering myocardial and 
renal protection in cardiovascular medicine [145–151]. Results of an RCT propose 
usefulness from remote ischemic preconditioning in preventing CIN [152]. The 
likely usefulness may arise from its capability to attenuate the CM-induced ischemia 
reperfusion injury. Recently, ischemic preconditioning has lost its credibility as it 
was unable to translate successful results in laboratories into clinical practice [153].
7. Sequelae
Patients who develop CIN have greater complications, a worse prognosis, more 
serious long-term outcomes, and longer duration of hospital stay, which result in 
elevated medical costs [154, 155]. Less than 0.5–2% of patients who develop CIN 
require dialysis [156]. Those requiring dialysis are more likely to exhibit serious 
short- and long-term outcomes. Nearly 30% of those patients experience chronic 
renal impairment [154]. CIN may also be linked to an increased mortality which is 
independent of other risk factors [157]. Hospital death rates in such patients have 
been reported as 36% and the 2-year survival rate as only 19% [158, 159]. Levy et al. 
compared 181 inpatients that developed CIN with matched control patients who 
did not develop it; both groups underwent contrast-related procedures [156]. The 
mortality rate in the control group was 7%, compared to 34% in the CIN group. In 
another study of 7230 patients who underwent percutaneous coronary interven-
tions, patients who developed CIN had more common myocardial infarctions, 
more hospital stays, and higher 1-year mortality rates compared to those without 
CIN. CIN patients are more likely to have target vessel revascularization after 1 
year, bypass surgery, bleeding which mandates transfusion, and various vascular 
complications [160]. Patients who undergo a primary percutaneous intervention for 
acute myocardial infarction and the procedure complicates by CIN were reported to 
be significantly more likely to have major complications within hospital admission 
such as acute pulmonary edema, the need for pacemaker insertion, cardiogenic 
shock, and respiratory failure [160]. Patients with renal insufficiency are at more 
significant risk of developing atherosclerosis [19]. Actually, following a contrast 
procedure, a rise in serum creatinine is a more significant indicator of late mortality 
compared to an elevated creatine kinase-MB isoenzyme [160].
8. Conclusion
Contrast-induced nephropathy is a not an uncommon sequela of coronary 
angioplasty. It can lead to increased morbidity and mortality. One should be aware 
of the risk factors that increase its incidence and thus limit the amount of contrast 
so as to avoid such a deleterious complication. Prevention is better than treatment in 
this case.
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remote from the site of target organ, it is called remote ischemic preconditioning. 
This technique has been used with only variable success in offering myocardial and 
renal protection in cardiovascular medicine [145–151]. Results of an RCT propose 
usefulness from remote ischemic preconditioning in preventing CIN [152]. The 
likely usefulness may arise from its capability to attenuate the CM-induced ischemia 
reperfusion injury. Recently, ischemic preconditioning has lost its credibility as it 
was unable to translate successful results in laboratories into clinical practice [153].
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another study of 7230 patients who underwent percutaneous coronary interven-
tions, patients who developed CIN had more common myocardial infarctions, 
more hospital stays, and higher 1-year mortality rates compared to those without 
CIN. CIN patients are more likely to have target vessel revascularization after 1 
year, bypass surgery, bleeding which mandates transfusion, and various vascular 
complications [160]. Patients who undergo a primary percutaneous intervention for 
acute myocardial infarction and the procedure complicates by CIN were reported to 
be significantly more likely to have major complications within hospital admission 
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shock, and respiratory failure [160]. Patients with renal insufficiency are at more 
significant risk of developing atherosclerosis [19]. Actually, following a contrast 
procedure, a rise in serum creatinine is a more significant indicator of late mortality 
compared to an elevated creatine kinase-MB isoenzyme [160].
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angioplasty. It can lead to increased morbidity and mortality. One should be aware 
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Abstract
Unruptured intracranial aneurysms (UIAs) represent a major public health 
issue due to their unpredictable natural history. Whether to actively treat them or 
to maintain them under observation remains a hotly disputed topic. In this chapter, 
we present a review of the literature regarding the history of clipping and its use 
in UIAs, as well as the experience of our senior author in this field. We performed 
an extensive Medline and Google Academic search of the relevant literature. We 
have also made a retrospective analysis on patients harboring UIAs and multiple 
intracranial aneurysms (MIAs) clipped by the senior author between 1997 and 
2017. About 89 patients had solitary UIAs, alongside 101 with MIAs possessing 257 
individual aneurysms in total. All UIA patients were discharged with a favorable 
neurological outcome and no mortality. Concerning MIAs, the majority of cases 
had 2 aneurysms, the highest number being 6. And, 61 patients from this group had 
a favorable outcome. In the hands of experienced vascular neurosurgeons, clipping 
remains a safe option for both UIAs and MIAs. This procedure offers a long-lasting 
protection from aneurysmal rupture. In the future, new clip technologies and 
intraprocedural methods of verifying vessel patency and aneurysmal occlusion may 
further enhance postoperative results.
Keywords: intracranial aneurysm, multiple aneurysms, unruptured, surgery, 
clipping
1. Introduction
Once considered as the definitive curative option for intracranial aneurysms 
(IAs), clipping has steadily lost its footing in the face of the less invasive and lower-
risk-laden endovascular procedures. Successful clipping implies completely occlud-
ing the aneurysmal sack at its origin on the parent artery, significantly diminishing 
the risk of rupture and ensuing morbidity. The procedure is especially indicated 
for ruptured aneurysms. However, there is ongoing debate regarding the neces-
sity for surgery in the case of unruptured intracranial aneurysms (UIAs). Since 
many of these patients also harbor more than one aneurysm, another controversial 
aspect in neurosurgery is whether to treat all aneurysms in the same session or to 
leave the unruptured lesions for a delayed intervention or even for an endovascular 
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procedure. In this chapter, we present our considerable experience and attitude in 
the surgical management of unruptured and multiple aneurysms.
Preventing rupture from IAs represents a major concern for neurosurgeons, 
neuroradiologists, and neurointerventionists, as this represents a catastrophic 
and potentially life-threatening occurrence in the natural history of this pathol-
ogy. UIAs are defined as not possessing a known history or signs of rupture or 
that have been diagnosed incidentally for symptoms unrelated to intracranial 
hemorrhage. They are a veritable “ticking time bomb” that, under certain condi-
tions, can “detonate” and cause a devastating hemorrhagic stroke with severe 
and often irreversible consequences. Therefore, preventive surgical treatment 
of UIAs, especially clipping of the aneurysmal sack, is a valuable and possibly 
life-saving option.
A successful clipping means that the vascular clip completely isolates the aneu-
rysmal lumen from blood flow at its origin on the parent artery. This point of origin 
is generally located at either a bifurcation or a sharp turn of an artery. Surgical 
clipping may prevent rupture of that particular aneurysm, although an incomplete 
occlusion can result in recurrence. Since the development of less invasive endovas-
cular techniques, clipping has lost most of its standing in the treatment of UIAs, 
being reserved for hemorrhagic lesions or those otherwise unsuitable for endo-
vascular procedures. Certain highly experienced centers still favor the intracranial 
approach for UIAs due to the longevity of procedure and excellent postoperative 
neurological outcome.
Additionally, some patients may harbor more than one aneurysm, occurring 
either concomitantly or sequentially. These may be diagnosed incidentally, during 
the rupture of at least one of the aneurysms or at a variable point in time during 
postprocedural control. The treatment of multiple intracranial aneurysms (MIAs) 
to this day remains a highly debated topic, lacking a general consensus regarding 
indications, timing, and modality. Our experience supports the single-stage single-
opening surgical treatment of multiple UIAs.
2. Short history and evolution of aneurysm surgery
Although the pathology of intracranial aneurysms had been scrupulously 
studied by the beginning of the twentieth century, treatment options were scarce 
and most often fruitless [1]. Harvey Cushing (1869–1939) himself doubted whether 
these lesions could be approached surgically due to the technical limitations, 
reduced accessibility and visibility of the lesions, as well as a general lack of experi-
ence in the surgical community [1–3]. Up until that point, the treatment of intra-
cranial aneurysms relied on the proximal ligation technique, as described by John 
Hunter (1728–1793). This resulted in thrombosis and occlusion inside the aneu-
rysm. In 1885, Sir Victor Horsley (1857–1916) was reportedly the first to successfully 
perform such an intervention for an intracranial aneurysm by ligating the right 
common carotid artery [1, 2, 4]. Cushing is credited with developing the wrapping 
technique for the treatment of intracranial aneurysms; however, in 1931 his pupil, 
Dott Norman McComish (1897–1973), performed the first elective frontal crani-
otomy in order to wrap and reinforce a ruptured aneurysm with autologous muscle 
from the patient’s thigh [3–5]. Axel Herbert Olivecrona (1891–1980) was the first 
to perform a successful surgical trapping and removal of an intracranial aneurysm 
in 1932, a technique then further elaborated by Walter Dandy (1886–1946) [5]. In 
1937, Dandy used a modified version of the Cushing clip to occlude a posterior com-
municating artery (PCoA) aneurysm via a “hypophyseal approach,” being the first 
ever documented intervention of its kind [1, 2–5].
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Since then, aneurysm clipping has undergone extensive improvements in 
both technique and instrumentation. The Cushing clip was malleable; however, 
according to Kenneth George McKenzie (1892–1964), the two sides of the clips 
were frequently of unequal length, had rough ends, and had a habit of turning 
in the holder [6]. Furthermore, it could not be reopened or repositioned; thus, 
an improper placement could compromise the entire intervention [5]. In 1927, 
McKenzie conceived a more versatile alternative to the instruments used [6–9]. 
In 1949, Duane William Jr. changed the McKenzie-modified clip holder to punch 
out more effective U-shaped clips [5]. Olivecrona made a considerable redesign 
of the clips in 1953 that allowed reopening and repositioning of the clips [4, 5, 
9]. However, the drawback to these clips were crushing the aneurysmal neck and 
producing shearing and tearing of the fragilized vascular walls. Thus, Henry 
Schwartz introduced the cross-action alpha clip, basically a miniaturized spring 
forceps that could close by itself [3, 5, 9]. Despite this concept being brilliant, its 
utilization in aneurysm surgery was problematic due to its large size and the bulki-
ness of its applicator. In 1952, Frank Mayfield and George Kees Jr. made delicate 
yet crucial enhancements to clip technology, significantly reducing the size of the 
shank, while also constructing clips of diverse lengths and angles, as well as having 
wider blade openings [3–5, 9–11]. They were also responsible for the bayoneted 
design of the clip that would permit better visualization during manipulation. 
Joseph McFadden suggested a modification of Kees’ design, with rounded blades 
and blunted tips [3, 11].
Charles Drake (1920–1998) was credited with developing the fenestrated clip 
in 1969, which could allow placement of the clips on more inaccessible aneurysms 
without compromising the parent vessel [1, 3, 4]. This was especially useful for 
treating posterior fossa aneurysms, for which Drake also pioneered innovative 
techniques and surgical approaches (such as the subtemporal approach for aneu-
rysms of the basilar apex) [4]. George Smith (1916–1964) also made an essential 
innovation with a vessel-encompassing clip that could occlude aneurysms on the 
opposite side of the affected artery [3, 12]. Elaborating on this concept, Thoralf 
Sundt (1930–1992) devised a Teflon-lined clip-graft that could also mend small 
tears or irregularities in the artery [1, 3–5, 12, 13]. At present, adjustments are still 
made regarding configuration, instrumentation, and clip composition.
The next most important bound in aneurysm surgery came in the form of 
the operating microscope, allowing better visualization and illumination of the 
aneurysm neck and surrounding vessels [1, 4, 5, 14]. Gazi Yasargil, the father of 
microneurosurgery, had probably the greatest contribution in this field by not 
only standardizing the use of the operating microscope in aneurysm surgery but 
also by developing and refining procedures and instruments now commonly used 
in vascular neurosurgery [1, 3, 4]. The clips he created were specifically designed 
for use alongside microscopic magnification. Moreover, he also underscored the 
necessity of understanding cisternal and microvascular anatomy in neurosur-
gery. Drake’s seemingly most remarkable addition to vascular neurosurgery was 
comprehending the intricate anatomy of posterior circulation aneurysms, as well 
as improving outcomes following their surgical treatment [4, 5]. Magnetic reso-
nance imaging (MRI) became crucial in the diagnosis of cerebrovascular patholo-
gies. Although, since the first clips introduced in neurosurgery were made of 
stainless steel, they were not compatible with MRI. After rigorous compatibility 
testing, Robert Spetzler introduced the pure titanium clips as a nonferromagnetic 
alternative with the same mechanical properties as other clips available at that 
time [4, 5, 15, 16].
Yasargil also described the end-to-side anastomosis between the superficial 
temporal artery and middle cerebral artery (MCA), which bypassed the blood 
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flow from the extracranial circulation to the intracranial compartment [5]. The 
bypass techniques are currently used in the management of more complex giant 
aneurysms, however with less satisfactory outcomes than the standard surgical 
approaches for smaller aneurysms [5, 17]. A more recent advancement has been the 
introduction of intraoperative videoangiography by means of fluorescent dyes such 
as fluorescein sodium or indocyanine green [18]. Charles Wrobel first described this 
method in 1994 for real-time testing of aneurysmal obliteration and the patency of 
adjacent arteries [5, 19]. This tool renders intraoperative catheter-based angiogra-
phy or Doppler ultrasonography obsolete in certain cases and allows repositioning 
of inconveniently placed clips before the onset of permanent damage [5, 18–20]. 
Other contemporary innovations include the endoscopic endonasal approaches in 
order to clip skull base aneurysms; however, this technique awaits further valida-
tion [5, 21–23].
Evidently, not all aneurysms were amenable to clipping. Before the dawn of 
endovascular procedures, surgeons attempted various methods of introducing 
foreign materials into the aneurysm sack to achieve thrombosis, with variable 
results. The materials ranged from heated silver enameled wire [24], copper wire 
[25], and silk sutures [26], to magnetically guided iron suspensions [27] to even 
animal hair from horse or dog [28]. Despite these techniques being mostly obso-
lescent, they indisputably paved the way to endovascular treatment of intracranial 
vasculopathies. The most important step in this direction belonged to the invention 
of the angiography as a superior instrument for diagnosing intracranial pathologies. 
The first cerebral angiography was performed by Egas Moniz (1874–1955) in 1927, a 
technique which remained the only dependable diagnostic method for identifying 
intracranial lesions until the introduction of computed tomography (CT) nearly 
50 years later [1, 4, 29–31]. Fascinatingly enough, an editorial published in The 
Lancet in 1931 predicted the probability of not only diagnosing intracranial aneu-
rysms through this tool but also as an opportunity for therapy in later years [1, 29]. 
The endovascular coils presently used were preceded by detachable balloons that 
could be deployed inside vascular lesions and would harden to result in a controlled 
localized thrombosis [1, 4, 32]. However, this technique resulted in significant 
complications and was soon replaced. The first successful treatment of an intra-
cranial aneurysm via coiling belonged to Ira Braun in 1985 [1, 4]. Guido Guglielmi 
undoubtedly had the most significant role in developing modern coils that were 
electrolytically detachable [33–35].
Ever since, the role of microneurosurgery in the treatment of aneurysms has 
diminished in the face of a safer, easier, less invasive, and satisfyingly durable 
procedure with a shorter hospital stay and faster recovery time [36–38]. Many other 
endovascular techniques and tools have been elaborated in the wake of this innova-
tion the technology experiencing an exponential growth. A thorough description of 
such instruments is beyond the scope of this chapter. In what follows, we detail the 
microsurgical treatment options for unruptured solitary and multiple aneurysms, 
with a special emphasis on clipping, its effects, outcome, and consequences while 
also sharing our operative experience.
3. Natural history of unruptured aneurysms
To quote physicist Niels Bohr (1885–1962), “Prediction is very difficult, 
especially about the future.” This also applies to UIAs regarding what can cause 
them to bleed and when. There is a high variability between populations in the 
prevalence of UIAs, being cited between 1% and as much as 7% of the general 
population [39–42]. They are more commonly found in the anterior circulation, 
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at more advanced ages, and more often in women. The natural history seems to 
differ according to the shape, location, and size of the lesion, with a significant 
incongruity between the number of incidentally discovered aneurysms each year 
(2000–4000 per 100,000 persons/year) and the annual incidence of aneurysmal 
subarachnoid hemorrhage (aSAH) (approximately 10 per 100,000 persons/year) 
[43]. In other words, out of 200 to 400 patients diagnosed yearly with an intra-
cranial aneurysm, chances are that only one of these may rupture. The annual and 
cumulative risk of rupture has been appraised at approximately 1%/year and at 9% 
at 9 years for the Japanese and Korean populations [44], similar to that of Western 
countries (0.2–1.6%/year and 10% at 10 years) [45–48]. Factors attributed to 
impact the natural history of UIAs may be related to the aneurysm itself, the 
patient, or even external influences.
Concerning patient-related factors, it seems that women have a higher preva-
lence of UIAs than men, and the peak incidence was found between the fifth and 
sixth decades of age. Patients with polycystic kidney disease, type IV Ehlers-Danlos 
syndrome, and Marfan syndrome are more likely to develop UIAs during their 
lifetime. Hypertension is the comorbidity most likely associated with this finding, 
while a positive family history is also an important risk factor among siblings. Up to 
15–30% of these patients harbor at least two UIAs, either concomitantly or sequen-
tially. The most common modifiable risk factors attributed to UIAs are smoking, 
alcohol and drug abuse, as well as using oral contraceptives [49].
According to the results of the PHASE 2 of the International Study of 
Unruptured Intracranial Aneurysms (ISUIA) trial, patients that had no previ-
ous aSAH and harbored aneurysms under 7 mm in diameter possessed no risk of 
rupture for UIAs in the anterior circulation [50]. However, the risk of bleeding 
was 2.5%/year for aneurysms located at the PCoA and the posterior cerebral 
circulation. Concerning patients with a history of aSAH, the risk of rupture for 
aneurysms smaller than 7 mm in the anterior cerebral circulation reached 1.5%/
year, whereas for the posterior circulation, it rose to 3.4%/year. Similarly, the 
Unruptured Cerebral Aneurysm Study (UCAS) performed in Japan proved that size 
influenced the risk of rupture, starting from 0.36% for microaneurysms (between 
3 and 4 mm), climbing at 4.37% for lesions between 10 to 24 mm to reaching as 
much as 33.4% for giant aneurysms (≥25 mm) [42]. Analogous results were also 
reported for the South Korean population [44]. Apparently, as an aneurysm swells, 
the risk of subsequent rupture rises [51]. However, according to Serrone et al., the 
single predictor of aneurysm enlargement was the initial size of the lesion, with 
the annual risk of growth being evaluated at a mean of 3.5%, though higher for 
larger aneurysms [52]. The morphology of the aneurysm was also incriminated 
in influencing the risk of rupture, especially the formation of a daughter sac, the 
shape of the sac, and regions possessing a thinned arterial wall [53]. Pertaining to 
UIAs selected for conservative treatment, Ramachandran stated that “None of the 
metrics—including aneurysm size, nonsphericity index, peak wall tension, and low 
shear stress area—differentiated the stable from unstable groups with statistical 
significance,” suggesting that there might not actually be such a thing as a “stable” 
intracranial aneurysm [54].
Aneurysmal rupture can also occur during stressful or strenuous activities such 
as sexual intercourse, labor, defecation, physical exertion, or sports [55]. However, 
these external factors may in fact conceal the climate impact, as numerous studies 
indicate a higher incidence of aneurysm rupture during the winter season, as well as 
during daytime [56–59]. Our experience of operated aneurysms also supports this 
statement, as illustrated in Figure 1.
In summary, the natural history of aneurysms is complicated and shrouded in 
uncertainty, except for one surety: UIAs do not spontaneously heal.
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undoubtedly had the most significant role in developing modern coils that were 
electrolytically detachable [33–35].
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diminished in the face of a safer, easier, less invasive, and satisfyingly durable 
procedure with a shorter hospital stay and faster recovery time [36–38]. Many other 
endovascular techniques and tools have been elaborated in the wake of this innova-
tion the technology experiencing an exponential growth. A thorough description of 
such instruments is beyond the scope of this chapter. In what follows, we detail the 
microsurgical treatment options for unruptured solitary and multiple aneurysms, 
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also sharing our operative experience.
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population [39–42]. They are more commonly found in the anterior circulation, 
151
Preventing Rupture: Clipping of Unruptured Intracranial Aneurysms
DOI: http://dx.doi.org/10.5772/intechopen.88038
at more advanced ages, and more often in women. The natural history seems to 
differ according to the shape, location, and size of the lesion, with a significant 
incongruity between the number of incidentally discovered aneurysms each year 
(2000–4000 per 100,000 persons/year) and the annual incidence of aneurysmal 
subarachnoid hemorrhage (aSAH) (approximately 10 per 100,000 persons/year) 
[43]. In other words, out of 200 to 400 patients diagnosed yearly with an intra-
cranial aneurysm, chances are that only one of these may rupture. The annual and 
cumulative risk of rupture has been appraised at approximately 1%/year and at 9% 
at 9 years for the Japanese and Korean populations [44], similar to that of Western 
countries (0.2–1.6%/year and 10% at 10 years) [45–48]. Factors attributed to 
impact the natural history of UIAs may be related to the aneurysm itself, the 
patient, or even external influences.
Concerning patient-related factors, it seems that women have a higher preva-
lence of UIAs than men, and the peak incidence was found between the fifth and 
sixth decades of age. Patients with polycystic kidney disease, type IV Ehlers-Danlos 
syndrome, and Marfan syndrome are more likely to develop UIAs during their 
lifetime. Hypertension is the comorbidity most likely associated with this finding, 
while a positive family history is also an important risk factor among siblings. Up to 
15–30% of these patients harbor at least two UIAs, either concomitantly or sequen-
tially. The most common modifiable risk factors attributed to UIAs are smoking, 
alcohol and drug abuse, as well as using oral contraceptives [49].
According to the results of the PHASE 2 of the International Study of 
Unruptured Intracranial Aneurysms (ISUIA) trial, patients that had no previ-
ous aSAH and harbored aneurysms under 7 mm in diameter possessed no risk of 
rupture for UIAs in the anterior circulation [50]. However, the risk of bleeding 
was 2.5%/year for aneurysms located at the PCoA and the posterior cerebral 
circulation. Concerning patients with a history of aSAH, the risk of rupture for 
aneurysms smaller than 7 mm in the anterior cerebral circulation reached 1.5%/
year, whereas for the posterior circulation, it rose to 3.4%/year. Similarly, the 
Unruptured Cerebral Aneurysm Study (UCAS) performed in Japan proved that size 
influenced the risk of rupture, starting from 0.36% for microaneurysms (between 
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the risk of subsequent rupture rises [51]. However, according to Serrone et al., the 
single predictor of aneurysm enlargement was the initial size of the lesion, with 
the annual risk of growth being evaluated at a mean of 3.5%, though higher for 
larger aneurysms [52]. The morphology of the aneurysm was also incriminated 
in influencing the risk of rupture, especially the formation of a daughter sac, the 
shape of the sac, and regions possessing a thinned arterial wall [53]. Pertaining to 
UIAs selected for conservative treatment, Ramachandran stated that “None of the 
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significance,” suggesting that there might not actually be such a thing as a “stable” 
intracranial aneurysm [54].
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indicate a higher incidence of aneurysm rupture during the winter season, as well as 
during daytime [56–59]. Our experience of operated aneurysms also supports this 
statement, as illustrated in Figure 1.
In summary, the natural history of aneurysms is complicated and shrouded in 
uncertainty, except for one surety: UIAs do not spontaneously heal.
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4. Treatment strategies
The purpose of active treatment for UIAs is to permanently and safely occlude 
the aneurysmal lumen while preserving the normal cerebral vasculature. In order to 
achieve this, two types of approaches have been conceived: surgical (via craniotomy), 
which includes clipping and bypass procedures, or endovascular. As certain lesions 
cannot be safely and efficiently removed from arterial circulation either by clipping or 
by endovascular procedures, bypass surgery has been elaborated to remove the aneu-
rysm and its parent vessel, without sacrificing arterial supply to the involved tissues.
Currently, there are no controlled randomized studies that single out the supe-
rior form of treatment for UIAs. Optimal treatment should focus on the following 
aspects:
• Age and clinical features of the patient
• Anatomy, size, and location of the aneurysm
• Institutional and personal experience in a certain field
• Technical capabilities of the facility
Since the majority of studies in the reported literature are retrospective in 
nature, they may suffer from bias. As of yet, the best sources of information regard-
ing the outcome of UIA treatment originate from comparative studies between 
natural history and complication rates of certain therapies [60]. As our surgical 
experience exceeds that of endovascular procedures, as well as our standing con-
cerning its importance in the prevention of rupture, we will exclusively present the 
technical breakdown of aneurysm clipping, according to our practice.
5. Aneurysm clipping: technical breakdown
Although seemingly easy in theory, placing a clip at the neck of the aneurysm 
(i.e., its point of origin) represents a genuine surgical challenge because of the need 
Figure 1. 
Multiannual incidence of aneurysmal rupture, as hospitalized and surgically treated in our institution between 
January and December 2017.
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to preserve the anatomical and functional integrity of the normal vasculature, brain 
parenchyma, and cranial nerves. This not only implies a good proximal control of 
the arteries but also adequate exposure of the aneurysm and the vessels, beginning 
with the craniotomy. In the following paragraphs, we describe the key points of 
aneurysmal clipping.
5.1 Positioning
This is a crucial stage that can either facilitate or hinder the surgical intervention. 
The patient is placed in a dorsal decubitus. The patient’s head should be positioned 
so that the planned craniotomy is easy to perform, while ensuring that there is no 
substantial jugular compression (i.e., if the head is rotated excessively to one side) 
or that proper ventilation is not impeded (i.e., much too little distance between the 
tip of the mandible and the sternum). The head can be immobilized by a headholder, 
if this does not hamper venous drainage. We recommend shaving the head, or at 
the very least the area around the incision, to minimize the risk of infection. Using 
cutaneous antiseptics such as iodine solution or chlorhexidine, the skin must be thor-
oughly cleansed, with special attention toward the auricle and the external ear canal.
5.2 Surgical exposure
The skin incision should always be larger than the bone opening, considering the 
possible need to enlarge the craniotomy. A wide enough craniotomy must be performed 
for an ideal surgical exposure. Brain relaxation increases visibility and motility, while 
also diminishing the risk of damaging the brain and vessels. This is vital for certain 
aneurysms, especially of the skull base (internal carotid artery (ICA), anterior commu-
nicating artery (AcoA), basilar apex, etc.) or when attempting to clip mirror aneurysms 
during the same opening. There are a few methods to achieve brain relaxation, such as 
hyperventilation, cerebrospinal fluid (CSF) drainage (realized via lumbar drainage or 
ventriculostomy), intracisternal drainage (the most effective form of intraoperative 
brain relaxation in our experience, performed by opening the basal cisternae and the 
Sylvian valley), or with intravenous diuretics (mannitol or furosemide).
5.3 Craniotomy
The bone opening should be entirely adapted to the location, size, and morphol-
ogy of the aneurysm. It must be able to reveal the Circle of Willis and be spacious 
enough to allow the exploration of the main blood vessels. The most commonly 
used craniotomy for aneurysms of the anterior circulation and of the basilar apex 
is the frontolateral approach as described by Samii, the classical pterional opening 
being used in MCA aneurysms and for contralateral clipping in the case of multiple 
aneurysms. A burr hole is placed at the orbitofrontal angle (keyhole), being careful 
not to open the orbit or the frontal sinus (if it is large enough to reach this point). 
The craniotome can then be used to complete the flap. Additional burr holes may be 
needed. In the classical pterional approach, the sphenoid wing should be drilled as 
close as possible to the anterior cranial fossa. In the event of a tensioned dura, slight 
elevation of the head and opening the lumbar drainage will result in proper brain 
relaxation.
5.4 Dura mater incision
The dura can be opened in a cross-shape or a C shape. We favor the latter, leav-
ing the tip of the convexity upward and at least 2 cm above the sphenoid bone. By 
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with the craniotomy. In the following paragraphs, we describe the key points of 
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oughly cleansed, with special attention toward the auricle and the external ear canal.
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possible need to enlarge the craniotomy. A wide enough craniotomy must be performed 
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also diminishing the risk of damaging the brain and vessels. This is vital for certain 
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during the same opening. There are a few methods to achieve brain relaxation, such as 
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brain relaxation in our experience, performed by opening the basal cisternae and the 
Sylvian valley), or with intravenous diuretics (mannitol or furosemide).
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The bone opening should be entirely adapted to the location, size, and morphol-
ogy of the aneurysm. It must be able to reveal the Circle of Willis and be spacious 
enough to allow the exploration of the main blood vessels. The most commonly 
used craniotomy for aneurysms of the anterior circulation and of the basilar apex 
is the frontolateral approach as described by Samii, the classical pterional opening 
being used in MCA aneurysms and for contralateral clipping in the case of multiple 
aneurysms. A burr hole is placed at the orbitofrontal angle (keyhole), being careful 
not to open the orbit or the frontal sinus (if it is large enough to reach this point). 
The craniotome can then be used to complete the flap. Additional burr holes may be 
needed. In the classical pterional approach, the sphenoid wing should be drilled as 
close as possible to the anterior cranial fossa. In the event of a tensioned dura, slight 
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suspending the dural flap, we ensure a wide enough opening. The rest of the dura is 
left in place to protect the brain.
5.5 Arachnoidal dissection
Although sometimes difficult due to extensive adhesions, this step is mandatory 
for exploring the optochiasmatic region. The opening in the Sylvian valley is made 
just above the ipsilateral optic nerve, the most constant landmark and the place 
where the arachnoid is the furthest from the cortex. Next, the opening is extended 
both laterally and medially using a thin aspirator and microsurgical scissors. 
Evacuation of the CSF will further relax the brain and offer a large operating field. 
Dissection resumes medially for ACoA aneurysms and laterally for PCoA aneu-
rysms, whereas it continues along the artery itself for internal carotid artery lesions. 
Once the valley has been opened, the bifurcation of the ICA is visible, and the neck 
of the aneurysm can be distinguished. The neck is then dissected and isolated from 
the surrounding normal vasculature. For middle cerebral artery aneurysms, the 
ICA should be dissected laterally, as well as the proximal portion of the MCA. This 
type of opening has some drawbacks, as it first brings the surgeon to the tip of the 
aneurysmal sac and the proximal control is lacking at this moment. But a delicate 
dissection proximal to the aneurysm will shortly offer the visibility over the M1 seg-
ment, where a temporary clip could be safely placed. The interoptic triangle allows 
access toward basilar apex aneurysms; however, accessing the neck of the aneurysm 
itself is much more challenging, especially since the first element that “greets” the 
surgeon in this approach is the aneurysmal fundus.
The parent vessel has to be exposed proximally to the aneurysm to ensure 
blood flow control in the case of intraoperative rupture. The main vessel should 
be adequately exposed before the neck of the aneurysm, which, in turn, should 
be dissected before the fundus. The perforators adjacent to the lesion must be 
separated from the neck before placing the permanent clip. If the aneurysm sac 
is too wide and complex to be clipped, prudent use of the bipolar coagulator can 
adjust its diameter. Immediately after the clip is placed, the permeability of sur-
rounding vessels and perforators must be demonstrated. If intraoperative rupture 
occurs, lowering arterial pressure, tamponing, temporary clipping of parent vessel, 
and aspirating the aneurysmal sac will favor neck definition and placement of 
definitive clip.
5.6 Clipping
Once the aneurysm has been successfully dissected from the surrounding ves-
sels, a permanent clip is placed at the aneurysmal neck. It has to be parallel to the 
parent artery in order to avoid stretching or occluding it. The length and shape of 
the clip should be adapted to the morphology of the aneurysm and must trap the 
neck entirely, without also trapping perforators or adjacent structures. Sometimes, 
it is necessary to reduce the volume of the aneurysm by applying a temporary clip 
proximal to the aneurysm. Timing in this step is crucial, as more than 10 min of 
temporary occlusion of a major vessel such as the MCA or ICA can lead to severe 
consequences. Once the aneurysm has shrunk enough, the permanent clip can be 
carefully applied (Figure 2).
5.7 Intraoperative aneurysmal rupture (IAR)
This is a dreadful but preventable incident, more hazardous if it occurs early, 
such as during induction of anesthesia or while opening of the dura. Arguably 
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the most challenging of IARs may be those of basilar apex aneurysms. The aims 
in this scenario are hemostasis, avoiding further aneurysmal damage, preventing 
accidental injury to main vessels and perforators, and, finally, clipping the aneu-
rysm. Certain steps should be followed to avoid IAR: careful positioning of the 
head to minimize brain traction; vigilant induction of anesthesia and ensuring that 
hypertension bouts do not occur; a sufficiently wide craniotomy that guarantees 
appropriate access, as well as adequate brain relaxation (using diuretics or a pre-
operative lumbar drainage); and last but not least, sharp instruments are safer for 
dissection than blunt instruments. Ensuring proximal control before aneurysmal 
neck dissection can diminish the risk of IAR. Also, using the anatomical paths 
through the arachnoidal planes will also lower the chance of IAR. In our practice, 
we apply temporary clips if we anticipate a difficult dissection, for example, giant 
aneurysms, polylobulated aneurysms, or those that have recently bled. Even so, 
the occlusion via temporary clip should not exceed a cumulative 20–25 min with 
repeated placements. However, temporary clips are the most useful in IAR if placed 
as early as possible.
5.8 Closure
Without exception, this is performed after thorough hemostasis. For this, we 
employ hemostatic materials (Surgicel® or Gelfoam®) and the judicious use of 
the bipolar coagulator. Patience is essential, as rushing this step can compromise 
the entire operation. In nearly all our surgeries, we use autologous periosteum to 
perform dural plasty. In our opinion, near-watertight closure of the dura with a 
5/0 thread (either with continuous or separate sutures) is sufficient. The bone is 
inserted back into place and fixed either with titanium mesh and screws or sutures 
with thick threads passing through small burr holes. Placing an external drainage 
under the aponeurosis for a period of 24 h is mandatory. The skin closure is per-
formed either continuously or with separate sutures or staples.
5.9 Postoperative control
We usually perform a CTA after closure, with the patient still sedated and intu-
bated. It is much safer to make sure that the vessels are angiographically permeable, 
or to correct any abnormality under the same anesthesia, than to wait for the patient 
to awake and develop ischemic complications. We have also used intraoperative 
Figure 2. 
Representation of an unruptured aneurysm before (A) and after clipping (B) (drawings provided by the first 
author of this chapter).
New Insight into Cerebrovascular Diseases - An Updated Comprehensive Review
154
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the most challenging of IARs may be those of basilar apex aneurysms. The aims 
in this scenario are hemostasis, avoiding further aneurysmal damage, preventing 
accidental injury to main vessels and perforators, and, finally, clipping the aneu-
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appropriate access, as well as adequate brain relaxation (using diuretics or a pre-
operative lumbar drainage); and last but not least, sharp instruments are safer for 
dissection than blunt instruments. Ensuring proximal control before aneurysmal 
neck dissection can diminish the risk of IAR. Also, using the anatomical paths 
through the arachnoidal planes will also lower the chance of IAR. In our practice, 
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the entire operation. In nearly all our surgeries, we use autologous periosteum to 
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5/0 thread (either with continuous or separate sutures) is sufficient. The bone is 
inserted back into place and fixed either with titanium mesh and screws or sutures 
with thick threads passing through small burr holes. Placing an external drainage 
under the aponeurosis for a period of 24 h is mandatory. The skin closure is per-
formed either continuously or with separate sutures or staples.
5.9 Postoperative control
We usually perform a CTA after closure, with the patient still sedated and intu-
bated. It is much safer to make sure that the vessels are angiographically permeable, 
or to correct any abnormality under the same anesthesia, than to wait for the patient 
to awake and develop ischemic complications. We have also used intraoperative 
Figure 2. 
Representation of an unruptured aneurysm before (A) and after clipping (B) (drawings provided by the first 
author of this chapter).
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fluorescence angiography to not only verify the occlusion of the aneurysmal sack 
but also the patency of the surrounding normal vessels.
6. Hemodynamic consequences of aneurysm clipping
The hemodynamic characteristics of intracranial aneurysms are thought to play 
a pivotal role in their development, evolution, and eventual rupture, interfering 
and modifying the local biology of the vascular wall [61–63]. The theory suggests 
that the wall is exposed to a higher degree of sheer stress than it can physiologically 
withstand. This leads to a local weakening and abnormal remodeling, which in time 
will form an aneurysm. Its growth can be a result of local proliferation of mural 
cells, a distention of the cellular and intercellular structures, or possibly a mixture 
of the two. A meticulous in vitro study affirmed that growth cannot be entirely the 
result of simple fluid physics [64], a non-Newtonian model being more precise in 
ascertaining the altered hemodynamics in intracranial aneurysms [65]. However, as 
it is impossible to perform direct measurements on hemodynamic stress in patients 
or living experimental models, methods implying computational fluid dynamics are 
used to estimate these phenomena [65–67].
Aneurysmal rupture results from the mechanical weakening of the arterial 
wall that is subsequently unable to contain the force of the flowing blood [68]. 
The wall sheer stress is defined as the tangential frictional force that the blood 
exerts upon the endothelium, being the highest at the neck and the apex of the 
aneurysm [65]. The innerworkings of endovascular procedures are closely linked 
to these hemodynamic conditions, as the presence of a coil determines alterations 
in wall shear stress and blood flow that conclude with the intraluminal thrombosis 
of the aneurysm [69]. In MIA, wall sheer stress is apparently increased in UIAs 
distal to a ruptured aneurysm after treatment, whether surgical or endovascular, 
leading to a theoretical rise in the risk of rupture [66]. Moreover, also in MIA, 
ruptured aneurysms may possess a more irregular shape, larger size, and dome-
to-neck ratio, as well as a lower minimum wall shear stress than with their unrup-
tured counterparts [70].
After clipping, a series of local and distal changes in hemodynamics may occur. 
Nevertheless, these are not as intensely analyzed as for untreated aneurysms. 
Successful surgical obliteration of the aneurysm results in the complete cessation 
of blood flow inside the lumen. However, it is not clear what impact the presence of 
the aneurysmal clip itself has on the wall shear stress or its effects on the vascular 
wall. A residual neck (i.e., a portion of the neck that was not occluded by the blades 
of the clip) may in time lead to aneurysmal regrowth, depending on the size of 
the remnant as well as its location [71]. Apparently, a distal remnant is at a higher 
risk for aneurysmal regrowth than a proximal residue. Therefore, it is crucial to 
ensure an adequate placement of the clip during surgery and to adjust its position 
if required. The alterations in dynamic flow can also be observed systemically after 
clipping or coiling, especially in the period after vasospasm caused by aneurysmal 
rupture [72]. In the study conducted by Inoue et al., patients treated by coiling pre-
sented a significantly lower cardiac index, as well as a significantly higher systemic 
vascular resistance index than the group managed via clipping, although this might 
have been the result of systemic therapy for managing vasospasm and aggressive 
volume loading rather than of the procedure itself, especially as the patients in the 
coiling group arrived in a worse neurological state than those of the clipping group. 
Needless to say, more studies are required to discern the actual impact that clipping 
has on the cerebral vasculature, especially concerning aneurysmal regrowth, reoc-
currence, and rerupture.
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7. Clipping of solitary unruptured aneurysms
The cerebrovascular diseases causing such controversy in regard to treatment 
are few in number [73]. The reasoning behind this continuous debate is that the 
prophylactic management of UIAs must be justified by a suitable procedure-
related outcome when compared to the anticipated natural history [74]. Despite 
clipping once being the management centerpiece, the swift refinement of 
endovascular procedures and innovation of flow diversion devices have steadily 
replaced surgery as the first line of therapy for UIAs. However, certain countries 
still favor clipping due to its longevity, effectiveness, and the lower risk of recana-
lization than endovascular techniques, as well as lower procedure-related costs 
[75–77]. Consequently, whereas older patients who are unsuitable for surgery may 
benefit the most from endovascular procedures, clipping is considered preferable 
for younger patients with lower-grade aneurysms and that may be able to tolerate 
this intervention [76, 78]. The unruptured intracranial aneurysm treatment score 
(UIATS) provides a fast and easy method of triaging between the two treatment 
options; however, it has not yet been prospectively tested on patients harboring 
UIAs [79].
Studies such as ISAT, ISUIA, and UCAS are among the most cited concerning 
aneurysm treatment and natural history. The first of these revealed superior 1-year 
clinical outcomes for ruptured aneurysms by coiling in comparison to clipping, yet 
these results cannot be accurately extrapolated to clipping of UIAs [80]. The condi-
tions in the unruptured setting are more advantageous, as the purpose of therapy is 
to ensure lifelong protection against aneurysm rupture, whereas the treatment of 
ruptured lesions is to allow survival of the patient during the acute phase of SAH 
without rebleeding or postoperative morbidity. Likewise, MCA aneurysms, which are 
generally considered more easily approached by surgery, were grossly underrepre-
sented in this study. Several authors obtained much higher rates of complete oblitera-
tion via clipping than through endovascular procedures for aneurysms in this location 
[77, 81, 82]. This is more likely a consequence of the particular configurations of MCA 
aneurysms, rendering it more difficult to completely occlude the neck via endovas-
cular procedures (wide-necked, possessing a small dome-to-neck ratio, the neck 
encompassing one of the arterial branches, etc.) [77]. Moreover, these aneurysms are 
generally adjacent to or surrounded by small perforators that may prohibit the use of 
stents. This technique also has the fundamental drawback of postprocedural throm-
boembolic events that may ensue at a higher frequency [83, 84]. In the largest mul-
ticenter study of very small UIAs treated via surgery, Bruneau et al. showed that the 
lesions found distal to the M1 segment were the safest to treat [85]. Despite additional 
enquires being required to reach a definitive conclusion, it is still worth regarding 
surgical clipping as the principal treatment modality for UIAs of the MCA.
Aneurysms of the anterior communicating artery are the most frequently 
reported in a large number of studies, possessing a higher risk of rupture than 
other locations while also being amenable to both endovascular and microsurgical 
techniques [36, 74, 86–89]. The term may actually be overly broad, also including 
aneurysms of the A1 and A2 junctions of the anterior cerebral artery or belong-
ing entirely to these two segments, but being indistinguishable from true ACoA 
aneurysms on angiographic studies [88]. This location represents a genuine chal-
lenge for either approach. On the one hand, microvascular clipping is made difficult 
by depth, presence of perforators, and placement along the midline, implying 
increased cerebral traction in the absence of adequate relaxation [87, 89]. On the 
other hand, certain intrinsically unfavorable characteristics of aneurysms found 
in this location, such as a small dome, wide neck, multiple adjacent perforators, 
acute vessel angles, complex morphology, or posterior projection, can hinder 
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endovascular procedures as well [74, 90]. In their systematic analysis, O’Neill et al. 
discovered that coiling delivers the most favorable clinical results, while stent-
assisted coiling produced the highest incidence of treatment-related morbidity, 
without improving the rates of angiographically detectable recurrences or retreat-
ment [74]. However, microsurgical clipping offered the most definitive aneurysm 
repair of the three methods and significantly lower rates of recurrence or reinter-
vention. The best course of action for UIAs of this location remains to be decided.
UIAs of the internal carotid artery, including its smaller branches such as the 
anterior choroidal artery, ophthalmic artery, hypophyseal artery, and artery PCoA, 
are also fairly common, some sources citing them as the second most frequent after 
aneurysms of the ACoA [36, 91, 92]. Because the parent artery is located in proximity 
to the skull base, the surgical access of these aneurysms is often difficult. In order to 
address this issue, and many others, the first flow diverter device sanctioned for use 
was in 2011, being designated for wide-necked intracranial aneurysms of the ICA in 
adults [37]. Fortunately, small aneurysms of the cavernous segment generally present 
a low risk of rupture [73]. Therefore, taking into consideration the hemorrhage rates 
described by ISUIA for aneurysms of this location, it is generally not advisable to treat 
asymptomatic lesions smaller than 5 mm in any way [39, 73]. Aneurysms larger than 
7 mm or those that are symptomatic can be safely treated by either method with satis-
factory postoperative results. Once again, endovascular procedures are less invasive, 
but microsurgical clipping yields a higher rate of complete occlusion [93]. Despite 
this, due to the hemodynamic charge of the ICA, it is possible that pulsations, differ-
ences in wall thickness, and tension may cause clip rotation [94]. Additionally, after 
retractors are removed, the ensuing brain shift may determine additional kinking and 
subsequent stenosis of the anterior choroidal artery. ICA bifurcation aneurysms are 
generally scarce and, as a result, underrepresented in large prospective observational 
studies, leading to an enigmatic natural history [93]. For aneurysms of the paraclinoid 
ICA or of the ophthalmic artery, it is advisable to remove the anterior clinoid process 
to ensure better access and proximal control. This also alleviates the risk of causing 
postoperative visual disturbances, which represent a common complication of ICA 
aneurysm management, especially for this segment [95]. Using a bone microrongeur 
or an ultrasonic aspirator to perform piecemeal removal of the anterior clinoid instead 
of a high-speed drill leads to fewer such complications [95, 96]. Small UIAs of the 
paraclinoid ICA that are medially pointing can also be safely approached from the 
contralateral side, thus diminishing the need of mobilizing the optic nerves as well as 
of performing anterior clinoidectomy [97]. As a remark, appropriate selection of ther-
apeutic method for unruptured aneurysms of the ICA and its branches should factor 
in the individualities of the lesions themselves. Ideally, a hybrid unit would allow 
either approach and the possibility of converting an endovascular procedure into an 
open surgical intervention in the case of intraprocedural complications (Figure 3).
Aneurysms of the posterior circulation, including the basilar artery apex or the 
posteroinferior cerebellar artery (PICA), have a much higher propensity to rupture 
[36, 73, 98]. Therefore, a conservative approach would be inadvisable for UIAs of 
this location. However, there is little data comparing the endovascular and surgi-
cal treatment of posterior circulation UIAs. After ISAT and the ensuing paradigm 
shift, there has been a scarcity of microsurgical reports on basilar apex aneurysms. 
Tjahjadi et al. reported a significantly higher rate of good and fair outcome (71 
and 16%, respectively) after surgery of UIAs of the basilar apex than after clip-
ping of ruptured lesions of the same site (49 and 19%, respectively) [99]. Nanda 
et al. also reported good outcomes following microsurgical clipping (71.9%) and 
asserted that a non-dominant PCoA (especially if hypoplastic) can be safely divided 
in the perforator-free area as to allow additional retraction of the ICA [100]. 
ISUIA revealed similar clinical outcomes for the patients recruited; however, the 
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endovascular procedures only achieved complete occlusion in approximately half 
of the cases treated [50, 101]. In contrast, aneurysms of the PICA (and to a certain 
extent the vertebral artery—VA) are still primarily treated via clipping due to their 
wide necks, generally multilobulated and nonsacular characteristic, thrombosed 
lumens, emerging arteries, or distal locations that render coiling substandard [102]. 
The lower cranial nerves encountered in the surgical field can easily and securely be 
avoided, especially via the transcondylar approach [103]. Moreover, cases in which 
microsurgery should be more fervidly supported number those with unfavorable 
endovascular access, very small aneurysm domes, or contraindications for stent 
usage (intolerance to dual antiplatelet therapy, nickel allergy, etc.) [85, 101].
The previously mentioned UCAS and ISUIA are regarded as the most prudently 
devised large studies vis-à-vis the natural history of UIA, with numerous guidelines 
having been published in their wake in order to improve management decision-
making [78]. However, imaging control was not compulsory in ISUIA; therefore, it 
could not tackle the possibility of aneurysms eventually changing their morphology 
or size. Moreover, there is the question of the UCAS not being relevant for popula-
tions outside Japan. There are still centers that recommend treatment for all small 
aneurysms possessing risk of developing SAH, the presence of a daughter sack or 
multiple aneurysms [78, 104]. After the ISAT was published, endovascular tech-
niques gained a boost in popularity in the USA for both ruptured and unruptured 
aneurysms, overtaking surgical treatment in number of procedures performed 
[105]. Previous analyses show that coiling was associated with fewer complica-
tions, lower mortality, faster hospital discharge, and significantly lower costs than 
clipping [105, 106]. However, in centers outside the USA, where hospitalization, 
procedure, and nursing costs are lower, the differences concerning patient expenses 
are smaller. In South Korea, it seems that coiling is more expensive than clipping for 
UIAs, and this may also be available for developing countries [106]. The principal 
reason for this is the cost of endovascular implantable devices themselves (stents, 
coils and flow diverters, etc.), constituting more than 50% of procedure-related 
costs [107, 108]. Even so, a previous meta-analysis concluded that coiling generated 
a higher independent outcome and lower mortality rate, being the more cost-
effective method of the two [108].
Figure 3. 
Illustrative case 1. (A) Preoperative CTA of a 21-year-old male with an incidentally discovered aneurysm of 
the right internal carotid artery (paraclinoidal segment). Video 1 is available at: https://bit.ly/2Z8W6rm. 
We used a right frontolateral craniotomy and approached the aneurysm via the Sylvian fissure. We drilled the 
anterior clinoid process, but the aneurysm ruptured during initial attempt at clipping. Because of its sheer size, 
we used three fenestrated clips to occlude the aneurysmal sac. The patient was discharged with no neurological 
deficit. (B) MRI scan, TOF sequence, at 1-year follow-up, showing the presence of the clip and no intraluminal 
flow.
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Figure 3. 
Illustrative case 1. (A) Preoperative CTA of a 21-year-old male with an incidentally discovered aneurysm of 
the right internal carotid artery (paraclinoidal segment). Video 1 is available at: https://bit.ly/2Z8W6rm. 
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In aspects to randomized studies comparing endovascular therapy to surgery, 
the literature is extremely limited. The Collaborative Unruptured Endovascular 
Versus surgery (CURES) trial, which randomized 104 patients harboring unrup-
tured between 3 and 25 millimeters to either coiling (n = 56) or clipping (n = 48), 
showed that there were no significant differences regarding in aneurysm occlusion 
rate, mortality, and morbidity after 1 year [80, 109]. Nevertheless, there were more 
patients with perioperative neurological deficit after clipping and with hospitaliza-
tions beyond 5 days. Mortality and morbidity rates for CURES were lower than 
reported in the ISUIA regarding both clipping and coiling [109]. Another pro-
spective study, the trial on endovascular management of unruptured intracranial 
aneurysms (TEAM), which compared coiling to observational management, was 
halted less than 3 years after initiation as a result of poor recruitment [110].
Another controversial subject is the management of aneurysm remnant or reper-
meabilization after clipping or coiling. It has been repeatedly demonstrated that 
microsurgery leads to fewer such instances [75–82]. Although the issue of hemor-
rhage after initial treatment and its consequences have been extensively covered for 
ruptured aneurysms, there is currently no such data for UIAs [39]. Patients should 
therefore be regularly monitored (we recommend yearly CTA investigations), 
regardless of the form of treatment and any increase in size or change in morphol-
ogy be contended judiciously.
Currently, the ideal strategy for solitary unruptured aneurysms is elusive. 
Although of great consequence, an issue seldom considered in these studies is the 
experience and proficiency of the neurosurgeon [73]. This is expressly observed in 
high-volume centers with a large number of operated cases, where outcomes are 
unquestionably much more favorable. Regardless, surgical prophylaxis of rupture 
via clipping remains a safe, effective, and possibly curative option. It remains 
to be seen whether the trends will continue to favor endovascular procedures 
or if an unexpected shift in balance might rejuvenate the popularity of surgical 
intervention.
8. Clipping of multiple aneurysms
In the Western population, it is estimated that 10–13% of patients with IAs 
possess MIAs, and it is sometimes difficult to find the source of SAH, but even more 
so to treat each lesion [70, 111–114]. A number of cases have been correlated with 
either congenital or chronic disorders such as Gaucher’s disease, Fahr’s disease, 
or Behcet’s disease, although whether there is an etiologic correlation or merely 
a diagnostic coincidence is unknown [115–118]. Mirror aneurysms denote a rare 
condition in which the multiple aneurysms are placed symmetrically in the cerebral 
hemispheres. The most common sites are the non-cavernous segments of the ICAs 
[119, 120]. Mirror aneurysms also display a decreased propensity to rupture and 
improved outcomes than non-mirror aneurysms. Certain risk factors such as female 
gender (which also strongly influences the number of IAs), advanced age, smoking, 
uncontrolled hypertension, and increased body mass have been linked to a height-
ened chance of developing MIA [121, 122]. However, due to contradictory and 
inconclusive results, it is currently unknown whether the presence of MIAs implies 
a greater risk of rupture than that of single IAs [122]. Aneurysm morphology and 
size are thought to play the most important roles in the risk of rupture [91, 70]. 
Apparently, endovascular procedures lead to fewer neurologic complications than 
surgical clipping; however clipping yields higher occlusion rates, fewer total com-
plications, and angiographic recurrence [69]. In theory, hemodynamic alterations 
occurring in an untreated distal UIA after the treatment of a proximal IA might 
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increase the risk of bleeding, underlying the necessity of treating all aneurysms 
simultaneously and by any means [66]. It is sometimes feasible to treat all aneu-
rysms at the same time during the same sitting and using the same craniotomy, thus 
lowering hospital stay, surgical exposure, and risk of complications [119, 123–125].
We support the classical pterional approach for tackling multiple aneurysms 
of the anterior circulation in the same opening. It offers a wide enough opening to 
approach even the aneurysms of the M1 segment on the opposite side. This is mostly 
useful for selected patients with simple contralateral UIA with narrow necks and 
which project inferiorly or anteriorly [119, 123]. The craniotomy should be per-
formed on the side of the most complex aneurysm, or the one which has ruptured. 
On one hand, this methodology provides the highest visibility of the aneurysm and 
shortest distance to the dome and hematoma in case of bleeding. On the other hand, 
because of the hemodynamic changes that might occur during the clipping of the 
other IAs, it is easier to control bleeding on this side.
Clipping the contralateral aneurysms first may prevent a complicated and hard 
to manage bleeding on this side. After that, clipping the aneurysms more proximal 
to the surgeon can be performed. There are, however, some drawbacks to this 
technique [123, 126]. Firstly, it implies a heightened brain retraction compared to 
that of the same-side craniotomy, yet this can be managed by adequate brain relax-
ation. The maneuverability is lower, and the vision is reduced on the opposite side. 
However, a larger craniotomy, wider arachnoid dissection, and brain relaxation can 
aid in this situation. Contralateral MCA bifurcation and PCoA aneurysms are more 
difficult to find and clip, requiring maneuvering around thin perforators and fragile 
veins. Hemostasis is not as easy on the distal side in the case of rupture, which is 
why these IAs should be clipped first. Lastly, this technique requires an experienced 
vascular neurosurgical team; however, surgical simulation with 3D reconstruc-
tions may alleviate results [127]. However, this surgery should only be performed 
in selected cases, as the risks associated with a single challenging surgery do not 
compensate for the expenses of two easier interventions (Figure 4).
From our operative experience, we contraindicate performing two surgeries on 
two separate days, as the risk of rupture of the remaining untreated UIAs during 
this interval is not negligible. If a single opening is not indicated, we recommend 
approaching the more complex aneurysms first through one craniotomy, and after-
ward, during the same anesthesia, performing another craniotomy and clipping 
the residual UIAs. However, there is no consensus regarding this treatment method 
[119, 120, 126]. Alternatively, a combined surgical-endovascular approach can be 
performed, with surgery reserved for the ruptured and more difficult aneurysms 
[128, 129]. To summarize, deciding the management of multiple aneurysms should 
take into account the individual characteristics of the patient and of each the 
aneurysms, as well as the experience of the neurosurgical team involved.
9. Aneurysm clipping in elderly
At present, there are no corroborated management guidelines for UIAs in elderly 
patients, yet the retrospective reports reveal excellent results for both treatment 
strategies [130–132]. It has been shown that elderly patients with UIAs are less likely to 
die following aneurysmal rupture SAH than younger and/or female patients [37, 40, 
78, 133, 134]. Therefore, a conservative approach may also be considered especially for 
small UIAs. Even so, the advanced age in itself supposedly increases the risk of peri-
procedural complications. Surgical interventions are correlated with larger amounts of 
blood loss, higher treatment-related costs, and longer hospitalizations than endovas-
cular techniques, though provide a complete and maintainable aneurysmal occlusion 
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cular techniques, though provide a complete and maintainable aneurysmal occlusion 
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[130, 135, 136]. Despite the differences in regard to mortality being relatively small, 
they are nonetheless significant and favor endovascular coiling as the safest of the 
two [136]. Aside from preventing rupture, interventional therapy has demonstrated 
cognitive improvement without causing further intellectual deficits, in addition to a 
decrease in anxiety levels [137, 138]. Older patients harboring MIAs without a history 
of SAH can be managed conservatively, whereas those at risk or with a previous SAH 
should be treated in a one- or two-staged intervention [119]. Moreover, coiling might 
prove more appropriate for those with serious comorbidities and in an altered clini-
cal state, while clipping is more suitable in the presence of intracranial vasospasm or 
hematomas [69]. The same as for younger patients with MIAs, the ruptured lesion 
should always be managed first and foremost, yet for unruptured MIAs treatment 
may only be indicated if the risk related to observation outweighs those of therapy.
10. Neurological and clinical outcome after clipping
There are conflicting reports regarding the postprocedural outcomes for these 
interventions. Short-term outcomes generally favor endovascular procedures, 
with a higher incidence of postinterventional adverse events after surgery [74, 
139]. According to Kim et al., there is no significant difference regarding all-cause 
mortality at 7 years after the elective treatment of UIAs via either clipping or coiling 
[140]. The meta-analysis performed by Ruan et al. showed similar outcomes for 
the two procedures [141]. On the other hand, in their meta-analysis, Falk Delgado 
et al. reported a higher independent outcome and lower mortality after coiling of 
UIAs [108]. The outcomes may be improved with the intraoperative use of electro-
physiological monitoring, fluorescence angiography, or Doppler ultrasonography 
[142]. Surgical clipping of UIAs does not negatively impact quality of life nor does 
it affect cognitive functions in such a way that patients are unable to work or drive 
at 6 weeks or 1 year after the intervention [143, 144]. The risk of poor outcome for 
patients below the age of 65 stands at around 2–4% and rises with aneurysm size, 
which when compared to the 0.3–0.9% risk of annual rupture might outclass the 
natural history in a few years after treatment [89, 103, 145]. Nonetheless, mortal-
ity is extremely low, if not inexistent in these series. Therefore, a more aggressive 
treatment may be acceptable for UIAs in younger patients. Although some series 
Figure 4. 
Illustrative case 2. (A) CTA 3D reconstruction of a 55-year-old male with multiple cerebral aneurysms—
two on the right middle cerebral artery and one the left middle cerebral artery bifurcation. He presented 
to emergency department with right-sided weakness with gradual onset 3 days prior to surgery. Video 2 
is available at: https://bit.ly/2Z8W6rm. He underwent microsurgical clipping via a right frontolateral 
craniotomy. All the clips were placed in the same procedure. (B) Postoperative CTA 3D reconstruction showing 
proper clip placement. He was discharged without any additional deficit.
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have demonstrated clipping of UIAs is effective and has no mortality even in elderly 
[131], the risk of a poorer outcome increases in this age group, with higher instances 
of disability and death than endovascular procedures specifically in the presence of 
comorbidities [132, 136]. Retreatment of intracranial aneurysms is also associated 
with a higher mortality rate [146]. However, in our experience, clipping of solitary 
UIAs yields excellent results, with no mortality and a high degree of functional 
independence, as will be shown in a later subchapter.
11. Complications of surgical clipping
Since clipping is a surgical intervention, there are chances of developing com-
plications related to the procedure, medical and infectious complications as well as 
those attributable to anesthesia. The following paragraphs will focus on the compli-
cations of clipping itself. These can be divided according to timing of onset after the 
intervention into immediate and delayed complications.
IAR is one of the most frequent and most dreaded periprocedural complica-
tions [147]. This is especially the case for inexperienced (and oftentimes reckless) 
surgeons; however, preoperative GCS has also been shown to play a role in predict-
ing this event [148]. It occurs especially around the time of neck dissection and clip 
placement or adjustment and is capable of hampering the microsurgical procedure, 
sometimes being life-threatening [149]. Nevertheless, it is significantly less frequent 
for UIAs than for the ruptured lesions [147]. A steady technique, proper discovery 
of the parent artery, temporary clipping proximal to the aneurysm, and aspiration 
can regain control of the situation and ensure proper clip placement.
Ischemic complications may also arise from improper clip placement or due 
to thromboembolism from the aneurysm. The type and severity of neurological 
consequences depend mostly on the location of the aneurysm [150–153]. The most 
frequent type of postoperative events and possibly even underestimated, ischemia 
leads to poorer outcomes at discharge and often entails a reintervention [153, 154]. 
After clipping of UIAs, transcranial Doppler studies show a decrease in transient 
reduction in cerebrovascular reactivity on the side of the aneurysm, leading to a 
proneness toward cerebral ischemia [155]. Endovascular procedures apparently 
bear a higher risk for thromboembolic events and ischemia [156], yet a recent 
meta-analysis showed that there was no statistical difference between coiling and 
clipping in respect to this event [141]. Incidence of perforator territory ischemia is 
higher for aneurysms of the A1 segment, whereas olfactory disturbances are more 
common for lesions of the ACoA [157]. Silent ischemic lesions are fairly frequent 
(up to 10% of procedures) and mostly irreversible, though rarely disabling [153, 
157]. It has been argued that induced hypertension may reduce the effects of 
delayed cerebral ischemia [158]. Regardless, there is still no conclusive data to 
sustain the benefits of induced hypertension, whereas serious adverse events are 
sometimes unavoidable.
Another undesirable complication is the occlusion of the surrounding arteries, 
especially deep and subtle perforators. Again, dissection, proper magnification and 
illumination of the surgical field, and adequate brain relaxation can improve the 
visibility of the aneurysmal neck and surrounding structures. It is also important to 
utilize clips adjusted to aneurysm size and morphology. Electrophysiological moni-
toring, micro-Doppler ultrasonography, or intraoperative angiography can rapidly 
detect an arterial occlusion and facilitate repositioning of the clip [152, 159].
Clip slippage can happen when advanced atherosclerosis thickens the aneurysmal 
wall, making it impossible for the clip to close properly [151, 160]. Clip rotation and kink-
ing of the parent vessel can also be the result of uneven arterial walls due to atheromatous 
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degeneration [94]. Using a double-clip technique can often prevent this from occurring, 
yet certain aneurysms may require more complex techniques [151, 125, 160].
Aneurysmal residue or incomplete occlusion signifies an aneurysm sac or neck 
that is still permeable and has a significant chance of rupture [37, 80, 86, 161, 162]. 
Aneurysmal rest (or dog ear) occurs when a small triangular portion of the neck is 
not occluded by the aneurysmal blades. In time, and under certain hemodynamic 
conditions, this residual neck can lead to aneurysm regrowth, and eventual rupture, 
requiring further imaging studies and possibly another intervention [104]. In the 
microsurgical series described by Nanda, the majority of recurrences were found 
at the ACoA, followed by ICA, VA, and PICA [163]. Adequate neck dissection and 
using suitable clips may avoid this complication [164]. Also using intraoperative 
angiographic procedures can confirm proper clip placement.
Clipping UIAs of the ophthalmic artery can lead to visual disturbances [162]. 
Apparently, if visual deficit was present before treatment, clipping may offer a 
higher degree of improvement than coiling [162, 165]. From our own experience, 
we can add that the clipping of aneurysms of the paraclinoid segment of the ICA or 
the superior hypophyseal artery may in some cases result in acute pituitary defi-
ciency. Some of these patients will require lifelong hormone substitution therapy.
Cerebral vasospasm is predominantly a complication of ruptured aneurysms, 
but it has rarely been described as occurring after clipping of UIA [166]. The exact 
etiological mechanism is unknown, although it might be multifactorial, especially 
after aggressive manipulation of the vessels.
Cognitive dysfunction after UIA therapy may occur, regardless of treatment 
method [137]. Nevertheless, the exact effect clipping has on cognitive functions 
remains uncertain.
Some patients with surgically treated UIAs may develop a chronic subdural hema-
toma in time, being at a higher risk for this than patients with ruptured lesions [167]. 
Risk factors include brain atrophy, male sex, chronic antiplatelet use, and advanced age.
As long as the risk of complications remains, the incentive of perfecting 
microsurgical techniques will persist. The purpose of gaining surgical experience 
is to ensure a long-term survival of the patient with the best possible neurological 
outcome, while also striving to lower or eliminate the chance of adverse events.
12. Our experience
During many years of practice, we learned that trying to make an asymptom-
atic patient feel better is ridiculously challenging. As for the patients themselves, 
the notion of living with an “undetonated bomb” might be daunting. As we have 
already shown, the issue of UIAs in a patient harboring multiple aneurysms out of 
which one has bled is equally controversial in the contemporary scientific literature.
We reviewed the experience of a single neurosurgeon (Professor Ioan Ștefan 
Florian MD, PhD—Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-
Napoca, Romania) in microsurgical clipping over 21 years (1997–2017). This 
amounted to a consecutive series of 872 patients with intracranial aneurysms (1004 
separate lesions in total), both ruptured and unruptured.
From this patient pool, 89 (10.2%) presented with solitary UIA, the ages at the 
two extremes being 11 and 86 years, respectively. Among these, 46 (51.69%) were 
admitted with Hunt and Hess grade 0, while the remaining 43 (48.31%) were admit-
ted with grade 1a. Regarding clinical outcome, our most important conclusion was 
that we encountered no mortality in this particular group. Eighty-seven patients 
(97.8%) were discharged with a Glasgow Outcome Score (GOS) of 5 (Figure 5).
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Figure 5. 
Outcome of patients with solitary unruptured aneurysms at time of discharge—author’s case series (0, Hunt 
and Hess grade 0; 1a, Hunt and Hess grade 1a; GOS, Glasgow Outcome Score).
Figure 6. 
Location of lesions in the multiple cerebral aneurysms group. MCA, middle cerebral artery; ICA, internal 
carotid artery; ACoA, anterior communicating artery; PCoA, posterior communicating artery; ACA, anterior 
cerebral artery; BA, basilar artery; Opht, ophthalmic artery.
Figure 7. 
Number of lesions per patient with multiple intracranial aneurysms. The majority of patients with two 
aneurysms had both lesions on the same side, whereas for three or more lesions, these were bilateral. The highest 
number of aneurysms in a single patient was six.
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In our series, we identified 101 patients (11.58%) with multiple aneurysms, 
harboring a total of 257 lesions. The most common location was the middle cere-
bral artery, followed by the internal carotid and anterior communicating artery 
(Figure 6). Initially, our approach in treating them was to clip the ruptured aneu-
rysms or the ones with the higher risk, leaving the others for a later procedure. 
However, after we lost two patients with MIA on the night before the second planned 
intervention due to the rupture of the single unclipped lesion, we overhauled our 
methodology. The current goal in all cases is single-stage surgery (unilateral fronto-
pterional approach) with all aneurysms clipped during the same procedure. If this is 
unfeasible, we perform a second craniotomy during the same anesthesia, as we believe 
the process of patient waking elevates the risk of rupture of any unclipped UIA.
Most patients presented with two aneurysms (57.6%). The highest number of 
aneurysms was six (one patient, female). The male-to-female ratio was 1:3, with the 
higher number of aneurysms leading to an increase of female predominance. Our 
series too suggests that MIA is primarily a pathology of the female gender (Figure 7).
We analyzed the complication rate, mortality, and state at discharge between 
groups with unilateral and bilateral aneurysms of the anterior circulation. There 
were no statistically significant differences between the two groups regarding 
the rate of complications or the outcome (P > 0.05, Table 1). When we compared 
patients with mirror middle cerebral aneurysms to the rest of the lot, no statistically 
significant difference could be observed either (P > 0.05). 60.39% of patients (61) 
were discharged with a favorable neurological outcome (GOS of 4 or 5).
Our data demonstrates that, with an appropriate selection of cases, surgery 
yields definitive and favorable results in solitary UIAs if handled by an experienced 
team. “Single-stage, single-opening surgery” is a viable option for treating the 
unruptured lesions in the context of multiple intracranial aneurysms.
13. Final remarks and future directions
Clipping of UIAs remains a valuable treatment option in preventing rupture 
and subsequent hemorrhagic stroke. In the hands of experienced vascular neuro-
surgeons, it is still a secure and long-lasting procedure, despite the relative ease and 
comparable safety and durability of endovascular procedures. Since aneurysmal 
rupture cannot be accurately predicted, clipping stands as a virtually curative 
procedure. Nevertheless, being an invasive procedure, it still harbors inherent 
risks. While our experience shows that clipping of solitary UIAs is not associated 
with mortality and only minimal morbidity, clipping of MIAs can pose a challenge. 
Parameter Statistical test Odds ratio Confidence interval 95% P
Hunt and Hess scale Mann-Whitney U — — 0.588
Associated complications Chi square 1.35 0.25–7.75 0.73
Age t — — 0.25
Preoperative days t — — 0.37
Glasgow Outcome Scale Chi square 1.5 0.9–11.53 0.69
Complications Chi square 2.6 0.53–13.11 0.22
Mortality Chi square 0.4 0.03–5.24 0.47
Table 1. 
Comparison between the two groups on admission (Hunt and Hess scale, associated complications, and age) 
and on discharge (preoperative days, Glasgow Outcome Scale, complications, and mortality).
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Topic: Chapter discussing the indications for treatment of brain aneurysms, 
endovascular techniques, tips and tricks. 1. Pathophysiology of aneurysms: 
Discuss the formation of aneurysms, current thinking of aneurysm development 
2. Prevalence/Incidence of aneurysms: Discussion of current state of aneurysm 
prevalence and how it differs in different populations 3. Unruptured Aneurysms: 
Diagnosis, Management and Treatment: Imaging paradigms of brain aneurysms, 
current thoughts on how to follow aneurysms which are being observed, different 
treatment options for unruptured aneurysms, including clipping, coiling, stent 
assisted coiling, flow diverter stent, flow disruptors, including the medical manage-
ment of stent placement 4. Ruptured Aneurysms: Diagnosis, Management and 
Treatment: Imaging paradigms of ruptured aneurysms, management options for 
co-morbidities associated with aneurysm rupture, treatment options including coil-
ing, clipping, flow diverter stents, flow disruptors 5. Complication Avoidance: Tips 
and tricks to avoid complications in the treatment of brain aneurysms.
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flow disruption
1. Pathophysiology of aneurysms
A cerebral aneurysm is defined as a local outpouching of an intracranial 
artery and can either be saccular or fusiform. The formation of aneurysms is an 
incompletely understood gradual process [1] involving genetics, epidemiology and 
pathobiology, in conjugation with the study of biophysics provides a more complete 
picture on how these factors interact [2]. The natural history of saccular intracra-
nial aneurysms consists of three phases: initiation, growth, and either stabilization 
or rupture, and the application of scientific principles to biological processes has 
made it easier to understand the behavior of aneurysm formation and rupture.
1.1 Genetic factors
Various genome studies and subsequent replication case control studies suggest 
genetic components in the formation of intracranial aneurysms (IA), no specific 
genes strongly associated with formation have yet been identified. A meta-analysis 
[3], identified three single nucleotide polymorphisms (SNPs) located on chromo-
some 9 within the CDKN2B-AS1 gene, on chromosome 8 near the SOX17 transcrip-
tion regulator gene, and on chromosome 4 near the endothelin receptor gene 
associated with the presence of sporadic IAs. A new IA susceptibility locus on 13q 
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A cerebral aneurysm is defined as a local outpouching of an intracranial 
artery and can either be saccular or fusiform. The formation of aneurysms is an 
incompletely understood gradual process [1] involving genetics, epidemiology and 
pathobiology, in conjugation with the study of biophysics provides a more complete 
picture on how these factors interact [2]. The natural history of saccular intracra-
nial aneurysms consists of three phases: initiation, growth, and either stabilization 
or rupture, and the application of scientific principles to biological processes has 
made it easier to understand the behavior of aneurysm formation and rupture.
1.1 Genetic factors
Various genome studies and subsequent replication case control studies suggest 
genetic components in the formation of intracranial aneurysms (IA), no specific 
genes strongly associated with formation have yet been identified. A meta-analysis 
[3], identified three single nucleotide polymorphisms (SNPs) located on chromo-
some 9 within the CDKN2B-AS1 gene, on chromosome 8 near the SOX17 transcrip-
tion regulator gene, and on chromosome 4 near the endothelin receptor gene 
associated with the presence of sporadic IAs. A new IA susceptibility locus on 13q 
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was identified [4]. Subsequent genome-wide association studies [5, 6] have found 
additional loci on chromosome 7 near HDAC9, as well as in chromosomal regions 
1p34.3–p36.13, 19q13.3, Xp22 and 7q11. The strongest evidence for linkage was with 
a locus on 7q11 near the perlecan gene that encodes elastin, a protein that is involved 
in the preservation of vessel wall integrity.
1.2 Structural changes and hemodynamics
Cerebral arteries are prone to aneurysm formation due to presence of cerebro-
spinal fluid, sparse tunica adventitia, lower proportion of elastic fibers and disrup-
tion of internal lamina at bifurcation [7–9]. Blood is an active participant in the 
formation of aneurysms, its flow provides the mechanical triggers for reactions in 
the vessels at the level of the endothelium, while it is also a biological participant in 
the inflammatory cascade [10, 11]. This dual function of blood contributes signifi-
cantly to the degradation of the arterial wall in the formation of aneurysms [2].
Cohort studies on people with a familial preponderance to saccular aneurysm have 
shown that the geometry of bifurcations around the circle of Willis adds additional 
stress to the vessel walls, given the significant shifts in flow velocity, dynamic forces, 
and shear stress. Thus, high flow across a wall that is not “designed” for the exposed 
pressures results in tissue injury and remodeling. The biological result may be plaque 
or may be an aneurysm, depending on the presence (or absence) of an intact media 
[2]. Fluid-dynamic models calculate and visualize wall shear stress or wall shear 
gradients, intra-aneurysmal flow, impingement zones, and flow patterns or velocities. 
Wall shear stress constitutes the degree of friction in the intracranial aneurysm wall 
that results from blood inflow and impingement into the aneurysm. High and low 
wall shear stress can both be present during aneurysm formation but the relevance of 
these flow conditions to the pathogenesis, growth and rupture of an aneurysm remain 
unclear [12]. The role of shear stress is very controversial, responsible for damage at 
specific phases of aneurysmal development and rupture. Some studies suggest the 
direct effect of shear stress on the vessel wall resulting in injury and degeneration of 
the wall’s media, leading to aneurysm formation. Others suggest that low shear stress 
in the aneurysm and the vessel wall may result in small thrombus formation, endo-
thelial reactivity, and inflammation at the site, thus weakening the vessel.
Data generated from fluid-dynamic models could help improve our understand-
ing of aneurysm formation patterns and potential structural deficiencies in aneu-
rysms. The relevance of existing data derived from computational fluid modeling 
is limited, however, because the majority of studies compared ruptured with 
unruptured aneurysms. An ideal approach would be to compare the same aneurysm 
before and after rupture [13–16].
1.3 Molecular changes
In response to internal elastic lamina disruption and the subsequent mechanical 
overload and shift in tensile forces, vascular smooth muscle cells and fibroblasts 
synthesize collagen types I and V, which are the main molecular constituents of 
intracranial aneurysms [17].
Once the molecular mechanisms fail to compensate for the mechanical overload 
of the vessel wall and myo-intimal injury, cellular and humoral inflammatory 
responses become the main drivers of aneurysm formation [17–20]. These responses 
are mediated by inflammatory cytokines such as tumor necrosis factor (TNF), 
IL-1β and matrix metalloproteinases (MMPs), promote influx of macrophages and 
continuous degradation of collagen and elastin fibers. Wall shear stress might also 
contribute to cellular inflammatory responses during aneurysm formation.
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1.4 Can aneurysm rupture be predicted?
Aneurysm rupture has been suggested to occur as aneurysm expansion 
approaches and exceeds the physical limits of the tissue. It has also been suggested 
that the vibrations induced by pulsatile flow and the subsequent resonant frequency 
may promote aneurysmal rupture [21, 22]. Although not directly resulting in 
aneurysmal rupture, vibrational irregularities secondary to the presence of the 
aneurysm may accelerate the degeneration of the aneurysmal wall and subsequently 
lead to rupture. A shift to quantitative and not just qualitative analysis, and a focus 
on flow and flow dynamics as a force of influence in rupture have changed the 
landscape of research for cerebral aneurysms [2].
2. Prevalence and incidence of aneurysms
Although Unruptured Intracranial Aneurysms (UIA) are common [23, 24]. 
Their prevalence is subject to changes due to the improvements in invasive and non-
invasive imaging techniques, the increasing knowledge about the related factors 
that determines screening in asymptomatic populations and the increase in the life 
expectancy. Historically, the methods used to address prevalence were retrospec-
tive or prospective autopsy studies in the decades from 1950’s to the earliest 2000’s 
[25] but non-invasive imaging studies have demonstrated higher prevalence and 
prevalence ratios compared to autopsy studies (PR 3•5, 95% CI 2•1–6•1)3. To study 
UIA, the Magnetic Resonance Angiography (MRA) is the most common method 
for detection in asymptomatic patients [26] and compared to Intra-Arterial Digital 
Subtraction Angiography (IA-DSA), systematic reviews have found no significant 
differences in the prevalence reported between these two imaging techniques 
(more details will be elucidated in the next section of this chapter). However, it’s 
important to highlight that prevalence reported in non-invasive imaging studies 
can present limitations due to the interobserver agreement, training, experience, 
quality of equipment and expert’s judgment [27].
The IA characteristics are also a major concern in prevalence studies; technical 
limitations in regard to location, size and morphology can decrease the sensitiv-
ity and specificity of the diagnostic methods. Both, large and relatively small [28] 
cohort’s studies had shown that saccular morphology is the most common form of 
presentation and that among patients without history of subarachnoid hemorrhage 
(SAH) the distribution of IA in the internal carotid artery (ICA) and middle cerebral 
artery (MCA) are 24.8 and 22.7% [29] respectively, however in patients with previous 
history of SAH, the prevalence is higher in the MCA. In regard to the size, modern 
imaging techniques can easily detect aneurysms from 2 mm, which is extremely 
important to determine the risks of possible treatments or natural history, so far, the 
current evidence is that UIA > 5 mm, location in basilar artery apex and decrease in 
BMI over the follow-up period are related to speed up the 2.9% of aneurysm growth 
per year. However, irrespective of aneurysm size, the irregular shape and daughter sac 
are more likely to rupture [30, 31]. Although we know these are contributing factors, 
there is still a need to understand better the contribution of aneurysm related factors.
The prevalence of UIA among the general population is 3–5% [32] but there are 
several differences between populations that increase the risk for having a IA or a 
SAH. The risk factors commonly associated to IA development and rupture whether 
there’s a previous history of SAH or not, are age > 30, female sex, African-American 
race, smoking, alcoholism, hypercholesterolemia, high blood pressure, first and 
second-degree relatives with SAH history, and other comorbidities as polycystic 
kidney disease, connective tissue disorders and brain tumors [33–36]. However, 
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was identified [4]. Subsequent genome-wide association studies [5, 6] have found 
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responses become the main drivers of aneurysm formation [17–20]. These responses 
are mediated by inflammatory cytokines such as tumor necrosis factor (TNF), 
IL-1β and matrix metalloproteinases (MMPs), promote influx of macrophages and 
continuous degradation of collagen and elastin fibers. Wall shear stress might also 
contribute to cellular inflammatory responses during aneurysm formation.
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per year. However, irrespective of aneurysm size, the irregular shape and daughter sac 
are more likely to rupture [30, 31]. Although we know these are contributing factors, 
there is still a need to understand better the contribution of aneurysm related factors.
The prevalence of UIA among the general population is 3–5% [32] but there are 
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SAH. The risk factors commonly associated to IA development and rupture whether 
there’s a previous history of SAH or not, are age > 30, female sex, African-American 
race, smoking, alcoholism, hypercholesterolemia, high blood pressure, first and 
second-degree relatives with SAH history, and other comorbidities as polycystic 
kidney disease, connective tissue disorders and brain tumors [33–36]. However, 
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lifelong follow-up studies of UIA suggested that only female sex and smoking status 
were significant risk factors for aSAH [37]. Across countries, compared to USA 
prevalence, China, Japan, European countries including (UK, Netherlands, Finland, 
Germany and Italy) had no significant differences in the prevalence ratios adjusted 
to age, sex and comorbidities [38–41]. Other studies in Iranian population [42] have 
shown a prevalence of 3.2% but more studies in non-Caucasian populations are still 
required to further understand the impact of genetics and cultural practices.
The incidence of aneurysmal SAH (aSAH) reports are questionable, first, in 
average 20% of the aSAH deaths occur suddenly, away from hospital or in emer-
gency rooms [43]. Therefore, incidence can vary between countries with different 
autopsy rates and medical study protocols. In the case of Finland, the PHASES 
study showed a 3–6 times increased risk of aneurysm rupture in compared to other 
European nations and USA [44]. However, these findings can be a proof of how 
epidemiological studies need to improve their parameters more than a proof that 
Finnish people have more risk of aSAH. Finland has high rates of autopsy studies in 
sudden deaths [45] and all nonhospital deaths and moreover, longer life expectancy 
and pyramid shrinking due to the increasing of elderly population [46]. So, there’s 
no currently strong evidence to conclude that aSAH in Finland cohorts is truly 
higher than the other countries included in the PHASES study.
In spite of this evidence, careful consideration must be taken when we think 
about the pros and cons to treat a patient based on their personal risk factors. Most 
of the large cohort’s publications and meta-analysis have been done in popula-
tions where ethnicity diversity was limited, the impact of social stratus had not 
been assessed and criteria for collecting data and analysis was not standardized. 
Therefore, perfect epidemiological studies do not exist so, great efforts will be nec-
essary to determine inclusion and exclusion criteria in future prospective cohorts.
3. Unruptured intracranial aneurysms
Diagnosis of unruptured intracranial aneurysms (UIA) in most of the cases is 
incidentally during evaluations of other conditions [44] because the vast majority 
are asymptomatic or have subtle manifestations. Only, 10 to 15.5% of patients have 
symptoms related to UIA [45]. These symptoms generally are associated to mass 
effect due to the aneurysm size and growth, rarely cranial neuropathy or even more 
rare with sentinel hemorrhage, due to minimal blood leaking with the consequent 
meningeal irritation [45]. Symptomatic UIA often present with neurological deficits 
as visual dysfunction, ocular nerve palsy, bilateral temporal hemianopsia and other 
neurological symptoms as headaches, embolic cerebral ischemia, poorly defined 
spells, and seizures [46, 47]. Patients with symptomatic UIA need more attention 
because this can be a manifestation about riskier distribution and morphological 
[45] characteristics of the aneurysm, and a warning sign of an impending rupture 
[48]. The diagnoses modality after incidental discovery of an UIA, is based on 
which imaging modality is more sensitive depending on aneurysms characteristics, 
patients related factors, medical history and moreover, methods available in each 
center. Therefore, there is no specific diagnoses algorithm for UIA. The decision 
of screening or further imaging after finding an incidental aneurysm is still on the 
specialist judgment. These considerations are discussed below:
It has been mentioned that most of the UIA are diagnosed incidentally, and some 
of the non-invasive imaging methods have also been mentioned in the “prevalence” 
section of this chapter. However, there are still different evidences about the rates of 
diagnosis and prevalence reported through these non-invasive imaging methods as 
the MRA or CTA and IA-DSA, the current gold standard [22, 49]. Many authors had 
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suggested that the MRA and CTA to be the best methods for preliminary screen-
ing of IA [50, 51], the sensitivity and specificity of both methods are 87 and 95% 
for MRA and 90 and 86% for CTA [47]. But the effectiveness of the diagnoses can 
decrease depending on the IA characteristics; in UIA < 3 mm, MRA and CTA sensi-
tivity plummet to 38 and 61%, respectively [52]. Moreover, the high rates of comor-
bidities in people with UIA product of common pathophysiology (like hypertension 
with the consequent kidney failure) or to the old age of patients can limit the use 
of the contrast dye in CTA for screening. Therefore, MRA is the most frequent tool 
for screening nowadays. Other non-invasive techniques like transcranial Doppler 
(TCD) have been explored, but whether power Doppler is done with or without 
contrast enhancement, it’s sensitivity and specificity together are not superior to 
MRA and CTA [51]. Nevertheless, TCD can be a screening tool in countries were the 
expensive costs of MRA or CTA makes them inaccessible.
Sensitivity and specificity of imaging methods for diagnostic are important, but 
more considerations should be taken to study UIA characteristics. IADSA, provides 
the better spatial resolution than other techniques [44], but this method may not 
provide a good sense of aneurysm volume and can present difficulties when vessels 
are overlapped, and therefore 3D reconstructions are often needed to fully evaluated 
for intracranial aneurysms. Moreover, IADSA as an invasive method, can carry risks; 
2.3% of patients can present transient neurological complications, 0.4% permanent 
neurological complications and 14.7% of non-neurological complications [52]. Novel 
imaging methods as the Optical coherence tomography (OCT) can be useful to assess 
key factors in aneurysm structure due to the power to increase 10 times image resolu-
tion compared to other current techniques [44] and furthermore, OCT has a nearly-
biopsy resolution [53] and enhance resolution of birefringent tissues as artery laminas 
[54] which is major concern in pathophysiology, as mentioned before in this chapter.
Furthermore, considerations need to be taken as to imaging modality if the 
patient has had previously treated aneurysms. MRA is not sensitive for patients 
with previously treated clipped aneurysms. For these patients CTA is preferred. 
MRA is still sensitive for previously coiled aneurysms. For patients treated with 
flow diverter stents either MRA with contrast or CTA can be used. If the patient had 
coils with any kind of stent, then MRA with contrast is the preferred modality.
Taken together the results of imaging for UIA, the neuro-interventional team 
consider the possible treatments for each patient based on the risks and benefits 
between prevent treatment and natural history, however due to lack of evidence 
of the natural history in some categories of UIA is not uncommon to balance the 
pros and cos between prevent treatment and aSAH outcomes. Some of the current 
available treatments will be discussed below.
3.1 Conservative management
First of all, having an aneurysm does not imply always the need to undergo 
surgical or endovascular treatment. Most of the UIA will never cause symptoms 
neither rupture or at least the probability of this events will not be over 1% per year. 
Therefore, many patients decide to take the risk of conservative management over 
the risks of preventive treatments. However, conservative management is not equal 
to doing nothing, this management bear intervention from the physician to educate 
well the patient about the risk factors that will increase the probabilities of rupture 
and an active participation of the patients to modify their risky habits. There is 
strong evidence that supports the conservative management when lifetime risk of 
morbidity and mortality is low [42] as represented in Figure 1.
Nevertheless, in patients under conservative management, imaging follow-ups at 
1 year intervals have been recommended with CTA or MRA [25] to assess aneurysm 
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lifelong follow-up studies of UIA suggested that only female sex and smoking status 
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symptoms related to UIA [45]. These symptoms generally are associated to mass 
effect due to the aneurysm size and growth, rarely cranial neuropathy or even more 
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as visual dysfunction, ocular nerve palsy, bilateral temporal hemianopsia and other 
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spells, and seizures [46, 47]. Patients with symptomatic UIA need more attention 
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[45] characteristics of the aneurysm, and a warning sign of an impending rupture 
[48]. The diagnoses modality after incidental discovery of an UIA, is based on 
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(TCD) have been explored, but whether power Doppler is done with or without 
contrast enhancement, it’s sensitivity and specificity together are not superior to 
MRA and CTA [51]. Nevertheless, TCD can be a screening tool in countries were the 
expensive costs of MRA or CTA makes them inaccessible.
Sensitivity and specificity of imaging methods for diagnostic are important, but 
more considerations should be taken to study UIA characteristics. IADSA, provides 
the better spatial resolution than other techniques [44], but this method may not 
provide a good sense of aneurysm volume and can present difficulties when vessels 
are overlapped, and therefore 3D reconstructions are often needed to fully evaluated 
for intracranial aneurysms. Moreover, IADSA as an invasive method, can carry risks; 
2.3% of patients can present transient neurological complications, 0.4% permanent 
neurological complications and 14.7% of non-neurological complications [52]. Novel 
imaging methods as the Optical coherence tomography (OCT) can be useful to assess 
key factors in aneurysm structure due to the power to increase 10 times image resolu-
tion compared to other current techniques [44] and furthermore, OCT has a nearly-
biopsy resolution [53] and enhance resolution of birefringent tissues as artery laminas 
[54] which is major concern in pathophysiology, as mentioned before in this chapter.
Furthermore, considerations need to be taken as to imaging modality if the 
patient has had previously treated aneurysms. MRA is not sensitive for patients 
with previously treated clipped aneurysms. For these patients CTA is preferred. 
MRA is still sensitive for previously coiled aneurysms. For patients treated with 
flow diverter stents either MRA with contrast or CTA can be used. If the patient had 
coils with any kind of stent, then MRA with contrast is the preferred modality.
Taken together the results of imaging for UIA, the neuro-interventional team 
consider the possible treatments for each patient based on the risks and benefits 
between prevent treatment and natural history, however due to lack of evidence 
of the natural history in some categories of UIA is not uncommon to balance the 
pros and cos between prevent treatment and aSAH outcomes. Some of the current 
available treatments will be discussed below.
3.1 Conservative management
First of all, having an aneurysm does not imply always the need to undergo 
surgical or endovascular treatment. Most of the UIA will never cause symptoms 
neither rupture or at least the probability of this events will not be over 1% per year. 
Therefore, many patients decide to take the risk of conservative management over 
the risks of preventive treatments. However, conservative management is not equal 
to doing nothing, this management bear intervention from the physician to educate 
well the patient about the risk factors that will increase the probabilities of rupture 
and an active participation of the patients to modify their risky habits. There is 
strong evidence that supports the conservative management when lifetime risk of 
morbidity and mortality is low [42] as represented in Figure 1.
Nevertheless, in patients under conservative management, imaging follow-ups at 
1 year intervals have been recommended with CTA or MRA [25] to assess aneurysm 
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growth, although it is unclear whether this frequency of time-interval is truly 
necessary. However, is not uncommon to have mixed factors in UIA patients, to make 
it clear, a systematic review showed that if hypertension and history of SAH are pres-
ent (considering this both as major risk factors) in a patient under 70 years, with an 
<10 mm UIA in the anterior circulation, we will still be talking about a probability of 
risk of ~1% per year [24]. So, a standardized timing for imaging follow-ups accord-
ing to each patients and aneurysm related factors does not exist, in part because 
aneurysm growing is discontinuous but the ELAPSS score (mentioned in Figure 1) 
can be helpful to determine the need of follow-up at 3 or 5 years based on the risk 
of aneurysm growth [55]. These patients who choose conservative management live 
with a small very definite risk of rupture. Recently, a study showed that patients 
with untreated UIA, may decrease their quality of life (QoL) and moreover, trigger 
mental disorder as anxiety and depression [56, 57] possibly due to the uncertainty of 
whether their aneurysm is going to burst and when.
3.2 Surgical management
Successful surgery is achieved in most of the cases by excluding aneurysms from 
circulation but currently, there is a lack of prospective, multicenter and randomized 
Figure 1. 
Giant right vertebral aneurysm before and after coiling.
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trials that report outcomes in a uniform way. Moreover, most of the studies were done in 
patients with previous aSAH like the ISAT trial [58], which makes difficult to extrapo-
late those results to patients with UIA and no history of aSAH. The ISUIA-2 study 
did evaluate the surgical outcomes of nearly 1500 patients. They reported a mortality 
rate of 2.7% at 1 year and poor outcome (mRS 3–5) of 1.4% at 1 year. In this study, 
age > 70, posterior circulation and giant aneurysms were all associated with higher 
surgical morbidity and mortality. A meta-analysis done in the US with patients without 
previous history of aSAH that underwent to elective surgical clipping (SC) 14,411 and 
to endovascular treatment (EVT) 16,659 reported that iatrogenic stroke, intracranial 
hemorrhage, pulmonary complications, sepsis and status epilepticus were significantly 
higher after SC [59]. Moreover, the reduced recovery time and shorter stays in hospital 
[60] play a major role in the final decision of patient to avoid surgery. Nowadays, SC is 
usually reserved to younger patients that will benefit more from an immediate occlusion 
of the aneurysm, less need to have follow-up imaging, less probability of retreatment 
and the ones with large and giant aneurysms or locations in the MCA.
3.3 Endovascular treatment (EVT)
Since its conception, endovascular treatment has rapidly taken over as the 
major treatment for most intracranial aneurysms. While there is supporting data 
for ruptured intracranial aneurysms from the ISAT trial, there is no randomized 
controlled trial comparing surgery and endovascular treatment to surgical clipping 
for unruptured aneurysms. Relative indications for endovascular treatment are poor 
surgical candidate, favorable aneurysm and vascular anatomy, high risk for anesthe-
sia complications and posterior circulation aneurysms. In 2012, a systematic review 
and meta-analysis reported different outcomes between endovascular treatments; 
>52 years, >10 mm and posterior circulation location were main risk factors to poor 
outcomes [61]. Coiling alone was safer compared to the percent of complications 
reported with balloon-assisted coiling 7.1% (99% CI 3.9–12.7), 9.3% (99% CI 4.9–
16.9) with stent-assisted coiling and 11.5% (99% CI 4.9–24.6) with flow-diverting 
stents. However, the increase of the complications reported with additional devices 
can be due to the more-complex aneurysm cases or due to the number and type of 
devices placed. Furthermore, in the last decade the neuro-interventional procedures 
have improved their outcomes with increased understanding of the various treat-
ments and technological innovation improving safety and efficacy.
3.4 Coiling
EVT emerged in the 1990’s with coiling [62]. Since then, technological advances 
in coil properties made neuro-interventional procedures safer with improved out-
comes. Recently, a single center study reported 0% of poor outcomes when coiling 
was used [25], however >20% of poor outcomes have been reported after coiling in 
aneurysms >10 mm size, with wide necks, unfavorable dome-to-neck ratio < 2 and 
fusiform configuration [63]. So, using coiling alone must be used just in aneurysms 
with specific characteristics, otherwise new devices must be considered.
3.5 Stent assisted coiling
This method represents a solution for aneurysms in which coiling alone will not 
be the best option (mentioned in Figure 1), as coiling this endovascular technique 
has the same concerns about patient selection, recovery and risks. However, when 
leaving a stent placed in the artery it is important to manage the tolerance and 
adherence of the patient to dual anti-platelet therapy (DAPT) (Figure 2)[64].
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Figure 1. 
Giant right vertebral aneurysm before and after coiling.
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trials that report outcomes in a uniform way. Moreover, most of the studies were done in 
patients with previous aSAH like the ISAT trial [58], which makes difficult to extrapo-
late those results to patients with UIA and no history of aSAH. The ISUIA-2 study 
did evaluate the surgical outcomes of nearly 1500 patients. They reported a mortality 
rate of 2.7% at 1 year and poor outcome (mRS 3–5) of 1.4% at 1 year. In this study, 
age > 70, posterior circulation and giant aneurysms were all associated with higher 
surgical morbidity and mortality. A meta-analysis done in the US with patients without 
previous history of aSAH that underwent to elective surgical clipping (SC) 14,411 and 
to endovascular treatment (EVT) 16,659 reported that iatrogenic stroke, intracranial 
hemorrhage, pulmonary complications, sepsis and status epilepticus were significantly 
higher after SC [59]. Moreover, the reduced recovery time and shorter stays in hospital 
[60] play a major role in the final decision of patient to avoid surgery. Nowadays, SC is 
usually reserved to younger patients that will benefit more from an immediate occlusion 
of the aneurysm, less need to have follow-up imaging, less probability of retreatment 
and the ones with large and giant aneurysms or locations in the MCA.
3.3 Endovascular treatment (EVT)
Since its conception, endovascular treatment has rapidly taken over as the 
major treatment for most intracranial aneurysms. While there is supporting data 
for ruptured intracranial aneurysms from the ISAT trial, there is no randomized 
controlled trial comparing surgery and endovascular treatment to surgical clipping 
for unruptured aneurysms. Relative indications for endovascular treatment are poor 
surgical candidate, favorable aneurysm and vascular anatomy, high risk for anesthe-
sia complications and posterior circulation aneurysms. In 2012, a systematic review 
and meta-analysis reported different outcomes between endovascular treatments; 
>52 years, >10 mm and posterior circulation location were main risk factors to poor 
outcomes [61]. Coiling alone was safer compared to the percent of complications 
reported with balloon-assisted coiling 7.1% (99% CI 3.9–12.7), 9.3% (99% CI 4.9–
16.9) with stent-assisted coiling and 11.5% (99% CI 4.9–24.6) with flow-diverting 
stents. However, the increase of the complications reported with additional devices 
can be due to the more-complex aneurysm cases or due to the number and type of 
devices placed. Furthermore, in the last decade the neuro-interventional procedures 
have improved their outcomes with increased understanding of the various treat-
ments and technological innovation improving safety and efficacy.
3.4 Coiling
EVT emerged in the 1990’s with coiling [62]. Since then, technological advances 
in coil properties made neuro-interventional procedures safer with improved out-
comes. Recently, a single center study reported 0% of poor outcomes when coiling 
was used [25], however >20% of poor outcomes have been reported after coiling in 
aneurysms >10 mm size, with wide necks, unfavorable dome-to-neck ratio < 2 and 
fusiform configuration [63]. So, using coiling alone must be used just in aneurysms 
with specific characteristics, otherwise new devices must be considered.
3.5 Stent assisted coiling
This method represents a solution for aneurysms in which coiling alone will not 
be the best option (mentioned in Figure 1), as coiling this endovascular technique 
has the same concerns about patient selection, recovery and risks. However, when 
leaving a stent placed in the artery it is important to manage the tolerance and 
adherence of the patient to dual anti-platelet therapy (DAPT) (Figure 2)[64].
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3.6 Flow diversion
This method was developed in the 2000s. The concept of Flow Diversion is that 
a high-mesh density stent placed in the parent artery will disrupts blood flow into 
the aneurysm with the subsequent thrombosis of the aneurysm, this process takes 
6 weeks to 6 months in average in radiographic follow-ups. Moreover, the stent in 
parent artery provides a scaffold for which endothelium can grow [62]. In 2011, the 
FDA approved the Pipeline Embolization Device (PED) for large or giant (≥10 mm) 
wide-necked intracranial aneurysms from the petrous to the superior hypophyseal 
segments of the ICA [65]. Since then, a second flow diverter stent (Surpass) has 
come to market. Flow diverter stents now have expanded indications, including 
smaller aneurysms, and aneurysm up to the internal carotid artery bifurcation. 
Recently, a multicenter group published a retrospective study of follow-ups 
after PED placement [66], in this report overall complications were 3.4% and in 
multivariate analysis older age > 70, larger diameter > 15 mm and fusiform were 
identified as independent variables with higher rates of incomplete occlusion in 
6-month follow-up. However, currently there is not a standardized scale to report 
Figure 2. 
Pipeline placement in a wide neck aneurysm in the left vertebral artery.
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radiographic outcomes that can be useful to meta-analysis studies or to new pro-
spective randomized cohorts. Flow diverter stents are currently also limited usually 
to unruptured aneurysms, given the need for DAPT, however their use has found a 
niche in the treatment of ruptured blister aneurysms. Consequently, the next gener-
ation of this technology is looking into the possibility of special coating to mitigate 
the need for DAPT. Further investigation is still needed before this advancement 
will come to market.
3.7 Flow disruptors and web endoluminal bridge (WEB)
Although flow diversion devices can work out for many types of aneurysms as 
off-label uses; aneurysms located in bifurcations with wide neck and dome-to-neck 
ratio > 1 and < 2 remains a challenge for this technology. Therefore, the WEB device 
was created in regard of these concerns in flow diversion and has proven promising 
to overcome those limitations. The WEB device is placed intra-aneurysm with a 
subsequent change in the blood flow at the aneurysm neck [67]. In European multi-
center prospective studies, the WEB device placed in basilar, MCA, Acomm and ICA 
bifurcation showed 2.7% of morbidity and at 1 year of follow-up, 56% of aneurysm 
complete occlusion [68]. Owing this method does not require to put the patient 
under DAPT unlike the PED, it can be used also in aSAH cases. Further investigation 
is needed as to the long-term outcomes for this device (Figures 3 and 4).
3.8 Medical management after flow diverter placement
All the patients that can be good candidates for PED placement based on their 
UIA characteristics needs also to be eligible for prolonged DAPT. Acetylsalicylic 
acid (ASA) plus clopidogrel is the DAPT of reference used for preventing thrombo-
sis in such procedures [69]. The laboratory tests pre and post-procedure are yet to 
be standardized; due to the risk of clopidogrel resistant (28–68%) [70], is has been 
considered necessary to assess platelet reactivity. High platelet reactivity (HPR) 
is related with thromboembolic evens after stenting arteries [71]. Depending on 
institutional protocols, some neuro-interventional teams use the VerifyNow P2Y12 
assay which has been widely studied however, the results of this tests may not be 
completely reliable [72] due to the fact that P2Y12 response units (PRU) cannot dif-
ferentiate aspirin-induced platelet inhibition in patients administered clopidogrel. 
Other studies recommend the use of the Thromboelastography (TEG), which is 
dynamic and real time tool to measure clot formation. The advantages of VerifyNow 
assay is that can be done very fast with instant results, however in patients with 
programed procedures for UIA stenting this concerning may not be transcendental.
Figure 3. 
Web Endoluminal bridge placement in left ICA bifurcation.
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complete occlusion [68]. Owing this method does not require to put the patient 
under DAPT unlike the PED, it can be used also in aSAH cases. Further investigation 
is needed as to the long-term outcomes for this device (Figures 3 and 4).
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considered necessary to assess platelet reactivity. High platelet reactivity (HPR) 
is related with thromboembolic evens after stenting arteries [71]. Depending on 
institutional protocols, some neuro-interventional teams use the VerifyNow P2Y12 
assay which has been widely studied however, the results of this tests may not be 
completely reliable [72] due to the fact that P2Y12 response units (PRU) cannot dif-
ferentiate aspirin-induced platelet inhibition in patients administered clopidogrel. 
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dynamic and real time tool to measure clot formation. The advantages of VerifyNow 
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programed procedures for UIA stenting this concerning may not be transcendental.
Figure 3. 
Web Endoluminal bridge placement in left ICA bifurcation.
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VerifyNow can overestimate the rate of clopidogrel resistance when compared to 
TEG. However, there is currently no randomized trials that have assessed the utility 
of this tests. Moreover, there’s no strong evidence to support that the assessment 
of platelet reactivity improves clinical and imaging outcomes after stent place-
ment. Nevertheless, the neuro-interventional teams at these days usually starts the 
DAPT with 325 mg of ASA and 75 mg of clopidogrel 7 days prior and maintain for 
3–6 months after PED placement.
4. Ruptured intracranial aneurysms
A 50-year-old female was preparing her children for school when she experi-
enced a headache severe enough to make her lie down on the sofa. She managed 
to get the children off to school, but the headache did not abate. She was used to 
headaches, as she had migraines periodically that were controlled with over-the-
counter medications, but this one was different and much more intense. She took a 
couple of acetaminophen, and when the pain was not relieved, she brought herself 
to the emergency department (ED) [73].
Headache is seen in up to 2% of patients, presenting to the emergency department 
(ED). Most are benign, but it is imperative to understand and discern the life-threat-
ening causes of headache when they present. Headache caused by a subarachnoid 
hematoma (SAH) from a ruptured aneurysm is one of the deadliest, but fortunately, 
also rare, comprising only 1% of all headaches presenting to the ED [74].
Rupture is the most serious consequence of intracranial aneurysms. 
Subarachnoid hemorrhage (SAH) from a leaking aneurysm is a neurological 
emergency. While SAH is typical of aneurysmal rupture, it is also associated with 
intraventricular hemorrhage, intracerebral hemorrhage, and subdural hematoma. 
The force of rupture and location of an aneurysm determine the presence of the 
other types of hemorrhage. Although the prevalence of aneurysms is high, the 
Figure 4. 
Flowchart of management after incidental UIA diagnosis.
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global annual incidence of subarachnoid hemorrhage is 10/100,000person years, 
so the best possible treatment plan would be to determine exactly those aneurysms 
that will rupture and the ones that never will.
4.1 Presentation
The presenting symptom of SAH is acute headache, generally described as “the 
worst headache of my life.”
Some cohort studies mention it as “thunderclap” headache that peaks at head-
ache onset or reaches severity within minutes to an hour of onset [75].
1. Signs of meningeal irritation-meningismus, photophobia
2. Signs of intracranial hypertension-nausea, vomiting, diminished level of 
consciousness
3. Epileptic seizures
4. Focal neurological deficits
5. Intraocular hemorrhage [76, 77]
• Terson syndrome: hemorrhage in vitreous humor, associated with high 
mortality [78]
• Subhyaloid (pre-retinal) hemorrhage [79].
4.2 Scoring system
Several scoring systems have been developed to predict patient outcomes 
for those with aneurysm related sub-arachnoid hemorrhage (a-SAH). The Hunt 
and Hess score and World Federation of Neurological Surgeons grading system 
are both used to predict patient outcome, and the Fisher grade helps to predict 
vasospasm [80, 81].
The severity of neurologic impairment and the amount of subarachnoid bleed-
ing on admission are the strongest predictors of neurologic complications and 
outcome [82]. Therefore, it is essential that patients with SAH be scored promptly 
after arrival and stabilization. The World Federation of Neurological Surgeons Scale 
(WFNSS) and the modified Fisher Scale are the most reliable and simple to perform 
[74, 75]. Higher WFNSS and modified Fisher Scale scores are associated with worse 
clinical outcome and a higher proportion of neurologic complications. The modi-
fied Fisher scale is designed to predict the development of delayed cerebral ischemia 
(DCI) which is the most common cause of disability secondary to rupture next the 
actual rupture itself (Tables 1–3).
4.3 Initial imaging
With such a large number of patients presenting to the ED with a chief com-
plaint of headache [79–84], the description of headache can help differentiating 
those with a benign cause from those with an emergent etiology such as SAH. The 
diagnosis of SAH should be considered in any patient with a severe and sudden 
onset or rapidly escalating headache (Figure 5).
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global annual incidence of subarachnoid hemorrhage is 10/100,000person years, 
so the best possible treatment plan would be to determine exactly those aneurysms 
that will rupture and the ones that never will.
4.1 Presentation
The presenting symptom of SAH is acute headache, generally described as “the 
worst headache of my life.”
Some cohort studies mention it as “thunderclap” headache that peaks at head-
ache onset or reaches severity within minutes to an hour of onset [75].
1. Signs of meningeal irritation-meningismus, photophobia
2. Signs of intracranial hypertension-nausea, vomiting, diminished level of 
consciousness
3. Epileptic seizures
4. Focal neurological deficits
5. Intraocular hemorrhage [76, 77]
• Terson syndrome: hemorrhage in vitreous humor, associated with high 
mortality [78]
• Subhyaloid (pre-retinal) hemorrhage [79].
4.2 Scoring system
Several scoring systems have been developed to predict patient outcomes 
for those with aneurysm related sub-arachnoid hemorrhage (a-SAH). The Hunt 
and Hess score and World Federation of Neurological Surgeons grading system 
are both used to predict patient outcome, and the Fisher grade helps to predict 
vasospasm [80, 81].
The severity of neurologic impairment and the amount of subarachnoid bleed-
ing on admission are the strongest predictors of neurologic complications and 
outcome [82]. Therefore, it is essential that patients with SAH be scored promptly 
after arrival and stabilization. The World Federation of Neurological Surgeons Scale 
(WFNSS) and the modified Fisher Scale are the most reliable and simple to perform 
[74, 75]. Higher WFNSS and modified Fisher Scale scores are associated with worse 
clinical outcome and a higher proportion of neurologic complications. The modi-
fied Fisher scale is designed to predict the development of delayed cerebral ischemia 
(DCI) which is the most common cause of disability secondary to rupture next the 
actual rupture itself (Tables 1–3).
4.3 Initial imaging
With such a large number of patients presenting to the ED with a chief com-
plaint of headache [79–84], the description of headache can help differentiating 
those with a benign cause from those with an emergent etiology such as SAH. The 
diagnosis of SAH should be considered in any patient with a severe and sudden 
onset or rapidly escalating headache (Figure 5).
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4.4 Management
Once the patient has been diagnosed with an SAH, treatment should focus on 
limiting secondary neurologic injuries to improve the patient’s functional outcome.
• Resuscitation of a patient with SAH should follow all established protocols 
with immediate attention to airway and circulatory support.




In patients with a suspected ruptured aneurysm, seizures can lead to aneu-
rysmal rebleeding and result in intracranial hypertension and herniation, the 
Grade Criteria Survival
I Asymptomatic, mild headache, slight nuchal rigidity 70%
II Moderate to severe headache, nuchal rigidity, no neurological deficit other than 
cranial nerve palsy
60%
III Drowsiness/confusion and mild focal neurological deficit 50%
IV Stupor, moderate to severe hemiparesis 20%
V Coma, decerebrate positioning 10%
Table 2. 
Hunt and Hess scale.
Grade Appearance of blood on CT Risk of cerebral 
hemorrhage
0 No sub arachnoid hemorrhage (SAH) or ventricular hemorrhage 
(VH)
0%
1 Minimal SAH, No VH in 2 lateral ventricles 6%
2 Minimal SAH, VH in 2 lateral ventricles 14%
3 Large SAH, No VH in 2 lateral ventricles 12%
4 Large SAH, VH in 2 lateral ventricles 28%
Table 3. 
Modified fisher grading system [82].
Grade Glasgow coma scale (GCS) Neurological exam
1 15 No motor deficit
2 13–14 No motor deficit
3 13–14 Motor deficit
4 7–12 With/without motor deficit
5 5–6 With/without motor deficit
Table 1. 
World Federation of Neurological Surgeons Grading System for Subarachnoid Hemorrhage - (WFNS) scale.
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risk of being highest in patients with poor Hunt and Hess grade and those with 
thick subarachnoid blood [85]. Routine prophylactic antiepileptic drug use in 
patients with SAH is a common practice despite limited evidence The American 
Stroke Association (ASA) guideline recommends consideration of short-term 
prophylactic antiepileptic drug use in the immediate post hemorrhage period [86]. 
No randomized controlled trials have investigated the safety and effectiveness of 
antiepileptic drugs in SAH [87].
4.6 Nimodipine
Delayed cerebral ischemia (DCI) is one of the most serious complications associ-
ated with SAH, occurring in one-third of patients surviving the initial hemorrhage 
and results in poor outcome in half of the patients with this complication [86]. 
Nimodipine is a calcium antagonist that is thought to reduce the rate of cerebral 
vasospasm by reducing the influx of calcium into the vascular smooth muscle cells. 
The administration of nimodipine to reduce the risk of poor outcome and DCI is the 
only level IA evidence recommended by the ASA [86].
4.7 Blood pressure management
There is general consensus that hypertension should be controlled after SAH 
and until the ruptured aneurysm is secured. However, specific parameters for blood 
pressure have not been defined and data are sparse. Early retrospective studies sug-
gest a higher rate of rebleeding with SBP greater than 160 mm Hg and severity of 
initial hemorrhage [88]. Therefore, the ASA and Neurocritical Care Society recom-
mend maintaining SBP less than 160 mm Hg and mean arterial pressure less than 
110 mm Hg before the ruptured aneurysm is secured to reduce the risk of rebleed-
ing [86, 87, 89, 90]. The ideal antihypertensive to use in SAH would be a parenteral 
agent that produces a rapid and reproducible dose response while concurrently 
minimizing adverse cerebral effects. Labetalol, nicardipine, and clevidipine are 
agents recommended by the ASA [86].
Figure 5. 
Flowchart of management aSAH [1, 10–12].
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4.8 Antifibrinolytics
When early definitive treatment of the ruptured aneurysm is not possible, anti-
fibrinolytic therapies such as amino epsilon caproic acid or tranexamic acid can be 
considered to reduce the risk of early aneurysmal rebleeding. Early studies showed 
a reduction in rebleeding but an increase in cerebral ischemia with prolonged use 
of antifibrinolytics [88]. Neither aminocaproic acid or tranexamic acid is approved 
by the US Food and Drug Administration for prevention of aneurysmal rebleeding, 
thus the use of antifibrinolytic therapies should be discussed on a case-by-case 
basis.
4.9 Rebleeding
Rebleeding can occur before the ruptured aneurysm is secured, and is associ-
ated with significant mortality and poor prognosis for functional recovery, most 
common within the first 24 hours, with some studies reporting peak time of 
rebleeding within 2 hours [88]. Factors associated with rebleeding include longer 
time to aneurysm treatment, worse neurologic status on presentation, initial loss 
of consciousness, previous sentinel headaches, larger aneurysm size, and possibly 
SBP greater than 160 mm Hg [91]. Although early definitive treatment of ruptured 
aneurysms can reduce the risk of rebleeding, approximately 12–15% of patients die 
before reaching the hospital [90].
4.10 External ventricular drainage
Acute hydrocephalus is common in patients with SAH and is a common cause of 
early neurologic decline. Treatment of symptomatic hydrocephalus often requires 
placement of an external ventricular drain, which allows ICP monitoring as well as 
CSF drainage. Untreated hydrocephalus can lead to intracranial hypertension and 
cerebral ischemia with potential cerebral herniation. Identification of the presence 
of hydrocephalus on CT and communication of this finding with neurosurgical 
consultants are key steps in the management of SAH.
4.11 Microsurgical clipping versus endovascular coiling
Definitive treatment of SAH is early microsurgical clipping or endovascular 
coiling of the ruptured aneurysm to prevent rebleeding and its associated complica-
tions. Choice of treatment modality depends on aneurysm size, characteristics, 
and location, as well as the patient’s clinical grade and comorbidities [92]. The 
International Subarachnoid Aneurysm Trial (ISAT) [93] is a multicenter, random-
ized clinical trial, which compares a policy of neurosurgical clipping with a policy 
of endovascular treatment with detachable platinum coils in patients with ruptured 
intracranial aneurysms considered suitable for either treatment. The results show 
that endovascular intervention with detachable platinum coils in patients with 
ruptured intracranial aneurysms can improve the chances of independent survival 
compared with neurosurgical intervention to clip the neck of the aneurysm.
4.12 Pipeline embolization device
The PED has mostly been used to treat unruptured aneurysms, whereas its 
use for acutely ruptured aneurysms has been limited and is theoretically contra-
indicated, given the need for dual antiplatelet therapy as it increases the risk of 
re-hemorrhage [94].
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However, in certain cases of complex ruptured aneurysms, the PED may still 
serve as a good alternative (and sometimes may be the only available option) because 
these aneurysms are anatomically and technically more difficult to treat using 
standard techniques [93]. Furthermore, certain anticoagulation protocols can be 
put into place to prevent the feared consequences associated with PED placement in 
ruptured aneurysms due to dual antiplatelet therapy. The standard management for 
the prevention of thromboembolic events when using flow diverters is pretreatment 
with aspirin and clopidogrel for 7–10 days prior to the procedure. When treating 
ruptured aneurysms with the PED in conjunction with this dual antiplatelet therapy, 
there is a concern for hemorrhagic complications. Chalouhi and colleagues [95] 
described a new regimen for anticoagulation that was recently implemented in the 
hope of minimizing the risk of thromboembolic and hemorrhagic complications. In 
summary, the PED may be particularly helpful in acutely ruptured aneurysms that 
are not amenable to coiling or clipping. It can also be used in a staged fashion 1 or 
2 weeks after partial coiling of the aneurysm dome. It is generally preferable to place 
an external ventricular drain if treatment with the PED is contemplated [96].
5. Future directions
The future of neuroendovascular surgery is bright. The technology platforms 
for access, delivery and treatment continue to improve at exponential rates. As it 
is there has been a rapid change in the number of brain aneurysm patients treated 
with endovascular treatment versus open surgical clipping. With this change comes 
a great void in experience and skill in the open surgical management of brain aneu-
rysms. It remains to be seen whether this skill will be needed in the future [97].
5.1 Flow disruptor
Currently there is only one flow disruptor available in the US market; the WEB 
device. Currently, its limitations lie in the fact that it is only available in sizes to 
treat aneurysms 3–10 mm in size. The second limitation exists in its delivery system 
which, at larger sizes requires a 33-microcatheter, and at smallest sizes requires a 
21-microcatheter. As newer generations come to market over the next 5 years, we 
expect there to be improved deliverability, different shapes available, and smaller 
designs for smaller ruptured aneurysms [98].
5.2 Flow diverter
Currently there are two flow diverter stents available in the US Market, the 
Pipeline Flex (2nd generation), and the Surpass. Currently the bulk of innovation 
required with this technology is in finding a coating for the stent that might miti-
gate the need for dual anti-platelet therapy. The second area of innovation is in the 
deliverability of the stents, currently needing 27-microcatheter for delivery, there 
is an expectation that these stents can be delivered through a 21-microcatheter in 
the near future, with also smaller diameter stent sizes available to treat more distal 
aneurysms. We fully expect the indications on which type of aneurysms can be 
treated in the near future.
5.3 Endosaccular coiling
Coiling has likely reached its technological pinnacle. There has been little 
advancement in this technology over the last 5 years. One area of interest is in 
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4.8 Antifibrinolytics
When early definitive treatment of the ruptured aneurysm is not possible, anti-
fibrinolytic therapies such as amino epsilon caproic acid or tranexamic acid can be 
considered to reduce the risk of early aneurysmal rebleeding. Early studies showed 
a reduction in rebleeding but an increase in cerebral ischemia with prolonged use 
of antifibrinolytics [88]. Neither aminocaproic acid or tranexamic acid is approved 
by the US Food and Drug Administration for prevention of aneurysmal rebleeding, 
thus the use of antifibrinolytic therapies should be discussed on a case-by-case 
basis.
4.9 Rebleeding
Rebleeding can occur before the ruptured aneurysm is secured, and is associ-
ated with significant mortality and poor prognosis for functional recovery, most 
common within the first 24 hours, with some studies reporting peak time of 
rebleeding within 2 hours [88]. Factors associated with rebleeding include longer 
time to aneurysm treatment, worse neurologic status on presentation, initial loss 
of consciousness, previous sentinel headaches, larger aneurysm size, and possibly 
SBP greater than 160 mm Hg [91]. Although early definitive treatment of ruptured 
aneurysms can reduce the risk of rebleeding, approximately 12–15% of patients die 
before reaching the hospital [90].
4.10 External ventricular drainage
Acute hydrocephalus is common in patients with SAH and is a common cause of 
early neurologic decline. Treatment of symptomatic hydrocephalus often requires 
placement of an external ventricular drain, which allows ICP monitoring as well as 
CSF drainage. Untreated hydrocephalus can lead to intracranial hypertension and 
cerebral ischemia with potential cerebral herniation. Identification of the presence 
of hydrocephalus on CT and communication of this finding with neurosurgical 
consultants are key steps in the management of SAH.
4.11 Microsurgical clipping versus endovascular coiling
Definitive treatment of SAH is early microsurgical clipping or endovascular 
coiling of the ruptured aneurysm to prevent rebleeding and its associated complica-
tions. Choice of treatment modality depends on aneurysm size, characteristics, 
and location, as well as the patient’s clinical grade and comorbidities [92]. The 
International Subarachnoid Aneurysm Trial (ISAT) [93] is a multicenter, random-
ized clinical trial, which compares a policy of neurosurgical clipping with a policy 
of endovascular treatment with detachable platinum coils in patients with ruptured 
intracranial aneurysms considered suitable for either treatment. The results show 
that endovascular intervention with detachable platinum coils in patients with 
ruptured intracranial aneurysms can improve the chances of independent survival 
compared with neurosurgical intervention to clip the neck of the aneurysm.
4.12 Pipeline embolization device
The PED has mostly been used to treat unruptured aneurysms, whereas its 
use for acutely ruptured aneurysms has been limited and is theoretically contra-
indicated, given the need for dual antiplatelet therapy as it increases the risk of 
re-hemorrhage [94].
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treat aneurysms 3–10 mm in size. The second limitation exists in its delivery system 
which, at larger sizes requires a 33-microcatheter, and at smallest sizes requires a 
21-microcatheter. As newer generations come to market over the next 5 years, we 
expect there to be improved deliverability, different shapes available, and smaller 
designs for smaller ruptured aneurysms [98].
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Pipeline Flex (2nd generation), and the Surpass. Currently the bulk of innovation 
required with this technology is in finding a coating for the stent that might miti-
gate the need for dual anti-platelet therapy. The second area of innovation is in the 
deliverability of the stents, currently needing 27-microcatheter for delivery, there 
is an expectation that these stents can be delivered through a 21-microcatheter in 
the near future, with also smaller diameter stent sizes available to treat more distal 
aneurysms. We fully expect the indications on which type of aneurysms can be 
treated in the near future.
5.3 Endosaccular coiling
Coiling has likely reached its technological pinnacle. There has been little 
advancement in this technology over the last 5 years. One area of interest is in 
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endosaccular flow disruptor type coils such as the Medina system. This is not as 
of yet FDA approved and remains to be seen whether this is efficacious or safe. 
Also the adjunctive tools for coiling continue to improve such as the Atlas stent, 
Pulserider stent and barrel stent which all are improvements for the treatment 
of bifurcation aneurysms and make difficult to coil aneurysms easier. We expect 
further improvements in these designs, and with improvements in deliverability. 
In addition to stents, the balloons available for balloon assisted coiling continue to 
improve in shape, design and deliverability which are particularly helpful in the 
setting of a ruptured small or wide necked aneurysm [99].
5.4 Imaging and aneurysm rupture prediction
Currently other than aneurysm size, and certain bio-social risk factors, there is 
no way to accurately predict which aneurysms are at risk for rupture. Over the next 
5 years we expect to see, further advancement in the arena of MR vessel wall imag-
ing, and flow-modeling. We hope that this will help improve our predictive models.
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The function of the cerebrospinal fluid (CSF) has long been considered for 
mechanical protection and recently attributed to the supply of nutrients to the 
brain. However, we hypothesize that the brain is a water-cooled and water-cleaned 
system. Recent studies on the glymphatic pathways and the introduction of cis-
ternostomy as a surgical procedure for traumatic brain injury reveal a vast and 
in-depth functionality of the CSF, which works in synchrony with the cardiopul-
monary rhythms to act as a buffer for optimum cerebral function. The nasal sinuses 
are located around the suprasellar cistern, and the evaporating wet mucosa within 
them during the breathing contributes to local cooling, whereas the nocturnal 
activation of AQP4 channels allows CSF-ISF exchange. The resultant “cooling and 
cleaning” of the brain not only maintains a physiological equilibrium but also opens 
doors for understanding and treating pathophysiology underlying common degen-
erative and neuro-inflammatory diseases. This chapter describes the novel theory 
of brain cooling and cleaning and the clinical and experimental evidence to support 
this hypothesis.
Keywords: glymphatic pathway, cisternostomy, CSF shift, Virchow Robin spaces, 
subarachnoid cisterns, hydrocephalus, aquaporin-4
1. Introduction
The cerebrospinal fluid (CSF) is an ultrafiltrate of plasma, which resides in 
two compartments within the central nervous system (Figure 1). The ventricular 
system comprises four interconnected cavities in the brain and contains a network 
of ependymal cells forming the choroid plexus which has been believed to be the 
site of production of the CSF. The ventricular system is continuous with the central 
canal of the spinal cord (from the fourth ventricle) and allows the CSF to continu-
ously bathe the cranium and the spine. The subarachnoid spaces form openings 
termed as subarachnoid cisterns which separate the arachnoid and the pia mater, 
thereby creating an anatomic space between the two meninges. These cisterns are 
filled with cerebrospinal fluid and form the second compartment where the CSF 
flows within the cranial cavity.
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2. Cerebrospinal fluid: dynamics and function
Adult CSF volume is estimated to be 150 ml with a distribution of 125 ml within 
the subarachnoid spaces and 25 ml within the ventricles. This difference in the 
volume of CSF between the two compartments is important to understand the 
function of the CSF in a unique perspective.
The CSF secretion varies between individuals, usually ranging between 400 
and 600 ml per day in an adult. The constant secretion of CSF contributes to a four 
to five times turnover per 24-h period. This turnover is of immense importance in 
exploring the functions of the CSF which have not yet been understood quite well. 
While the CSF has been considered as a source of nutrition and waste removal and 
a mechanically buoyant substance, cushioning the brain, the newer insights of the 
glymphatic pathways have demonstrated a critical role of CSF flow as a physiologi-
cal buffer for brain functioning.
With a closely regulated composition, the CSF is valuable in analyzing cerebral 
pathologies. Alterations in the regulation of localized temperatures, malformation 
of proteins, and impeding clearance of pathologic proteins are the pathophysi-
ological mechanisms for onset and progress of most neurodegenerative disorders as 
well as secondary brain damage in the setting of trauma. It is, however, interesting 
to analyze how the impairment of CSF inflow or outflow through the glymphatic 
system might lead to the cascade of these degenerative and traumatic pathologies.
2.1 The glymphatic pathway and the Virchow Robin (paravascular) spaces
The amount of CSF within the CSF compartments is a consequence of the net 
filtration and absorption of water through the selectively permeable capillary walls 
traversing through the brain tissue. This net effect is governed by the physiological 
Figure 1. 
The anatomy of the fluid compartments of the brain: ventricular and cisternal systems.
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or pathological conditions prevailing within these compartments. The glymphatic 
system branches along the course of the arteries, arterioles, capillaries, and venules, 
forming a paravascular cast. This CSF interacts with the end feet of glia and indi-
rectly with neurons to establish an exchange with the brain ISF (Figure 2).
The AQP4 channels mediate the bidirectional transport of water in response to 
passive osmotic and hydraulic pressure gradients [2, 3], resulting in the CSF-ISF 
exchange [4]. This makes the glymphatic system extremely pressure dependent. 
Any increase of pressure in the glymphatic system would produce the passage of 
fluid toward the interstitial space until the pressure in both compartments is equal-
ized. This exchange drives the removal of exogenous molecules from the interstitial 
spaces of the brain [5, 6] (Figure 3).
Figure 2. 
Artistic representation that depicts the persistence of the paravascular system through the arteries, arterioles, 
capillaries, venules, and veins. This indicates that just as there is a vascular cast of the brain, there is a 
paravascular system cast as well. Courtesy: Cherian and Beltran [1].
Figure 3. 
The anatomy of the Virchow Robin spaces forming an extensive network of communication within the 
glymphatic pathway. Courtesy: Orešković and Klarica [7].
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2.2 Introducing the concept of “CSF-shift” edema
The dependence of AQP4 to pressure gradients in both senses might be the 
underlying mechanism leading to the recently described “shift edema” following 
trauma [8] and also would explain the advantages of cisternostomy over crani-
ectomy for the treatment in the short- and long-term follow-up of the patients 
[9]. Subsequent to subarachnoid hemorrhage, red blood cells are confined to the 
subarachnoid space and do not enter the VRS as pial membranes between the PVS 
and the SAS prevent the exchange of large molecules [10] (Figure 4).
3. Brain as a water-cooled and water-cleaned system
3.1 The subarachnoid cisterns and paranasal sinuses: anatomical relationships
The brain can be assumed as a water-cooled system with the CSF as a medium of 
heat removal and the paranasal sinuses as cooling surfaces. The close contact of the 
PNS with the suprasellar cisterns helps create a radiation system, and the mechanical 
process of breathing allows the sinuses to deliver the acquired heat from the brain 
parenchyma which is dumped by the CSF residing in the cisterns. Evaporation at the 
sinus surface causes cooling effect that is transmitted to the cisterns, dissipating the 
heat from the CSF which is acquired from the brain parenchyma [1] (Figure 5).
This cooling unit can be hypothesized to be a fundamental thermostat, and 
any hindrance in CSF flow might explain the cascade of protein misfolding sec-
ondary to heat accumulation as seen in neurodegeneration. While brain cooling 
is a passive process that occurs throughout the day, brain cleaning is more pro-
nounced nocturnally. It is believed that brain cleaning is regulated by AQP4 and 
exchanges between interstitial fluid and CSF have been demonstrated to be more 
Figure 4. 
Schematic representation of the mechanism of CSF-shift edema following traumatic brain injury. The AQP-4 
channels on the lining of VRS allow the shift of CSF from the cisterns into the brain parenchyma leading to 
brain edema.
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active during sleep due to an expansion of the extracellular space, being increased 
by 60% during sleep [11], particularly in the lateral position [12]. The increased 
glymphatic clearance of the metabolic waste products generated by neural activity 
in the awake brain occurs during sleep, explaining the need to sleep for restoring 
alertness and activity.
3.2 Hypothesis of the CSF-driven brain cooling and cleaning mechanism
CSF is permanently produced and absorbed in the whole CSF system as a 
consequence of filtration and reabsorption of water volume through the capil-
lary walls into the surrounding brain tissue. The three- to fourfold turnover rate 
in CSF production allows for a rigorous cerebral buffering at physiological states 
which helps maintain brain function. The brain generates tremendous amount of 
heat throughout the day which needs to be removed essentially to prevent protein 
misfolding and generation of free radicals. This warrants a system to allow for heat 
removal in the form of cooling as well as cleaning of metabolic wastes to prevent 
accumulation of toxic metabolites.
At a physiological state, the difference in arterial and venous hydrostatic and 
osmotic pressures allows a unidirectional flow of water and other molecules (solu-
ble waste), with water leaving from the arterial end and molecules entering at the 
venous end. This simultaneous exchange of water and waste at two different ends 
can thus be regarded as a means of cleaning for the brain [5].
A deeper insight to this simultaneous exchange of water and waste in the blood 
vessels reveals the orientation of the brain vasculature, which, unlike other organs, 
runs in an opposite fashion, with the primary arteries lying ventral and more medi-
ally, whereas the principal veins run in a dorsal and lateral manner. Additionally, 
the disposition of white matter tracts creates an anisotropic field that facilitates the 
direction of fluid and molecules toward the main veins, which is further directed by 
changes in arteriovenous pressure gradients.
The paravascular system therefore maintains a very intricate and evolved system 
through extensive branching of vessels in the brain along with its paravascular 
Figure 5. 
Close communication of the paranasal sinuses with the cisterns creating a brain cooling unit. Courtesy: Cherian 
and Beltran [1].
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system, thus following the vascular cast of the brain. This intricate system is limited 
by the selectively permeable capillary walls which is only large enough for a red 
blood cell to permeate through and may indeed be even more intricate than the 
vessels, since the limiting dimension of the capillaries is 3 in diameter, which is just 
large enough for a red blood corpuscle to squeeze through (Figure 6).
3.3 Role of breathing in brain cooling
The arteriovenous pressure difference described above can lead to the potential 
role of breathing on the dynamics of CSF flow within the extensive paravascular 
system. The close relationship of the paranasal sinuses with the basal cisterns 
provides an excellent radiation chamber that can help in buffering the thermal envi-
ronment of the brain through continuous evaporation of the mucosa-lined sinus 
surfaces in contact with the external atmosphere, hence the hypothesis of breathing 
playing an important role in the cooling of the brain and possibly the clearance of 
molecules within the paravascular system.
3.4 Sleep and aquaporin-4 in brain cleaning
Attributed to the expression and function of the AQP-4 channels, the brain 
cleaning mechanism is predominant during sleep. Sleep increases the expansion 
of the extracellular spaces by up to 60% which allows for a maximal exchange of 
substances to and fro the CSF and the ISF compartments [11]. This phenomenon is 
particularly observed in the lateral position [12]. Therefore, the restorative prop-
erties of sleep may be linked to increased glymphatic clearance of the metabolic 
waste products that are generated by neural activity in the awake brain. This might 
underpin the beneficial effects of sleep, in clearance of metabolic byproducts, the 
phenomenon of jetlag, and the problems with lack of sleep.
4. Cardiopulmonary regulation of the CSF flow
The primary CSF delivery mechanism, from the subarachnoid space into 
the paravascular system and along the paravascular space, appears to be arterial 
pulsatility [6, 13], coupled with brain compliance [2] (Figure 7). Arterial pulsatil-
ity, coupled with a perivascular compliance, generates successive physical brain 
compression and expansion, allowing the brain to act like a sponge by virtue of 
the cycle-dependent systolic-diastolic circulatory movement of blood through 
Figure 6. 
Schematic representation of the Virchow Robin spaces traveling around the blood vessels from the cisterns into 
the brain. Courtesy: Cherian and Beltran [1].
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the brain [14]. This reciprocal movement influences the flow of fluids in the brain 
parenchyma to initiate a “pumping” effect of CSF around the vessels. These move-
ments are driven by physiological oscillations of arterial and venous blood during 
craniospinal blood circulation, which are influenced by respiration, body activity, 
and posture [7].
Loss of arterial elasticity may lead to an impairment of this “pumping” effect in 
the paravascular system. This is classically seen in small vessel disease or as a conse-
quence of low craniospinal compliance that impedes the expansion of the arteries, 
as can be seen in normal pressure hydrocephalus, gliosis [15], or post-traumatic 
hypertension. This would result in a decrease of CSF turnover that hinders the 
clearance of metabolites [16] and generates excess metabolic heat, thereby contrib-
uting to the pathogenesis of neurological diseases.
Aging is a phenomenon that leads to a decline in the exchange efficiency 
between CSF in the paravascular spaces, and ISF occurs. This can be related to a 
reduction in the vessel wall pulsatility of intracortical arterioles and the widespread 
loss of perivascular AQP4 channels [17]. This “hardening” of vessel walls, as a 
consequence of aging, decreases the drainage of amyloid peptides, which may 
deposit in the paravascular pathways as cerebral amyloid angiopathy (CAA). These 
deposits further impede the drainage of ISF along the paravascular spaces, resulting 
in loss of homeostasis of the neuronal environment that may contribute to neuronal 
malfunction [15, 18]. The concurrent loss of localized thermal regulation by the 
paravascular pathway may add to the cascade of damage by modification of pro-
teinaceous components, which are very sensitive to subtle changes in temperature. 
These structural changes in molecular geometries might disturb solubility and thus 
the drainage of this metabolic waste, giving rise to a vicious circle.
5.  Alterations in the glymphatic system: impaired brain cleaning  
and cooling
The functional impairment of the paravascular system appears to be an under-
lying condition of the aging human brain [19], which has also been related to 
various CNS disorders, such as neurodegenerative disorders that are brought on by 
the accumulation of misfolded, prion-like proteins (e.g., Alzheimer’s or amyloid 
angiopathy) [17, 20, 21], normal pressure hydrocephalus [19, 22, 23], post-traumatic 
encephalopathy [24, 25], or neuroinflammatory disorders, such as multiple scle-
rosis. Furthermore, the presence of the paravascular system would explain the 
Figure 7. 
Graphical representation of pulsations in the artery and veins being the driving force to the CSF in the 
paravascular pathway.
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advantages of cisternostomy over decompressive craniectomy, in the treatment of 
acute brain trauma [8, 26].
Decreased intracranial compliance leads to increased intraparenchymal pres-
sure, affecting the arterial perfusion of the brain and promoting venous conges-
tion. On the whole, the kinetics of the fluid in the paravascular spaces is impaired. 
Should there be a loss of AQP4 localization, as seen in reactive astrogliosis and the 
aging brain, or following trauma or ischemia, or if the CSF outflow is reduced as a 
consequence of either CSF flow obstruction, cerebral artery pulsatility inefficiency, 
cerebrospinal venous insufficiency, or lymphatic disorders [27], the localized 
perivascular CSF recirculation may be impaired.
5.1 Clinical implication
5.1.1 Cisternostomy: the clinical implementation of CSF-shift reversal in TBI
The corresponding author serendipitously uncovered the fact that opening 
cisterns in severe head trauma had the effect of abating severe brain swelling while 
drastically reducing the requirement for decompressive hemicraniectomies [24, 28]. 
His decade-long work on this led him to believe that CSF was ingressing to the brain 
through the Virchow Robin spaces, producing a condition which has been recently 
termed as CSF shift edema. Experimental studies on the glymphatic system by Iliff 
et al. categorically proved the communication of the CSF with the brain through the 
Virchow Robin spaces, or paravascular spaces, and that this pathway was critical 
for clearing the brain of metabolites [5, 6]. Perhaps the biggest clinical implication 
of this finding is the microsurgical opening of the cisterns: cisternostomy, in cases 
of moderate to severe head injury in order to reverse CSF shift edema, which is the 
mainstay of the cascade of the TBI damage. This procedure has been discussed in 
detail in previous publications and prevents progression to diffuse axonal damage 
or cortical stretch as otherwise seen in decompressive procedures. The phenomenal 
prognosis in the patients undergoing cisternostomy led the author to investigate the 
paravascular system in further depth, as well as CSF shifts, and subsequently the 
likely functionality of the paravascular system (Figure 8).
Today, cisternostomy has shown to be efficacious as a primary surgical interven-
tion in moderate to severe traumatic brain injury. While following the principles of 
reversal of CSF shift edema, cisternostomy has proven to help in the prognosis by 
decreasing the rates of morbidities and mortalities [22]. It is now being practiced 
in many neurosurgical centers around the world [25] and has also been accepted 
Figure 8. 
(a) Raised cisternal pressure due to the traumatic subarachnoid hemorrhage shifts cerebrospinal fluid into the 
brain, causing raised intracerebral pressure. (b) Opening of the cisterns reverses the cisternal pressure gradient, 
causing cerebrospinal fluid to flow back into the cisterns, thus decreasing the brain pressure. (c) Decompressive 
hemicraniectomy allows extracalvarial herniation, leading to further deterioration due to axonal stretch and 
altered blood flow dynamics. Courtesy: Cherian et al. [24].
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as one of the options of surgical intervention in the ongoing Global Neurotrauma 
Outcomes Study [29].
5.1.2 Road to further research
The paravascular system, its cleaning and cooling properties, and the conse-
quent pathophysiological conditions secondary to the impedance of this system 
as well as potential treatment measures have not yet been investigated in detail. 
Reports of an experiment where a bacteriophage is being introduced into the olfac-
tory system of a mouse resulted in the reversal of Alzheimer’s symptoms. This could 
be due to the clearance of the obstructed paravascular system as the phage traveled 
into the cisterns through the perineural space of the olfactory. This observation 
opens doors for a paradigm shift in the management of neurodegenerative diseases 
and warrants extensive research. Further experimental work in this area will 
include the injection of paramagnetic nanoparticles into the suprasellar cisterns of 
mice, porcine, or baboon models, where the movement of these nanoparticles may 
be observed with a T1 W3T MRI.
6. Conclusion
The paravascular system is a branching structure that extensively connects the 
cells and vessels within the brain. The intricacy of the system and the challenges in 
performing studies have been a hurdle in exploring this system. However, an in-
depth analysis of brain fluid dynamics and its relationship to the cardiopulmonary 
mechanisms can provide a game changing pathway to the preventive and therapeu-
tic measures of various pathophysiological brain disorders.
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Abstract
Vasospasm refers to a condition in which an arterial spasm leads to vasoconstric-
tion. This can lead to tissue ischemia and necrosis. Coronary vasospasm can lead 
to significant cardiac ischemia associated with symptomatic ischemia or cardiac 
arrhythmia. Cerebral vasospasm is an essential source of morbidity and mortality 
in subarachnoid hemorrhage patients. It can happen within 3–15 days with a peak 
incidence at 7 days after aneurysmal subarachnoid hemorrhage (SAH). Calcium 
channel blockers are widely used in the treatment of hypertension, angina pectoris, 
cardiac arrhythmias, and other disorders like SAH vasospasm related and Migraine. 
The specific treatment of cerebral vasospasm helps improving cerebral blood flow 
to avoid delayed ischemic neurologic deficit by reducing ICP, optimizing the rate 
of cerebral oxygen demand, and enhancing cerebral blood flow with one of the 
following approaches: indirect pharmacological protection of brain tissue or direct 
mechanical dilation of the vasospastic vessel. Nimodipine is the standard of care 
in aneurysmal SAH patients. Nimodipine 60 mg every 4 hours can be used for all 
patients with aneurysmal SAH once the diagnosis is made for 21 days.
Keywords: coronary vasospasm, cerebral vasospasm, calcium channel blockers, 
cerebral blood flow, nimodipine
1. Introduction
Vasospasm is a condition which is associated with an arterial spasm and vasocon-
striction, which may lead to tissue ischemia and necrosis. Coronary vasospasm can 
lead to significant cardiac ischemia associated with symptomatic ischemia or cardiac 
arrhythmia. Cerebral vasospasm may arise as a complication of subarachnoid hem-
orrhage (SAH). The most common cause of delayed cerebral ischemia after SAH is 
assumed to be vasospasm; delayed cerebral ischemia contributes substantially to 
morbidity and mortality after SAH especially aneurysmal SAH. Calcium channel 
blockers are widely used in the treatment of hypertension, angina pectoris, cardiac 
arrhythmias, and other disorders like SAH vasospasm related and migraine. Data is 
suggesting that their use reduces the risk of subsequent cardiovascular events [1, 2]. 
Besides, some meta-analyses have suggested that calcium channel blockers may be 
more effective than other drugs in reducing stroke risk [3, 4]. Fleckenstein’s work in 
the 1960s led to the concept that drugs alter cardiac and smooth muscle contraction 
by blocking the entry of Ca2+ into myocytes. Godfraind and associates showed that 
the effect of the diphenylpiperazine analogs in the prevention of agonist-induced 
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lead to significant cardiac ischemia associated with symptomatic ischemia or cardiac 
arrhythmia. Cerebral vasospasm may arise as a complication of subarachnoid hem-
orrhage (SAH). The most common cause of delayed cerebral ischemia after SAH is 
assumed to be vasospasm; delayed cerebral ischemia contributes substantially to 
morbidity and mortality after SAH especially aneurysmal SAH. Calcium channel 
blockers are widely used in the treatment of hypertension, angina pectoris, cardiac 
arrhythmias, and other disorders like SAH vasospasm related and migraine. Data is 
suggesting that their use reduces the risk of subsequent cardiovascular events [1, 2]. 
Besides, some meta-analyses have suggested that calcium channel blockers may be 
more effective than other drugs in reducing stroke risk [3, 4]. Fleckenstein’s work in 
the 1960s led to the concept that drugs alter cardiac and smooth muscle contraction 
by blocking the entry of Ca2+ into myocytes. Godfraind and associates showed that 
the effect of the diphenylpiperazine analogs in the prevention of agonist-induced 
vascular smooth muscle contraction could be overcome by raising the concentration 
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of Ca2+ in the extracellular medium. Hass and Hartfelder reported in 1962 that 
verapamil, a coronary vasodilator, possessed negative inotropic and chronotropic 
effects that were not seen with other vasodilatory agents, such as GTN. In 1967, 
Fleckenstein suggested that the negative inotropic effect resulted from an inhibition 
of excitation-contraction coupling and that the mechanism involved reduced move-
ment of Ca2+ into cardiac myocytes. Verapamil was the first clinically available Ca2+ 
channel blocker; it is a congener of papaverine. Many other Ca2+ entry blockers with 
a wide range of structures are now available [5].
2. Mechanism of action and effects
Calcium is an essential element for excitation-contraction coupling in muscle 
cells. The increase in the cytosolic Ca2+ concentration leads to an increased contrac-
tion in both cardiac and vascular smooth muscle cells [6]:
1. In smooth muscle and cardiac muscle cells, Ca2+ can enter cells through  
transmembrane voltage-gated and ligand-gated channels (Figures 1 and 2).
2. In striated and cardiac muscle cells, a rise in intracellular free Ca2+ promotes 
the release of further Ca2+ from the sarcoplasmic reticulum (SR) through  
actions at ryanodine receptors (Figures 1 and 2).
3. Ligand-gated channels linked to G-protein-coupled receptors promote the 
release of Ca2+ from intracellular stores in the sarcoplasmic reticulum.
4. Ca2+ leaves striated and cardiac muscle cells in exchange for Na + via the  
Na+/Ca2+ exchanger (Figure 1).
Therefore, in striated muscle, free Ca2+ in the cytosol comes only from the 
sarcoplasmic reticulum, while in smooth muscle, it must enter the cell through 
transmembrane Ca2+ channels. Cardiac muscle uses both mechanisms.
Four types of transmembrane calcium channels, differing in location and 
function, have been identified:
A. L type, located in skeletal, cardiac, and smooth muscles, causing contraction 
of muscle cells.
B. T type, found in pacemaker cells, causing Ca2+ entry, inactivated at more nega-
tive potentials and more rapid than the L type.
C. N type is available in neurons and acting in transmitter release.
D. P type is in Purkinje cells whose function is unknown currently.
5- Voltage-gated L-type Ca2+ channels (long-acting, high threshold-activated, 
slowly inactivated) are found in the cell membranes of a large number of excitable 
cells, including cardiac and vascular smooth muscle. Ca2+ enters the cell through 
these channels when the cell membrane is depolarized. The cardiac and vascular 
smooth muscle L-type Ca2+ channels have different subunit structures. L-type 
channels are essential therapeutically. The L-type calcium channel, acted on by cal-
cium channel blockers, consists of five different subunits (α1, α2, β, δ, γ). Figure 3 




6- Voltage-gated T-type Ca2+ channels (transient, low threshold-activated, fast 
inactivated) are found in pacemaker cells of the sinoatrial and atrioventricular 
nodes and are also present in vascular smooth muscle. Calcium channel blockers 
Figure 2. 
Mechanism of contraction of the cardiac myocyte by L-type voltage-gated Ca channel.
Figure 3. 
Subunits of the L-type calcium channel.
Figure 1. 
Regulation of calcium in cardiac myocytes and blood vessels.
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a wide range of structures are now available [5].
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tion in both cardiac and vascular smooth muscle cells [6]:
1. In smooth muscle and cardiac muscle cells, Ca2+ can enter cells through  
transmembrane voltage-gated and ligand-gated channels (Figures 1 and 2).
2. In striated and cardiac muscle cells, a rise in intracellular free Ca2+ promotes 
the release of further Ca2+ from the sarcoplasmic reticulum (SR) through  
actions at ryanodine receptors (Figures 1 and 2).
3. Ligand-gated channels linked to G-protein-coupled receptors promote the 
release of Ca2+ from intracellular stores in the sarcoplasmic reticulum.
4. Ca2+ leaves striated and cardiac muscle cells in exchange for Na + via the  
Na+/Ca2+ exchanger (Figure 1).
Therefore, in striated muscle, free Ca2+ in the cytosol comes only from the 
sarcoplasmic reticulum, while in smooth muscle, it must enter the cell through 
transmembrane Ca2+ channels. Cardiac muscle uses both mechanisms.
Four types of transmembrane calcium channels, differing in location and 
function, have been identified:
A. L type, located in skeletal, cardiac, and smooth muscles, causing contraction 
of muscle cells.
B. T type, found in pacemaker cells, causing Ca2+ entry, inactivated at more nega-
tive potentials and more rapid than the L type.
C. N type is available in neurons and acting in transmitter release.
D. P type is in Purkinje cells whose function is unknown currently.
5- Voltage-gated L-type Ca2+ channels (long-acting, high threshold-activated, 
slowly inactivated) are found in the cell membranes of a large number of excitable 
cells, including cardiac and vascular smooth muscle. Ca2+ enters the cell through 
these channels when the cell membrane is depolarized. The cardiac and vascular 
smooth muscle L-type Ca2+ channels have different subunit structures. L-type 
channels are essential therapeutically. The L-type calcium channel, acted on by cal-
cium channel blockers, consists of five different subunits (α1, α2, β, δ, γ). Figure 3 




6- Voltage-gated T-type Ca2+ channels (transient, low threshold-activated, fast 
inactivated) are found in pacemaker cells of the sinoatrial and atrioventricular 
nodes and are also present in vascular smooth muscle. Calcium channel blockers 
Figure 2. 
Mechanism of contraction of the cardiac myocyte by L-type voltage-gated Ca channel.
Figure 3. 
Subunits of the L-type calcium channel.
Figure 1. 
Regulation of calcium in cardiac myocytes and blood vessels.
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have different chemical structures, but their standard action is to reduce Ca2+ influx 
through voltage-gated L-type Ca2+ channels in smooth cardiac muscle (Figure 2).
There are clinically significant differences among the different types of calcium 
channel blockers, which bind to discrete receptors on the L-type Ca2+ channel. The 
receptor for verapamil is intracellular, while diltiazem and the dihydropyridines 
(e.g., nifedipine, amlodipine) have extracellular binding sites; however, the recep-
tor domains for verapamil and diltiazem overlap. Verapamil and diltiazem exhibit 
frequency-dependent receptor binding and gain access to the Ca2+ channel when 
it is in the open state; in contrast, the dihydropyridines preferentially bind to the 
channel in its inactivated state. As more Ca2+ channels are in the inactive state, dihy-
dropyridines selectively bind to Ca2+ channels in vascular smooth muscle. These 
receptor binding characteristics account for the relative vascular selectivity of the 
dihydropyridines and the antiarrhythmic properties of verapamil and diltiazem [6].
Calcium concentrations in cardiac cells and vascular smooth muscles are under 
the influence of different mechanisms. Calcium entry through voltage-gated L-type 
Ca2+ channels stimulates ryanodine receptors (RyR) in the sarcoplasmic reticulum, 
releasing stored Ca2+ (a process known as Ca2+ −induced calcium release, CICR). 
Intracellular Ca2+ is also regulated by exchange with Na + via the Na+/Ca2+ exchang-
ers (NCX) in the cell membrane.
The depolarization phase during the action potential activates the voltage-gated 
channels, and the influx of Ca2+ into the cell results in myosin phosphorylation and 
muscle contraction. It also promotes further Ca2+ release from the sarcoplasmic 
reticulum by stimulation of ryanodine receptors. L-type Ca2+ channels can, there-
fore, be reduced directly by calcium channel blockers.
3. Pharmacokinetics
Most calcium channel blockers are lipophilic compounds with similar phar-
macokinetic properties. Calcium channel blockers are typically administered in 
oral dosage forms, but orally administered calcium channel blockers undergo 
significant first-pass metabolism in the gut and liver, which can significantly reduce 
bioavailability to 10–30%. Most oral calcium channel blockers have a rapid onset 
of action between 20 minutes and 2 hours like nifedipine resulting in reflex tachy-
cardia, which can worsen myocardial ischemia due to shortening diastolic phase 
of the cardiac cycle. Most of the agents typically have short elimination half-lives 
(2–10 hours), necessitating short dosing intervals or extended-release formations. 
Amlodipine was developed in an attempt to overcome the pharmacokinetic limita-
tions of nifedipine. This drug has an increased oral bioavailability of 60%. The time 
of onset is 6 hours, and prolonged elimination half-life is 40 hours. These kinetic 
properties are likely due, in part, to its lipophilic character and its positive charge 
at physiologic pH, which leads to increased association with negatively charged 
plasma membranes. Some of the calcium channel blockers also have intravenous 
formulations like diltiazem and verapamil, while clevidipine is a dihydropyridine 
agent that is available only as an intravenous formulation. All calcium channel 
blockers are metabolized by the liver. Diltiazem is primarily excreted by the liver, 
while dihydropyridines and verapamil are mainly excreted in the urine [6–8].
4. Pharmacological actions
The main targets of calcium channel blockers are vascular tissue and cardiac 




smooth muscle and decrease Ca2+ entry. All Ca2+ channel antagonists relax arterial 
smooth muscle and thereby reduce arterial resistance, blood pressure, and cardiac 
afterload. Ca2+ channel blockers do not influence cardiac preload significantly when 
given at regular doses, suggesting that capacitance veins that determine venous 
return to the heart are resistant to the relaxing effect of Ca2+ channel antagonists. 
Depolarization in the SA and AV nodes depends mainly on the movement of Ca2+ 
through the slow channel. The impact of a Ca2+ channel blocker on AV conduction 
and the rate of the sinus node pacemaker depend on whether the agent delays the 
recovery of the slow channel.
Diltiazem and verapamil decrease the rate of the SA node pacemaker and slow 
AV conduction at clinically used doses; the latter effect is the basis for their use in 
the treatment of supraventricular tachyarrhythmias [6–8].
5. Cardiovascular effects of different Ca2+ channel blockers
The hemodynamic profiles of the Ca2+ channel blockers approved for clinical use 
differ and depend mainly on the ratio of vasodilating and negative inotropic and 
chronotropic effects on the heart (Table 1, Figures 4 and 5). Although all calcium 
channel blockers are vasodilators, dihydropyridine derivatives such as nifedipine 
and amlodipine are the most potent and have the most significant vascular selectiv-
ity. Arterial dilation reduces peripheral resistance and lowers blood pressure, which 
reduces the work of the left ventricle and therefore reduces myocardial oxygen 
demand. Most dihydropyridines have a rapid onset of action. A rapid reduction 
in blood pressure can lead to reflex sympathetic nervous system activation and 
tachycardia. Amlodipine or modified-release formulations of short-acting dihydro-
pyridines are more slowly absorbed and gradually reduce blood pressure with little 
reflex tachycardia. But generally, the differences between the relatively vaso-selec-
tive dihydropyridines and the much less-selective diltiazem and verapamil have 
essential consequences because the decrease in arterial blood pressure elicits reflex 
sympathetic activation, resulting in the stimulation of heart rate, AV conduction 
velocity, and myocardial force, just the opposite of the direct effect of Ca2+ channel 
blockers. While direct and indirect impacts usually balance each other in the case 
of verapamil and diltiazem, sympathetic stimulation often prevails in dihydropyri-
dines, causing an increase in heart rate and contractility. Cardiac depressant effects 
Table 1. 
Comparative cardiovascular effects of calcium channel blockers graded from 0 (no effect) to 5 (prominent 
effect).
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Depolarization in the SA and AV nodes depends mainly on the movement of Ca2+ 
through the slow channel. The impact of a Ca2+ channel blocker on AV conduction 
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Diltiazem and verapamil decrease the rate of the SA node pacemaker and slow 
AV conduction at clinically used doses; the latter effect is the basis for their use in 
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differ and depend mainly on the ratio of vasodilating and negative inotropic and 
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and amlodipine are the most potent and have the most significant vascular selectiv-
ity. Arterial dilation reduces peripheral resistance and lowers blood pressure, which 
reduces the work of the left ventricle and therefore reduces myocardial oxygen 
demand. Most dihydropyridines have a rapid onset of action. A rapid reduction 
in blood pressure can lead to reflex sympathetic nervous system activation and 
tachycardia. Amlodipine or modified-release formulations of short-acting dihydro-
pyridines are more slowly absorbed and gradually reduce blood pressure with little 
reflex tachycardia. But generally, the differences between the relatively vaso-selec-
tive dihydropyridines and the much less-selective diltiazem and verapamil have 
essential consequences because the decrease in arterial blood pressure elicits reflex 
sympathetic activation, resulting in the stimulation of heart rate, AV conduction 
velocity, and myocardial force, just the opposite of the direct effect of Ca2+ channel 
blockers. While direct and indirect impacts usually balance each other in the case 
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of dihydropyridines may be unmasked, though, in the presence of β blockers and 
patients with heart failure.
Also, they can have a significant impact on coronary artery dilation; for this 
reason, CCB can prevent or relieve coronary vasospasm and improve myocardial 
blood flow. On the other hand, CCBs have negative chronotropic effect. Verapamil 
and diltiazem (but not the dihydropyridines) slow the rate of firing of the sinoatrial 
node and slow the conduction of the electrical impulse through the atrioventricular 
node. Reflex tachycardia does not occur with these drugs, and they also slow the 
rate of rising in heart rate during exercise. CCBs play an essential role in reducing 
cardiac contractility as most calcium channel blockers (particularly verapamil) 
have some negative inotropic effects. Amlodipine does not impair myocardial 
contractility.
Figure 4. 
Effects of calcium channel blocker agents.
Figure 5. 




6. Calcium channel blocker agents
There are two types of CCBs:
A. Dihydropyridines: amlodipine, clevidipine, felodipine, isradipine, lercanidi-
pine, nicardipine, nifedipine, nimodipine, and nisoldipine
Dihydropyridines exhibit much higher arterial vasodilation than non-
dihydropyridines while having relatively little impact on cardiac tissue (i.e., 
there is less depression on myocardial contractility, less impairment on SA 





Non-dihydropyridines are more effective in tissue with frequent channel 
openings (i.e., SA node, AV node, and cardiac myocytes), and channel inhibition 
increases in proportion to heart rate. The negative chronotropic and inotropic 
effects on non-dihydropyridine agents appear greater for verapamil than diltiazem. 
The phenylalkylamine verapamil and the benzothiazepine diltiazem have both 
cardiac and vascular actions (Table 1, Figure 4). These drugs have antiarrhythmic, 
antianginal, and antihypertensive activity.
6.1 Nifedipine
It is a dihydropyridine that does not resemble the other calcium antagonists in 
chemical structure. Although it is not a nitrate, its nitro group is essential for its 
antianginal effect. Also, it has peripheral vasodilatory effects. It works by inhibiting 
the voltage-dependent calcium channel in the vascular smooth muscles and has 
little or no direct suppressant effect on the SA or AV nodes. Nifedipine is thought 
to be more effective in patients with coronary vasospasm, and it is usually used for 
vasospastic angina along with angina pectoris.
Additionally, it is used in selected patients to treat hypertension because of its 
vasodilatory properties. Nifedipine has efficient absorption with buccal or oral 
administration. Around 90% of nifedipine is protein-bound. The bioavailability of 
an oral dose reaches 65%. Nifedipine gets metabolized into two inactive metabo-
lites which are found in equilibrium with each other. Only a limited amount of 
unchanged nifedipine is found in the urine [7].
6.2 Amlodipine
Similar to second-generation dihydropyridines, it has a higher selectivity for 
the vascular smooth muscles than the myocardial tissue. It has a longer half-life 
(34 hours) but less negative inotropic effect than nifedipine. It is used in the treat-
ment of chronic stable angina and essential hypertension [7]. Amlodipine increases 
exercise duration, decreases anginal attacks, and reduces the consumption of 
nitroglycerin. It is given once daily (at a dose of 5 or 10 mg). Common side effects 
of the dihydropyridines are less likely with amlodipine.
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6.3 Nicardipine
It is a short-acting dihydropyridine with a side effect profile similar to nife-
dipine; it has also been shown to be useful in angina. It is remarkably effective in 
vasospastic angina.
6.4 Felodipine
It is a second-generation dihydropyridine channel blocker of the nifedipine 
type. It is more selective for vascular smooth muscles than myocardial tissue. And 
it serves as an effective vasodilator. It is usually used in the treatment of angina and 
essential hypertension. Additionally, it exhibits a high degree of protein binding 
and has a half-life ranging from 10 to 18 hours.
6.5 Nimodipine
It is a dihydropyridine calcium channel blocker that differs from other dihydro-
pyridines as it dilates the cerebral blood vessels more than other dihydropyridines 
do. It is indicated in the treatment of subarachnoid hemorrhage-associated neuro-
logical deficits.
6.6 Verapamil
It is a phenylalkylamine. It was introduced in 1962 as a coronary vasodilator. It 
is used for the treatment of angina pectoris, arrhythmias due to ischemic cardiac 
syndromes, and supraventricular arrhythmias as well. Verapamil’s primary effect 
is on the slow Ca2+ channel, which results in a slowing of AV conduction and the 
sinus rate. It has a rapid absorption following oral administration. However, it is 
metabolized quickly and, therefore, has low bioavailability. Its main site of first-
pass metabolism is the liver, forming several products. Yet, its metabolites have 
no significant biological effects. Verapamil has an elimination half-life of around 
5 hours. Verapamil, like the dihydropyridines, causes little impact on venous return 
and preload but has more direct negative inotropic and chronotropic effects than 
the dihydropyridines at doses that produce arteriolar dilation and afterload reduc-
tion (Figure 4). Thus, the consequences of a reflex increase in adrenergic tone 
are generally offset by the direct cardio depressant effects of the drug. In patients 
without heart failure, oral administration of verapamil reduces peripheral vascular 
resistance and blood pressure with minimal changes in heart rate. Ventricular 
performance is not impaired and may improve, especially if ischemia limits perfor-
mance. In contrast, in patients with heart failure, intravenous verapamil can cause 
a marked decrease in contractility and left ventricular function. The antianginal 
effect of verapamil, like that of all Ca2+ channel blockers, is due primarily to a 
reduction in myocardial O2 demand [7].
6.7 Diltiazem
It was introduced in Japan as a cardiovascular agent for the treatment of angina pec-
toris. It was detected to dilate peripheral arteries and arterioles. By relieving coronary 
artery spasm, diltiazem increases myocardial oxygen supply, and by decreasing heart 
rate, it reduces myocardial oxygen demand. It is used in patients with variant angina as 
well. Additionally, it has electrophysiological properties similar to those of verapamil 
and, therefore, is used as an antiarrhythmic agent, but it is less potent than verapamil. 




levels within 1 hour of administration. Nevertheless, the sustained-release prepara-
tions provide peak plasma levels within 3–4 hours of oral administration.
Diltiazem is metabolized extensively by the first-pass metabolism after oral 
administration. Hence, its bioavailability is about 40%. It undergoes several bio-
transformations, including deacetylation, oxidative O- and N-demethylations, 
and conjugation of the phenolic metabolites. Although it has various metabolites, 
only deacetyldiltiazem is pharmacologically active, which has about 40–50% of the 
potency of the parent drug [7].
6.8 Side effects
• Headache, flushing, and dizziness due to arterial dilation, although tolerance 
often occurs with continued use.
• Ankle edema probably arises from increased transcapillary hydrostatic pres-
sure. It happens mostly with dihydropyridines, and it is frequently resistant to 
diuretics.
• Decompensated heart failure is due to reduced cardiac contractility, especially 
in patients with preexisting poor left ventricular function, particularly with 
verapamil, but amlodipine does not depress cardiac contractility.
• Tachycardia and palpitations can arise with dihydropyridines, especially with 
rapid-release formulations.
• Bradycardia and heart block can occur with verapamil and diltiazem.
• Constipation is most common with verapamil and less with diltiazem.
• Heartburn associated with Amlodipine and other dihydropyridines use is due 
to lower esophageal sphincter relaxation.
• Gum hyperplasia.
7. Calcium channel blocker indications
7.1 Calcium channel blockers for hypertension
CCBs are prevalent antihypertensive drugs. CCBs lower BP by causing periph-
eral arterial dilation, with the rank order of potency being dihydropyridines > 
diltiazem > verapamil. They are generally well-tolerated, do not require monitoring 
with blood tests, and have proven safe and effective in many large RCTs. CCBs also 
have antianginal and some antiarrhythmic effects and seem to provide more protec-
tion against stroke than other antihypertensive agents do.
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack 
Trial (ALLHAT) and subsequent RCTs showed that CCBs (represented by amlodip-
ine) prevent coronary events as effectively as diuretics and RAS blockers do.
7.2 Calcium channel blockers for coronary vasospasm
Coronary spasm results in transient functional occlusion of a coronary artery 
that is reversible with nitrate vasodilation. It occurs in the setting of coronary 
New Insight into Cerebrovascular Diseases - An Updated Comprehensive Review
224
6.3 Nicardipine
It is a short-acting dihydropyridine with a side effect profile similar to nife-
dipine; it has also been shown to be useful in angina. It is remarkably effective in 
vasospastic angina.
6.4 Felodipine
It is a second-generation dihydropyridine channel blocker of the nifedipine 
type. It is more selective for vascular smooth muscles than myocardial tissue. And 
it serves as an effective vasodilator. It is usually used in the treatment of angina and 
essential hypertension. Additionally, it exhibits a high degree of protein binding 
and has a half-life ranging from 10 to 18 hours.
6.5 Nimodipine
It is a dihydropyridine calcium channel blocker that differs from other dihydro-
pyridines as it dilates the cerebral blood vessels more than other dihydropyridines 
do. It is indicated in the treatment of subarachnoid hemorrhage-associated neuro-
logical deficits.
6.6 Verapamil
It is a phenylalkylamine. It was introduced in 1962 as a coronary vasodilator. It 
is used for the treatment of angina pectoris, arrhythmias due to ischemic cardiac 
syndromes, and supraventricular arrhythmias as well. Verapamil’s primary effect 
is on the slow Ca2+ channel, which results in a slowing of AV conduction and the 
sinus rate. It has a rapid absorption following oral administration. However, it is 
metabolized quickly and, therefore, has low bioavailability. Its main site of first-
pass metabolism is the liver, forming several products. Yet, its metabolites have 
no significant biological effects. Verapamil has an elimination half-life of around 
5 hours. Verapamil, like the dihydropyridines, causes little impact on venous return 
and preload but has more direct negative inotropic and chronotropic effects than 
the dihydropyridines at doses that produce arteriolar dilation and afterload reduc-
tion (Figure 4). Thus, the consequences of a reflex increase in adrenergic tone 
are generally offset by the direct cardio depressant effects of the drug. In patients 
without heart failure, oral administration of verapamil reduces peripheral vascular 
resistance and blood pressure with minimal changes in heart rate. Ventricular 
performance is not impaired and may improve, especially if ischemia limits perfor-
mance. In contrast, in patients with heart failure, intravenous verapamil can cause 
a marked decrease in contractility and left ventricular function. The antianginal 
effect of verapamil, like that of all Ca2+ channel blockers, is due primarily to a 
reduction in myocardial O2 demand [7].
6.7 Diltiazem
It was introduced in Japan as a cardiovascular agent for the treatment of angina pec-
toris. It was detected to dilate peripheral arteries and arterioles. By relieving coronary 
artery spasm, diltiazem increases myocardial oxygen supply, and by decreasing heart 
rate, it reduces myocardial oxygen demand. It is used in patients with variant angina as 
well. Additionally, it has electrophysiological properties similar to those of verapamil 
and, therefore, is used as an antiarrhythmic agent, but it is less potent than verapamil. 




levels within 1 hour of administration. Nevertheless, the sustained-release prepara-
tions provide peak plasma levels within 3–4 hours of oral administration.
Diltiazem is metabolized extensively by the first-pass metabolism after oral 
administration. Hence, its bioavailability is about 40%. It undergoes several bio-
transformations, including deacetylation, oxidative O- and N-demethylations, 
and conjugation of the phenolic metabolites. Although it has various metabolites, 
only deacetyldiltiazem is pharmacologically active, which has about 40–50% of the 
potency of the parent drug [7].
6.8 Side effects
• Headache, flushing, and dizziness due to arterial dilation, although tolerance 
often occurs with continued use.
• Ankle edema probably arises from increased transcapillary hydrostatic pres-
sure. It happens mostly with dihydropyridines, and it is frequently resistant to 
diuretics.
• Decompensated heart failure is due to reduced cardiac contractility, especially 
in patients with preexisting poor left ventricular function, particularly with 
verapamil, but amlodipine does not depress cardiac contractility.
• Tachycardia and palpitations can arise with dihydropyridines, especially with 
rapid-release formulations.
• Bradycardia and heart block can occur with verapamil and diltiazem.
• Constipation is most common with verapamil and less with diltiazem.
• Heartburn associated with Amlodipine and other dihydropyridines use is due 
to lower esophageal sphincter relaxation.
• Gum hyperplasia.
7. Calcium channel blocker indications
7.1 Calcium channel blockers for hypertension
CCBs are prevalent antihypertensive drugs. CCBs lower BP by causing periph-
eral arterial dilation, with the rank order of potency being dihydropyridines > 
diltiazem > verapamil. They are generally well-tolerated, do not require monitoring 
with blood tests, and have proven safe and effective in many large RCTs. CCBs also 
have antianginal and some antiarrhythmic effects and seem to provide more protec-
tion against stroke than other antihypertensive agents do.
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack 
Trial (ALLHAT) and subsequent RCTs showed that CCBs (represented by amlodip-
ine) prevent coronary events as effectively as diuretics and RAS blockers do.
7.2 Calcium channel blockers for coronary vasospasm
Coronary spasm results in transient functional occlusion of a coronary artery 
that is reversible with nitrate vasodilation. It occurs in the setting of coronary 
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stenosis. Variant angina results from reduced blood flow (a consequence of tran-
sient localized vasoconstriction) rather than increased O2 demand. Drug-induced 
causes (e.g., cocaine, amphetamines, sumatriptan, and related antimigraine 
drugs) should be excluded. CCBs are effective in about 90% of patients. These 
agents are considered first-line treatment and may be combined with nitrate. The 
effects of pharmacologic vasodilators on coronary flow reflect direct actions on 
vascular smooth muscle as well as secondary adjustments in resistance artery tone. 
All calcium channel blockers induce vascular smooth muscle relaxation and are 
to various degrees pharmacologic coronary vasodilators (Figure 6). In epicardial 
arteries, the vasodilator response is like nitroglycerin and is effective in preventing 
coronary vasospasm superimposed on coronary stenosis as well as in normal arter-
ies of patients with variant angina. They also submaximally vasodilate coronary 
resistance vessels. In this regard, dihydropyridine derivatives such as nifedipine are 
particularly potent and can sometimes precipitate subendocardial ischemia in the 
presence of critical stenosis. This arises from a transmural redistribution of blood 
flow (coronary steal) as well as the tachycardia and hypotension that transiently 
occur with short half-life formulations of nifedipine. One study demonstrated 
that the use of calcium channel blocker therapy was an independent predictor of 
myocardial infarct-free survival in vasospastic angina patients.
7.3 Calcium channel blockers for stable angina
All calcium channel blockers can be used in the treatment of stable angina 
pectoris. They vasodilate coronary arteries, reduce coronary resistance, increase 
coronary blood flow, and may enhance the development of coronary collaterals. The 
vasodilatation and increase in coronary artery blood flow result from the blockade 
of calcium influx as well as an increase in the levels of nitric oxide and bradykinin; 
therefore, the increase in coronary artery blood flow is a result of bradykinin/nitric 
oxide-dependent and bradykinin/nitric oxide-independent mechanisms. They elicit 
a strong reflex beta-adrenergic response, making any potential negative inotropic or 
chronotropic effect clinically insignificant. This adrenergic response often includes 
Figure 6. 




a reflex tachycardia. Verapamil and diltiazem are useful in angina because they 
decrease myocardial oxygen demand by acting as a negative inotropic and chrono-
tropic effect, by lowering the systemic blood pressure, and by lowering heart rate 
by blocking AV node (Figure 6). The use of short-acting dihydropyridines, such as 
nifedipine, can exacerbate ischemia due to reflex tachycardia, and therefore, it can 
be used as a monotherapy in this setting. Calcium channel blockers are used with 
combination therapy with beta-blockers, which can be more effective than either 
therapy alone. Amlodipine or felodipine could be considered before other calcium 
channel blockers, given their better side effect profiles when used in combina-
tion with beta-blockers. In stable angina patients with suspension of a vasoactive 
component, a trial of a calcium channel blocker can be added to beta blocker agents. 
Calcium channel blockers, particularly verapamil and diltiazem, should be used 
with caution in patients with left ventricular systolic dysfunction, such as those 
with an ejection fraction less than 40 percent or heart failure due to their negative 
inotropic effect.
7.4 Calcium channel blockers for acute coronary syndrome
Calcium channel blockers have been effective in reducing ischemia in patients 
with NSTE-ACS and persistent ischemia despite treatment with full-dose nitrates 
and beta-blockers as well as in patients with contraindications to beta-blockers and 
among those with hypertension. Such patients should receive non-dihydropyridine 
calcium channel-blocking agents that lower the heart rate [9, 10].
7.5 Calcium channel blockers for hypertrophic cardiomyopathy (HCM)
Verapamil improves left ventricular outflow obstruction and symptoms in 
patients with HCM.
7.6 Calcium channel blockers in the treatment of cardiac arrhythmias
Calcium channel blockers (CCBs) are useful antiarrhythmic agents in the 
management of certain arrhythmias, primarily supraventricular tachyarrhythmias. 
Verapamil is the drug of choice to terminate idiopathic fascicular ventricular 
tachycardia.
7.7 Calcium channel blockers for migraine
Verapamil can be used in the prevention of migraine headaches but is considered 
a second-choice drug.
7.8 Calcium channel blockers for aneurysmal subarachnoid hemorrhage
It is essential to review the cause behind intracranial arterial spasm, mecha-
nisms, diagnostic tools, and management to understand the role of CCBs in vaso-
spasm among patients with aneurysmal subarachnoid hemorrhage.
Vascular calcification is specific for arteries, which can involve all arteries, 
including the carotid artery and cerebral arteries. Intracranial arterial calcification 
(IAC) was first detected in the early 1960s. It is associated with atherosclerosis, espe-
cially in older people. Vascular calcification is an integral part of the active process 
of atherosclerosis, occurring in up to 90% of atherosclerotic lesions. Recent clinical 
studies have consistently found the intracranial internal carotid artery (IICA) to be 
the most common site of IAC. The incidence of IICA calcification has been reported 
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to range from 60 to 90% according to ethnicity, age, and stroke or other risk factors. 
The vertebral artery is the second most common artery affected by calcification, 
while other arteries have been affected only by less than 5%. An unenhanced CT 
scan is the most accessible and direct method to evaluate IAC in patients.
The prevalence of intracranial artery calcification is:
• Internal carotid artery: 60%
• Vertebral artery: 20%
• Middle cerebral artery: 5%
• Basilar artery: 5%





History of cardiovascular disease.
Excessive alcohol intake.
End-stage renal disease with long duration of hemodialysis [11–13].
7.8.1 Hemodynamic and clinical effects of IAC
IAC can lead to three significant hemodynamic effects: Firstly, it can lead to 
increase the arterial stiffness. This phenomenon is associated with aging and accel-
erated by other vascular risk factors. It can be measured by the pulse wave velocity 
(PWV) and may indicate early atherosclerotic changes. Several studies have verified 
the correlation between IAC and arterial stiffness, and this may increase the risk 
of stroke. Secondly, arterial stenosis can be linked to arterial calcification, which 
may lead to ischemic stroke due to direct luminal stenosis. Thirdly, IAC may lead 
to plaque stability. Intravascular ultrasound studies found heavily calcified plaques 
to be more resistant to plaque progression. Therefore, the findings for CAC suggest 
that substantial calcification may help stabilize atherosclerotic plaques. Also, a 
heavy plaque burden hidden in heavily calcified arteries may partially account for 
the association between severe arterial calcification and ischemic events regardless 
of plaque vulnerability.
7.8.2 Vasospasm and delayed cerebral ischemia
Cerebral vasospasm is an essential source of morbidity and mortality in 
subarachnoid hemorrhage patients. Vasospasm is one of the most common acute 
complications. It can happen within 3–15 days with a peak incidence at 7 days after 
aneurysmal SAH. Symptomatic vasospasm occurs in 20–40% of subarachnoid hem-
orrhage cases and is considered as the least understood component in their care. 
The symptom severity depends upon the artery affected and the degree of collateral 
circulation. Strokes from vasospasm account for nearly 50% of the early deaths in 
patients who survive the initial subarachnoid hemorrhage treatment. It is character-
ized by a pathological; diffuse, affecting all layers of the involved arterial wall; and 




at the base of the brain either close or distal to the bleeding site. And it is associated 
with reduced perfusion of the territories distal to the affected vessel.
Risk factors for vasospasm include:
1. The severity of bleeding
2. The proximity to the significant intracerebral blood vessels
3. The location and extent of blood on CT scan and radiologic grading scales
4. Age less than 50 years
5. Hyperglycemia
6. Glasgow Coma Scale score < 14
7.8.3 Mechanism
While the underlying mechanisms causing vasospasm are not fully understood, 
a proliferative inflammatory arteriopathy is the pathological feature of cerebral 
vasospasm. The intima shows disruption of the internal elastic lamina, and the 
media is thickened and fibrotic, with an increased smooth muscle cell proliferation. 
The adventitia is infiltrated with inflammatory cells, and the neuronal endings are 
impaired [14]. A significant predictor of vasospasm after SAH is the volume of blood 
present around the cerebral arteries of the circle of Willis which can be measured 
by transcranial Doppler (TCD), although it has been clearly demonstrated that 
prolonged exposure of cerebral arteries to perivascular blood is essential for the 
development of vasospasm. It is not possible to identify a single causative molecule as 
the culprit of vasospasm. However, vasospasm is believed to be produced by spasmo-
genic substances generated during the lysis of subarachnoid blood such as oxyhemo-
globin (a product of auto-oxidation of hemoglobin), nitric oxide, and endothelin-1. 
Those agents may be contributors to the pathological event of vasospasm.
Oxyhemoglobin may directly or indirectly trigger arterial vasoconstriction.
Oxyhemoglobin can also exert a scavenging effect on nitric oxide. It has been 
demonstrated that nitric oxide (a potent vasodilator) depleted during vasospasm 
and can stimulate endothelial cells to produce endothelin-1.
Endothelin-1 is the most potent and long-lasting vasoconstrictor effect, which 
is also associated with morphological changes, mimicking the delayed cerebral 
vasospasm. It has been shown that endothelin-1 levels are increased, not only in 
the cerebrospinal fluid during SAH and severe neuronal injury due to vasospasm or 
bleeding event. Moreover, endothelin levels change in neurological symptoms, but 
they do not predict vasospasm as assessed by transcranial Doppler. These observa-
tions suggest that endothelin-1 acts as a marker of cerebral ischemic injury [15, 16].
7.8.4 Diagnosis
7.8.4.1 Transcranial Doppler
It is a noninvasive tool and is useful for the detection and evaluation of vaso-
spasm. It can be performed at the bedside.
It used as a screening tool in high-grade World Federation of Neurological 
Surgeons (WFNS) scale patients in whom a neurological examination cannot be 
readily followed to identify those at higher risk [17].
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It is a highly specific noninvasive exam but has a low level of sensitivity, and it is 
operator-patient dependent, and its value is debated.
In 2004, the American Academy of Neurology conducted a systematic review 
of the literature and concluded that TCDs could be used reliably to screen for the 
presence of vasospasm in the only MCA. Their criteria for the diagnosis or exclu-
sion of vasospasm include flow velocity > 200 or 120 cm/s, respectively, significant 
increase in the flow velocities from day to day (>50 cm/s), and a Lindegaard ratio 
(MCAvelocity/ICAvelocity) > 6 [18].
7.8.4.2 CT scan
Noninvasive angiography with CT angiography (CTA) to confirm vasospasm for 
patients with elevated velocities on transcranial Doppler ultrasound. The plane CT 
scan is useful for ruling out other causes in the event of the occurrence of a deficit 
or worsening of the clinical state like rebleeding or ischemia. Several prospective 
cohorts showed a correlation between CTA and DSA in predicting vasospasm and 
that many unnecessary angiograms could be avoided by using CTA as a screening 
test [19, 20]. A recent meta-analysis found a sensitivity and specificity for CTA of 
80 and 93%, respectively [21].
7.8.4.3 MRI
MRI can help to identify and diagnose cerebral ischemia at the early stage.
7.8.4.4 Cerebral angiography
Cerebral angiography is the gold standard radiographic tool for the diagnosis 
of cerebral vasospasm. Angiography is used to identify patients with symptomatic 
vasospasm who might benefit from treatment.
In 30–70% of patients with SAH, angiographic vasospasm occurs, but it leads 
to clinically evident signs and symptoms in 20–30% of patients who experience 
delayed ischemic neurological deficits. About half of the symptomatic group of 
patients suffer severe permanent neurological dysfunction or death.
7.8.5 Treatment
The specific treatment of cerebral vasospasm helps improving cerebral blood 
flow to avoid delayed ischemic neurologic deficit by reducing ICP, optimizing the 
rate of cerebral oxygen demand, and enhancing cerebral blood flow with one of the 
following approaches: indirect pharmacological protection of brain tissue or direct 
mechanical dilation of the vasospastic vessel.
Nimodipine is the standard of care in aneurysmal SAH patients. Nimodipine 
60 mg every 4 hours can be used for all patients with aneurysmal SAH once the 
diagnosis is made for 21 days. Nimodipine is to be given orally or by nasogastric tube 
because intravenous administration causes serious adverse events, including death. 
The mechanism of benefit of nimodipine in SAH is unknown. Oral nimodipine 
is the only Class I evidence regarding cerebral vasospasm used in the publication 
of the AHA subarachnoid hemorrhage guidelines [22]. Early aneurysm treatment, 
HHH-therapy (hypertension, hypervolemia, and hemodilution), cerebral angio-





In summary, nimodipine was initially studied in SAH to prevent vasospasm. 
However, despite its vasodilatory effects on cerebral vessels, the evidence of 
nimodipine effects on the incidence of either angiographic or symptomatic vaso-
spasm is not convincing [23]. Nevertheless, nimodipine has been demonstrated to 
improve outcomes in SAH and is the agent of choice in these patients [23].
7.9 Calcium channel blockers for reversible cerebral vasoconstriction syndrome
Reversible cerebral vasoconstriction syndrome (RCVS) represents a group of 
conditions that show a reversible narrowing of the cerebral arteries with clinical 
manifestations that typically include thunderclap headache and less commonly 
neurologic deficits related to brain edema, seizure, or stroke. The clinical outcome 
is usually benign, although major strokes can result in severe disability and death in 
a minority. The pathophysiology of the abrupt-onset headache and the prolonged 
but reversible vasoconstriction is not known. Reversible angiographic narrowing 
suggests an abnormality in the control of cerebrovascular tone [24].
RCVS has been associated with a variety of conditions including pregnancy, 
migraine, use of vasoconstrictive drugs, neurosurgical procedures, hypercalcemia, 
unruptured saccular aneurysms, cervical artery dissection, and cerebral venous 
thrombosis. The diagnosis of RCVS is based upon the characteristic clinical, brain 
imaging, and angiographic features. Nimodipine and verapamil and brief courses of 
magnesium sulfate, serotonin antagonists, and dantrolene have been administered 
to relieve the vasoconstriction. Data from two prospective case series suggest that 
nimodipine does not affect the time course of cerebral vasoconstriction [25, 26]. 
However, nimodipine might relieve the number and intensity of headaches and has 
documented effects on the smaller vasculature not easily imaged by angiography. 
Calcium channel blockers can be discontinued after resolution of symptoms or 
angiographic abnormalities if they are used.
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Aneurysmal subarachnoid hemorrhage (SAH) is a severe life-threatening dis-
ease and an important source of neurological disability. Therapeutic interventions 
over the last few decades have repeatedly failed to improve functional outcome after 
SAH; however, resolution of inflammation has largely been ignored as a potential 
therapeutic target. The omega-3 fatty acids (FAs), eicosapentaenoic acid (EPA), 
and docosahexaenoic acid (DHA) are the precursors of key mediators involved 
in resolution of inflammation and endogenous neuroprotection. EPA also plays a 
major role in microvascular function, and DHA accretion in the brain is crucial for 
normal neuronal function. Although considerable loss of brain DHA has been iden-
tified in SAH patients, the pathological significance of this process has also been 
overlooked. Current Western diets provide insufficient amounts of omega-3 FAs to 
compensate for the loss of brain DHA following SAH. Here, we review the rationale 
for future clinical trials of omega-3 FAs in SAH. Furthermore, the potential role 
of defective resolution of inflammation in the growth and rupture of intracranial 
aneurysms is inferred from recent findings in atherosclerosis and nutrition. The 
novel concepts of resolution of inflammation and endogenous neuroprotective 
signaling may open new avenues for public health interventions and innovative 
research in intracranial aneurysms and SAH.
Keywords: fish oil, inflammation, intracranial aneurysms, omega-3 fatty acids, 
pharmaconutrition, subarachnoid hemorrhage, translational approach
1. Introduction
Aneurysmal subarachnoid hemorrhage (SAH) is a complex condition with an 
intricate and poorly understood pathophysiology. Increasing evidence strongly 
suggests that neuroinflammation plays a critical role after SAH, but conventional 
anti-inflammatory treatments have failed to improve clinical outcome [1]. Clinical 
research on SAH has mainly focused on delayed cerebral ischemia (DCI); however, 
DCI does not encompass the entire spectrum of pathological and clinical manifesta-
tions of SAH [2–4]. Although cerebral infarction is associated with poor clinical 
outcome and death after SAH, a significant proportion of SAH patients without 
cerebral infarction suffer from cognitive deficits and mood disorders and a reduced 
ability for activities of daily living and working, even in the long term [5, 6]. The 
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1. Introduction
Aneurysmal subarachnoid hemorrhage (SAH) is a complex condition with an 
intricate and poorly understood pathophysiology. Increasing evidence strongly 
suggests that neuroinflammation plays a critical role after SAH, but conventional 
anti-inflammatory treatments have failed to improve clinical outcome [1]. Clinical 
research on SAH has mainly focused on delayed cerebral ischemia (DCI); however, 
DCI does not encompass the entire spectrum of pathological and clinical manifesta-
tions of SAH [2–4]. Although cerebral infarction is associated with poor clinical 
outcome and death after SAH, a significant proportion of SAH patients without 
cerebral infarction suffer from cognitive deficits and mood disorders and a reduced 
ability for activities of daily living and working, even in the long term [5, 6]. The 
absence of a close correlation between DCI and functional recovery indicates an 
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ongoing pathophysiological process has been overlooked in SAH. The failure of 
the recent major NEWTON 2 clinical trial, of sustained intraventricular release of 
nimodipine, is the latest in a series of unsuccessful phase 3 randomized controlled 
trials (RCTs) to improve clinical outcome after SAH and further reinforces the need 
to identify novel therapeutic strategies [7, 8].
Nutrition is essential to human health, and appropriate nutritional support is 
currently considered a standard of care for critically ill patients. Malnutrition—
including depletion of essential micronutrients—frequently occurs among critically 
ill patients and is associated with an increased risk of morbimortality [9]. However, 
the clinical relevance of key nutrient deficiencies in acute neurological illnesses 
has not been thoroughly investigated. EPA and DHA are essential constituents 
of endothelial and neuronal membranes, respectively, and also the precursors of 
key mediators involved in resolution of inflammation and endogenous neuropro-
tection [10, 11]. Although massive loss of brain DHA in SAH patients was first 
reported over 15 years ago, the pathological significance of this process and the 
role of inflammation resolution following SAH have largely been ignored [11, 12]. 
Therapeutic interventions aimed at stimulating inflammation resolution and recov-
ering the homeostasis of the brain and other vital organs after SAH could improve 
patients’ functional outcome [13].
This chapter provides an overview of the potentially harmful consequences 
of selective deficiency of omega-3 FAs on brain structure and function in SAH 
patients. Moreover, given the possible clinical relevance to SAH and the growth and 
rupture of intracranial aneurysms (IAs), we provide a detailed discussion of recent 
findings on the role of omega-3 FAs in resolution of inflammation, with a focus on 
brain homeostasis.
2. Role of omega-3 FAs in resolution of acute inflammation
Remarkable progress in our understanding of the pathophysiology of acute 
inflammation has been achieved through basic science over the last 20 years. 
Resolution of acute inflammation is now considered to be an active biochemical 
process that is required to enable tissues to restore normal structure and function 
following an injury [14]. Interference with the resolution phase of acute inflamma-
tion may result in necrosis, chronic inflammation, fibrosis, and organ dysfunction. 
The resolution process is triggered at the beginning of inflammation by a temporal 
switch in lipid mediator classes, which is induced by cross talk between cells of the 
innate immune system and other cells in the inflammatory microenvironment [11].
A diverse range of biologically active pro-resolving and anti-inflammatory 
mediators are synthetized by complex pathways that involve several enzymes, 
including cyclooxygenase 2 (COX-2), cytochrome P450s and several lipoxygenases 
(LOX). The majority of these endogenous mediators are derived from the long-
chain omega-3 fatty acids (FAs) EPA and DHA and are members of the specialized 
pro-resolving mediator (SPM) superfamily [15]. SPMs represent an essential bio-
chemical interface between inflammation and tissue repair and regeneration. The 
resolution of inflammation is a highly orchestrated adaptive process that depends 
on both the availability of SPMs precursors and the efficiency of the related biosyn-
thetic pathways.
2.1 Specialized pro-resolving mediators
Each endogenous lipid mediator is structurally distinct and possesses specific 
biological functions which have been extensively studied in diverse experimental 
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models. EPA is the precursor of the E-series resolvins (RvEs), which contains four 
main mediators (RvE1-RvE3 and 18-HEPE). DHA is the precursor of the D-series 
resolvins (RvDs), which contains six mediators (RvD1-RvD6), as well as the protec-
tins (PD1-PDX) and the maresins (MaR1-MaR2); DHA derivatives are also known 
as docosanoids [15].
SPMs are active at pico-nanogram ranges and exert pleiotropic actions at the 
inflammatory microenvironment. SPMs stimulate the clearance of bacteria, dead cells, 
and debris that is required during tissue repair. SPMs also reduce leukocyte transendo-
thelial migration, platelet activation, and production of inflammatory cytokines, thus 
providing multi-organ protection. The maresins (macrophage mediators in resolving 
inflammation) exert potent phagocyte-directed actions that include phenotypic 
conversion of proinflammatory macrophages into macrophages that suppress inflam-
mation and promote tissue regeneration [16]. Collectively, SPMs actively promote 
resolution of inflammation and recovery of tissue homeostasis [15]. Interestingly, 
resolution of systemic inflammation appears to have its counterpart in the CNS repre-
sented by different DHA-derived endogenous mediators (see Section 5.1).
The biosynthetic pathways that generate SPMs are clinically relevant and 
have been comprehensively studied [15, 16]. Drugs that inactivate the enzymes 
involved in SPM biosynthesis, such as selective COX-2 inhibitors and certain 
LOX inhibitors, delay the return to homeostasis and are considered resolution 
antagonists. Importantly, selective COX-2 inhibitors were synthesized before 
the identification of inflammation resolution pathways and are currently 
widely used as anti-inflammatory agents. Aspirin and statins also modify 
COX-2 by acetylation and S-nitrosylation, respectively, which results in genera-
tion of longer-acting SPM R-epimers. Thus, aspirin and statins are resolution 
agonists [15, 16].
3. Incorporation and transport of omega-3 FAs
Incorporation and transport of omega-3 FAs have been comprehensively 
described; here, we focus on the clinically relevant aspects [10, 17, 18]. Several 
studies have consistently shown that in vivo conversion of alpha linolenic acid 
(ALA), the short-chain omega-3 FAs from vegetable origin, to its bioactive 
long-chain derivatives (EPA and DHA) is very low in humans. In addition, the 
metabolism of omega-6 and omega-3 FAs is tightly linked, and thus a high dietary 
intake of omega-6 FAs further reduce the conversion of ALA to EPA and DHA 
and their biological effects. The body has also a limited capacity to store long-
chain omega-3 FAs; only very small amounts of EPA and DHA are present in 
adipose tissue, and the brain retains DHA for its own function. Thus, providing 
preformed EPA and DHA is the most efficient method of increasing the concen-
trations of EPA and DHA in plasma and tissues.
EPA and DHA are incorporated into different blood lipid fractions after absorp-
tion by the gastrointestinal tract or after release from intravenously infused fish 
oil-based lipid emulsions (FOLE). These lipid fractions reflect the diverse means by 
which FAs are transported in the circulation and execute their physiological func-
tions. The fractions incorporated in the phospholipid coat of plasma lipoproteins 
and plasma nonesterified FAs (NEFAs) are considered transport pools. Notably, the 
NEFA pool seems to be the main DHA plasma fraction that supplies the brain. The 
NEFA pool also represents a direct source of FAs to cells for generation of SPMs, as 
this pool readily transfers to inflammatory tissue via edema formation [19]. The FAs 
fraction incorporated in peripheral blood mononuclear cells (PBMCs) represents a 
functional pool due to the crucial roles of PBMCs in inflammation.
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models. EPA is the precursor of the E-series resolvins (RvEs), which contains four 
main mediators (RvE1-RvE3 and 18-HEPE). DHA is the precursor of the D-series 
resolvins (RvDs), which contains six mediators (RvD1-RvD6), as well as the protec-
tins (PD1-PDX) and the maresins (MaR1-MaR2); DHA derivatives are also known 
as docosanoids [15].
SPMs are active at pico-nanogram ranges and exert pleiotropic actions at the 
inflammatory microenvironment. SPMs stimulate the clearance of bacteria, dead cells, 
and debris that is required during tissue repair. SPMs also reduce leukocyte transendo-
thelial migration, platelet activation, and production of inflammatory cytokines, thus 
providing multi-organ protection. The maresins (macrophage mediators in resolving 
inflammation) exert potent phagocyte-directed actions that include phenotypic 
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sented by different DHA-derived endogenous mediators (see Section 5.1).
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COX-2 by acetylation and S-nitrosylation, respectively, which results in genera-
tion of longer-acting SPM R-epimers. Thus, aspirin and statins are resolution 
agonists [15, 16].
3. Incorporation and transport of omega-3 FAs
Incorporation and transport of omega-3 FAs have been comprehensively 
described; here, we focus on the clinically relevant aspects [10, 17, 18]. Several 
studies have consistently shown that in vivo conversion of alpha linolenic acid 
(ALA), the short-chain omega-3 FAs from vegetable origin, to its bioactive 
long-chain derivatives (EPA and DHA) is very low in humans. In addition, the 
metabolism of omega-6 and omega-3 FAs is tightly linked, and thus a high dietary 
intake of omega-6 FAs further reduce the conversion of ALA to EPA and DHA 
and their biological effects. The body has also a limited capacity to store long-
chain omega-3 FAs; only very small amounts of EPA and DHA are present in 
adipose tissue, and the brain retains DHA for its own function. Thus, providing 
preformed EPA and DHA is the most efficient method of increasing the concen-
trations of EPA and DHA in plasma and tissues.
EPA and DHA are incorporated into different blood lipid fractions after absorp-
tion by the gastrointestinal tract or after release from intravenously infused fish 
oil-based lipid emulsions (FOLE). These lipid fractions reflect the diverse means by 
which FAs are transported in the circulation and execute their physiological func-
tions. The fractions incorporated in the phospholipid coat of plasma lipoproteins 
and plasma nonesterified FAs (NEFAs) are considered transport pools. Notably, the 
NEFA pool seems to be the main DHA plasma fraction that supplies the brain. The 
NEFA pool also represents a direct source of FAs to cells for generation of SPMs, as 
this pool readily transfers to inflammatory tissue via edema formation [19]. The FAs 
fraction incorporated in peripheral blood mononuclear cells (PBMCs) represents a 
functional pool due to the crucial roles of PBMCs in inflammation.
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3.1 Omega-3 index
The EPA and DHA content of red blood cells (RBCs) membrane which can be 
quantified by a specific and standardized analytical procedure—the HS-Omega-3 
Index® methodology—reliably reflects the omega-3 FAs content of several tissues 
[20]. This omega-3 index has been increasingly utilized as a surrogate marker of 
omega-3 status. Long-term intake of EPA and DHA is the main predictor of the 
omega-3 index, but other factors influence its variability. Acute supplementation 
of omega-3 FAs does not modify the omega-3 index, as expected given the long 
lifetime of RBCs (100–120 days). In terms of clinical relevance, strong inverse 
correlations have been observed between the omega-3 index and cardiovascular 
morbimortality, particularly sudden cardiac death, as well as depression [21–23].
4. Role of EPA in microvascular thromboinflammation
Microvascular inflammation is an early event in the pathogenesis of atherosclerosis 
and other inflammatory conditions and is inextricably linked to microthrombosis [24]. 
Eicosanoid metabolism and leukocyte-endothelial interactions are interrelated pro-
cesses and in turn are major drivers of thromboinflammation [25, 26]. Inflammation 
stimulates eicosanoid synthesis and expression of cell-surface adhesion molecules 
through upregulation of the nuclear factor kappa B (NF-kB), a master transcription 
factor necessarily involved in the inflammatory response.
Most eicosanoids derived from the long-chain omega-6 FAs arachidonic acid 
(ARA), including prostaglandins, leukotrienes, and thromboxanes, are potent vaso-
constrictors, platelet activators, and leukocyte chemotactic factors. Moreover, the 
expression of cell-surface adhesion molecules on endothelial and inflammatory cells 
is essential for leukocyte-endothelial interactions; rolling and adhesion on vascular 
surfaces are the first step in the recruitment of circulating leukocytes or platelets to 
sites of thromboinflammation [27].
EPA incorporated in the membrane phospholipids of inflammatory cells can 
modulate eicosanoid metabolism by replacing ARA as an eicosanoid precursor 
[25]. EPA-derived eicosanoids are significantly less potent than those derived from 
ARA, and nonesterified EPA can also directly inhibit the production of eicosanoids 
from ARA. In addition, EPA has been shown to decrease the expression of several 
cell-surface adhesion molecules on inflammatory cells. EPA appears to elicit these 
pleiotropic effects by modulating the activity of the NF-kB.
Additionally, recent mechanistic studies have shown that minor changes in the 
EPA content of endothelial membranes may markedly alter the biophysical proper-
ties of the membrane [28]. Furthermore, changes in membrane fluidity, thickness, 
and deformability induced by modifications to lipid dynamics and/or structural 
organization can profoundly impact endothelial function [29]. Given the intimate 
association between brain capillary pericytes and endothelial cells, it would not be 
surprising if EPA also incorporates into pericyte cell membranes and potentiates the 
function of these cells as regulators of brain homeostasis [30, 31].
5. Unique function of DHA in the brain
DHA is widely distributed throughout the human body in membrane phospho-
lipids and is particularly abundant in neural tissues such as the brain and retina 
[10]. DHA represents 30–40% of the fatty acid content of the gray matter in the 
cortex and is absorbed into the brain by a specific transporter that is found in 
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the endothelium of the blood-brain barrier (BBB) microvasculature [32, 33]. The 
functional significance of selective enrichment of DHA in neural tissues has been 
actively researched over the last few decades. DHA possesses unique biophysical 
and biochemical characteristics that make it particularly suitable for brain and 
retinal membranes. DHA has been highly conserved during evolution and is pres-
ent throughout the entire spectrum of living organisms [34]. DHA has even been 
suggested to be a major determinant for evolution of the modern hominid brain 
due to its unique encephalization potential [35].
DHA is an essential component of neuronal membrane architecture and com-
position and promotes selective accumulation of phosphatidylserine (PS), a crucial 
phospholipid involved in intracellular signaling [36]. PS participates in the signal-
ing events of several key enzymes, including protein kinase C, Raf-1 kinase, and 
Akt, which play essential roles in cell proliferation, differentiation, and survival. 
Thus, DHA significantly modulates the activity of essential cellular kinases in 
neuronal cells.
5.1 DHA and endogenous neuroprotective signaling
In addition to its function as a unique building block of cell membranes, DHA is 
also a precursor for docosanoids and other bioactive endogenous derivatives in the 
neural tissue [37]. The number of recently identified DHA derivatives in neural tis-
sue is increasingly growing and includes neuroprotectin D1 (NPD1), synaptamide, 
endocannabinoid epoxides, and elovanoids [38–40]. Collectively, the potent 
bioactive properties of these DHA derivatives contribute to preservation of normal 
neuronal function, tissue homeostasis, and neuronal survival [37–41]. In addition, 
the DHA derivatives exert a range of potent neuroprotective properties that include 
inhibition of proinflammatory gene expression and leukocyte infiltration. A strik-
ing hallmark of the DHA derivatives is their ability to potentiate microglial polar-
ization from a proinflammatory phenotype to a surveillance-repair state and reduce 
NF-kB-mediated expression of inflammatory cytokines in the brain. Moreover, 
DHA derivatives contribute to BBB integrity and are neurogenic and synaptogenic 
[38, 42]. Thus, the DHA derivatives seem to be key mediators of the resolution of 
inflammation and recovery of homeostasis in the CNS microenvironment.
5.2 DHA and neurovascular unit
The concept of neurovascular unit emphasizes the intimate relationship 
between the brain and its vessels, particularly the coupling between neural activ-
ity and cerebral blood flow [43]. Although the role of DHA neurolipidomics in 
neurovascular coupling appears to be underestimated, substantial experimental 
evidence suggests that the morphologic and functional integrity of the neurovas-
cular unit largely depends on high DHA enrichment [37, 40, 43]. Moreover, the 
potential role of EPA in microvascular function further supports the evolutionary 
importance of these essential nutrients to maintain efficient functional couplings 
between neural and vascular networks [28, 29]. A functional neurovascular unit 
may be crucial not only for neurovascular coupling but also for BBB integrity and 
neurogenesis.
A regular dietary supply of DHA is required to preserve normal brain and retinal 
function. Under physiologic conditions, the net DHA incorporation rate for the 
entire human brain is very low and equivalent to the net rate of DHA consumption 
by the brain (3.8 ± 1.7 mg/day) [44]. However, loss of DHA in pathological states 
or due to nutritional deficiency of omega-3 FAs may severely impair neurovascular 
integrity and have far-reaching implications on normal brain function [36].
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the endothelium of the blood-brain barrier (BBB) microvasculature [32, 33]. The 
functional significance of selective enrichment of DHA in neural tissues has been 
actively researched over the last few decades. DHA possesses unique biophysical 
and biochemical characteristics that make it particularly suitable for brain and 
retinal membranes. DHA has been highly conserved during evolution and is pres-
ent throughout the entire spectrum of living organisms [34]. DHA has even been 
suggested to be a major determinant for evolution of the modern hominid brain 
due to its unique encephalization potential [35].
DHA is an essential component of neuronal membrane architecture and com-
position and promotes selective accumulation of phosphatidylserine (PS), a crucial 
phospholipid involved in intracellular signaling [36]. PS participates in the signal-
ing events of several key enzymes, including protein kinase C, Raf-1 kinase, and 
Akt, which play essential roles in cell proliferation, differentiation, and survival. 
Thus, DHA significantly modulates the activity of essential cellular kinases in 
neuronal cells.
5.1 DHA and endogenous neuroprotective signaling
In addition to its function as a unique building block of cell membranes, DHA is 
also a precursor for docosanoids and other bioactive endogenous derivatives in the 
neural tissue [37]. The number of recently identified DHA derivatives in neural tis-
sue is increasingly growing and includes neuroprotectin D1 (NPD1), synaptamide, 
endocannabinoid epoxides, and elovanoids [38–40]. Collectively, the potent 
bioactive properties of these DHA derivatives contribute to preservation of normal 
neuronal function, tissue homeostasis, and neuronal survival [37–41]. In addition, 
the DHA derivatives exert a range of potent neuroprotective properties that include 
inhibition of proinflammatory gene expression and leukocyte infiltration. A strik-
ing hallmark of the DHA derivatives is their ability to potentiate microglial polar-
ization from a proinflammatory phenotype to a surveillance-repair state and reduce 
NF-kB-mediated expression of inflammatory cytokines in the brain. Moreover, 
DHA derivatives contribute to BBB integrity and are neurogenic and synaptogenic 
[38, 42]. Thus, the DHA derivatives seem to be key mediators of the resolution of 
inflammation and recovery of homeostasis in the CNS microenvironment.
5.2 DHA and neurovascular unit
The concept of neurovascular unit emphasizes the intimate relationship 
between the brain and its vessels, particularly the coupling between neural activ-
ity and cerebral blood flow [43]. Although the role of DHA neurolipidomics in 
neurovascular coupling appears to be underestimated, substantial experimental 
evidence suggests that the morphologic and functional integrity of the neurovas-
cular unit largely depends on high DHA enrichment [37, 40, 43]. Moreover, the 
potential role of EPA in microvascular function further supports the evolutionary 
importance of these essential nutrients to maintain efficient functional couplings 
between neural and vascular networks [28, 29]. A functional neurovascular unit 
may be crucial not only for neurovascular coupling but also for BBB integrity and 
neurogenesis.
A regular dietary supply of DHA is required to preserve normal brain and retinal 
function. Under physiologic conditions, the net DHA incorporation rate for the 
entire human brain is very low and equivalent to the net rate of DHA consumption 
by the brain (3.8 ± 1.7 mg/day) [44]. However, loss of DHA in pathological states 
or due to nutritional deficiency of omega-3 FAs may severely impair neurovascular 
integrity and have far-reaching implications on normal brain function [36].
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6. Loss of brain DHA after SAH
To date, three clinical studies have examined the loss of DHA from the brain 
after SAH. Pilitsis et al. conducted the first observational study to analyze free fatty 
acid (FFA) concentrations in cerebrospinal fluid (CSF) [12]. The concentrations of 
ARA, DHA, linoleic acid, myristic acid, oleic acid, and palmitic acid were measured 
over the first 14 days following SAH in 20 patients. A cohort of 73 patients with no 
evidence of acute neurological disease served as the control group. Compared to 
control patients, the concentrations of all FFAs tested were significantly elevated 
in CSF during the first 2 days after SAH, with a significant secondary increase in 
FAA concentrations at 8–10 days. The concentrations of DHA exhibited a biphasic 
increase and remained significantly elevated (200–600%) throughout the first 
14 days after SAH.
Increased levels of free DHA in CSF after SAH are likely to be the result of the 
cleavage of DHA from membrane phospholipids by either direct structural damage 
or an increase in phospholipase A2 activity in response to neuroinflammation. DHA 
can also be readily oxidized due to its high degree of unsaturation and excessive 
generation of free radicals following SAH [45]. Such nonenzymatic oxidation of 
DHA generates F4-neuroprostanes (F4-NPs), which represent a lipid marker of 
oxidative stress in the CNS. Two clinical studies confirmed that the concentrations 
of F4-NPs in CSF significantly increased within the first 24 hours following SAH 
compared to control patients [46, 47]. Hsieh et al. also showed the concentrations 
of F4-NPs in CSF remained significantly elevated throughout the first 10 days after 
SAH and suggested a positive correlation exists between F4-NP concentrations and 
clinical outcome at 3 months after SAH. Despite the limited number of patients 
analyzed, these studies provided valuable evidence that substantial loss of brain 
DHA occurs after SAH.
Moreover, it is highly likely that SAH may increase metabolic consumption of 
DHA though increased generation of neuroprotective derivatives. This potential 
additional source of DHA loss has not yet been evaluated but could be significant. 
Net cumulative DHA loss from the brain (DHA loss + DHA consumption) follow-
ing SAH may be massive in some cases and is likely to impose a severe burden  
on the brain.
6.1 Selective brain malnutrition
A current Western diet may provide sufficient amounts of FAs to compensate for 
the loss of other FAs, but not DHA. Current Western diets are characterized by very 
low intakes of long-chain omega-3 FAs and high intakes of other FAs, especially 
omega-6 FAs such as ARA and linoleic acid [48]. Thus, a significant imbalance 
between brain DHA loss and inadequate nutritional intake of omega-3 FAs may 
persist over the long term in SAH patients, hindering the recovery of DHA accretion 
in the brain required for normal neuronal function [35, 36].
Loss of EPA after SAH has not yet been examined; however, it is reasonable to 
assume that depletion of EPA from cerebral endothelial membranes may play a 
significant role in microvascular dysfunction after SAH. Indeed, EPA seems to have 
a more potent effect than DHA in the treatment of mood disorders, though the 
underlying mechanisms remain elusive [22].
We coined the term “selective brain malnutrition” to describe the pathological 
consequences of EPA and DHA loss following SAH on the structure and function 
of the brain. This novel hypothesis of selective brain malnutrition offers a plausible 
explanation for some of the intriguing clinical features of SAH, including diffuse 
cerebral atrophy and the frequently observed long-lasting functional sequelae, such 
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as cognitive dysfunction and mood disorders, that occur even in the absence of focal 
injury [5, 49]. Importantly, a higher omega-3 index has been associated with larger 
total brain and hippocampal volumes in observational studies in humans [50].
7. Roles of EPA and DHA in resolution of inflammation after SAH
Consensus has emerged on the pressing need to find a multipronged therapeutic 
intervention to address the various deleterious effects of early brain injury (EBI) 
after SAH [51]. Nonetheless, the loss of brain DHA after SAH is likely to be an 
unrecognized effect of EBI, and in turn loss of DHA may represent a critical event 
in the pathogenesis of secondary brain injury after SAH. Depending on the severity 
of SAH, the cumulative burden of brain DHA loss may be massive and decreases 
endogenous neuroprotective capacity in the short term [12, 36]. Thus, unresolved 
homeostatic disturbances within the cerebral microenvironment may lead to neuro-
vascular uncoupling, which may spread over the cerebral cortex in the most severe 
cases [52]. The loss of an entire series of signaling events required for maintenance 
of neurovascular network integrity may further increase the risk of focal injury, 
diffuse cerebral atrophy, and functional sequelae [37]. In this context, it is reason-
able to assume that large-artery vasospasm may paradoxically be a compensatory 
mechanism to preserve tissue oxygen availability in the presence of progressive 
microvascular failure, i.e., when capillary transit time heterogeneity substantially 
increases [3, 31]. Unresolved inflammation may also induce hyperproliferation of 
arachnoid cap cells, which increases the risk of hydrocephalus [4]. Uncontrolled 
systemic complications, such as severe cardiopulmonary dysfunction, may further 
aggravate homeostatic disturbances and have devastating consequences on brain 
function [53].
Theoretically, EPA, DHA, and their respective SPMs possess the bioactive 
capacity to counteract the major homeostatic disturbances that occur after 
SAH. EPA-RvEs could reduce thromboinflammation at the cerebral microvas-
culature by inhibiting vasoconstriction, leukocyte transendothelial migration, 
and platelet aggregation [15, 26]. DHA and its derivatives may trigger the critical 
signals required to maintain functional neurovascular coupling and cell survival 
[16, 36, 37]. DHA-induced upregulation of the enzyme heme oxygenase 1 (HO-1) 
may accelerate the clearance of subarachnoid clots and thus decrease heme-
induced cerebral inflammation [54]. SMPs may attenuate inflammation-induced 
hyperproliferation of arachnoid cap cells, further contributing to diminish the risk 
of hydrocephalus. SPMs may also provide multi-organ protection and enhance the 
immune response against infections.
Furthermore, the promising role of DHA derivatives in reducing microglial 
polarization toward an inflammatory phenotype may offer a novel approach to 
reduce the brain inflammation induced by neurosurgical trauma in surgically 
treated SAH patients [55]. Neurogenesis has also been identified in SAH patients, 
and thus DHA could represent a novel therapeutic strategy to improve neurological 
recovery by stimulating neurogenesis [56]. Moreover, subtle changes on microvas-
cular function and synaptogenesis induced by EPA and DHA may improve cogni-
tive function and mood and thus increase the likelihood of complete functional 
recovery of SAH patients.
7.1 Clinical rationale for omega-3 FAs therapy in SAH
The theoretical framework described above provides scientific rationale for 
future clinical trials of omega-3 FAs in SAH patients. The disappointing results 
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of RCTs of isolated pharmaceutical interventions in SAH could be overcome if 
a translational approach is correctly implemented [8]. In support of this notion, 
the recently published phase 3 REDUCE-IT trial provided a robust demonstration 
of the clinical efficacy and therapeutic potential of EPA to reduce cardiovascular 
events in chronic cardiovascular (CV) patients with hypertriglyceridemia [57]. 
Obviously, there are major differences between patients with chronic CV disease 
and hypertriglyceridemia and patients with SAH. Nevertheless, the consider-
able clinical benefits of EPA observed in patients with CV disease (who were 
already on statin therapy) may be due not only to the triglyceride-lowering effect 
of EPA. Interestingly, the results of the REDUCE-IT trial resemble those of the 
GISSI-Prevenzione trial conducted 20 years ago, in which a low-dose oral treatment 
of EPA plus DHA significantly reduced CV morbimortality in patients who had 
suffered a recent myocardial infarction and were already on aspirin treatment [58].
Minor changes in overall membrane FAs composition and the increase in local 
production of longer-acting SPM R-epimers after combined treatment with omega-3 
FAs and aspirin or statins are likely to mediate a wide variety of biological effects and 
have a profound impact on cellular and multi-organ function [15]. Indeed, emerging 
evidence clearly indicates a strong association between a higher omega-3 index and 
major health benefits (reduced risk of both CV and all-cause mortality) over the 
long term [21]. However, the acute and critical nature of SAH imposes a particularly 
demanding therapeutic challenge as the homeostatic disturbances in the brain and 
other vital organs must be effectively addressed in the short term. An intervention 
based exclusively on oral supplementation with omega-3 FAs is unlikely to be fully 
effective on its own in the clinical context of SAH. However, the superiority of par-
enteral administration over oral or enteral administration of omega-3 FAs has been 
reliably demonstrated in short-term interventions [17, 59]. Parenteral administra-
tion of omega-3 FAs allows rapid delivery of higher doses of EPA and DHA without 
bioavailability issues and does not depend on the patient’s clinical condition. Indeed, 
the incorporation profiles of EPA and DHA in the transport and functional pools 
after a single parenteral dose are equivalent to up to several weeks of oral supplemen-
tation. EPA and DHA appear in PBMCs as rapidly as 6 hours after a single parenteral 
dose, thus highlighting the ability of parenterally administered omega-3 FAs to easily 
reach the innate immune system [59]. The concentration of omega-3 FAs in the main 
plasmatic fraction that supplies the brain and other vital organs (the NEFA pool) also 
increases rapidly after a single parenteral dose [17, 60]. Thus, the SPM precursors EPA 
and DHA seem to be rapidly and widely available to activate resolution of inflam-
mation on demand in different organs after parenteral administration. Therefore, 
parenteral administration may be the most efficient way to deliver omega-3 FAs 
during the acute stage of SAH. This novel therapy is in accordance with the concept of 
pharmaconutrition, in which key nutrients are utilized as pharmacological agents and 
delivered in appropriate doses via the most efficient administration route [61]. Oral or 
enteral administration may be suitable for medium- or long-term treatment when the 
patient’s gastrointestinal function has completely recovered.
8. Omega-3 FAs dosage for clinical use
A regular supplementation dose for healthy subjects defined by several health 
associations worldwide is around 500–750 mg/day of EPA plus DHA and can be 
achieved by consuming a regular diet that contains two portions of fatty fish per 
week [62]. Therapeutic anti-inflammatory doses of EPA plus DHA are usually 
considered to be above 2 g/day [25]. A daily dose of at least 1 g EPA plus DHA/
day (EPA > 60% DHA) has been shown to be effective in patients with depressive 
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disorders [22]. EPA doses above 1.8 g/day seem to be required to produce clinically 
meaningful effects on endothelial and vascular function [63]. In patients with 
age-related cognitive decline, 900 mg DHA/day improved learning and memory 
function [64]. Importantly, omega-3 FAs doses can be significantly reduced by 
decreasing the dietary intake of omega-6 FAs. This fact likely explains the notably 
different dosages of EPA required to obtain beneficial outcomes in patients with 
chronic CV disease in a Japanese trial (1.8 g/day) and the REDUCE-IT trial (4 g/
day) conducted in 11 Western countries [48, 57, 63].
The therapeutic dose of parenteral fish oil (FO) to complement total parenteral 
nutrition (TPN) is of 0.1–0.2 g of FO/kg/day [59]. This dosage is equivalent to 1–2 ml/ 
kg/day of a specific FOLE that contains 10 g of FO/100 ml.
8.1 Bioavailability of omega-3 FAs oral formulations
Bioavailability refers to both the speed of absorption and the quantity of the 
substance absorbed in the gastrointestinal tract. The bioavailability of omega-3 FAs 
oral formulations should be carefully considered as it may have direct clinical impli-
cations [65]. The bioavailability of EPA and DHA depends on the chemical form 
in which they are bound (phospholipids > triglycerides > free fatty acids > ethyl 
esters) as well as their Galenic form (i.e., microencapsulation, emulsification) and 
also matrix effects (capsule ingestion with concomitant content of food, fat con-
tent in food). Galenic form and matrix effects are the most important factors that 
influence the bioavailability of EPA and DHA. Thus, administration of high-quality 
pharmaceutical formulations with fatty meals is necessary to ensure the effective-
ness of oral therapy.
9.  Experimental models and clinical interventional studies  
of omega-3 FAs in SAH
9.1 Experimental models
To date, only two preclinical studies of omega-3 FAs in experimental models of 
SAH have been published. Yin et al. suggested that pre-treatment with omega-3 FAs 
by oral gavage elicited anti-inflammatory and anti-apoptotic effects in a rat model 
of SAH [66]. Zhang et al. showed intravenous administration of DHA may prevent 
oxidative stress-induced apoptosis by improving mitochondrial dynamics in a rat 
model of SAH induced by endovascular perforation [67]. However, the scarcity 
of preclinical studies on omega-3 FAs in SAH contrasts with the large number of 
experimental studies on ischemic stroke. The effects of omega-3 FAs (or specific 
derivatives) in neural tissue have been widely examined in experimental ischemia-
reperfusion models [55, 68, 69]. These studies have consistently shown that 
omega-3 FAs significantly reduce cerebral infarction volume by around 40–50% 
and are associated with a drastic decrease in the neuroinflammatory response [70, 
71]. Interestingly, the long-term neurobehavioral recovery in experimental models 
of ischemic stroke is associated with neuroprotective effects of DHA on both gray 
and white matter [55]. It is noteworthy that one of these studies used a specific 
FOLE that is widely approved for clinical use [70].
9.2 Clinical studies
A limited number of omega-3 FAs interventional studies have been performed 
in SAH patients [13, 72–74]. The main characteristics and findings of these studies 
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of RCTs of isolated pharmaceutical interventions in SAH could be overcome if 
a translational approach is correctly implemented [8]. In support of this notion, 
the recently published phase 3 REDUCE-IT trial provided a robust demonstration 
of the clinical efficacy and therapeutic potential of EPA to reduce cardiovascular 
events in chronic cardiovascular (CV) patients with hypertriglyceridemia [57]. 
Obviously, there are major differences between patients with chronic CV disease 
and hypertriglyceridemia and patients with SAH. Nevertheless, the consider-
able clinical benefits of EPA observed in patients with CV disease (who were 
already on statin therapy) may be due not only to the triglyceride-lowering effect 
of EPA. Interestingly, the results of the REDUCE-IT trial resemble those of the 
GISSI-Prevenzione trial conducted 20 years ago, in which a low-dose oral treatment 
of EPA plus DHA significantly reduced CV morbimortality in patients who had 
suffered a recent myocardial infarction and were already on aspirin treatment [58].
Minor changes in overall membrane FAs composition and the increase in local 
production of longer-acting SPM R-epimers after combined treatment with omega-3 
FAs and aspirin or statins are likely to mediate a wide variety of biological effects and 
have a profound impact on cellular and multi-organ function [15]. Indeed, emerging 
evidence clearly indicates a strong association between a higher omega-3 index and 
major health benefits (reduced risk of both CV and all-cause mortality) over the 
long term [21]. However, the acute and critical nature of SAH imposes a particularly 
demanding therapeutic challenge as the homeostatic disturbances in the brain and 
other vital organs must be effectively addressed in the short term. An intervention 
based exclusively on oral supplementation with omega-3 FAs is unlikely to be fully 
effective on its own in the clinical context of SAH. However, the superiority of par-
enteral administration over oral or enteral administration of omega-3 FAs has been 
reliably demonstrated in short-term interventions [17, 59]. Parenteral administra-
tion of omega-3 FAs allows rapid delivery of higher doses of EPA and DHA without 
bioavailability issues and does not depend on the patient’s clinical condition. Indeed, 
the incorporation profiles of EPA and DHA in the transport and functional pools 
after a single parenteral dose are equivalent to up to several weeks of oral supplemen-
tation. EPA and DHA appear in PBMCs as rapidly as 6 hours after a single parenteral 
dose, thus highlighting the ability of parenterally administered omega-3 FAs to easily 
reach the innate immune system [59]. The concentration of omega-3 FAs in the main 
plasmatic fraction that supplies the brain and other vital organs (the NEFA pool) also 
increases rapidly after a single parenteral dose [17, 60]. Thus, the SPM precursors EPA 
and DHA seem to be rapidly and widely available to activate resolution of inflam-
mation on demand in different organs after parenteral administration. Therefore, 
parenteral administration may be the most efficient way to deliver omega-3 FAs 
during the acute stage of SAH. This novel therapy is in accordance with the concept of 
pharmaconutrition, in which key nutrients are utilized as pharmacological agents and 
delivered in appropriate doses via the most efficient administration route [61]. Oral or 
enteral administration may be suitable for medium- or long-term treatment when the 
patient’s gastrointestinal function has completely recovered.
8. Omega-3 FAs dosage for clinical use
A regular supplementation dose for healthy subjects defined by several health 
associations worldwide is around 500–750 mg/day of EPA plus DHA and can be 
achieved by consuming a regular diet that contains two portions of fatty fish per 
week [62]. Therapeutic anti-inflammatory doses of EPA plus DHA are usually 
considered to be above 2 g/day [25]. A daily dose of at least 1 g EPA plus DHA/
day (EPA > 60% DHA) has been shown to be effective in patients with depressive 
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disorders [22]. EPA doses above 1.8 g/day seem to be required to produce clinically 
meaningful effects on endothelial and vascular function [63]. In patients with 
age-related cognitive decline, 900 mg DHA/day improved learning and memory 
function [64]. Importantly, omega-3 FAs doses can be significantly reduced by 
decreasing the dietary intake of omega-6 FAs. This fact likely explains the notably 
different dosages of EPA required to obtain beneficial outcomes in patients with 
chronic CV disease in a Japanese trial (1.8 g/day) and the REDUCE-IT trial (4 g/
day) conducted in 11 Western countries [48, 57, 63].
The therapeutic dose of parenteral fish oil (FO) to complement total parenteral 
nutrition (TPN) is of 0.1–0.2 g of FO/kg/day [59]. This dosage is equivalent to 1–2 ml/ 
kg/day of a specific FOLE that contains 10 g of FO/100 ml.
8.1 Bioavailability of omega-3 FAs oral formulations
Bioavailability refers to both the speed of absorption and the quantity of the 
substance absorbed in the gastrointestinal tract. The bioavailability of omega-3 FAs 
oral formulations should be carefully considered as it may have direct clinical impli-
cations [65]. The bioavailability of EPA and DHA depends on the chemical form 
in which they are bound (phospholipids > triglycerides > free fatty acids > ethyl 
esters) as well as their Galenic form (i.e., microencapsulation, emulsification) and 
also matrix effects (capsule ingestion with concomitant content of food, fat con-
tent in food). Galenic form and matrix effects are the most important factors that 
influence the bioavailability of EPA and DHA. Thus, administration of high-quality 
pharmaceutical formulations with fatty meals is necessary to ensure the effective-
ness of oral therapy.
9.  Experimental models and clinical interventional studies  
of omega-3 FAs in SAH
9.1 Experimental models
To date, only two preclinical studies of omega-3 FAs in experimental models of 
SAH have been published. Yin et al. suggested that pre-treatment with omega-3 FAs 
by oral gavage elicited anti-inflammatory and anti-apoptotic effects in a rat model 
of SAH [66]. Zhang et al. showed intravenous administration of DHA may prevent 
oxidative stress-induced apoptosis by improving mitochondrial dynamics in a rat 
model of SAH induced by endovascular perforation [67]. However, the scarcity 
of preclinical studies on omega-3 FAs in SAH contrasts with the large number of 
experimental studies on ischemic stroke. The effects of omega-3 FAs (or specific 
derivatives) in neural tissue have been widely examined in experimental ischemia-
reperfusion models [55, 68, 69]. These studies have consistently shown that 
omega-3 FAs significantly reduce cerebral infarction volume by around 40–50% 
and are associated with a drastic decrease in the neuroinflammatory response [70, 
71]. Interestingly, the long-term neurobehavioral recovery in experimental models 
of ischemic stroke is associated with neuroprotective effects of DHA on both gray 
and white matter [55]. It is noteworthy that one of these studies used a specific 
FOLE that is widely approved for clinical use [70].
9.2 Clinical studies
A limited number of omega-3 FAs interventional studies have been performed 
in SAH patients [13, 72–74]. The main characteristics and findings of these studies 
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are summarized in Table 1. Two studies utilized EPA and DHA, and only one study 
included a parenteral regimen. In total, 229 patients with SAH have received an 
omega-3 FAs intervention; most patients were surgically treated (n = 223). Although 
two studies were published as RCTs, one study had significant methodological short-
comings in the randomization process that conferred a high risk of selection bias [74]. 
While these preliminary clinical studies reported encouraging results (see Table 1), 
high-quality RCTs are needed to confirm the benefits of omega-3 FAs in SAH patients.
9.3 Safety considerations
Evidence obtained over more than two decades in other clinical fields indicates 
omega-3 FAs interventions are unlikely to lead to serious clinical harm in SAH 
patients [25, 59]. Nevertheless, parenteral administration of omega-3 FAs may raise 
some safety concerns. Total parenteral nutrition is associated with an increased 
risk of complications in critically ill patients [9]. Furthermore, administration of 
lipid emulsions (LEs) may cause fat overload syndrome; the amount of fat admin-
istered and LE infusion rate are the primary risk factors. In this regard, it should 
be emphasized that the therapeutic dose of FO (0.1–0.2 g of FO/kg/day) is about 
one order of magnitude lower than that of regular LE (0.7–1.5 g of fat/kg/day) [59]. 
Additionally, the plasma clearance rate is faster for FAs administered in FOLE than 
soybean oil-based LEs. These unique features contribute to the good safety profile 
of FOLE. Fish oil has been widely used as a component of total parenteral nutri-
tion and is associated with reduced rates of infection, shorter hospital stay, and 
decreased mortality, particularly in surgically treated patients [59].
Furthermore, isolated parenteral administration of FO has increasingly been 
used in pediatric patients with parenteral nutrition-associated liver disease 
(PNALD). Several case series published since 2006 have reported parenteral FO 
monotherapy (PFOM) remarkably improved clinical outcome of patients with 
PNALD [75]. Importantly, PFOM has demonstrated a good safety profile in these 
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critically ill patients, even at FO doses up to 1.5 g FO/kg/day and overextended 
treatments beyond 4 weeks, well beyond the manufacturer’s recommendations.
The aim of replacement FO therapy in PNALD is obviously different to SAH 
patients. Parenteral administration of FO is intended to address key nutrient defi-
ciencies during the acute stage after SAH, and thus only short-term administration 
of a regular FO dose should be necessary. In fact, a 5-day parenteral perioperative 
regimen did not increase the occurrence of major postoperative complications in 19 
surgically treated SAH patients [13]. Thus, there is good quality evidence to warrant 
further clinical trials of parenteral pharmaconutrition as an integral component of 
interventions with omega-3 FAs in SAH patients.
10.  Role of inflammation resolution in the growth and rupture  
of intracranial aneurysms
The role of inflammation in the growth and rupture of intracranial aneurysms 
(IAs) has been increasingly recognized over the last few decades; however, the 
specific role of resolution of inflammation in IAs has not yet been considered [76]. 
Although the pathophysiology of atherosclerosis and the growth and rupture of IAs 
are distinct, both conditions are mediated by an underlying inflammatory process 
[77]. The progression of atherosclerotic plaques determines plaque morphology and 
the risk of rupture. The degree of macrophage infiltration plays a crucial role in the 
progression of atherosclerotic plaques. Interestingly, IAs have also been recently 
regarded as a macrophage-mediated inflammatory disease in which prostaglandin 
E2 and the master transcription factor NF-kB may be crucial drivers of inflam-
matory signals [78, 79]. It should be remembered that prostaglandin E2 is derived 
from the long-chain omega-6 FAs ARA and that EPA can inhibit the generation of 
eicosanoids from ARA and also downregulates the activity of NF-kB [25].
Atherosclerotic plaques readily incorporate omega-3 FAs, and a higher plaque 
EPA content is associated with a reduced number of foam cells and macrophages, as 
well as increased plaque stability, as determined by a well-formed fibrous cap [80]. 
Additionally, signs of defective resolution of inflammation have been identified in 
atherosclerotic plaques [81]. One major function of SPMs (particularly maresins) 
is to induce phenotypic conversion of macrophages, which decrease inflamma-
tion and promote tissue regeneration [16]. In animal models of atherosclerosis, a 
traditional Western high-fat diet disrupts the homeostasis of inflammation resolu-
tion by nutrigenetic modulation of the 12/15-LOX pathways, thereby inhibiting the 
generation of protective SPMs [81, 82]. These recent findings in atherosclerosis, 
particularly the involvement of docosanoids in vascular inflammation, provide 
biological plausibility that defective resolution of inflammation is implicated in the 
pathogenesis of IA growth and rupture.
Human beings evolved, and their genetic patterns were established on a diet with an 
omega-6/omega-3 FAs ratio of 1/1, whereas in current Western diets, this ratio is around 
16/1 [83]. Thus, this extreme nutritional imbalance in current Western diets should be 
seriously considered as a potential aggravating factor for the growth and rupture of 
IAs [48, 82]. This suggestion may appear somewhat counterintuitive considering the 
high prevalence of IAs with increased risk of rupture in the Japanese population, which 
has one of the highest dietary intakes of omega-3 FAs worldwide [48, 84]. However, 
nutritional deficiency of long-chain omega-3 FAs may not be the only factor associated 
with defective resolution of inflammation. Inter-individual and ethnic variations in the 
susceptibility to IA growth and rupture could be related to tissue-specific enzymatic 
deficiencies in the biosynthetic routes that regulate the resolution of inflammation. 
However, while defective resolution has already been associated with other chronic 
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are summarized in Table 1. Two studies utilized EPA and DHA, and only one study 
included a parenteral regimen. In total, 229 patients with SAH have received an 
omega-3 FAs intervention; most patients were surgically treated (n = 223). Although 
two studies were published as RCTs, one study had significant methodological short-
comings in the randomization process that conferred a high risk of selection bias [74]. 
While these preliminary clinical studies reported encouraging results (see Table 1), 
high-quality RCTs are needed to confirm the benefits of omega-3 FAs in SAH patients.
9.3 Safety considerations
Evidence obtained over more than two decades in other clinical fields indicates 
omega-3 FAs interventions are unlikely to lead to serious clinical harm in SAH 
patients [25, 59]. Nevertheless, parenteral administration of omega-3 FAs may raise 
some safety concerns. Total parenteral nutrition is associated with an increased 
risk of complications in critically ill patients [9]. Furthermore, administration of 
lipid emulsions (LEs) may cause fat overload syndrome; the amount of fat admin-
istered and LE infusion rate are the primary risk factors. In this regard, it should 
be emphasized that the therapeutic dose of FO (0.1–0.2 g of FO/kg/day) is about 
one order of magnitude lower than that of regular LE (0.7–1.5 g of fat/kg/day) [59]. 
Additionally, the plasma clearance rate is faster for FAs administered in FOLE than 
soybean oil-based LEs. These unique features contribute to the good safety profile 
of FOLE. Fish oil has been widely used as a component of total parenteral nutri-
tion and is associated with reduced rates of infection, shorter hospital stay, and 
decreased mortality, particularly in surgically treated patients [59].
Furthermore, isolated parenteral administration of FO has increasingly been 
used in pediatric patients with parenteral nutrition-associated liver disease 
(PNALD). Several case series published since 2006 have reported parenteral FO 
monotherapy (PFOM) remarkably improved clinical outcome of patients with 
PNALD [75]. Importantly, PFOM has demonstrated a good safety profile in these 
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critically ill patients, even at FO doses up to 1.5 g FO/kg/day and overextended 
treatments beyond 4 weeks, well beyond the manufacturer’s recommendations.
The aim of replacement FO therapy in PNALD is obviously different to SAH 
patients. Parenteral administration of FO is intended to address key nutrient defi-
ciencies during the acute stage after SAH, and thus only short-term administration 
of a regular FO dose should be necessary. In fact, a 5-day parenteral perioperative 
regimen did not increase the occurrence of major postoperative complications in 19 
surgically treated SAH patients [13]. Thus, there is good quality evidence to warrant 
further clinical trials of parenteral pharmaconutrition as an integral component of 
interventions with omega-3 FAs in SAH patients.
10.  Role of inflammation resolution in the growth and rupture  
of intracranial aneurysms
The role of inflammation in the growth and rupture of intracranial aneurysms 
(IAs) has been increasingly recognized over the last few decades; however, the 
specific role of resolution of inflammation in IAs has not yet been considered [76]. 
Although the pathophysiology of atherosclerosis and the growth and rupture of IAs 
are distinct, both conditions are mediated by an underlying inflammatory process 
[77]. The progression of atherosclerotic plaques determines plaque morphology and 
the risk of rupture. The degree of macrophage infiltration plays a crucial role in the 
progression of atherosclerotic plaques. Interestingly, IAs have also been recently 
regarded as a macrophage-mediated inflammatory disease in which prostaglandin 
E2 and the master transcription factor NF-kB may be crucial drivers of inflam-
matory signals [78, 79]. It should be remembered that prostaglandin E2 is derived 
from the long-chain omega-6 FAs ARA and that EPA can inhibit the generation of 
eicosanoids from ARA and also downregulates the activity of NF-kB [25].
Atherosclerotic plaques readily incorporate omega-3 FAs, and a higher plaque 
EPA content is associated with a reduced number of foam cells and macrophages, as 
well as increased plaque stability, as determined by a well-formed fibrous cap [80]. 
Additionally, signs of defective resolution of inflammation have been identified in 
atherosclerotic plaques [81]. One major function of SPMs (particularly maresins) 
is to induce phenotypic conversion of macrophages, which decrease inflamma-
tion and promote tissue regeneration [16]. In animal models of atherosclerosis, a 
traditional Western high-fat diet disrupts the homeostasis of inflammation resolu-
tion by nutrigenetic modulation of the 12/15-LOX pathways, thereby inhibiting the 
generation of protective SPMs [81, 82]. These recent findings in atherosclerosis, 
particularly the involvement of docosanoids in vascular inflammation, provide 
biological plausibility that defective resolution of inflammation is implicated in the 
pathogenesis of IA growth and rupture.
Human beings evolved, and their genetic patterns were established on a diet with an 
omega-6/omega-3 FAs ratio of 1/1, whereas in current Western diets, this ratio is around 
16/1 [83]. Thus, this extreme nutritional imbalance in current Western diets should be 
seriously considered as a potential aggravating factor for the growth and rupture of 
IAs [48, 82]. This suggestion may appear somewhat counterintuitive considering the 
high prevalence of IAs with increased risk of rupture in the Japanese population, which 
has one of the highest dietary intakes of omega-3 FAs worldwide [48, 84]. However, 
nutritional deficiency of long-chain omega-3 FAs may not be the only factor associated 
with defective resolution of inflammation. Inter-individual and ethnic variations in the 
susceptibility to IA growth and rupture could be related to tissue-specific enzymatic 
deficiencies in the biosynthetic routes that regulate the resolution of inflammation. 
However, while defective resolution has already been associated with other chronic 
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inflammatory diseases, it is not yet known whether enzymatic deficiencies contribute to 
IA growth and rupture, and this novel hypothesis requires further investigation [85, 86].
11. Final remarks
The vital roles of EPA and DHA in the human body emphasize the evolutionary 
importance of maintaining efficient functional couplings between chemical and 
biological systems as well as between the vasculature and the brain [87]. Resolution 
of inflammation and endogenous neuroprotective signaling are interrelated processes 
that largely depend on EPA and DHA derivatives. This novel concept may open new 
avenues for public health interventions and innovative research in IAs and SAH.
Although nutrition has been traditionally viewed as a supportive measure, increas-
ing evidence strongly suggests that a more balanced dietary intake of omega-6 and 
omega-3 FAs may represent the most efficient means of improving the status of 
inflammation resolution at the population level [48, 82, 83]. This specific dietary 
recommendation could contribute to decrease the risk of IAs growth and rupture and 
the devastating consequences of SAH, along with other important health benefits.
The pathological significance of the loss of brain DHA after SAH has been 
widely ignored, even though strong preclinical evidence supports the hypothesis 
that the integrity of the neurovascular unit largely depends on high DHA enrich-
ment. This previously unrecognized pathophysiological process may significantly 
increase the risk of secondary brain injury following SAH.
The robust demonstration of the clinical efficacy of EPA in patients with chronic 
CV disease supports the encouraging results obtained in preliminary clinical studies 
of omega-3 FAs in SAH and warrants a large-scale RCT. It needs to be emphasized 
that DHA should always be included in neuroprotective interventions, as DHA 
plays an essential role in neural tissue and is the cornerstone for docosanoid genera-
tion. Parenteral pharmaconutrition with FO offers major clinical advantages for the 
treatment of SAH patients and should also be an integral component of omega-3 
FAs interventions during the acute stage of the disease.
The design of future RCTs of omega-3 FAs in SAH should bear in mind a potentially 
important factor. Clinical approaches that mainly focus on large-artery vasospasm may 
actually counteract the beneficial effects of omega-3 FAs and other neuroprotective 
interventions. The main rationale behind this seemingly paradoxical notion is based 
on both theoretical models and clinical perspectives [3, 31]. An unpublished subgroup 
analysis of our pilot pharmaconutrition trial of omega-3 FAs showed unexpected 
differences in the occurrence of cerebral infarction due to DCI between study centers, 
each of which had different clinical approaches to large-artery vasospasm [13]. In addi-
tion, a recently published observational study performed in the UK showed centers 
that screened for large-artery vasospasm using transcranial Doppler ultrasound (TCD) 
had poorer inhospital outcomes and similar rates of DCI diagnosis compared to centers 
that did not [88]. These results support the dissociation between large-artery vaso-
spasm and clinical outcome that has been observed in major phase 3 RCTs in SAH [8]. 
Therefore, reliance on a surrogate clinical endpoint such as large-artery vasospasm may 
lead to the adoption of useless or even harmful clinical approaches [88–91]. Indeed, 
some research centers in Europe do not include TCD ultrasound or endovascular rescue 
therapy in their treatment protocols for SAH patients [92].
Moreover, it would be clinically meaningful to determine if correlations exist 
between the omega-3 index and the concentrations of EPA and DHA as well as the 
status of inflammation resolution in the wall of ruptured and non-ruptured IAs. 
There may be a real opportunity for a readily implementable and low-cost therapy if 
the walls of IAs are as responsive to omega-3 FAs as atherosclerotic plaques.
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The interplay between omega-3 FAs and widely used drugs (aspirin and statins) 
that lead to the generation of longer-acting SPM R-epimers provides ample oppor-
tunities for future translational approaches in IAs and SAH. Indeed, combined 
therapies with omega-3 FAs and aspirin or statins could represent a viable, easy-to-
implement therapeutic strategy for patients with unruptured IAs.
Parenteral pharmaconutrition with FO could also be a clinically effective inter-
vention for perioperative neuroprotection for patients subjected to other surgeries 
at high risk of neurological injury, such as carotid endarterectomy, cardiac surgery, 
or diverse neurosurgical procedures.
In the future, new drug delivery systems capable of carrying synthetic analogues 
of SPMs could become a viable therapeutic strategy for patients with tissue-specific 
enzymatic deficiencies in the resolution pathways [93].
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inflammatory diseases, it is not yet known whether enzymatic deficiencies contribute to 
IA growth and rupture, and this novel hypothesis requires further investigation [85, 86].
11. Final remarks
The vital roles of EPA and DHA in the human body emphasize the evolutionary 
importance of maintaining efficient functional couplings between chemical and 
biological systems as well as between the vasculature and the brain [87]. Resolution 
of inflammation and endogenous neuroprotective signaling are interrelated processes 
that largely depend on EPA and DHA derivatives. This novel concept may open new 
avenues for public health interventions and innovative research in IAs and SAH.
Although nutrition has been traditionally viewed as a supportive measure, increas-
ing evidence strongly suggests that a more balanced dietary intake of omega-6 and 
omega-3 FAs may represent the most efficient means of improving the status of 
inflammation resolution at the population level [48, 82, 83]. This specific dietary 
recommendation could contribute to decrease the risk of IAs growth and rupture and 
the devastating consequences of SAH, along with other important health benefits.
The pathological significance of the loss of brain DHA after SAH has been 
widely ignored, even though strong preclinical evidence supports the hypothesis 
that the integrity of the neurovascular unit largely depends on high DHA enrich-
ment. This previously unrecognized pathophysiological process may significantly 
increase the risk of secondary brain injury following SAH.
The robust demonstration of the clinical efficacy of EPA in patients with chronic 
CV disease supports the encouraging results obtained in preliminary clinical studies 
of omega-3 FAs in SAH and warrants a large-scale RCT. It needs to be emphasized 
that DHA should always be included in neuroprotective interventions, as DHA 
plays an essential role in neural tissue and is the cornerstone for docosanoid genera-
tion. Parenteral pharmaconutrition with FO offers major clinical advantages for the 
treatment of SAH patients and should also be an integral component of omega-3 
FAs interventions during the acute stage of the disease.
The design of future RCTs of omega-3 FAs in SAH should bear in mind a potentially 
important factor. Clinical approaches that mainly focus on large-artery vasospasm may 
actually counteract the beneficial effects of omega-3 FAs and other neuroprotective 
interventions. The main rationale behind this seemingly paradoxical notion is based 
on both theoretical models and clinical perspectives [3, 31]. An unpublished subgroup 
analysis of our pilot pharmaconutrition trial of omega-3 FAs showed unexpected 
differences in the occurrence of cerebral infarction due to DCI between study centers, 
each of which had different clinical approaches to large-artery vasospasm [13]. In addi-
tion, a recently published observational study performed in the UK showed centers 
that screened for large-artery vasospasm using transcranial Doppler ultrasound (TCD) 
had poorer inhospital outcomes and similar rates of DCI diagnosis compared to centers 
that did not [88]. These results support the dissociation between large-artery vaso-
spasm and clinical outcome that has been observed in major phase 3 RCTs in SAH [8]. 
Therefore, reliance on a surrogate clinical endpoint such as large-artery vasospasm may 
lead to the adoption of useless or even harmful clinical approaches [88–91]. Indeed, 
some research centers in Europe do not include TCD ultrasound or endovascular rescue 
therapy in their treatment protocols for SAH patients [92].
Moreover, it would be clinically meaningful to determine if correlations exist 
between the omega-3 index and the concentrations of EPA and DHA as well as the 
status of inflammation resolution in the wall of ruptured and non-ruptured IAs. 
There may be a real opportunity for a readily implementable and low-cost therapy if 
the walls of IAs are as responsive to omega-3 FAs as atherosclerotic plaques.
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The interplay between omega-3 FAs and widely used drugs (aspirin and statins) 
that lead to the generation of longer-acting SPM R-epimers provides ample oppor-
tunities for future translational approaches in IAs and SAH. Indeed, combined 
therapies with omega-3 FAs and aspirin or statins could represent a viable, easy-to-
implement therapeutic strategy for patients with unruptured IAs.
Parenteral pharmaconutrition with FO could also be a clinically effective inter-
vention for perioperative neuroprotection for patients subjected to other surgeries 
at high risk of neurological injury, such as carotid endarterectomy, cardiac surgery, 
or diverse neurosurgical procedures.
In the future, new drug delivery systems capable of carrying synthetic analogues 
of SPMs could become a viable therapeutic strategy for patients with tissue-specific 
enzymatic deficiencies in the resolution pathways [93].
Conflict of interest
The authors have no conflicts of interest to declare.
Notes/thanks/other declarations
We express our appreciation to our patients from whom we have learned so much.
Author details
Geisi Saito1 and Rodrigo Zapata2*
1 Department of Anaesthesiology, Asenjo Neurosurgery Institute, Santiago, Chile
2 Neurosurgery Service, Regional Hospital of Rancagua, Hospital Regional 
Libertador Bernardo O’Higgins, Rancagua, Chile
*Address all correspondence to: rzapata.barra@gmail.com
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
250
New Insight into Cerebrovascular Diseases - An Updated Comprehensive Review
[1] Miller BA, Turan N, Chau M, Pradilla 
G. Inflammation, vasospasm, and brain 
injury after subarachnoid hemorrhage. 
BioMed Research International. 
2014;2014:384342
[2] Veldeman M, Hollig A, Clusmann H,  
Stevanovic A, Rossaint R, Coburn 
M. Delayed cerebral ischaemia 
prevention and treatment after 
aneurysmal subarachnoid haemorrhage: 
A systematic review. British Journal of 
Anaesthesia. 2016;117(1):17-40
[3] Ostergaard L, Aamand R, 
Karabegovic S, Tietze A, Blicher JU, 
Mikkelsen IK, et al. The role of the 
microcirculation in delayed cerebral 
ischemia and chronic degenerative 
changes after subarachnoid hemorrhage. 
Journal of Cerebral Blood Flow and 
Metabolism. 2013;33(12):1825-1837
[4] Massicotte EM, Del Bigio MR.  
Human arachnoid villi response to 
subarachnoid hemorrhage: Possible 
relationship to chronic hydrocephalus. 
Journal of Neurosurgery. 
1999;91(1):80-84
[5] Al-Khindi T, Macdonald RL, 
Schweizer TA. Cognitive and 
functional outcome after aneurysmal 
subarachnoid hemorrhage. Stroke. 
2010;41(8):e519-e536
[6] Haug Nordenmark T, Karic T, Roe 
C, Sorteberg W, Sorteberg A. The 
post-aSAH syndrome: A self-reported 
cluster of symptoms in patients with 
aneurysmal subarachnoid hemorrhage. 
Journal of Neurosurgery. 2019:1-10
[7] Hanggi D, Etminan N, Mayer SA, 
Aldrich EF, Diringer MN, Schmutzhard 
E, et al. Clinical trial protocol: Phase 3, 
multicenter, randomized, double-blind, 
placebo-controlled, parallel-group, 
efficacy, and safety study comparing 
EG-1962 to standard of care oral 
nimodipine in adults with aneurysmal 
subarachnoid hemorrhage [NEWTON-2 
(nimodipine microparticles to enhance 
recovery while reducing toxicity 
after subarachNoid hemorrhage)]. 
Neurocritical Care. 2019;30(1):88-97
[8] Etminan N, Vergouwen MD, 
Ilodigwe D, Macdonald RL. Effect 
of pharmaceutical treatment on 
vasospasm, delayed cerebral ischemia, 
and clinical outcome in patients 
with aneurysmal subarachnoid 
hemorrhage: A systematic review 
and meta-analysis. Journal of 
Cerebral Blood Flow and Metabolism. 
2011;31(6):1443-1451
[9] Ziegler TR. Parenteral nutrition 
in the critically ill patient. The 
New England Journal of Medicine. 
2009;361(11):1088-1097
[10] Arterburn LM, Hall EB, Oken 
H. Distribution, interconversion, 
and dose response of n-3 fatty 
acids in humans. The American 
Journal of Clinical Nutrition. 
2006;83(6):1467S-1476S
[11] Serhan CN, Chiang N, Van Dyke 
TE. Resolving inflammation: Dual 
anti-inflammatory and pro-resolution 
lipid mediators. Nature Reviews 
Immunology. 2008;8(5):349-361
[12] Pilitsis JG, Coplin WM, O’Regan 
MH, Wellwood JM, Diaz FG, Fairfax 
MR, et al. Free fatty acids in human 
cerebrospinal fluid following 
subarachnoid hemorrhage and 
their potential role in vasospasm: A 
preliminary observation. Journal of 
Neurosurgery. 2002;97(2):272-279
[13] Saito G, Zapata R, Rivera R, 
Zambrano H, Rojas D, Acevedo H, 
et al. Long-chain omega-3 fatty 
acids in aneurysmal subarachnoid 
hemorrhage: A randomized pilot trial of 




Aneurysmal Subarachnoid Hemorrhage and Resolution of Inflammation
DOI: http://dx.doi.org/10.5772/intechopen.88297
[14] Serhan CN, Savill J. Resolution 
of inflammation: The beginning 
programs the end. Nature Immunology. 
2005;6(12):1191-1197
[15] Serhan CN, Levy BD. Resolvins 
in inflammation: Emergence of the 
pro-resolving superfamily of mediators. 
The Journal of Clinical Investigation. 
2018;128(7):2657-2669
[16] Serhan CN, Dalli J, Colas RA, 
Winkler JW, Chiang N. Protectins and 
maresins: New pro-resolving families 
of mediators in acute inflammation 
and resolution bioactive metabolome. 
Biochimica et Biophysica Acta. 
2015;1851(4):397-413
[17] Hall TC, Bilku DK, Neal CP, 
Cooke J, Fisk HL, Calder PC, et al. 
The impact of an omega-3 fatty acid 
rich lipid emulsion on fatty acid 
profiles in critically ill septic patients. 
Prostaglandins, Leukotrienes, and 
Essential Fatty Acids. 2016;112:1-11
[18] Spector AA. Plasma lipid transport. 
Clinical Physiology and Biochemistry. 
1984;2(2-3):123-134
[19] Kasuga K, Yang R, Porter TF, 
Agrawal N, Petasis NA, Irimia D, et al. 
Rapid appearance of resolvin precursors 
in inflammatory exudates: Novel 
mechanisms in resolution. Journal of 
Immunology. 2008;181(12):8677-8687
[20] von Schacky C. Omega-3 index 
and cardiovascular health. Nutrients. 
2014;6(2):799-814
[21] Harris WS, Tintle NL, Etherton 
MR, Vasan RS. Erythrocyte long-chain 
omega-3 fatty acid levels are inversely 
associated with mortality and with 
incident cardiovascular disease: The 
Framingham heart study. Journal of 
Clinical Lipidology. 2018;12(3):718-727
[22] Grosso G, Pajak A, Marventano S,  
Castellano S, Galvano F, Bucolo C, 
et al. Role of omega-3 fatty acids in 
the treatment of depressive disorders: 
A comprehensive meta-analysis of 
randomized clinical trials. PLoS One. 
2014;9(5):e96905
[23] Bigornia SJ, Harris WS, Falcon LM, 
Ordovas JM, Lai CQ , Tucker KL. The 
omega-3 index is inversely associated 
with depressive symptoms among 
individuals with elevated oxidative 
stress biomarkers. The Journal of 
Nutrition. 2016;146(4):758-766
[24] Levi M, van der Poll T, Buller 
HR. Bidirectional relation between 
inflammation and coagulation. 
Circulation. 2004;109(22):2698-2704
[25] Calder PC. Omega-3 
polyunsaturated fatty acids and 
inflammatory processes: Nutrition 
or pharmacology? British Journal 
of Clinical Pharmacology. 
2013;75(3):645-662
[26] McBride DW, Blackburn SL, 
Peeyush KT, Matsumura K, Zhang 
JH. The role of thromboinflammation 
in delayed cerebral ischemia after 
subarachnoid hemorrhage. Frontiers in 
Neurology. 2017;8:555
[27] Albelda SM, Smith CW, Ward 
PA. Adhesion molecules and 
inflammatory injury. The FASEB 
Journal. 1994;8(8):504-512
[28] Mason RP, Jacob RF, Shrivastava S,  
Sherratt SCR, Chattopadhyay A. 
Eicosapentaenoic acid reduces 
membrane fluidity, inhibits 
cholesterol domain formation, 
and normalizes bilayer width in 
atherosclerotic-like model membranes. 
Biochimica et Biophysica Acta. 
2016;1858(12):3131-3140
[29] Morioka T, Emoto M, Imamura S, 
Kakutani Y, Yamazaki Y, Motoyama K,  
et al. Plasma polyunsaturated fatty 
acid profile is associated with vascular 
endothelial function in patients with 
250
New Insight into Cerebrovascular Diseases - An Updated Comprehensive Review
[1] Miller BA, Turan N, Chau M, Pradilla 
G. Inflammation, vasospasm, and brain 
injury after subarachnoid hemorrhage. 
BioMed Research International. 
2014;2014:384342
[2] Veldeman M, Hollig A, Clusmann H,  
Stevanovic A, Rossaint R, Coburn 
M. Delayed cerebral ischaemia 
prevention and treatment after 
aneurysmal subarachnoid haemorrhage: 
A systematic review. British Journal of 
Anaesthesia. 2016;117(1):17-40
[3] Ostergaard L, Aamand R, 
Karabegovic S, Tietze A, Blicher JU, 
Mikkelsen IK, et al. The role of the 
microcirculation in delayed cerebral 
ischemia and chronic degenerative 
changes after subarachnoid hemorrhage. 
Journal of Cerebral Blood Flow and 
Metabolism. 2013;33(12):1825-1837
[4] Massicotte EM, Del Bigio MR.  
Human arachnoid villi response to 
subarachnoid hemorrhage: Possible 
relationship to chronic hydrocephalus. 
Journal of Neurosurgery. 
1999;91(1):80-84
[5] Al-Khindi T, Macdonald RL, 
Schweizer TA. Cognitive and 
functional outcome after aneurysmal 
subarachnoid hemorrhage. Stroke. 
2010;41(8):e519-e536
[6] Haug Nordenmark T, Karic T, Roe 
C, Sorteberg W, Sorteberg A. The 
post-aSAH syndrome: A self-reported 
cluster of symptoms in patients with 
aneurysmal subarachnoid hemorrhage. 
Journal of Neurosurgery. 2019:1-10
[7] Hanggi D, Etminan N, Mayer SA, 
Aldrich EF, Diringer MN, Schmutzhard 
E, et al. Clinical trial protocol: Phase 3, 
multicenter, randomized, double-blind, 
placebo-controlled, parallel-group, 
efficacy, and safety study comparing 
EG-1962 to standard of care oral 
nimodipine in adults with aneurysmal 
subarachnoid hemorrhage [NEWTON-2 
(nimodipine microparticles to enhance 
recovery while reducing toxicity 
after subarachNoid hemorrhage)]. 
Neurocritical Care. 2019;30(1):88-97
[8] Etminan N, Vergouwen MD, 
Ilodigwe D, Macdonald RL. Effect 
of pharmaceutical treatment on 
vasospasm, delayed cerebral ischemia, 
and clinical outcome in patients 
with aneurysmal subarachnoid 
hemorrhage: A systematic review 
and meta-analysis. Journal of 
Cerebral Blood Flow and Metabolism. 
2011;31(6):1443-1451
[9] Ziegler TR. Parenteral nutrition 
in the critically ill patient. The 
New England Journal of Medicine. 
2009;361(11):1088-1097
[10] Arterburn LM, Hall EB, Oken 
H. Distribution, interconversion, 
and dose response of n-3 fatty 
acids in humans. The American 
Journal of Clinical Nutrition. 
2006;83(6):1467S-1476S
[11] Serhan CN, Chiang N, Van Dyke 
TE. Resolving inflammation: Dual 
anti-inflammatory and pro-resolution 
lipid mediators. Nature Reviews 
Immunology. 2008;8(5):349-361
[12] Pilitsis JG, Coplin WM, O’Regan 
MH, Wellwood JM, Diaz FG, Fairfax 
MR, et al. Free fatty acids in human 
cerebrospinal fluid following 
subarachnoid hemorrhage and 
their potential role in vasospasm: A 
preliminary observation. Journal of 
Neurosurgery. 2002;97(2):272-279
[13] Saito G, Zapata R, Rivera R, 
Zambrano H, Rojas D, Acevedo H, 
et al. Long-chain omega-3 fatty 
acids in aneurysmal subarachnoid 
hemorrhage: A randomized pilot trial of 




Aneurysmal Subarachnoid Hemorrhage and Resolution of Inflammation
DOI: http://dx.doi.org/10.5772/intechopen.88297
[14] Serhan CN, Savill J. Resolution 
of inflammation: The beginning 
programs the end. Nature Immunology. 
2005;6(12):1191-1197
[15] Serhan CN, Levy BD. Resolvins 
in inflammation: Emergence of the 
pro-resolving superfamily of mediators. 
The Journal of Clinical Investigation. 
2018;128(7):2657-2669
[16] Serhan CN, Dalli J, Colas RA, 
Winkler JW, Chiang N. Protectins and 
maresins: New pro-resolving families 
of mediators in acute inflammation 
and resolution bioactive metabolome. 
Biochimica et Biophysica Acta. 
2015;1851(4):397-413
[17] Hall TC, Bilku DK, Neal CP, 
Cooke J, Fisk HL, Calder PC, et al. 
The impact of an omega-3 fatty acid 
rich lipid emulsion on fatty acid 
profiles in critically ill septic patients. 
Prostaglandins, Leukotrienes, and 
Essential Fatty Acids. 2016;112:1-11
[18] Spector AA. Plasma lipid transport. 
Clinical Physiology and Biochemistry. 
1984;2(2-3):123-134
[19] Kasuga K, Yang R, Porter TF, 
Agrawal N, Petasis NA, Irimia D, et al. 
Rapid appearance of resolvin precursors 
in inflammatory exudates: Novel 
mechanisms in resolution. Journal of 
Immunology. 2008;181(12):8677-8687
[20] von Schacky C. Omega-3 index 
and cardiovascular health. Nutrients. 
2014;6(2):799-814
[21] Harris WS, Tintle NL, Etherton 
MR, Vasan RS. Erythrocyte long-chain 
omega-3 fatty acid levels are inversely 
associated with mortality and with 
incident cardiovascular disease: The 
Framingham heart study. Journal of 
Clinical Lipidology. 2018;12(3):718-727
[22] Grosso G, Pajak A, Marventano S,  
Castellano S, Galvano F, Bucolo C, 
et al. Role of omega-3 fatty acids in 
the treatment of depressive disorders: 
A comprehensive meta-analysis of 
randomized clinical trials. PLoS One. 
2014;9(5):e96905
[23] Bigornia SJ, Harris WS, Falcon LM, 
Ordovas JM, Lai CQ , Tucker KL. The 
omega-3 index is inversely associated 
with depressive symptoms among 
individuals with elevated oxidative 
stress biomarkers. The Journal of 
Nutrition. 2016;146(4):758-766
[24] Levi M, van der Poll T, Buller 
HR. Bidirectional relation between 
inflammation and coagulation. 
Circulation. 2004;109(22):2698-2704
[25] Calder PC. Omega-3 
polyunsaturated fatty acids and 
inflammatory processes: Nutrition 
or pharmacology? British Journal 
of Clinical Pharmacology. 
2013;75(3):645-662
[26] McBride DW, Blackburn SL, 
Peeyush KT, Matsumura K, Zhang 
JH. The role of thromboinflammation 
in delayed cerebral ischemia after 
subarachnoid hemorrhage. Frontiers in 
Neurology. 2017;8:555
[27] Albelda SM, Smith CW, Ward 
PA. Adhesion molecules and 
inflammatory injury. The FASEB 
Journal. 1994;8(8):504-512
[28] Mason RP, Jacob RF, Shrivastava S,  
Sherratt SCR, Chattopadhyay A. 
Eicosapentaenoic acid reduces 
membrane fluidity, inhibits 
cholesterol domain formation, 
and normalizes bilayer width in 
atherosclerotic-like model membranes. 
Biochimica et Biophysica Acta. 
2016;1858(12):3131-3140
[29] Morioka T, Emoto M, Imamura S, 
Kakutani Y, Yamazaki Y, Motoyama K,  
et al. Plasma polyunsaturated fatty 
acid profile is associated with vascular 
endothelial function in patients with 
New Insight into Cerebrovascular Diseases - An Updated Comprehensive Review
252
type 2 diabetes. Diabetes & Vascular 
Disease Research. 2018;15(4):352-355
[30] Fisher M. Pericyte signaling 
in the neurovascular unit. Stroke. 
2009;40(3):S13-S15
[31] Hall CN, Reynell C, Gesslein B, 
Hamilton NB, Mishra A, Sutherland 
BA, et al. Capillary pericytes regulate 
cerebral blood flow in health and 
disease. Nature. 2014;508(7494):55-60
[32] Lauritzen L, Hansen HS, Jorgensen 
MH, Michaelsen KF. The essentiality of 
long chain n-3 fatty acids in relation to 
development and function of the brain 
and retina. Progress in Lipid Research. 
2001;40(1-2):1-94
[33] Nguyen LN, Ma D, Shui G, Wong 
P, Cazenave-Gassiot A, Zhang X, et al. 
Mfsd2a is a transporter for the essential 
omega-3 fatty acid docosahexaenoic 
acid. Nature. 2014;509(7501):503-506
[34] Bradbury J. Docosahexaenoic 
acid (DHA): An ancient nutrient for 
the modern human brain. Nutrients. 
2011;3(5):529-554
[35] Crawford MA, Bloom M, 
Broadhurst CL, Schmidt WF, Cunnane 
SC, Galli C, et al. Evidence for the 
unique function of docosahexaenoic 
acid during the evolution of the 
modern hominid brain. Lipids. 
1999;34:S39-S47
[36] Kim HY, Akbar M, Kim YS.  
Phosphatidylserine-dependent 
neuroprotective signaling promoted by 
docosahexaenoic acid. Prostaglandins, 
Leukotrienes, and Essential Fatty Acids. 
2010;82(4-6):165-172
[37] Bazan NG, Musto AE, Knott EJ.  
Endogenous signaling by omega-3 
docosahexaenoic acid-derived 
mediators sustains homeostatic synaptic 
and circuitry integrity. Molecular 
Neurobiology. 2011;44(2):216-222




PKA-dependent signaling. Journal of 
Neuroinflammation. 2016;13(1):284
[39] McDougle DR, Watson JE, Abdeen 
AA, Adili R, Caputo MP, Krapf JE, 
et al. Anti-inflammatory omega-3 
endocannabinoid epoxides. Proceedings 
of the National Academy of Sciences 
of the United States of America. 
2017;114(30):E6034-E6043
[40] Bazan NG. Docosanoids and 
elovanoids from omega-3 fatty acids 
are pro-homeostatic modulators of 
inflammatory responses, cell damage 
and neuroprotection. Molecular Aspects 
of Medicine. 2018;64:18-33
[41] Belayev L, Mukherjee PK, 
Balaszczuk V, Calandria JM, Obenaus 
A, Khoutorova L, et al. Neuroprotectin 
D1 upregulates Iduna expression 
and provides protection in cellular 
uncompensated oxidative stress and 
in experimental ischemic stroke. 
Cell Death and Differentiation. 
2017;24(6):1091-1099
[42] Rashid MA, Katakura M, Kharebava 
G, Kevala K, Kim HY.  
N-Docosahexaenoylethanolamine is 
a potent neurogenic factor for neural 
stem cell differentiation. Journal of 
Neurochemistry. 2013;125(6):869-884
[43] Iadecola C. The neurovascular 
unit coming of age: A journey through 
neurovascular coupling in health and 
disease. Neuron. 2017;96(1):17-42
[44] Umhau JC, Zhou W, Carson RE, 
Rapoport SI, Polozova A, Demar J, et al. 
Imaging incorporation of circulating 
docosahexaenoic acid into the 
human brain using positron emission 
tomography. Journal of Lipid Research. 
2009;50(7):1259-1268
[45] Ayer RE, Zhang JH. Oxidative 
stress in subarachnoid haemorrhage: 
253
Aneurysmal Subarachnoid Hemorrhage and Resolution of Inflammation
DOI: http://dx.doi.org/10.5772/intechopen.88297
Significance in acute brain injury and 
vasospasm. Acta Neurochirurgica. 
Supplement. 2008;104:33-41
[46] Hsieh YP, Lin CL, Shiue AL, Yin H, 
Morrow JD, Hsu JC, et al. Correlation 
of F4-neuroprostanes levels in 
cerebrospinal fluid with outcome of 
aneurysmal subarachnoid hemorrhage 
in humans. Free Radical Biology & 
Medicine. 2009;47(6):814-824
[47] Corcoran TB, Mas E, Barden AE, 
Durand T, Galano JM, Roberts LJ, et al. 
Are isofurans and neuroprostanes 
increased after subarachnoid 
hemorrhage and traumatic brain injury? 
Antioxidants & Redox Signaling. 
2011;15(10):2663-2667
[48] Hibbeln JR, Nieminen LR, Blasbalg 
TL, Riggs JA, Lands WE.  
Healthy intakes of n-3 and n-6 
fatty acids: Estimations considering 
worldwide diversity. The American 
Journal of Clinical Nutrition. 
2006;83(6):1483S-1493S
[49] Bendel P, Koivisto T, Aikia M, 
Niskanen E, Kononen M, Hanninen 
T, et al. Atrophic enlargement of 
CSF volume after subarachnoid 
hemorrhage: Correlation with 
neuropsychological outcome. 
American Journal of Neuroradiology. 
2010;31(2):370-376
[50] Pottala JV, Yaffe K, Robinson 
JG, Espeland MA, Wallace R, Harris 
WS. Higher RBC EPA + DHA 
corresponds with larger total brain and 
hippocampal volumes: WHIMS-MRI 
study. Neurology. 2014;82(5):435-442
[51] Hou J, Zhang JH. Does prevention of 
vasospasm in subarachnoid hemorrhage 
improve clinical outcome? No. Stroke. 
2013;44(6):S34-S36
[52] Eriksen N, Rostrup E, Fabricius 
M, Scheel M, Major S, Winkler MKL, 
et al. Early focal brain injury after 
subarachnoid hemorrhage correlates 
with spreading depolarizations. 
Neurology. 2019;92(4):e326-e341
[53] Wartenberg KE, Mayer SA. Medical 
complications after subarachnoid 
hemorrhage. Neurosurgery Clinics of 
North America. 2010;21(2):325-338
[54] Zhang M, Wang S, Mao L, Leak 
RK, Shi Y, Zhang W, et al. Omega-3 
fatty acids protect the brain against 
ischemic injury by activating Nrf2 
and upregulating heme oxygenase 
1. The Journal of Neuroscience. 
2014;34(5):1903-1915
[55] Jiang X, Pu H, Hu X, Wei Z, Hong 
D, Zhang W, et al. A post-stroke 
therapeutic regimen with omega-3 
polyunsaturated fatty acids that 
promotes white matter integrity and 
beneficial microglial responses after 
cerebral ischemia. Translational Stroke 
Research. 2016;7(6):548-561
[56] Sgubin D, Aztiria E, Perin A, 
Longatti P, Leanza G. Activation 
of endogenous neural stem cells in 
the adult human brain following 
subarachnoid hemorrhage. 
Journal of Neuroscience Research. 
2007;85(8):1647-1655
[57] Bhatt DL, Steg PG, Miller M, 
Brinton EA, Jacobson TA, Ketchum 
SB, et al. Cardiovascular risk 
reduction with icosapent ethyl for 
hypertriglyceridemia. The New England 
Journal of Medicine. 2019;380(1):11-22
[58] Hopper L, Ness A, Higgins JP, Moore 
T, Ebrahim S. GISSI-prevenzione trial. 
Lancet. 1999;354(9189):1557
[59] Klek S. Omega-3 fatty acids in 
modern parenteral nutrition: A review 
of the current evidence. Journal of 
Clinical Medicine. 2016;5(3):e34
[60] Chen CT, Kitson AP, Hopperton 
KE, Domenichiello AF, Trepanier MO, 
Lin LE, et al. Plasma non-esterified 
docosahexaenoic acid is the major pool 
New Insight into Cerebrovascular Diseases - An Updated Comprehensive Review
252
type 2 diabetes. Diabetes & Vascular 
Disease Research. 2018;15(4):352-355
[30] Fisher M. Pericyte signaling 
in the neurovascular unit. Stroke. 
2009;40(3):S13-S15
[31] Hall CN, Reynell C, Gesslein B, 
Hamilton NB, Mishra A, Sutherland 
BA, et al. Capillary pericytes regulate 
cerebral blood flow in health and 
disease. Nature. 2014;508(7494):55-60
[32] Lauritzen L, Hansen HS, Jorgensen 
MH, Michaelsen KF. The essentiality of 
long chain n-3 fatty acids in relation to 
development and function of the brain 
and retina. Progress in Lipid Research. 
2001;40(1-2):1-94
[33] Nguyen LN, Ma D, Shui G, Wong 
P, Cazenave-Gassiot A, Zhang X, et al. 
Mfsd2a is a transporter for the essential 
omega-3 fatty acid docosahexaenoic 
acid. Nature. 2014;509(7501):503-506
[34] Bradbury J. Docosahexaenoic 
acid (DHA): An ancient nutrient for 
the modern human brain. Nutrients. 
2011;3(5):529-554
[35] Crawford MA, Bloom M, 
Broadhurst CL, Schmidt WF, Cunnane 
SC, Galli C, et al. Evidence for the 
unique function of docosahexaenoic 
acid during the evolution of the 
modern hominid brain. Lipids. 
1999;34:S39-S47
[36] Kim HY, Akbar M, Kim YS.  
Phosphatidylserine-dependent 
neuroprotective signaling promoted by 
docosahexaenoic acid. Prostaglandins, 
Leukotrienes, and Essential Fatty Acids. 
2010;82(4-6):165-172
[37] Bazan NG, Musto AE, Knott EJ.  
Endogenous signaling by omega-3 
docosahexaenoic acid-derived 
mediators sustains homeostatic synaptic 
and circuitry integrity. Molecular 
Neurobiology. 2011;44(2):216-222




PKA-dependent signaling. Journal of 
Neuroinflammation. 2016;13(1):284
[39] McDougle DR, Watson JE, Abdeen 
AA, Adili R, Caputo MP, Krapf JE, 
et al. Anti-inflammatory omega-3 
endocannabinoid epoxides. Proceedings 
of the National Academy of Sciences 
of the United States of America. 
2017;114(30):E6034-E6043
[40] Bazan NG. Docosanoids and 
elovanoids from omega-3 fatty acids 
are pro-homeostatic modulators of 
inflammatory responses, cell damage 
and neuroprotection. Molecular Aspects 
of Medicine. 2018;64:18-33
[41] Belayev L, Mukherjee PK, 
Balaszczuk V, Calandria JM, Obenaus 
A, Khoutorova L, et al. Neuroprotectin 
D1 upregulates Iduna expression 
and provides protection in cellular 
uncompensated oxidative stress and 
in experimental ischemic stroke. 
Cell Death and Differentiation. 
2017;24(6):1091-1099
[42] Rashid MA, Katakura M, Kharebava 
G, Kevala K, Kim HY.  
N-Docosahexaenoylethanolamine is 
a potent neurogenic factor for neural 
stem cell differentiation. Journal of 
Neurochemistry. 2013;125(6):869-884
[43] Iadecola C. The neurovascular 
unit coming of age: A journey through 
neurovascular coupling in health and 
disease. Neuron. 2017;96(1):17-42
[44] Umhau JC, Zhou W, Carson RE, 
Rapoport SI, Polozova A, Demar J, et al. 
Imaging incorporation of circulating 
docosahexaenoic acid into the 
human brain using positron emission 
tomography. Journal of Lipid Research. 
2009;50(7):1259-1268
[45] Ayer RE, Zhang JH. Oxidative 
stress in subarachnoid haemorrhage: 
253
Aneurysmal Subarachnoid Hemorrhage and Resolution of Inflammation
DOI: http://dx.doi.org/10.5772/intechopen.88297
Significance in acute brain injury and 
vasospasm. Acta Neurochirurgica. 
Supplement. 2008;104:33-41
[46] Hsieh YP, Lin CL, Shiue AL, Yin H, 
Morrow JD, Hsu JC, et al. Correlation 
of F4-neuroprostanes levels in 
cerebrospinal fluid with outcome of 
aneurysmal subarachnoid hemorrhage 
in humans. Free Radical Biology & 
Medicine. 2009;47(6):814-824
[47] Corcoran TB, Mas E, Barden AE, 
Durand T, Galano JM, Roberts LJ, et al. 
Are isofurans and neuroprostanes 
increased after subarachnoid 
hemorrhage and traumatic brain injury? 
Antioxidants & Redox Signaling. 
2011;15(10):2663-2667
[48] Hibbeln JR, Nieminen LR, Blasbalg 
TL, Riggs JA, Lands WE.  
Healthy intakes of n-3 and n-6 
fatty acids: Estimations considering 
worldwide diversity. The American 
Journal of Clinical Nutrition. 
2006;83(6):1483S-1493S
[49] Bendel P, Koivisto T, Aikia M, 
Niskanen E, Kononen M, Hanninen 
T, et al. Atrophic enlargement of 
CSF volume after subarachnoid 
hemorrhage: Correlation with 
neuropsychological outcome. 
American Journal of Neuroradiology. 
2010;31(2):370-376
[50] Pottala JV, Yaffe K, Robinson 
JG, Espeland MA, Wallace R, Harris 
WS. Higher RBC EPA + DHA 
corresponds with larger total brain and 
hippocampal volumes: WHIMS-MRI 
study. Neurology. 2014;82(5):435-442
[51] Hou J, Zhang JH. Does prevention of 
vasospasm in subarachnoid hemorrhage 
improve clinical outcome? No. Stroke. 
2013;44(6):S34-S36
[52] Eriksen N, Rostrup E, Fabricius 
M, Scheel M, Major S, Winkler MKL, 
et al. Early focal brain injury after 
subarachnoid hemorrhage correlates 
with spreading depolarizations. 
Neurology. 2019;92(4):e326-e341
[53] Wartenberg KE, Mayer SA. Medical 
complications after subarachnoid 
hemorrhage. Neurosurgery Clinics of 
North America. 2010;21(2):325-338
[54] Zhang M, Wang S, Mao L, Leak 
RK, Shi Y, Zhang W, et al. Omega-3 
fatty acids protect the brain against 
ischemic injury by activating Nrf2 
and upregulating heme oxygenase 
1. The Journal of Neuroscience. 
2014;34(5):1903-1915
[55] Jiang X, Pu H, Hu X, Wei Z, Hong 
D, Zhang W, et al. A post-stroke 
therapeutic regimen with omega-3 
polyunsaturated fatty acids that 
promotes white matter integrity and 
beneficial microglial responses after 
cerebral ischemia. Translational Stroke 
Research. 2016;7(6):548-561
[56] Sgubin D, Aztiria E, Perin A, 
Longatti P, Leanza G. Activation 
of endogenous neural stem cells in 
the adult human brain following 
subarachnoid hemorrhage. 
Journal of Neuroscience Research. 
2007;85(8):1647-1655
[57] Bhatt DL, Steg PG, Miller M, 
Brinton EA, Jacobson TA, Ketchum 
SB, et al. Cardiovascular risk 
reduction with icosapent ethyl for 
hypertriglyceridemia. The New England 
Journal of Medicine. 2019;380(1):11-22
[58] Hopper L, Ness A, Higgins JP, Moore 
T, Ebrahim S. GISSI-prevenzione trial. 
Lancet. 1999;354(9189):1557
[59] Klek S. Omega-3 fatty acids in 
modern parenteral nutrition: A review 
of the current evidence. Journal of 
Clinical Medicine. 2016;5(3):e34
[60] Chen CT, Kitson AP, Hopperton 
KE, Domenichiello AF, Trepanier MO, 
Lin LE, et al. Plasma non-esterified 
docosahexaenoic acid is the major pool 
New Insight into Cerebrovascular Diseases - An Updated Comprehensive Review
254
supplying the brain. Scientific Reports. 
2015;5:15791
[61] Jones NE, Heyland DK.  
Pharmaconutrition: A new emerging 
paradigm. Current Opinion in 
Gastroenterology. 2008;24(2):215-222
[62] Harris WS, Pottala JV, Sands SA,  
Jones PG. Comparison of the effects 
of fish and fish-oil capsules on the 
n 3 fatty acid content of blood cells 
and plasma phospholipids. The 
American Journal of Clinical Nutrition. 
2007;86(6):1621-1625
[63] Nosaka K, Miyoshi T, Iwamoto M, 
Kajiya M, Okawa K, Tsukuda S, et al. 
Early initiation of eicosapentaenoic 
acid and statin treatment is associated 
with better clinical outcomes than 
statin alone in patients with acute 
coronary syndromes: 1-year outcomes 
of a randomized controlled study. 
International Journal of Cardiology. 
2017;228:173-179
[64] Yurko-Mauro K, McCarthy 
D, Rom D, Nelson EB, Ryan AS, 
Blackwell A, et al. Beneficial 
effects of docosahexaenoic acid on 
cognition in age-related cognitive 
decline. Alzheimer’s & Dementia. 
2010;6(6):456-464
[65] Cholewski M, Tomczykowa M, 
Tomczyk M. A comprehensive review 
of chemistry, sources and bioavailability 
of omega-3 fatty acids. Nutrients. 
2018;10(11):e1662
[66] Yin J, Li H, Meng C, Chen D, Chen 
Z, Wang Y, et al. Inhibitory effects 
of omega-3 fatty acids on early brain 
injury after subarachnoid hemorrhage 
in rats: Possible involvement of 
G protein-coupled receptor 120/
beta-arrestin2/TGF-beta activated 
kinase-1 binding protein-1 signaling 
pathway. The International Journal 
of Biochemistry & Cell Biology. 
2016;75:11-22
[67] Zhang T, Wu P, Zhang JH, Li Y, 
Xu S, Wang C, et al. Docosahexaenoic 
acid alleviates oxidative stress-based 
apoptosis via improving mitochondrial 
dynamics in early brain injury after 
subarachnoid hemorrhage. Cellular 
and Molecular Neurobiology. 
2018;38(7):1413-1423
[68] Belayev L, Khoutorova L, Atkins 
KD, Eady TN, Hong S, Lu Y, et al. 
Docosahexaenoic acid therapy 
of experimental ischemic stroke. 
Translational Stroke Research. 
2011;2(1):33-41
[69] Yin P, Wei Y, Wang X, Zhu M, Feng 
J. Roles of specialized pro-resolving 
lipid mediators in cerebral ischemia 
reperfusion injury. Frontiers in 
Neurology. 2018;9:617
[70] Berressem D, Koch K, Franke N,  
Klein J, Eckert GP. Intravenous 
treatment with a long-chain omega-3 
lipid emulsion provides neuroprotection 
in a murine model of ischemic 
stroke-A pilot study. PLoS One. 
2016;11(11):e0167329
[71] Belayev L, Hong SH, Menghani H, 
Marcell SJ, Obenaus A, Freitas RS, et al. 
Docosanoids promote neurogenesis 
and angiogenesis, blood-brain barrier 
integrity, penumbra protection, 
and neurobehavioral recovery after 
experimental ischemic stroke. Molecular 
Neurobiology. 2018;55(8):7090-7106
[72] Nakagawa I, Yokoyama S, Omoto K,  
Takeshima Y, Matsuda R, Nishimura 
F, et al. Omega-3 fatty acids ethyl 
esters suppress cerebral vasospasm and 
improve clinical outcome following 
aneurysmal subarachnoid hemorrhage. 
World Neurosurgery. 2017;99:457-464
[73] Yoneda H, Shirao S, Kurokawa T, 
Fujisawa H, Kato S, Suzuki M. Does 
eicosapentaenoic acid (EPA) inhibit 
cerebral vasospasm in patients after 
aneurysmal subarachnoid hemorrhage? 
255
Aneurysmal Subarachnoid Hemorrhage and Resolution of Inflammation
DOI: http://dx.doi.org/10.5772/intechopen.88297
Acta Neurologica Scandinavica. 
2008;118(1):54-59
[74] Yoneda H, Shirao S, Nakagawara J, 
Ogasawara K, Tominaga T, Suzuki M. A 
prospective, multicenter, randomized 
study of the efficacy of eicosapentaenoic 
acid for cerebral vasospasm: The 
EVAS study. World Neurosurgery. 
2014;81(2):309-315
[75] de Meijer VE, Gura KM, Meisel 
JA, Le HD, Puder M. Parenteral fish 
oil monotherapy in the management 
of patients with parenteral nutrition-
associated liver disease. Archives of 
Surgery. 2010;145(6):547-551
[76] Signorelli F, Sela S, Gesualdo L, 
Chevrel S, Tollet F, Pailler-Mattei 
C, et al. Hemodynamic stress, 
inflammation, and intracranial 
aneurysm development and rupture: A 
systematic review. World Neurosurgery. 
2018;115:234-244
[77] Libby P. Inflammation in 
atherosclerosis. Arteriosclerosis, 
Thrombosis, and Vascular Biology. 
2012;32(9):2045-2051
[78] Shimizu K, Kushamae M, Mizutani 
T, Aoki T. Intracranial aneurysm as a 
macrophage-mediated inflammatory 
disease. Neurologia Medico-Chirurgica. 
2019;59(4):126-132
[79] Aoki T, Frosen J, Fukuda M, 
Bando K, Shioi G, Tsuji K, et al. 
Prostaglandin E2-EP2-NF-kappaB 
signaling in macrophages as a potential 
therapeutic target for intracranial 
aneurysms. Science Signaling. 
2017;10(465):eaah6037
[80] Borow KM, Nelson JR, Mason 
RP. Biologic plausibility, cellular 
effects, and molecular mechanisms 
of eicosapentaenoic acid (EPA) in 
atherosclerosis. Atherosclerosis. 
2015;242(1):357-366
[81] Fredman G, Spite M. Specialized 
pro-resolving mediators in 
cardiovascular diseases. Molecular 
Aspects of Medicine. 2017;58:65-71
[82] Merched AJ, Serhan CN, Chan L.  
Nutrigenetic disruption of 
inflammation-resolution homeostasis 
and atherogenesis. Journal of 
Nutrigenetics and Nutrigenomics. 
2011;4(1):12-24
[83] Simopoulos AP. The importance of 
the omega-6/omega-3 fatty acid ratio in 
cardiovascular disease and other chronic 
diseases. Experimental Biology and 
Medicine. 2008;233(6):674-688
[84] Investigators UJ, Morita A, Kirino T, 
Hashi K, Aoki N, Fukuhara S, et al. The 
natural course of unruptured cerebral 
aneurysms in a Japanese cohort. The 
New England Journal of Medicine. 
2012;366(26):2474-2482
[85] Tabas I. Macrophage death and 
defective inflammation resolution 
in atherosclerosis. Nature Reviews 
Immunology. 2010;10(1):36-46
[86] de Gaetano M, McEvoy C, Andrews 
D, Cacace A, Hunter J, Brennan E, 
et al. Specialized pro-resolving lipid 
mediators: Modulation of diabetes-
associated cardio-, reno-, and retino-
vascular complications. Frontiers in 
Pharmacology. 2018;9:1488
[87] Ruiz-Mirazo K, Briones C, de la 
Escosura A. Chemical roots of biological 
evolution: The origins of life as a 
process of development of autonomous 
functional systems. Open Biology. 
2017;7(4):170050
[88] Hollingworth M, Jamjoom AAB, 
Bulters D, Patel HC. How is vasospasm 
screening using transcranial Doppler 
associated with delayed cerebral 
ischemia and outcomes in aneurysmal 
subarachnoid hemorrhage? Acta 
Neurochirurgica. 2019;161(2):385-392
New Insight into Cerebrovascular Diseases - An Updated Comprehensive Review
254
supplying the brain. Scientific Reports. 
2015;5:15791
[61] Jones NE, Heyland DK.  
Pharmaconutrition: A new emerging 
paradigm. Current Opinion in 
Gastroenterology. 2008;24(2):215-222
[62] Harris WS, Pottala JV, Sands SA,  
Jones PG. Comparison of the effects 
of fish and fish-oil capsules on the 
n 3 fatty acid content of blood cells 
and plasma phospholipids. The 
American Journal of Clinical Nutrition. 
2007;86(6):1621-1625
[63] Nosaka K, Miyoshi T, Iwamoto M, 
Kajiya M, Okawa K, Tsukuda S, et al. 
Early initiation of eicosapentaenoic 
acid and statin treatment is associated 
with better clinical outcomes than 
statin alone in patients with acute 
coronary syndromes: 1-year outcomes 
of a randomized controlled study. 
International Journal of Cardiology. 
2017;228:173-179
[64] Yurko-Mauro K, McCarthy 
D, Rom D, Nelson EB, Ryan AS, 
Blackwell A, et al. Beneficial 
effects of docosahexaenoic acid on 
cognition in age-related cognitive 
decline. Alzheimer’s & Dementia. 
2010;6(6):456-464
[65] Cholewski M, Tomczykowa M, 
Tomczyk M. A comprehensive review 
of chemistry, sources and bioavailability 
of omega-3 fatty acids. Nutrients. 
2018;10(11):e1662
[66] Yin J, Li H, Meng C, Chen D, Chen 
Z, Wang Y, et al. Inhibitory effects 
of omega-3 fatty acids on early brain 
injury after subarachnoid hemorrhage 
in rats: Possible involvement of 
G protein-coupled receptor 120/
beta-arrestin2/TGF-beta activated 
kinase-1 binding protein-1 signaling 
pathway. The International Journal 
of Biochemistry & Cell Biology. 
2016;75:11-22
[67] Zhang T, Wu P, Zhang JH, Li Y, 
Xu S, Wang C, et al. Docosahexaenoic 
acid alleviates oxidative stress-based 
apoptosis via improving mitochondrial 
dynamics in early brain injury after 
subarachnoid hemorrhage. Cellular 
and Molecular Neurobiology. 
2018;38(7):1413-1423
[68] Belayev L, Khoutorova L, Atkins 
KD, Eady TN, Hong S, Lu Y, et al. 
Docosahexaenoic acid therapy 
of experimental ischemic stroke. 
Translational Stroke Research. 
2011;2(1):33-41
[69] Yin P, Wei Y, Wang X, Zhu M, Feng 
J. Roles of specialized pro-resolving 
lipid mediators in cerebral ischemia 
reperfusion injury. Frontiers in 
Neurology. 2018;9:617
[70] Berressem D, Koch K, Franke N,  
Klein J, Eckert GP. Intravenous 
treatment with a long-chain omega-3 
lipid emulsion provides neuroprotection 
in a murine model of ischemic 
stroke-A pilot study. PLoS One. 
2016;11(11):e0167329
[71] Belayev L, Hong SH, Menghani H, 
Marcell SJ, Obenaus A, Freitas RS, et al. 
Docosanoids promote neurogenesis 
and angiogenesis, blood-brain barrier 
integrity, penumbra protection, 
and neurobehavioral recovery after 
experimental ischemic stroke. Molecular 
Neurobiology. 2018;55(8):7090-7106
[72] Nakagawa I, Yokoyama S, Omoto K,  
Takeshima Y, Matsuda R, Nishimura 
F, et al. Omega-3 fatty acids ethyl 
esters suppress cerebral vasospasm and 
improve clinical outcome following 
aneurysmal subarachnoid hemorrhage. 
World Neurosurgery. 2017;99:457-464
[73] Yoneda H, Shirao S, Kurokawa T, 
Fujisawa H, Kato S, Suzuki M. Does 
eicosapentaenoic acid (EPA) inhibit 
cerebral vasospasm in patients after 
aneurysmal subarachnoid hemorrhage? 
255
Aneurysmal Subarachnoid Hemorrhage and Resolution of Inflammation
DOI: http://dx.doi.org/10.5772/intechopen.88297
Acta Neurologica Scandinavica. 
2008;118(1):54-59
[74] Yoneda H, Shirao S, Nakagawara J, 
Ogasawara K, Tominaga T, Suzuki M. A 
prospective, multicenter, randomized 
study of the efficacy of eicosapentaenoic 
acid for cerebral vasospasm: The 
EVAS study. World Neurosurgery. 
2014;81(2):309-315
[75] de Meijer VE, Gura KM, Meisel 
JA, Le HD, Puder M. Parenteral fish 
oil monotherapy in the management 
of patients with parenteral nutrition-
associated liver disease. Archives of 
Surgery. 2010;145(6):547-551
[76] Signorelli F, Sela S, Gesualdo L, 
Chevrel S, Tollet F, Pailler-Mattei 
C, et al. Hemodynamic stress, 
inflammation, and intracranial 
aneurysm development and rupture: A 
systematic review. World Neurosurgery. 
2018;115:234-244
[77] Libby P. Inflammation in 
atherosclerosis. Arteriosclerosis, 
Thrombosis, and Vascular Biology. 
2012;32(9):2045-2051
[78] Shimizu K, Kushamae M, Mizutani 
T, Aoki T. Intracranial aneurysm as a 
macrophage-mediated inflammatory 
disease. Neurologia Medico-Chirurgica. 
2019;59(4):126-132
[79] Aoki T, Frosen J, Fukuda M, 
Bando K, Shioi G, Tsuji K, et al. 
Prostaglandin E2-EP2-NF-kappaB 
signaling in macrophages as a potential 
therapeutic target for intracranial 
aneurysms. Science Signaling. 
2017;10(465):eaah6037
[80] Borow KM, Nelson JR, Mason 
RP. Biologic plausibility, cellular 
effects, and molecular mechanisms 
of eicosapentaenoic acid (EPA) in 
atherosclerosis. Atherosclerosis. 
2015;242(1):357-366
[81] Fredman G, Spite M. Specialized 
pro-resolving mediators in 
cardiovascular diseases. Molecular 
Aspects of Medicine. 2017;58:65-71
[82] Merched AJ, Serhan CN, Chan L.  
Nutrigenetic disruption of 
inflammation-resolution homeostasis 
and atherogenesis. Journal of 
Nutrigenetics and Nutrigenomics. 
2011;4(1):12-24
[83] Simopoulos AP. The importance of 
the omega-6/omega-3 fatty acid ratio in 
cardiovascular disease and other chronic 
diseases. Experimental Biology and 
Medicine. 2008;233(6):674-688
[84] Investigators UJ, Morita A, Kirino T, 
Hashi K, Aoki N, Fukuhara S, et al. The 
natural course of unruptured cerebral 
aneurysms in a Japanese cohort. The 
New England Journal of Medicine. 
2012;366(26):2474-2482
[85] Tabas I. Macrophage death and 
defective inflammation resolution 
in atherosclerosis. Nature Reviews 
Immunology. 2010;10(1):36-46
[86] de Gaetano M, McEvoy C, Andrews 
D, Cacace A, Hunter J, Brennan E, 
et al. Specialized pro-resolving lipid 
mediators: Modulation of diabetes-
associated cardio-, reno-, and retino-
vascular complications. Frontiers in 
Pharmacology. 2018;9:1488
[87] Ruiz-Mirazo K, Briones C, de la 
Escosura A. Chemical roots of biological 
evolution: The origins of life as a 
process of development of autonomous 
functional systems. Open Biology. 
2017;7(4):170050
[88] Hollingworth M, Jamjoom AAB, 
Bulters D, Patel HC. How is vasospasm 
screening using transcranial Doppler 
associated with delayed cerebral 
ischemia and outcomes in aneurysmal 
subarachnoid hemorrhage? Acta 
Neurochirurgica. 2019;161(2):385-392
New Insight into Cerebrovascular Diseases - An Updated Comprehensive Review
256
[89] Temple R. Are surrogate markers 
adequate to assess cardiovascular disease 
drugs? Journal of the American Medical 
Association. 1999;282(8):790-795
[90] Adami D, Berkefeld J, Platz J, 
Konczalla J, Pfeilschifter W, Weidauer S, 
et al. Complication rate of intraarterial 
treatment of severe cerebral vasospasm 
after subarachnoid hemorrhage 
with nimodipine and percutaneous 
transluminal balloon angioplasty: Worth 
the risk? Journal of Neuroradiology. 
2019;46(1):15-24
[91] Yao Z, Hu X, You C. Endovascular 
therapy for vasospasm secondary 
to subarachnoid hemorrhage: A 
meta-analysis and systematic review. 
Clinical Neurology and Neurosurgery. 
2017;163:9-14
[92] Cremers CH, Vos PC, van der 
Schaaf IC, Velthuis BK, Vergouwen 
MD, Rinkel GJ, et al. CT perfusion 
during delayed cerebral ischemia after 
subarachnoid hemorrhage: Distinction 
between reversible ischemia and 
ischemia progressing to infarction. 
Neuroradiology. 2015;57(9):897-902
[93] Dasa SSK, Suzuki R, Mugler E, Chen 
L, Jansson-Lofmark R, Michaelsson E, 
et al. Evaluation of pharmacokinetic and 
pharmacodynamic profiles of liposomes 
for the cell type-specific delivery of 





Rena D. Sukhdeo Singh, Abhi Pandhi 
and Andrei V. Alexandrov
Abstract
Depression is the most common neuropsychiatric disorder affecting over one 
third of all stroke patients. The presence of depression after a stroke greatly affects 
the ability of patients to participate in rehabilitation and can even affect their 
long-term mortality. Poststroke depression is a well-documented and studied aspect 
of stroke management because of the implications it has on morbidity, mortality 
and recovery. Despite post stroke depression being a well-studied phenomenon, 
it remains underdiagnosed. The development of poststroke depression is 
multifactorial and has been evaluated from the cellular, genetic, and environmental 
perspective. Using numerous studies this chapter will review facets of post stroke 
depression such as epidemiology, etiology and treatment, while evaluating how this 
phenomena effects patient recovery and rehabilitation.
Keywords: stroke, depression, post stroke depression, elderly, serotonin, anxiety, 
recovery, rehabilitation, function, rehab, acute stroke, ischemic, hemorrhagic, mood
1. Introduction
Stroke is one of the leading causes of long-term disability in the United States 
and is the third leading cause of mortality [1]. Brain parenchyma is densely packed 
with millions of neurons, where any assault such as an ischemic or hemorrhagic 
stroke can leave a patient with debilitating deficits [2]. A few of these deficits 
include the inability to speak or understand language; loss of vision, complete 
paralysis of one side of the body, quadriplegia, persistent balance issues, and loss of 
the ability swallow independently. Neuropsychological changes are also very com-
mon and well documented in poststroke patients; however, the number of patients 
that suffer from these changes are grossly underestimated [3].
More than one-third of all stroke survivors experience some form of depression 
[4]. Depression after a stroke can manifest in many different ways including feel-
ings of anger, frustration, hopelessness, guilt, mental slowing, fatigue, irritability, 
changes in appetite, social withdrawal, loss of interest in activities they once found 
enjoyable (also known as anhedonia), or even suicidal thoughts [2]. Patients that 
suffer from poststroke depression, often have these symptoms missed or under-
treated. Recovery and rehabilitation can be adversely affected if post stroke depres-
sion is not adequately treated. This can result in increased length of stay at postacute 
care facilities, increased morbidity, decreased quality of life and even increased 
mortality [5]. Numerous depression scales have been used to define poststroke 
depression including the Beck Depression Inventory (BDI), Montgomery-Åsberg 
Depression Rating Scale (MADRS), Centre for Epidemiologic Studies Depression 
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Abstract
Depression is the most common neuropsychiatric disorder affecting over one 
third of all stroke patients. The presence of depression after a stroke greatly affects 
the ability of patients to participate in rehabilitation and can even affect their 
long-term mortality. Poststroke depression is a well-documented and studied aspect 
of stroke management because of the implications it has on morbidity, mortality 
and recovery. Despite post stroke depression being a well-studied phenomenon, 
it remains underdiagnosed. The development of poststroke depression is 
multifactorial and has been evaluated from the cellular, genetic, and environmental 
perspective. Using numerous studies this chapter will review facets of post stroke 
depression such as epidemiology, etiology and treatment, while evaluating how this 
phenomena effects patient recovery and rehabilitation.
Keywords: stroke, depression, post stroke depression, elderly, serotonin, anxiety, 
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1. Introduction
Stroke is one of the leading causes of long-term disability in the United States 
and is the third leading cause of mortality [1]. Brain parenchyma is densely packed 
with millions of neurons, where any assault such as an ischemic or hemorrhagic 
stroke can leave a patient with debilitating deficits [2]. A few of these deficits 
include the inability to speak or understand language; loss of vision, complete 
paralysis of one side of the body, quadriplegia, persistent balance issues, and loss of 
the ability swallow independently. Neuropsychological changes are also very com-
mon and well documented in poststroke patients; however, the number of patients 
that suffer from these changes are grossly underestimated [3].
More than one-third of all stroke survivors experience some form of depression 
[4]. Depression after a stroke can manifest in many different ways including feel-
ings of anger, frustration, hopelessness, guilt, mental slowing, fatigue, irritability, 
changes in appetite, social withdrawal, loss of interest in activities they once found 
enjoyable (also known as anhedonia), or even suicidal thoughts [2]. Patients that 
suffer from poststroke depression, often have these symptoms missed or under-
treated. Recovery and rehabilitation can be adversely affected if post stroke depres-
sion is not adequately treated. This can result in increased length of stay at postacute 
care facilities, increased morbidity, decreased quality of life and even increased 
mortality [5]. Numerous depression scales have been used to define poststroke 
depression including the Beck Depression Inventory (BDI), Montgomery-Åsberg 
Depression Rating Scale (MADRS), Centre for Epidemiologic Studies Depression 
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scale (CES-D), Zung self-rating depression scale and the Hamilton Depression 
Rating Scale (HDRS) [5]. Post stroke depression has a great impact on the health-
care system as well as on the individual patient. In this chapter, we will examine 
all aspect of depression as it relates to stroke by using these scales and large meta-
analyses to define post-stroke depression, and assess how it relates to stroke and 
recovery.
2. Epidemiology
Advancements in acute medical therapies have led to the reduction of mortality 
due to acute ischemic or hemorrhagic stroke [5]. Studies have shown that 10% of 
patients recover without any residual deficits, a quarter have mild residual deficits, 
while 50% are severely disabled or require skilled nursing care within a medi-
cal facility able to manage their needs [6]. Along with severe physical disability, 
patients that suffer from a stroke also experience neuropsychiatric changes. The 
most common neuropsychiatric sequelae, post-stroke, are depression and anxiety 
[7]. Patients that survive stroke often experience anxiety and depression related to 
making adjustments to their new reality [7]. With more patients surviving stroke, 
quality of life becomes an area of focus. Poststroke depression has been regarded 
as one of the most important measures for quality of life after an acute stroke. The 
presence of depression after stroke results in impaired recovery, decreased par-
ticipation in rehab efforts, impaired cognition, and even increased mortality. The 
majority of the expressed concern from patients is related to their ability to work 
and provide financial stability for themselves/their families, the ability to manage 
their activities of daily living, and the loss of their functional independence [7].
The term poststroke depression puts a focus on ischemic rather than hemor-
rhagic strokes, which is mostly due to the fact that ischemic strokes have been stud-
ied more in the literature, and thus will be the focus of this chapter [8]. Poststroke 
depression can occur anywhere from days to years after an acute ischemic event 
with the peak incidence of poststroke depression occurring between 3 months and 
2 years, even if the patient’s symptoms are improving [9]. Patients that experi-
ence the onset of poststroke depression at or after 7 weeks from the acute event 
are less likely to have a spontaneous remission of this depression [9]. In the acute 
phase, patients that had a longer inpatient hospital stay were seen to score higher 
on the Beck Depression Inventory than those that were in the community or in a 
rehabilitation facility. However, many of these studies have excluded patients that 
are aphasic, have cognitive impairment, or experienced pre-stroke depression. This 
may be one of the main reasons that poststroke depression may be underdiagnosed 
and undertreated [10].
2.1 Demographics associated with poststroke depression
Patients younger than 60 are seen to have higher depression scores poststroke. 
In the general population, major depression is more prevalent in patients younger 
than 65 years old [11]. In multiple studies that adjusted for pre-stroke depression it 
was found that more than 30% of the patients younger than 65 could be diagnosed 
as having clinical depression using the Center for Epidemiologic Studies Depression 
Scale (CES-D). It was found that within this younger age group there was a higher 
rate of depression associated with lower socioeconomic status, familial stress, and 
the ability to provide financial stability [7, 11]. However, having good social support 
has been found to be protective against poststroke depression [7, 11]. Adults over 




However, multiple meta-analyses have shown that when controlling for other vari-
ables such as sex, patients younger than 65 experienced more poststroke depression, 
and more obvious depressive phenotype [6, 11].
Biologic sex and poststroke depression is a controversial issue. Numerous 
meta-analyses have looked at the relationship between ‘gender’ and how it affects or 
predicts poststroke depression. The results were mixed when looking at data from 
across the globe. In some studies, women have been found to experience double 
the risk of poststroke depression compared to men [12, 38]. The gender disparity 
may be related to how each sex reacts to stressful life events. Women have been 
demonstrated to have more stress in reaction to negative life events, such as a stroke, 
which results in feelings of depression [12]. On self-reported survey, women were 
seen to indicate they have more depressive symptoms, compared to men, when age 
was controlled for [12]. The risk factors for women developing depression after an 
acute stroke were: pre-stroke psychiatric comorbidity, age younger than 65, and 
impairment in cognition [13]. Similarly, men with higher level of physical disability 
after a stroke had more depressive symptoms than women, or men with less physi-
cal disability. In multicenter analysis from China, and India, these studies found 
that male sex had a higher correlation with poststroke depression [10, 15]. However, 
there may be confounding factors when evaluating sex differences and poststroke 
depression. For example, in China there may be a higher number of men in the gen-
eral population [14]. In the Indian study there were more men in the study [10]. In 
the USA, it is possible that there is a higher rate of self-reporting by women, as well 
as under reporting of depressive symptoms in men, based on their level of physical 
disability [14]. Therefore, more studies need to be done in this area to determine if 
gender is a definitive predictor of poststroke depression.
Socioeconomic status and education related to poststroke depression is also 
difficult to measure, due to multiple confounders and conflicting data. However, 
reviewing the meta-analysis of patient demographics and poststroke depression has 
shown that patients with lower overall education levels have an increased risk for 
poststroke depression with mild depressive symptoms [13]. A large meta-analysis 
of the literature found that there is an association between more years of educa-
tion and lower risk for depression after a stroke. This study demonstrated that on 
average the participants in the study without poststroke depression had 0.32 years 
of education more than those that did have depressive symptoms after their stroke 
[16]. The symptoms that were seen in this data set were defined as mild depressive 
symptoms, but could not be classified as clinically depressed. However, this may 
also have confounding factors in this category. Patients that have lower socioeco-
nomic status have been shown to have lower levels of education [16]. They may also 
be exposed to environmental factors that put them at increased risk for stroke, such 
as unhealthy diet, unhealthy lifestyle, more perceived stress, exposure to second 
hand smoke, and pollution in urban areas [10, 13, 16]. These factors may increase 
their risk of stroke, and thus their risk for poststroke depression.
3. Comorbidities associated with poststroke depression
Comorbid conditions prior to a stroke can affect the development of depression 
after an acute ischemic event. Conditions such as diabetes, and preexisting psychi-
atric disorders like depression, anxiety, and bipolar disorder can all have an effect 
on poststroke depression [17, 18]. One meta-analysis has demonstrated that patients 
that have vascular risk factors such as diabetes are at a higher risk for developing 
poststroke depression [17]. This is not thought to be related to the vascular depres-
sion theory, which will be discussed later in this chapter. In a Chinese study, it was 
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[16]. The symptoms that were seen in this data set were defined as mild depressive 
symptoms, but could not be classified as clinically depressed. However, this may 
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be exposed to environmental factors that put them at increased risk for stroke, such 
as unhealthy diet, unhealthy lifestyle, more perceived stress, exposure to second 
hand smoke, and pollution in urban areas [10, 13, 16]. These factors may increase 
their risk of stroke, and thus their risk for poststroke depression.
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Comorbid conditions prior to a stroke can affect the development of depression 
after an acute ischemic event. Conditions such as diabetes, and preexisting psychi-
atric disorders like depression, anxiety, and bipolar disorder can all have an effect 
on poststroke depression [17, 18]. One meta-analysis has demonstrated that patients 
that have vascular risk factors such as diabetes are at a higher risk for developing 
poststroke depression [17]. This is not thought to be related to the vascular depres-
sion theory, which will be discussed later in this chapter. In a Chinese study, it was 
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shown that at 3 months after an acute stroke, patients with diabetes were more 
likely to develop poststroke depression. This was an independent risk factor for the 
development of poststroke depression at or after 3 months [17]. The hypothesis 
behind this is based on the pathophysiology behind both diabetes and poststroke 
depression, which involves the inflammatory pathway, and the hypothalamic 
pituitary access. This will be discussed later in the chapter.
Preexisting psychiatric disorders such as depression, anxiety, and bipolar 
disorder can also predispose patients to worse poststroke depression in the subacute 
phase, which is within 3 months [17]. One meta-analysis that looked at predic-
tors of poststroke depression found that of the patients that had a preexisting 
mood disorders such as dysthymia, major depression, minor depression, anxiety, 
agoraphobia and adjustment disorder were all associated with increased risk of 
worsening depression after a stroke. Of 1058 patients with reported depression 
prior to their stroke, 27% had worse depressive symptoms after the acute ischemic 
event [18]. Premorbid anxiety was also predictive of worsening anxiety after the 
stroke. Anxiety poststroke results in impaired response to adverse events increased 
perceived stress and more depressive symptoms [18].
4. Poststroke depression etiology
Poststroke depression has been defined as a mood disorder resulting from a 
general medical condition, by the Diagnostic and Statistical Manual of Mental 
Disorders (DSM) IV, meaning it does not carry with it the same definition of major 
depression [16]. There has been some debate about the etiology of poststroke 
depression, where multiple hypotheses exist, including but not limited to disrup-
tion to monoamine pathways, inflammatory cytokines, and hypothalamic–pituitary 
axis within the brain that modulates mood. The other belief is based on a psycho-
social model, where depression develops after a stroke due to inability to adjust to 
new life circumstances, inability to care for oneself, fear of recurrence, financial 
insecurity and carrying a new diagnosis [7].
4.1 Localization of poststroke depression
One question that has been analyzed extensively with no definite answers 
is the location of a stroke as a predictor of poststroke depression. These studies 
used techniques such as voxel-based symptom lesion mapping, diffusion tensor 
imaging (DTI), functional magnetic resonance imaging (MRI), and positron 
emission tomography (PET) scans [19]. Functional neuroimaging has sought to 
determine neuronal circuitry to discover how damage to these circuits results in 
mood or personality changes. These imaging modalities demonstrate that there 
is less activity in the frontal cortex, anterior cingulate, dorsolateral and caudate 
nucleus, in patients that are experiencing depression. In pilot studies using DTI, 
there has been some data demonstrating that damage to the fronto-striato thalamic 
pathway and pathways involving emotional control, reward systems and decision 
making can lead to increased risk of poststroke depression [19]. DTI changes were 
seen in stroke patients that had damage to the genu and splenium of the corpus 
callosum, frontal lobe white matter and anterior left corona radiata, resulting in 
increased levels of apathy [20]. A few theories about lesion location and depressive 
symptoms include-anhedonia as associated with the stroke volume affecting the 
hypothalamic-pituitary-adrenal axis, and increased risk for depression in patients 
with basal ganglia, and frontal lobe strokes [20]. A study by Paradiso and colleagues 




more depressive symptoms [19]. They proposed that right hemispheric strokes 
experience fewer depressive symptoms due to anosognosia. If the patient is unaware 
of his or her deficits, they will less likely feel depression related to their loss of 
function. Left hemispheric strokes have also been seen to have an earlier onset of 
poststroke depression, usually in the first 6 months poststroke [13].
One of the models that have been proposed is that subcortical strokes like those 
in the basal ganglia, and strokes in the frontal lobes can result in disrupted sero-
toninergic and norepinephrinergic pathways that can be associated with poststroke 
depression [21]. The belief is that strokes that affected the amine-containing axons 
between the brainstem and specifically the left cerebral cortex would result in 
decreased production of serotonin (5-HT) and norepinephrine [22]. A reduction of 
these neurotransmitters in the frontal and temporal lobe limbic structures, and in 
the basal ganglia could result in difficulty with mood regulation [19]. This theory 
was supported by the finding that there were low levels of the 5-HT metabolite, 
5-hydroxyindoleacetic acid in the cerebrospinal fluid (CSF).
4.2 Biomarkers associated with poststroke depression
Inflammatory cytokines were also thought to be related to the development of 
poststroke depression [23, 24]. Jioa and colleagues found that interleukin (IL)-6 
was elevated in patients with post-stroke depression, even after controlling for 
confounders, with a confidence interval of 95% [23]. The elevation of IL-6 in 
patients that have strokes could possibly predict the development of poststroke 
depression [23, 24]. In another meta-analysis, brain-derived neurotrophic factor 
(BDNF) was found to be involved in the development of depression and poststroke 
depression [25, 26]. In these studies, a low serum level of BDNF in the acute phase 
after a stroke was associated with the development of poststroke depression. BDNF 
is inherently involved in hippocampal plasticity and memory [27]. One study found 
a significant negative relationship between BDNF and NIHSS [25–27]. In rodent 
models, low levels of BDNF in the hippocampus that had an acute stroke exhibited 
depressed behavior, however if BDNF was overexpressed there was a marked 
decrease in depressed behavior [21]. Increased BDNF in the rodent model also 
resulted in reduced infarct size and improved functionality of the rodent [25].
Increased serum level of C-reactive protein (CRP), neopterin, ferritin, and glu-
tamate could also be related to poststroke depression [24]. Proinflammatory markers 
such as tumor necrosis factor (TNF)-α, interleukins (IL)-1β, IL-6, IL-1, and interferon 
gamma (IFN-γ) were associated with the development of poststroke depression [23, 
24]. Additionally, inflammatory cytokines can activate the hypothalamic pituitary 
adrenal axis [24]. Activation of the HPA access can also lead to the downstream release 
of glucocorticoids, which can also result in increased blood glucose levels, and poten-
tially diabetes if this is a chronic process. After an acute stroke, patients often exhibit 
increased levels of serum adrenocorticotropic hormone, and cortisol. These hormones 
result in higher mortality and worse neurologic outcome [23]. Increased cytokine 
activity could also result in greater expression of genes involved in the metabolism 
of tryptophan such as indoleamine 2,3 dioxygenase (IDO) [27]. If IDO expression 
increases, tryptophan will be converted to kynurenine and not 5-HT. The downstream 
effect could result in decreased levels of 5-HT in the limbic system, temporal lobes, 
frontal lobes, and basal ganglia, which could potentially result in depression [27].
4.3 Genetic association with poststroke depression
There have also been studies that have shown a genetic contribution to post-
stroke depression. Multiple studies have evaluated the 5-HT gene located on 
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chromosome 17q11.1-17q12, which encodes the serotonin transporter [25–27]. In a 
meta-analysis of 7 studies, there was a significant relationship between 5-HTTLPR 
polymorphism and the development of poststroke depression symptoms. 
5-HTTLPR is an exon of the 5-HT transporter gene polymorphism [25, 26]. The 
hypothesis is that this gene polymorphism responds to the increased activity of the 
amygdala when responding to negative stimuli. An increase in 5-HTTLPR serum 
level has been positively associated with threefold increased risk of developing 
poststroke depression [25–28]. Another 5-HT polymorphism that has been analyzed 
is the STin2 VNTR, which is located within intron 2. It has variable number tandem 
repeats 9, 10, or 12. Repeats of the 9-allele have been well documented to be associ-
ated with multiple psychiatric disorders such as bipolar disorder, and major depres-
sion [25–28]. Repeats of the twelfth allele have been linked to the development of 
schizophrenia and bipolar affective disorder. It has been demonstrated that patients 
with variable tandem repeats of 9/12 and 12/12 were likely to have more depression 
after a stroke [25–28].
4.4 Psychosocial association with poststroke depression
Lastly, psychosocial factors must be considered when assessing who is at risk for 
poststroke depression. After suffering a life-altering event such as a stroke, even 
if there are no severe deficits, patients can undergo an adjustment period. They 
may feel depressed about the new diagnosis of a stroke. There is also the concern 
of getting back to their normal life routine such as working, caring for dependents, 
and caring for their own activities of daily living (ADLS) [11, 12]. Patients that do 
not have good social support tend to experience more depression after a stroke due 
to feeling helpless, and alone. Patients may also experience anxiety, related to the 
fear that another stroke may occur. Financial costs of health care also play a role in 
postacute stroke depression. If a patient is unable to work there may be a concern 
about medication compliance, affording medication, affording postacute special 
services like physical therapy or occupational therapy [11, 12].
5. Poststroke depression in elderly
Although there is a growing prevalence of stroke in patients aged 65 and 
younger, the majority of strokes affect patients that are elderly. With the prolonged 
life expectancy, there is an increased risk for stroke in the aging population, with 
70% risk being after the age of 65 [29]. In patients older than 80 years old that 
suffer from strokes, there is a greater risk of fatality, prolonged hospitalization, 
complications, and increased postacute care needs [30]. In elderly patients that 
suffer from stroke, depression may be difficult to diagnose. This is largely due to the 
symptoms being a vegetative phenotype. It is also confounded because depression 
is the most common psychiatric disorder among the elderly—with 1% of the elderly 
population having a formal diagnosis of major depression, and 15% with depressive 
symptoms according to the National Institutes of Health Consensus development 
conference [31]. This poses a challenge that practitioners face in distinguishing 
between premorbid depression, inherent stroke symptoms and poststroke depres-
sion, given that many of the features overlap. Some such features include cognitive 
impairment, psychomotor retardation, and social withdrawal [29]. One measure 
used to assess poststroke depression in the elderly is the geriatric depression scale 
(GDS) [32]. This is a self-reported scale where patients answer yes and no questions 
to determine if a patient is experiencing some form of depression. A score greater 




This scale is highly sensitive and predictive of poststroke depression in the geriatric 
population [32]. However, the GDS cannot be used by aphasic stroke patients or 
those with cognitive impairments caused by a stroke.
5.1 Vascular dementia and poststroke depression
Alexopoulos and colleagues found that elderly stroke patients that suffered 
ischemic strokes demonstrated increased encephalomalacia and MRI hyperintensi-
ties that would predispose these patients to develop depression [33]. Their study 
suggested that these changes were not seen in elderly patients that had depression 
without vascular risk factors. Elderly patients that have been observed to have 
signs of depression, but do not have any vascular risk factors were found to have 
less white matter hyperintensities on MRI, which were similar to the nondepressed 
controls [31]. It has also been demonstrated that patients that suffered from depres-
sion without vascular insult had phenotypically different depression with features 
of more agitation, aggression, feelings of guilt and dysphoria. This is the theory of 
vascular depression in the elderly [33]. The hypothesis behind vascular depression 
states that chronic small vessel changes or non-symptomatic cerebrovascular events 
accumulate over time, resulting in the disruption of cortico-striato-pallido-thal-
amo-cortical (CSPTC) pathways [31]. Vascular dementia is described as a subcorti-
cal phenomenon. This type of depression differs from poststroke depression, in that 
they are silent, and the patient is not aware that they have suffered a stroke [31]. In 
a Japanese sample, greater than 80% of the patients that had major depression had 
MRI evidence of multiple silent infarcts [32]. Up to 75% of these depressed patients 
had lesions in the basal ganglia and thalamus [31, 33].
Three pathways associated with CSPTC were proposed in the way that vascular 
depression can present phenotypically. Within the CSPTC are the orbitofrontal 
pathway, the cingulate pathway, and the dorsolateral pathway. Injury over time to 
the orbitofrontal pathway can result in irritability and disinhibition [31]. The cin-
gulate pathway can cause apathy, and lack of initiative if injured, and lastly, injury 
to the dorsolateral pathway can result in poor speech productions, and inability to 
learn. These symptoms can all be seen in elderly depression. Prefrontal dysfunction 
has shown to have a poor or delayed response to antidepressants in elderly patients 
[31, 33]. However, early administration of antidepressants, particularly selective 
serotonin reuptake inhibitors have been shown to improve neuropsychological 
rehabilitation in elderly stroke patients.
Lacunar infarcts have been seen to result in more depression among Alzheimer 
patients especially basal ganglia strokes and cortical strokes were found to have 
more cognitive impairment [31]. Severe cognitive impairment was also seen to be 
one of the leading causes of depression in the elderly. There are some questions of 
whether cognitive impairment or dementia can increase the risk of stroke, and thus 
poststroke depression among the elderly, or do strokes result in cognitive decline 
and vascular depression [31]. Dementia and depression can be difficult to dif-
ferentiate. In the elderly, pseudodementia can be secondary to depression however, 
the opposite is also true. This is a “what came first” type of scenario with dementia, 
stroke and vascular depression [31].
Although vascular depression and poststroke depression are different in the way 
they affect a patient, they likely lay on a continuum. Both are secondary to a vascu-
lar event, and both result in depression. Vascular depression has a higher incidence 
in elderly patients as they have an accumulation of more subcortical white matter 
changes that are seen as hyperintensities on MRI FLAIR. Poststroke depression is 
less subtle since the patient is usually aware that they have had a stroke [31, 33]. 
There may be a growing incidence of vascular depression among young patients, 
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due to poorly controlled hypertension, tobacco, diabetes, drug use, and poor diet 
and lifestyle choices causing small vessel disease. These risk factors put all patients 
at risk for an acute stroke, and chronic small vessel disease.
6. Large strokes and the effect on poststroke depression
In patients that suffer from large ischemic or hemorrhagic strokes, they are 
often left with a serious physical disability [2]. A proximal middle cerebral artery 
occlusion can result in severe expressive, or receptive aphasias, hemiparesis, facial 
weakness, sensory loss inability to swallow, neglect, apraxia, and a propensity 
toward developing seizures [34]. If the patient is relatively young, the probability of 
cerebral edema is high, which could result in complications such as brain herniation 
if a hemicraniectomy is not performed. Intracerebral hemorrhage in these vascular 
territories can result in similar findings that may necessitate an extra ventricular 
drain to remove blood from the ventricles, or a decompressive hemicraniectomy 
to evacuate the hemorrhage [34]. A patient with a large stroke in the posterior 
circulation can result in the patient being obtunded, having chronic balance issues, 
hemiparesis, vision loss, and ataxia [3].
Patients that survive these large strokes often experience the most debility, 
with the majority becoming bedbound, requiring a percutaneous endoscopic 
gastrostomy tube for nutrition and tracheostomy tube for assistance with breathing. 
Due to the severity of their disability, these patients require 24-hour care, by their 
families or nursing professionals. The majority of these patients experience severe 
depression and guilt, due to feeling like a financial or physical burden on their loved 
ones [35]. They also experience loss of autonomy due to their deficits. They are no 
longer able to manage their own activities of daily living, which results in feelings of 
inadequacy, and resentment for those that are doing the caregiving. Depression has 
also seen to be positively correlated with the national institute of health stroke scale 
(NIHSS) which measures stroke severity, wherein the higher the stroke scale, the 
more severe the depressive symptoms [36].
Patients with large strokes and increased debility often require management in 
a skilled nursing facility (SNF). At SNF, the patients do not participate in as much 
rehabilitation activities, as compared to other stroke patients in an inpatient reha-
bilitation setting [32]. These patients are therefore at disadvantage because their 
exposure to rehabilitation is limited. The combination of decreased functionality, less 
access to rehabilitation, and depression impairs the recovery for these patients. They 
too lose the desire to participate in meaningful interaction due to their disability [32].
7. Challenges in diagnosing depression after stroke
Diagnosing depression after a stroke may be difficult for practitioners given 
that stroke patients can have complex symptoms. The physicians that treat stroke 
patients should be aware that over a third of patients experience depression after a 
stroke, and to note that even subtle changes in behavior could represent an aspect 
of poststroke depression [17]. Small changes like irritability, frustration, extreme 
fatiguability, and refusing to partake in physical therapy and occupational therapy. 
Another challenge is that many symptoms of stroke and depression overlap, such 
as fatigue, pain, decreased motor activity, and decreased verbal output [7]. Only 
a few of the depression scales used to assess poststroke depression include somatic 
symptoms in their evaluation. The Beck Depression Inventory is one such scale. 




positive finding on a depression scale. It is important to be able to tease apart what 
symptoms are due to a stroke and what symptoms are related to depression. If a 
diagnosis of poststroke depression is missed, it can negatively affect how the patient 
recovers, and even affect their mortality.
The symptoms that make the diagnosis of poststroke depression the most dif-
ficult are aphasia, anosognosia, neglect, abulia and cognitive disabilities that result 
from their stroke [37]. Unfortunately, the majority of studies that evaluate poststroke 
depression exclude patients with these symptoms. This is largely due to their inability 
to answer questions, fill out questionnaires, or because it is difficult for medical staff 
to assign a score to the patient based on their daily interactions. Aphasia is indepen-
dently associated with an increased risk of developing poststroke depression [37]. 
However, three scales have been developed to assess depression in aphasic patients. 
These scales include the Stroke Aphasic Depression Questionnaire-10 (SADQ-10), 
the Aphasia Depression Rating Scale (ADRS), and the Perceived Stress Scale (PSS). 
The (SADQ/SADQ-10/SADQH-10) and the Aphasia Depression Rating Scale are 
based on the observation of other people to determine if the patient being assessed 
is in fact depressed or not. The SADQ-10 used caregivers as the observers, with 
non-aphasic patients as the controls [37]. A value of 14/30 or higher was correlated 
with the development of depression and depressive symptoms with a sensitivity of 
70% and specificity of 77%. The ADRS scoring system used external signs that could 
be observed such as fatigue, insomnia, changes in weight, and signs of anxiety. A 
score of 9/30 or higher was associated with the development of depression with a 
sensitivity of 83% and specificity of 71% [37]. After a comparative analysis, it was 
determined that either one of these tools could be used for assessing depression 
in aphasic patients. A review of the current studies could be more generalizable if 
aphasic patients were included and analyzed with these scales.
8. Poststroke depression effect on morbidity and mortality
Poststroke depression was found to be an independent predictor of symptom 
severity after a stroke, and difficulty with managing activities of daily living [35]. In 
a meta-analysis of seven studies, poststroke depression was found to have an asso-
ciation with increased mortality [39]. Specifically, patients that experienced early 
poststroke depression as defined to be within 3 months of stroke onset, were found 
to have 1.5 increased risk of death. A literature review by Robinson and colleagues, 
found that using the Hospital Anxiety and Depression scale (HADS), patients that 
had a score greater than 7 at 3 months had increased mortality than those with a 
score less than 7 [38]. These scores were evaluated up to 5 years poststroke, and the 
hazard ratio was found to be 1.41. It was seen that mortality was increased in patients 
with poststroke depression that were younger than 65 years old [38]. Their study also 
demonstrated that in greater than 50,000 veterans that suffered an ischemic stroke, 
those that developed poststroke depression had higher rates of mortality within 
3 years of that acute event. The hypothesis behind this being that early poststroke 
depression can occur in a patient with a severe disability such as neurocognitive 
decline, paralysis, aphasia, or dysphagia [38]. Due to the severity of their post-stroke 
symptoms these patients may be at increased risk of death due to complications like 
pneumonia secondary to dysphasia or infection from decubitus ulcers. Another 
hypothesis is that patients that are suffering from poststroke depression may be 
less likely to be compliant with medical recommendations, such as healthy diet, 
avoiding tobacco, alcohol, drug use, scheduled follow up appointments and medica-
tion compliance [37, 38]. These factors can increase the risk of mortality. Another 
theory states that mortality associated with poststroke depression may be related to 
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cardiovascular mortality [38, 39]. There is an association between depression and 
myocardial infarction, where it was found that depressed patients had less heart rate 
variability. This finding was also seen in patients with poststroke depression. This 
could put these patients at risk for myocardial infarction and subsequently, death. 
This meta-analysis also highlighted the idea that pharmacologic antidepressants have 
a mixed response in poststroke depression [38].
9. Treatment of poststroke depression
In order to treat poststroke depression, it needs to be accurately diagnosed. 
Currently the DSM IV is used to diagnose this disorder, along with multiple depres-
sion rating scales such as the Hamilton Rating Scale for Depression, Beck Depression 
Inventory, Montgomery-Åsberg Depression Rating Scale, Center for Epidemiological 
Studies Depression Scale, Zung self-rating depression scale and the Post-Stroke 
Depression Rating Scale [5]. There are many challenges in diagnosing depression in a 
patient after an acute stroke. Many of these patients have a somatic component to their 
symptoms, like pain, fatigue, or limited speech after a cerebrovascular event. These 
symptoms can confound a depression scale that account for somatic symptoms—
like the Beck Depression Index [5]. Depending on which scale is used to measure 
depression in these patients, there may be an overestimation or underestimation of 
depression. Since the hypothesis that stroke results in disruption of the monoamine 
pathways, there has been a focus on antidepressants like selective serotonin reuptake 
inhibitors, or tricyclic antidepressants to target poststroke depression. However, the 
role of antidepressants has been debated. There are some studies that show efficacy 
and reduction in mortality, and some that show a minimal effect or even adverse side 
effects [38–40]. Selective serotonin reuptake inhibitors (SSRIs) are well tolerated and 
can lead to fewer symptoms of depression at 3 weeks of use [40]. It is one therapy that 
is thought to work well in all age groups, regardless of comorbid conditions. SSRIs are 
better tolerated in all populations, compared to tricyclic antidepressants (TCA) [39, 40]. 
One endpoint found that patients that were started on SSRI early had decreased risk 
of myocardial infarction and recurrent stroke [40]. In a meta-analysis by Robinson 
and colleagues, the use of nortriptyline or fluoxetine demonstrated improvement in 
activities of daily living in poststroke depression compared to patients on placebo [38]. 
This study also demonstrated that the continued use over 12 weeks resulted in 
improved cognition in patients with poststroke depression, where the effect could last 
up to 2 years. Not only do SSRI inhibit reuptake of serotonin, but it was demonstrated 
in rodent models that SSRIs can decrease infarct volumes, reduced inflammation and 
increase neuroplasticity by modulating BDNF expression [38]. SSRI was also found to 
increase neurogenesis in the hippocampus, and improve cerebral blood flow autoregu-
lation which is thought to be related to the upregulation of BDNF [27, 38].
In the fluoxetine in motor recovery of patients with acute ischemic stroke 
(FLAME) trial, fluoxetine use for 3 months was tested to see if it would improve 
motor recovery in patients with hemiparesis [41]. This trial was used to assess if the 
use of fluoxetine would change the Fugl-Meyer motor scale (FMMS) score which 
is an index used to test motor recovery, with a score of 100 representing complete 
motor function without any deficit. Two groups were analyzed a fluoxetine dose of 
20 mg was the placebo and a 40 mg dose was used as the test treatment. At 3 months 
there was a significant improvement in motor function among the patients in the 
treatment arm [41]. At 90 days modified rankin scale (MRS) scores were better in 
the treatment arm as well. The frequency of depression was lower in the treatment 
arm when assessed with the MADRS score at 90 days. Even in patients that did not 




treatment arm. Patients that were assessed to be depressed at the onset of the trial, 
based on MADRS score, were excluded from this trial [41]. Pretreatment with SSRI 
prior to stroke was also an exclusion criterion. Although the FLAME trial seemed 
to be promising for improving motor function in poststroke patients and reducing 
depression within that 3-month period, newer studies have shown the use of SSRI 
prior to stroke, was negatively associated with ambulation poststroke [8].
In a study by Etherton et al., it was found that the use of SSRI prior to an acute 
stroke was associated with a decrease in discharges back to the patient’s home, and 
increasing need for ambulatory aids [8]. When examining the patients in the two 
groups: pre-SSRI/spread vs. non antidepressant, there were no significant differ-
ence in admission NIHSS or length of hospital stay. The authors thought this may 
be due to the possibility that patients that were on SSRI or antidepressants prior to 
admission for their stroke event may have suffered a stroke before or TIA, result-
ing in a larger stroke burden. Another ischemic event could cause recrudescence 
of old stroke symptoms due to an increased burden on that area that was receiving 
adequate blood flow, which could lead to the patient having more needs such as 
rehabilitation at discharge. Pre-SSRI use was also associated with increased mortal-
ity at 30 days, and worse stroke severity in patients with hemorrhagic stroke [8].
Another criticism for the use of SSRIs was due to the increase in the risk of major 
bleeding or death. In a meta-analysis of 31 case-controlled studies, it was found that 
SSRI use was associated with risk of major bleeding events, with the increased risk 
being 41% [40, 42]. This meta-analysis also examined cohort studies that evaluated the 
use of SSRI vs. non-SSRI in association with major bleeding risk of 36%. The pooled 
data from the meta-analysis found that SSRI was associated with major bleeding risk 
with an odds ratio of 1.41. Gastrointestinal bleeding accounted for the majority of these 
major bleeding events, with a few intracerebral hemorrhage cases [42]. The hypothesis 
behind the increased bleeding risk is that platelet activity is inhibited by serotonin. This 
hypothesis is strengthened by the idea that patients taking SSRI have less myocardial 
infarctions and fewer strokes. The major bleeding risk associated with SSRI are ampli-
fied with adjunct use of non-steroidal anti-inflammatory drugs (NSAIDS) [42].
Overall, antidepressants such as SSRI and TCA have been thought to be the best 
initial treatment for post-stroke depression. SSRI are overall better tolerated in all 
populations [40]. These antidepressants can help patients combat poststroke depres-
sion enough to allow them to participate in rehabilitation efforts. Psychotherapies 
such as cognitive behavioral therapy (CBT) have been studied to assess if it would be 
beneficial in the treatment of poststroke depression. Due to the small sample size of 
the studies, and other limitations there was no real effect seen with CBT [5]. It may 
be an area of adjunct therapy for patients with severe poststroke depression that need 
more than pharmaceutical treatment. However, the use of CBT should not delay the 
initiation of treatment with antidepressants.
10. Depression and stroke rehabilitation
Depression after stroke strongly affects the way patients participate in and respond 
to rehabilitation. Depression has been linked with decreased participation in reha-
bilitation efforts which in turn results in more increased morbidity and mortality and 
decreased quality of life. In a Japanese study that evaluated poststroke depression 
in patients admitted to a rehabilitation center, their results demonstrated that the 
patients that were identified as having poststroke depression had less response to rehab 
and minimal improvement in activities of daily living and functional independence 
measures [32]. This study found that the level of independence in the activities of daily 
living at the time of discharge from rehab was related to the severity of poststroke 
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cardiovascular mortality [38, 39]. There is an association between depression and 
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depression at the time of admission. Poststroke depression had a negative 5-year 
correlation with the ADL. Psychological factors accounted for a large part of how 
patients responded to rehabilitation [32]. This study found that patients with post-
stroke depression experience feelings of hopelessness and were thus not motivated to 
participate in rehabilitation. Depression in these patients also leads to listlessness and 
inattention, which predisposed the patients with poststroke depression to falls. Thus, 
another reason why mortality is higher in patients with poststroke depression. Falling 
was also correlated with a decreased ability to manage their ADL [32].
Another study on depression and rehabilitation found that patients with hemiparesis 
and poststroke depression had 51% less participation in rehabilitation activities [43]. This 
study showed that any amount of depression after a stroke can affect a patient’s quality of 
life despite the severity of the stroke. This is because each patient has a unique response 
to acute stress. The perceived stress score is valuable in rehabilitation because it helps 
practitioners identify which patients are more at risk of developing depression. If they are 
identified early, treatment of depression can be initiated, and rehabilitation does not need 
to be adversely affected. Some of the indexes used to measure the quality of life in patients 
with poststroke depression include the Stroke Specific Quality of Life Scale SS-QOL, 
stroke impact scale, Barthel index of ADL as well as the multiple depression rating scales 
[43]. The Scandinavian Stroke Scale (SSS) and Bergman Balance Scale (BBS) are mea-
sures used to assess the progress of rehabilitation, which is more encompassing than the 
Modified Rankin Score [10]. If patients are able to meaningfully participate in rehabilita-
tion, studies have proven that symptoms of depression can improve, and their quality 
of life scores increase as well [43]. This coupled with the use of antidepressants can help 
patients with depression poststroke manage their symptoms of depression and improve 
their functional outcome. It could also help prevent a subsequent ischemic event [43].
Depression has also been found to be a risk factor for stroke [44]. This has been 
demonstrated even when controlling for confounders like tobacco use or substance 
use. Patients with psychosocial stressors put patients at an increased risk of stroke [11, 
12, 44, 45]. Not only do these patients have an increased risk of hypertension, and 
diabetes, but also have an increased prevalence of tobacco use and substance use that 
also put them at greater risk for an ischemic stroke [44]. A meta-analysis by Dong and 
colleagues, looked at 17 prospective studies that included greater than 200,000 patients 
[45]. Of this subset of patients, greater than 6000 had a positive association between 
depression and a second stroke. A depressed patient had 34% higher risk of developing 
stroke, even when age and sex were controlled for [45]. Thus, stroke and depression 
may be a part of a vicious cycle where a stroke results in depression and then depres-
sion results in another stroke. This process repeats and, in turn, hinders recovery and 
rehabilitation. Thus, proving again why it is important to diagnose depression after a 
stroke, and treat it adequately.
11. Poststroke depression and effect on the health care system
Poststroke depression can increase the burden on the healthcare system. In two 
literature reviews the effect of depression after a stroke was assessed by looking at 
large veteran populations [46, 47]. These studies demonstrated that patients that 
suffered from poststroke depression had on average a longer hospital stay, as well 
as increased outpatient and inpatient physician visits over 1 year. These patients 
also had a higher likelihood of having significant deficits such as dysphagia after 
their stroke, and complex comorbidities that required frequent hospital visits, or 
prolonged stays in nursing facilities/rehabilitation centers [47]. They were also 
noted to have higher risk of a subsequent stroke within 1 year of their first stroke, 




pneumonia, or falls [47]. In Husaini and colleague’s analysis of 17,010 patients 
from Tennessee, their study demonstrated that patients with stroke and depression 
had higher average health care costs than patients with only stroke, or stroke with 
another comorbid psychiatric disorder, even while controlling for age, sex and race 
[48]. On average stroke patients with depression had a healthcare cost of $77,864, 
compared to $47,790 in patients with stroke only these costs are due to increase use 
of diagnostic tests, increased pharmacologic interventions, and addition therapist 
and physician consultations [47, 48]. If poststroke depression could be identified 
early, and treated it could reduce the total cost to the patient, and could decrease the 
overall healthcare burden (Figure 1).
Figure 1. 
The diagnostic and treatment procedures of PSD. MDD = major depressive disorder; PSD = poststroke 
depression [49].
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12. Conclusion
Depression and stroke have a bidirectional relationship where one acts as a risk 
for the other. Poststroke depression is an area of study that has evolved over the 
years. New studies on its etiology have been discovered, and continued research 
efforts are providing more insight on the questions we still have, such as the associa-
tions of lesion location, the role of inflammation, neuroplasticity, and even genet-
ics. Some patients are more at risk than others for developing poststroke depression, 
but the main goal is detection, management, and rehabilitation. Detecting post-
stroke depression is important, so treatment can be initiated as soon as possible, 
thus reducing morbidity, mortality, and assisting these patients with participating 
in rehabilitation efforts. Rehabilitation not only improves function in these patients, 
but also has beneficial effects on depression as well. If patients can effectively 
partake in rehabilitation efforts, their quality of life scores have been shown to 
improve (with quality of life being a measure for depression in these patients). 
Improvements in perceived quality of life can have downstream effects resulting in 
a reduction of readmissions to the hospital, and outpatient visits, and thus a reduc-
tion in the healthcare burden caused by this disease process. If depression can be 
effectively managed, patients will be more likely to have meaningful participation 
in poststroke rehabilitation, and reduce the risk of morbidity and mortality associ-
ated with their stroke.
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Abstract
Morbidity and mortality after a cerebrovascular event have increased during the
past few years, even after extensive efforts have been made concerning research in
prevention, acute treatment, pharmacotherapy, revascularization, and rehabilita-
tion. The functional deficits that arise from an ischemic event are related to the
increasing chronic disability that results from lower mortality rates. More people
are becoming chronically disabled; currently, as much as 90% of survivors are
affected and face difficulties to continue with daily life activities. In this chapter, we
briefly review the pathophysiology of ischemia and immediate clinical attention to
the event. We argue about the need to seek new pharmacological and non-
pharmacological alternatives and discuss the most representative in the field of
neuroprotection and neurorestoration. In addition, we review the most relevant
dietetic strategies and physical rehabilitation therapies, all aimed at improving the
survivors’ quality of life.
Keywords: cerebral ischemia, neuroprotection, neuroregeneration, rehabilitation,
immunomodulation
1. Introduction
Acute ischemic stroke (AIS) remains the second cause of death worldwide [1],
despite showing a mortality rate reduction of 1.19% [2]; only in 2017, there were 6
million 167, 291 deaths; 1, 291,000 more with respect to 1997. During the same
period, the survival rate increased by 0.02%; this caused an increment in
the disability-adjusted life years percentage (DALYs), which went from
4.17 to 5.29% [2].
Data from the World Health Organization (WHO) indicate that stroke repre-
sents the third cause of permanent adult disability worldwide [3], and is present in
90% of survivors. Motor deficits after stroke account for the high rates of long-
lasting disability. The most common impairments are related to speech, or language
and communication disorders (aphasia and dysphasia), apraxia [4], swallowing,
depression, cognitive impairment, and hemiparesis of the contralateral limb [5]
characterized by muscle weakness or spasticity in distal rather than proximal mus-
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1. Introduction
Acute ischemic stroke (AIS) remains the second cause of death worldwide [1],
despite showing a mortality rate reduction of 1.19% [2]; only in 2017, there were 6
million 167, 291 deaths; 1, 291,000 more with respect to 1997. During the same
period, the survival rate increased by 0.02%; this caused an increment in
the disability-adjusted life years percentage (DALYs), which went from
4.17 to 5.29% [2].
Data from the World Health Organization (WHO) indicate that stroke repre-
sents the third cause of permanent adult disability worldwide [3], and is present in
90% of survivors. Motor deficits after stroke account for the high rates of long-
lasting disability. The most common impairments are related to speech, or language
and communication disorders (aphasia and dysphasia), apraxia [4], swallowing,
depression, cognitive impairment, and hemiparesis of the contralateral limb [5]
characterized by muscle weakness or spasticity in distal rather than proximal mus-
cles [6]. These deficits ultimately cause chronic disability, affecting the ability to
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work and the patient’s independence and autonomy for performing daily life
activities such as dressing or eating, ensuring they will require long-lasting care,
which also deteriorates their quality of life and that of the patients’ caregivers.
Stroke complications represent a considerable economic burden both individu-
ally and as a society; such complications are associated with a substantial increase in
household expenses related to a higher requirement of medical attention, medica-
tion, lost workdays, and payment to external or additional caregivers, and in several
cases, physical rehabilitation. It is estimated that the United States alone had an
annual expenditure of 45.5 billion dollars during the 2014–2015 period, which is
only expected to increase through 2035, according to estimations of RTI
international [7].
It is therefore fundamental to revisit the procedures regarding basic and clinical
research points of view, as well as the most recent recommendations issued by the
American Heart Association/American Stroke Association (AHA/ASA), which
endorse multiple-component quality improvement initiatives including emergency
department education and multidisciplinary teams with neurological management
experience, thus increasing the application of fibrinolytic treatment IV.
The strategies that are currently being studied in search of treatments for cere-
bral ischemia can be categorized into four areas: clinical care, neuroprotection,
neurorestoration strategies, and rehabilitation therapy.
The term neuroprotection is defined as the intentional intervention, either inhi-
bition or modulation, that takes place at a certain point during the ischemic cascade,
to intervene in a specific mechanism of damage to prevent tissue injury from
increasing during the acute phase of ischemia [8]. The neurorestoration is devel-
oped through the stimulation of neurogenesis and neuroplasticity to restore the
tissue and functional integrity of the neural tissue.
In the clinical setting, several recanalization strategies have been explored to
restore blood flow to the injured area of tissue as soon as possible, to assure the
lesser damage and decrease secondary sequelae to the original lesion. Finally, phys-
ical therapy has become a rehabilitation tactic that has positively impacted the
recovery of patients’ independence, autonomy, and quality of life, which is worth
reviewing.
2. Pathophysiology of stroke
Cerebral ischemia is caused by an abrupt and sustained occlusion of blood flow
to a large artery that unties a series of biochemical alterations that are known as the
ischemic cascade, Figure 1 [9]; during the development of such changes, a set of
mechanisms that lead to cell death occurs: ionic imbalance and excitotoxicity,
oxidative stress, and inflammation [10].
The reduction of blood flow leads to a depletion in levels of glucose and O2,
which alters aerobic metabolism, increasing lactic acid accumulation. Simulta-
neously, astrocytes use stored glycogen to provide energy to the neurons in the
form of lactate [11]; but, because aerobic metabolism is interrupted at this time,
lactic acid continues to accumulate, causing lactic acidosis, which causes ionic
dysfunction [12]. Ionic alterations, together with Na+/K+ pump inactivity, give rise
to neuronal depolarization, which leads to the opening of the Ca2+ channels and the
subsequent release of excitatory neurotransmitters such as glutamate, causing
increased activation of ionotropic receptors, especially NMDA, increasing the Ca2+
flux into the cell [13].
Ca2+ is an essential protagonist within the ischemic cascade since it is capable of
activating a significant amount of proteins that lead to cell death, and
280
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overproduction of free radicals; such proteins are calpains [14], endonucleases [15],
calmodulin [16], and A2 phospholipase (Figure 1) [17]. Activation of these proteins
leads to a further increase in free radical production and other oxidant species that
directly damage structural molecules and activate inflammatory processes [18].
The mitochondria are where the highest production of free radicals takes place;
under normal conditions, superoxide anion (O2
) and hydrogen peroxide (H2O2)
are produced continuously and eliminated by antioxidant enzymes such as super-
oxide dismutase (SOD), catalase, and glutathione peroxidase [19]. Alternatively,
under ischemic conditions, reperfusion provides sufficient substrate for different
enzymatic oxidation reactions to take place, causing an overproduction of free
oxygen radicals (ROS) and the inactivation of antioxidant enzymes [20]. Concur-
rently, nitric oxide (NO) increases due to the activation of endothelial and neuronal
nitric oxide synthases as a result of increased Ca2+ concentration, NO reacts with
ROS and forms a highly toxic peroxynitric acid (ONOOH) [21].
Free radicals promote mitochondrial membrane permeability and allow for
cytochrome c to be released into the cytosol, where the intrinsic pathway of apo-
ptosis becomes activated, the concentration of free radicals also increases lipid
peroxidation and protein denaturalization [22], DNA fragmentation, and activate
several signaling pathways that lead to neural death, such as PI3K/AKT [23], Bcl2,
p53 [24] and others. From the moment of the occlusion, endothelial cells express
damage-associated molecular patterns (DAMPs), produce ROS and adhesion mole-
cules that allow for their activation and that of surrounding mast cells and macro-
phages, which, as a consequence, release histamine, proteases, TNF-a, and
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work and the patient’s independence and autonomy for performing daily life
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annual expenditure of 45.5 billion dollars during the 2014–2015 period, which is
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In the clinical setting, several recanalization strategies have been explored to
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flux into the cell [13].
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activating a significant amount of proteins that lead to cell death, and
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overproduction of free radicals; such proteins are calpains [14], endonucleases [15],
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chemokines [25]. The production and release of these molecules promote the blood-
brain barrier (BBB) rupturing, thus causing peripheral leukocyte invasion into the
injured brain parenchyma [26].
Microglial cells are then activated in the non-perfused region of the brain
parenchyma [27], microglial cells acquire phagocytic characteristics and a predom-
inantly pro-inflammatory phenotype (M1), which in turn increases the release of
interleukin-6 (IL-6), interleukin 1β (IL-1β), tumor necrosis factor-alpha (TNF-α),
NO molecules, and prostanoids [28]. Peripheral immune cells such as neutrophils,
B lymphocytes, T lymphocytes, and NK are recruited into the injured tissue, this
event is thought to contribute both beneficially by inducing the release of anti-
inflammatory cytokines and growth factors, and negatively by increasing the lesion
through a sustained release of proinflammatory cytokines and free radicals [29].
Within the process of the ischemic cascade, three points are identified that could
classify as strategic to restore neuroprotection (ionic imbalance, excitotoxicity, and
inflammation); nonetheless, most neuroprotective drugs act in many of the phases
of the ischemic cascade, which is why they cannot be classified into a single step of
neuroprotection.
3. Current stroke management in the clinical setting: the first
step after the stroke
Early diagnosis of stroke is a predictor for better clinical outcomes [30]; there-
fore, its confirmation is a pressing matter for the treatment to begin as soon as
possible from the recognition of symptoms onset [31]. Currently, different strate-
gies for acute ischemic stroke are being used in the clinical setting and are part of
the AHA/ASA clinical practice guidelines [32].
The differential diagnosis for stroke includes transient ischemic attacks, seizure,
syncope, migraine, and brain tumors [33]. To establish a correct and timely diag-
nosis and to determine the best course of action, the clinician must rely on labora-
tory testing [34] (blood glucose is usually high, total cholesterol, LDL, HDL, AST,
CPK-MB), and although the gold standard for diagnosis is a cerebral angiography,
clinicians try to avoid it by choosing different methods such as imaging testing,
including the first-line non-contrast CT scans, CT angiography, MRI, and MRI
angiography [32, 35, 36]. In the earliest stages of acute stroke, CT scans are less
useful for ischemic stroke diagnosis but can rule out hemorrhagic stroke [36]. Other
clinical tests such as EKG, EEG, and the National Institutes of Health Stroke Scale
(NIHSS) help establish differential diagnosis and treatment plan [35].
Specific and timely reperfusion treatment is essential to determine the course of
the clinical outcome and to improve survival. Once the ischemic etiology has been
established, and the patient is stable, treatment should start promptly. Currently,
two major therapeutic strategies are being used to treat cerebral ischemia to allow
for recanalization and reperfusion. The treatment of choice will depend on time to
treatment and etiology of the injury; these therapies are thrombolysis using phar-
macological agents and mechanical thrombectomy [35, 37–39].
At present and still after decades, the FDA only approves the use of recombinant
tissue plasminogen activator (rTPA), also known as alteplase, as the sole pharma-
cological option for recanalization [35, 39]. Alteplase initiates local fibrinolysis
when administered intravenously by hydrolyzing the peptide bond in plasminogen
to form plasmin [40]. The standard IV dosage is 0.9 mg/kg for 60 min, with a 10%
bolus over 1 min within 4.5 h of AIS onset [31].
Although alteplase is the only drug available for thrombolysis, most stroke
sufferers do not receive this drug as treatment. There usually is a delay in
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recognition of the symptoms and the time window in which rTPA must be admin-
istered is from 3 to 4.5 h from onset of symptoms, and benefits diminish over time
[39, 41], which is why the new AHA/ASA guidelines recommend not waiting for
clinical improvement before administration [32]. Also, not all patients are eligible,
since candidates must be ≤80 years of age, without diabetes or stroke history, with
an NIHSS score ≤ 25, not currently taking oral anticoagulation, and without
radiologic evidence of ischemic injury involving more than one-third of the MCA
territory [42].
Complications that are associated with its use are limited: BBB integrity alter-
ations, and hemorrhagic transformation, granting that other studies have shown it
to be well tolerated by patients using warfarin or other anticoagulants [38], in
controversy with the new AHA/ASA guidelines that suggest it should not be
administered if the patient received heparin 24 h before [32, 35, 43]. Other drugs
are also available, such as aspirin, which must be delivered within 24–48 h after
stroke onset. Although the guidelines emphasize that it should not be used to
replace mechanical thrombectomy or IV alteplase, aspirin continues to be the choice
for secondary prophylaxis [32, 44], even when the 2018 guidelines find no benefit
from its use for the treatment of an ongoing AIS [32].
Furthermore, the FDA approves of endovascular treatments, which are reported
to have a time window of up to 8 hours from the onset of symptoms [38].
For patients with large vessel occlusion, less responsive to rTPA, intra-arterial
therapy is recommended, since it leads to higher recanalization rates by being able
to infuse the drug directly into the occluded area or the clot itself [35, 45]. About
10% of patients with AIS fall into this category, but only a few centers can perform
endovascular procedures in proper conditions [46].
Also, endovascular mechanical thrombectomy using contact aspiration (CA) [47],
which has been described before [48], and stent retrievers (SR), especially those of
new generations [49], for clot rupturing and aspiration has shown significant bene-
fits in large vessel occlusion [50] regarding clinical outcomes and lower complication
rates [49]. Notwithstanding, CA alone, without the use of a SR, is associated with a
greater need for rescue treatment, and thus, worse outcomes [51]; the SR might also
increase the risk for hemorrhagic transformation and neurological deficit [52].
Increased costs of endovascular treatments, as well as their complexity and need
for trained personnel, cause patients to have less access to them. Therefore,
exploring new pharmacological therapies should be continued.
4. First neuroprotective pharmacological and non-pharmacological
treatments
In the search to find new alternatives of neuroprotective agents, a great variety
of molecules have been explored that affect one or several strategic points of the
pathophysiology, and that promise good results; some are mentioned below.
During the onset of AIS, glucose and oxygen concentrations decrease, and this
promotes the activation of adenosine monophosphate-activated protein kinase
(AMPK). This process upregulates cellular pathways that control energy metabo-
lism through catabolic pathways such as glycolysis and lipid oxidation to increase
adenosine triphosphate (ATP) production and decrease its consumption through
the inhibition of gluconeogenesis. Observations have been made regarding the fact
that the activation of this enzyme for short periods increases neural survival, but its
activation for extended periods will lead to cell death through apoptosis, necrosis,
and autophagy [53], which is why several drugs that modulate AMPK activation
have been tested recently in search for beneficial effects.
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gies for acute ischemic stroke are being used in the clinical setting and are part of
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The differential diagnosis for stroke includes transient ischemic attacks, seizure,
syncope, migraine, and brain tumors [33]. To establish a correct and timely diag-
nosis and to determine the best course of action, the clinician must rely on labora-
tory testing [34] (blood glucose is usually high, total cholesterol, LDL, HDL, AST,
CPK-MB), and although the gold standard for diagnosis is a cerebral angiography,
clinicians try to avoid it by choosing different methods such as imaging testing,
including the first-line non-contrast CT scans, CT angiography, MRI, and MRI
angiography [32, 35, 36]. In the earliest stages of acute stroke, CT scans are less
useful for ischemic stroke diagnosis but can rule out hemorrhagic stroke [36]. Other
clinical tests such as EKG, EEG, and the National Institutes of Health Stroke Scale
(NIHSS) help establish differential diagnosis and treatment plan [35].
Specific and timely reperfusion treatment is essential to determine the course of
the clinical outcome and to improve survival. Once the ischemic etiology has been
established, and the patient is stable, treatment should start promptly. Currently,
two major therapeutic strategies are being used to treat cerebral ischemia to allow
for recanalization and reperfusion. The treatment of choice will depend on time to
treatment and etiology of the injury; these therapies are thrombolysis using phar-
macological agents and mechanical thrombectomy [35, 37–39].
At present and still after decades, the FDA only approves the use of recombinant
tissue plasminogen activator (rTPA), also known as alteplase, as the sole pharma-
cological option for recanalization [35, 39]. Alteplase initiates local fibrinolysis
when administered intravenously by hydrolyzing the peptide bond in plasminogen
to form plasmin [40]. The standard IV dosage is 0.9 mg/kg for 60 min, with a 10%
bolus over 1 min within 4.5 h of AIS onset [31].
Although alteplase is the only drug available for thrombolysis, most stroke
sufferers do not receive this drug as treatment. There usually is a delay in
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since candidates must be ≤80 years of age, without diabetes or stroke history, with
an NIHSS score ≤ 25, not currently taking oral anticoagulation, and without
radiologic evidence of ischemic injury involving more than one-third of the MCA
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Complications that are associated with its use are limited: BBB integrity alter-
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to be well tolerated by patients using warfarin or other anticoagulants [38], in
controversy with the new AHA/ASA guidelines that suggest it should not be
administered if the patient received heparin 24 h before [32, 35, 43]. Other drugs
are also available, such as aspirin, which must be delivered within 24–48 h after
stroke onset. Although the guidelines emphasize that it should not be used to
replace mechanical thrombectomy or IV alteplase, aspirin continues to be the choice
for secondary prophylaxis [32, 44], even when the 2018 guidelines find no benefit
from its use for the treatment of an ongoing AIS [32].
Furthermore, the FDA approves of endovascular treatments, which are reported
to have a time window of up to 8 hours from the onset of symptoms [38].
For patients with large vessel occlusion, less responsive to rTPA, intra-arterial
therapy is recommended, since it leads to higher recanalization rates by being able
to infuse the drug directly into the occluded area or the clot itself [35, 45]. About
10% of patients with AIS fall into this category, but only a few centers can perform
endovascular procedures in proper conditions [46].
Also, endovascular mechanical thrombectomy using contact aspiration (CA) [47],
which has been described before [48], and stent retrievers (SR), especially those of
new generations [49], for clot rupturing and aspiration has shown significant bene-
fits in large vessel occlusion [50] regarding clinical outcomes and lower complication
rates [49]. Notwithstanding, CA alone, without the use of a SR, is associated with a
greater need for rescue treatment, and thus, worse outcomes [51]; the SR might also
increase the risk for hemorrhagic transformation and neurological deficit [52].
Increased costs of endovascular treatments, as well as their complexity and need
for trained personnel, cause patients to have less access to them. Therefore,
exploring new pharmacological therapies should be continued.
4. First neuroprotective pharmacological and non-pharmacological
treatments
In the search to find new alternatives of neuroprotective agents, a great variety
of molecules have been explored that affect one or several strategic points of the
pathophysiology, and that promise good results; some are mentioned below.
During the onset of AIS, glucose and oxygen concentrations decrease, and this
promotes the activation of adenosine monophosphate-activated protein kinase
(AMPK). This process upregulates cellular pathways that control energy metabo-
lism through catabolic pathways such as glycolysis and lipid oxidation to increase
adenosine triphosphate (ATP) production and decrease its consumption through
the inhibition of gluconeogenesis. Observations have been made regarding the fact
that the activation of this enzyme for short periods increases neural survival, but its
activation for extended periods will lead to cell death through apoptosis, necrosis,
and autophagy [53], which is why several drugs that modulate AMPK activation
have been tested recently in search for beneficial effects.
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To mention some, metformin has been widely studied for cerebral ischemia
since it possesses pleiotropic activity and modulates AMPK activation [54]. In 2016,
Zhang et al. administered 7 mg/kg of metformin intraperitoneally to C57BL/6 mice
for 7 days, before middle cerebral artery occlusion (MCAO). After MCAO, the
authors observed that it induced neuroprotection by reducing infarct size, through
lower AMPK, results that were not observed if administered for short periods of
1–3 days before MCAO, or after the occlusion; also, these benefits were not found in
the case of reperfusion [55]. Also, the neuroprotective effect of metformin was
observed in a global ischemia model in rats; after administration, apoptosis
decreased, and mitochondrial biogenesis was induced [56]. Other experiments have
demonstrated that metformin has the potential to improve memory and learning
through the increase in brain-derived neurotrophic factor (BDNF) and p7056k
protein [57]. On the other hand, it has also been implicated in the reduction of IL-6,
IL-1β, TNF-α, and adhesion molecule levels, as well as a decrease in neutrophil
infiltration [58]. Considering these results, it is crucial to clarify how this modula-
tion is carried out since there is some controversy about the mechanism (Table 1).
Atorvastatin is a statin that has pleiotropic effects, since it allows angiogenesis
and synaptogenesis, increases blood flow, blunts atherosclerotic plaque formation,
and provides neuroprotection in cerebral ischemia model [59] by reducing
aquaporin 4 expression (AQP4) [60], thus, preventing cerebral edema and the
increase of infarct size. This statin has also been reported to attenuate cognitive
deficit [61] through caspase 3 inhibition and avoiding neural death in the CA1
region of the hippocampus.
There is also a great variety of neuroprotective drugs or molecules that act closer
by modulating inflammation, through the promotion of an anti-inflammatory
microglial phenotype activation; only the most representative will be mentioned
below.
DRα1 recombinant protein linked to the MOG peptide has demonstrated the
ability to decrease macrophage migration and monocyte activation through its
binding to CD74, which translates to a reduction in infarct size [62]. It has also been
shown that it reduces proinflammatory cytokine expression, such as IL-1β, I-17,
TNF-α, and INF-ϒ, as well as lowers T lymphocyte infiltration and promotes a
polarization toward an M2 phenotype macrophage activation [63].
Cop-1 or glatiramer acetate is a copolymer formed by four amino acids
(L-alanine, L-lysine, L-glutamic, and L-tyrosine) that has shown to exert
neuroprotective effects by being able to reduce infarct size and improve neurolog-
ical deficit [64]. Cop-1 increases the expression of IL-10, BDNF, Insulin-like growth
factor-1 (IGF-1), and neurotrophin (NT-3) in the choroid plexus [65], and the
cortex, which stimulates greater neurogenesis [66]. Mangin et al. and their study
group obtained similar results; they reported that Cop-1 is capable of reducing
COX-2, CD32, TNF-α, and IL-1β, as well as inducing greater neurogenesis and thus,
reducing memory loss in mice with cerebral ischemia [67].
On the other hand, food strategies have also been proposed; for example, diet-
induced ketosis has demonstrated its neuroprotective effects. Xu et al. observed, in
2017, that the ketogenic diet induced a reduction in infarct size through the
overexpression of transcription factors HIF-1α, pAKT, and AMPK [68]; in 2018
Stefanovic, beneficial effects of administering exogenous β-hydroxybutyrate intra-
peritoneally were also observed in a model of cerebral ischemia induced by
endothelin-1 in rats. He reported that the ischemic penumbra cells had a diminished
glucose uptake, which translated into less ROS production, astrogliosis, and neuro-
nal death [69]. Ketone bodies or ketosis is worth further exploration since clinical
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shown that it reduces proinflammatory cytokine expression, such as IL-1β, I-17,
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factor-1 (IGF-1), and neurotrophin (NT-3) in the choroid plexus [65], and the
cortex, which stimulates greater neurogenesis [66]. Mangin et al. and their study
group obtained similar results; they reported that Cop-1 is capable of reducing
COX-2, CD32, TNF-α, and IL-1β, as well as inducing greater neurogenesis and thus,
reducing memory loss in mice with cerebral ischemia [67].
On the other hand, food strategies have also been proposed; for example, diet-
induced ketosis has demonstrated its neuroprotective effects. Xu et al. observed, in
2017, that the ketogenic diet induced a reduction in infarct size through the
overexpression of transcription factors HIF-1α, pAKT, and AMPK [68]; in 2018
Stefanovic, beneficial effects of administering exogenous β-hydroxybutyrate intra-
peritoneally were also observed in a model of cerebral ischemia induced by
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trials in Alzheimer’s patients with mild cognitive decline have shown improvements
in verbal memory after being treated with a ketogenic diet [73].
Dietary administration with docosahexaenoic acid (DHA) has also proven to
have anti-inflammatory and neuroprotective effects in cerebral ischemia through
the reduction of proinflammatory cytokine expression, such as TNF-α, IL-1β and
IL-6; even, a decrease in macrophage and microglial activation and a decrease in
leukocyte infiltration to the lesion site [70]. Similar observations were made by Cai
et al. who noted that macrophage, neutrophil, and T and B lymphocyte infiltration
was significantly decreased, besides stimulating an anti-inflammatory macrophage
(M2) activation [71]; DHA is also capable of inducing neurogenesis and angiogene-
sis [72], which makes it a promising molecule for future experimental research.
5. Neurorestoration
Many of the cytokines and growth factors that result from immunomodulation
processes are directly involved in neurorestoration processes, the latter understood
as the set of strategies that seek to reconstruct the affected neural circuits through
neuroplasticity or neurogenesis [74].
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Neurotrophins are a group of proteins that are involved in the maintenance and
survival of the central nervous system [75]; this includes BDNF, NT-3, NT-4, NT-5,
nerve growth factor (NGF), and IGF-1. Neurotrophins interact with two types of
receptors, Trk (tyrosine kinase receptors) and the p75 receptor that belongs to the
TNFR receptor family, implicated in apoptosis processes.
Among the most studied neurotrophins are BDNF and NT-3; BDNF is produced
by almost all brain cells and is known to participate in processes of proliferation,
survival, and neuronal differentiation. Its receptors are widely distributed [76] and
activate critical signaling pathways such as PLCγ, PI3K, and ERK, which ultimately
lead to phosphorylation and activation of the transcription factor CREB that medi-
ates the expression of genes that are essential for the survival and differentiation of
neurons [77]. NT-3 has also been involved in the processes of cell proliferation and
differentiation through the notch pathway [78], as well as participating in processes
of memory and learning [76].
Experiments have shown that the increase of neurotrophic factors in the ische-
mia model is commonly related to a better functional or memory recovery and that
it is usually associated with neurogenesis or neuroplasticity—as in the case of
metformin, which showed an increase in BDNF expression and that induced a more
significant recovery of memory and learning [57]. Also, Cop-1 was able to induce
the increase of BDNF, IGF-1, and NT-3; which correlated with the increase in
neurogenesis [65]; and the experiments of Luan et al. showed that patients with
cerebral ischemia who presented higher levels of NGF obtained a better functional
recovery at 3 months after the ischemia [79].
Stem cell transplantation has also been linked to better neurological recovery;
although clinical trials have not reported the expected results [80], basic research
using stem cells has shown an increase in neurological rehabilitation and suggested
mechanisms include the overexpression of BDNF and IGF-1 [81, 82], as well as
immunomodulatory cytokines like IL-10, which together induce a polarization
toward an anti-inflammatory M2 microglial phenotype [83].
In recent years, there has been an increase in the interest of studying how the
external environment has a direct effect on the structure and neuronal function,
that is, on neuroplasticity [84], and that is why researchers keep studying what kind
of external characteristics (specifically physical and social activity) can increase
these factors and thereby obtain more significant benefits.
In 2017, Chen et al. explored whether a specific type of environment stimulated
the production of BDNF in rats with cerebral ischemia, and what they observed was
that physical stimulation increases the expression of neurotrophic factors more than
social stimulation and obtains a higher neurological recovery [85]. Mang, on the other
hand, observed that the increase in BDNF after an ischemic event is determined by
the type of aerobic exercise and the val66met variant of the BDNF gene [86].
The effects on NT-3 have also been evaluated, and the results have been very
similar; there is an increase in its levels with physical stimulation after the ischemic
event and a more significant functional recovery [87]. Other proteins have also been
associated with neuronal plasticity through axonal growth, such as the growth-
associated protein 43 (GAP-43), which has been observed to increase when rats
with cerebral ischemia undergo fastigial electrostimulation [88].
Electrical stimulation directly into the fastigial nucleus (FNS) has proven to be
beneficial in a model of MCAO [89]. The mechanism through which FNS has shown
to improve walking balance and neurological scores is due to the activation of the
PKA/cAMP pathway, suppressing the expression of Rho-Kinase, and through the
overexpression of GAP-43 protein [89].
In this sense, experiments continue to be designed to establish the efficacy of
training types and times to modulate inflammation, the production of
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trials in Alzheimer’s patients with mild cognitive decline have shown improvements
in verbal memory after being treated with a ketogenic diet [73].
Dietary administration with docosahexaenoic acid (DHA) has also proven to
have anti-inflammatory and neuroprotective effects in cerebral ischemia through
the reduction of proinflammatory cytokine expression, such as TNF-α, IL-1β and
IL-6; even, a decrease in macrophage and microglial activation and a decrease in
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Many of the cytokines and growth factors that result from immunomodulation
processes are directly involved in neurorestoration processes, the latter understood
as the set of strategies that seek to reconstruct the affected neural circuits through
neuroplasticity or neurogenesis [74].
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associated protein 43 (GAP-43), which has been observed to increase when rats
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beneficial in a model of MCAO [89]. The mechanism through which FNS has shown
to improve walking balance and neurological scores is due to the activation of the
PKA/cAMP pathway, suppressing the expression of Rho-Kinase, and through the
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In this sense, experiments continue to be designed to establish the efficacy of
training types and times to modulate inflammation, the production of
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neurotrophins, and the impact on patient mobility, as in the proposal developed by
Scalzo et al. [89] that gives rise to the continued development of a well-founded
physical therapy for patients with cerebral ischemia.
6. Physical therapy as a coadjuvant to neural restoration through
stimulation of neural plasticity
Post-stroke physical rehabilitation (PR) is of utmost importance as a non-
pharmacological strategy for neuroprotection and neurorestoration but, most sig-
nificantly, should be aimed at restoring and regaining motor impairment during the
chronic period [90], and to promote the functional autonomy of the patient [4].
Recovery of body function assessment depends on whether the patients can per-
form everyday activities on their own and is measurable by several different scales
such as UE-FM score for the upper extremity, and the Barthel Index for Activities
for Daily Living scale [4].
Functional and cognitive deficit severity is related to tissue integrity [91], and it
is not clear whether recovery results from biological processes or physical rehabili-
tation [91, 92]. Some clinical parameters that can be observed at the bedside, such as
early finger extension and shoulder abduction, can act as predictors of long-term
(over 6 months) recovery after stroke [93]. Spontaneous recovery of upper and
lower limbs occurs depending on the type, location, and severity of the lesion, in
approximately 60–70% of cases [93] during the first 2–6 months [4, 94], period
after which most people believe they have achieved maximal recovery and stop
with either physical or pharmacological therapy [4, 95]. Interventions should be
designed according to the stage of neurological recovery the patient is in, with the
consideration that early chronicity is not a contraindication for continuing
rehabilitation [4].
Physical rehabilitation must start early, if possible, during the first week post-
stroke [96], because there is an intensification in neuroplasticity during the early
stages [91], employing different mechanisms such as the axon regeneration [88],
and the higher expression of growth-promoting genes, such as GAP-43. This lesion-
induced plasticity that happens during the first days post-stroke [90, 97, 98]
reportedly lasts around 6 months after stroke [4, 91, 95, 97]. Also, therapy must
continue after such a period, to take advantage of behavior-induced plasticity [95],
which is still possible after 1 year of having had the stroke [4].
PR has also been proven to elicit neuroprotection and neurorestoration in other
neurological disease models, such as Parkinson’s, through the upregulation of BDNF
and GDNF and prevention of inflammatory response [99]. The following therapies
are currently under study for neurorestorative purposes during the post-stroke
chronic period:
Environmental enrichment focuses on inducing adaptation to different environ-
ments, including toys and complex tasks, to improve functional outcomes [97].
Also, this type of therapy has shown to enhance angiogenesis by increasing CD31
and VEGF [97]. Furthermore, environmental enrichment upregulates BDNF secre-
tion, and other neurotrophic factors [85, 90].
Wang et al. found improvements in spatial learning and memory, number of
synapses, and an increase in the expression of synaptogenesis markers. GAP-43, a
protein involved in neural plasticity through axonal growth, is upregulated during
the first 28 days after stroke in mice exposed to environmental enrichment. Like-
wise, other markers involved in synaptogenesis like SYN and PSD-95 achieve better
concentrations in the brains of mice treated with environmental enrichment [97].
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Functional electrical therapy has been used alongside other types of electrical
stimulation to induce repetitive muscular contraction to mobilize certain joints [6].
Somatosensory stimulation might enhance neurorehabilitation after stroke through
the stimulation of corticomotoneuronal excitability [6]. It has been proposed that
this type of therapy increases muscle strength, reduces spasticity, and facilitates
voluntary movements, among other motor benefits [6].
Guided self-rehabilitation (GSR) is a method in which the intensity of training
can be increased inside the home environment. While combined with conventional
rehabilitation, it has proven to be efficacious in engaging the patients in their
recovery through a contract between the patient and the therapist, allowing for an
increased sense of responsibility and motivation for the patients, who are required to
register their progress in a diary [100]. Although not many physical therapists accept
such an approach [100], positive changes have been observed after 1 year of GSR and
conventional rehabilitation in ultrasound measuring of the soleus’ and medial gas-
trocnemius’ thickness and fascicle length, as well as clinical improvement, observed
in soleus extensibility and ambulation speed [101] in chronic stroke patients.
Constraint-induced therapy requires constraining the non-affected limb for 90%
of the waking hours, forcing the patient to use the paretic limb, inducing the
increase of use-dependent plasticity, although this therapy is not practical for most
of the population [6].
Videogame- or virtual reality-based (VRb) therapies have been under study for
upper extremity functional recovery in acute and subacute or chronic patients
[91, 96, 99, 102]; the rationale for such approaches is that they promote motor
learning and repetitive, intense movements, and in the specific case of virtual
reality, the patient is exposed to interactive visual, auditive, and proprioceptive
feedback [91, 102]. Different videogame and VRb therapies have reported
improvements in fine dexterity, grip strength [96], and grasp force [99] in upper
extremities, and, activities of daily living [91] and cognition [102] in young and
elderly patients after several weeks of rehabilitation. Better results have been
observed when combined with conventional therapy, although it is still not known
whether it enhances or speeds up recovery [91].
7. Final remarks and future directions
In addition to continuing the search for pharmacological agents that allow the
neuroprotection and neurorestoration of tissue affected by cerebral ischemia, the
development of physical therapy and diet modification offers new horizons that
have shown satisfactory results in the clinical setting in short times. However, it has
not yet been possible to establish a protocolized treatment that can be added to the
health care guidelines; so it is important to continue exploring all possible strategies
to improve the quality of life of people who have suffered a cerebral infarction and
that of their caregivers.
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the stimulation of corticomotoneuronal excitability [6]. It has been proposed that
this type of therapy increases muscle strength, reduces spasticity, and facilitates
voluntary movements, among other motor benefits [6].
Guided self-rehabilitation (GSR) is a method in which the intensity of training
can be increased inside the home environment. While combined with conventional
rehabilitation, it has proven to be efficacious in engaging the patients in their
recovery through a contract between the patient and the therapist, allowing for an
increased sense of responsibility and motivation for the patients, who are required to
register their progress in a diary [100]. Although not many physical therapists accept
such an approach [100], positive changes have been observed after 1 year of GSR and
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trocnemius’ thickness and fascicle length, as well as clinical improvement, observed
in soleus extensibility and ambulation speed [101] in chronic stroke patients.
Constraint-induced therapy requires constraining the non-affected limb for 90%
of the waking hours, forcing the patient to use the paretic limb, inducing the
increase of use-dependent plasticity, although this therapy is not practical for most
of the population [6].
Videogame- or virtual reality-based (VRb) therapies have been under study for
upper extremity functional recovery in acute and subacute or chronic patients
[91, 96, 99, 102]; the rationale for such approaches is that they promote motor
learning and repetitive, intense movements, and in the specific case of virtual
reality, the patient is exposed to interactive visual, auditive, and proprioceptive
feedback [91, 102]. Different videogame and VRb therapies have reported
improvements in fine dexterity, grip strength [96], and grasp force [99] in upper
extremities, and, activities of daily living [91] and cognition [102] in young and
elderly patients after several weeks of rehabilitation. Better results have been
observed when combined with conventional therapy, although it is still not known
whether it enhances or speeds up recovery [91].
7. Final remarks and future directions
In addition to continuing the search for pharmacological agents that allow the
neuroprotection and neurorestoration of tissue affected by cerebral ischemia, the
development of physical therapy and diet modification offers new horizons that
have shown satisfactory results in the clinical setting in short times. However, it has
not yet been possible to establish a protocolized treatment that can be added to the
health care guidelines; so it is important to continue exploring all possible strategies
to improve the quality of life of people who have suffered a cerebral infarction and
that of their caregivers.
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Poststroke rehabilitation requires a thorough understanding of the neural 
mechanisms underlying motor function recovery. This chapter outlines these 
mechanisms and also discusses the corresponding rehabilitation strategies based on 
the functional characteristics of the brain. The main topics we discuss are as follows: 
Although ipsilateral brain region activity is inhibited when using the limbs under 
normal conditions, it is thought that a decrease in this inhibition and the subsequent 
increased ipsilateral brain area activity post-injury promote recovery in the dam-
aged contralateral neural network. For optimal poststroke motor function recovery, 
it is important to normalize the resulting imbalance in brain activity. Therefore, 
increased corticomotor excitation in the injured hemisphere or decreased excita-
tion in the non-injured hemisphere must be promoted. Rehabilitation strategies 
include reducing non-paretic limb somatosensory input to decrease excitation in the 
non-injured hemisphere, increasing paretic limb somatosensory input to increase 
excitation in the injured hemisphere, increasing excitation in the injured hemi-
sphere through movement training of the paretic hand and anesthesia of the paretic 
upper arm, increasing excitation in the injured hemisphere, or reducing excitation 
in the non-injured hemisphere. Considering the functional characteristics of the 
primary motor area, during the early stages after stroke, it is important to increase 
the somatosensory input to the paralyzed side and combine mental practices using 
motor imagery.
Keywords: neurorehabilitation, stroke, brain injury, neural plasticity, functional 
recovery, motor imagery, mental practice
1. Introduction
Stroke is a central nervous system condition that is prevalent worldwide. 
According to a report from the World Health Organization [1], approximately 15 
million people experience a stroke each year globally, and stroke is the third leading 
cause of death after heart disease and cancer. As impairment of motor function 
after a stroke drastically impedes activities of daily living (ADL) and reduces the 
quality of life [2], the development of effective rehabilitation methods, which 
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1. Introduction
Stroke is a central nervous system condition that is prevalent worldwide. 
According to a report from the World Health Organization [1], approximately 15 
million people experience a stroke each year globally, and stroke is the third leading 
cause of death after heart disease and cancer. As impairment of motor function 
after a stroke drastically impedes activities of daily living (ADL) and reduces the 
quality of life [2], the development of effective rehabilitation methods, which 
encourage the recovery of motor function in patients who have sustained a stroke, is 
an important task.
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Although the 2014 Cochrane Stroke Systematic Review reported several reha-
bilitation methods demonstrating moderate results in the recovery of upper limb 
motor function after a stroke, a highly effective method is yet to be established [3]. 
Understanding the neural mechanisms underlying motor function recovery after 
brain injury is indispensable for the development of highly effective poststroke 
rehabilitation strategies. Therefore, in this chapter we will outline these mecha-
nisms and introduce strategies based on these mechanisms as well as on the func-
tional characteristics of the brain.
2. Brain reorganization after brain injury
The brain is a highly plastic organ with the ability to reorganize as a result of 
learning or injury. In cases of injury in the motor cortex or corticospinal tract, 
the recovery of motor function is taken care of by the surviving brain regions. 
Dancause [4] has reported on cortical reorganization accompanying injury in 
the primary motor cortex. Neurons in the hand area of the primary motor cortex 
receive input from the fingers as well as the wrist/forearm, and signals are sent 
from the hand area of the primary motor cortex to the corresponding ipsilateral 
premotor area. If the hand area of the primary motor cortex is injured, elimination 
of the inhibitory neurons in the primary motor cortex leads to an increase in the 
input to the hand area from the wrist/forearm. This results in an enlargement of the 
wrist/forearm area and shrinking of the hand area of the ipsilateral premotor area. 
However, as inhibitory neurons at the non-injured side are eliminated, the hand 
area of the premotor area and the primary motor cortex at the non-injured side also 
enlarge. Subsequently, reorganization leading to functional recovery occurs through 
learning and practice. The hand area of the primary motor cortex continues to 
enlarge as networks are stimulated or adjacent areas are inhibited through changes 
in synaptic receptor density or the creation of new synapses due to neuroplasticity. 
Neural networks are also reorganized through the formation of new connections 
between neurons and axonal sprouting. Thus, brain areas in both the injured and 
non-injured hemispheres are involved in the functional repair process accompany-
ing recovery after brain injury.
Premotor area activity is also important for the recovery of motor function after 
a brain injury. Apart from being responsible for certain functions of the motor 
network, the premotor area is also involved in the integration of sensory and cogni-
tive information in the course of goal-oriented behavior (actions carried out with a 
clearly established goal or aim, such as ADL). It receives sensory information from 
the parietal lobe and cognitive information from the dorsolateral prefrontal cortex 
and the supplementary motor cortex, which are then integrated and sent to the 
primary motor cortex. This information is also sent directly to the spinal cord via 
the corticospinal tract. These neural network connections are highly susceptible 
to plastic changes resulting from injury, learning, training, or therapy. Kantak 
et al. [5] discuss the reorganization of the premotor area involved in promoting 
motor function recovery after a brain injury. Reorganization of the premotor 
area on the injured/non-injured sides in the context of motor function recovery is 
influenced by the extent and site of the damage. For example, in cases of localized 
damage to the primary motor cortex or corticospinal tract, patients experience 
mild functional impairment. In this event, the premotor area on the injured side 
assists in the recovery of motor function, simultaneously increasing direct input 
to the corticospinal tract and to the remaining area of the primary motor cortex 
on the injured side. In cases of extensive damage to the primary motor cortex or 
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corticospinal tract, patients exhibit severe functional impairment. In contrast to 
cases of localized injury, in these cases, the premotor area on the non-injured side 
increases input to the surviving sensorimotor area of the injured side. Thus, the 
premotor areas of the injured and non-injured sides are involved in reorganization 
contributing to motor function recovery post-brain injury by way of two different 
strategies.
It is known that reorganization of the brain after an injury changes over time 
along with recovery of motor function. Nishimura et al. [6] caused injury to the 
corticospinal tracts of monkeys and then carried out rehabilitation to examine the 
changes in brain activity during the initial phase (1 month) and the stable phase 
(3 months) of motor function recovery. The study confirmed activity in both the 
contralateral and ipsilateral primary motor cortices during the initial recovery 
phase, during which the pinching motion success rate was 80%. Meanwhile, when 
the success rate reached 100% for the same motion during the stable recovery 
phase, ipsilateral primary motor cortex activity decreased, while contralateral 
activity increased and the contralateral area expanded. Based on this study, 
although the activity of ipsilateral brain regions is inhibited when using the hands 
or feet under normal situations, it is thought that a decrease in this inhibition and 
the subsequent activity in the ipsilateral brain areas post-injury promote recovery 
in the damaged contralateral neural network. Furthermore, it can be concluded 
that when the injured neural network has recovered substantially, either through 
repair of the original network or the mobilization of an adjacent network, the 
ipsilateral brain area returns to a state of inhibition similar to that observed before 
the injury.
Similarly, the abovementioned phenomenon can be observed in the process of 
motor function recovery in stroke patients. Using functional magnetic resonance 
imaging (fMRI), Ward et al. [7] explored the correlation between stroke patient 
motor outcomes (motor function evaluations) 3 months after the onset and brain 
activity when performing a visually induced motor task with the paretic hand,. The 
results demonstrated that the number of motor-related brain areas utilized during 
the motor task was higher in patients with a poor outcome, while patients with a 
favorable outcome utilized fewer of these areas—a pattern of brain activity close to 
that of healthy individuals. Further, a negative correlation between motor outcome 
and the activity of task-related brain areas, such as the supplementary motor area, 
cingulate motor area, premotor cortex, posterior parietal cortex, and cerebellum, 
was shown. This negative correlation was confirmed for both the non-injured and 
injured primary motor cortices. Thus, it was understood that when performing 
motions with the paretic hand, the worse a patient’s poststroke motor function, the 
more bilateral their brain activity. In a similar study, Rehme et al. [8] used fMRI to 
investigate longitudinal changes in motor network activity during the recovery of 
motor function in the initial phase after stroke onset. The authors measured the 
motor function recovery score and brain activity during movement of the non-
paretic and paretic hands in stroke patients 2, 5, and 10 days after onset. The results 
demonstrated activity of the bilateral primary motor cortex, dorsal and ventral 
premotor area, and supplementary motor cortex during movement of the paretic 
hand in stroke patients (Figure 1B). Further, when the results were compared by 
level of motor function impairment, patients with mild impairment showed activity 
resembling that of healthy individuals at 2, 5, and 10 days, whereas patients with 
severe impairment showed increased bilateral activity over time (Figure 1C). As 
this bilateral activity demonstrated a positive correlation with motor function 
recovery (Figure 1D), it is thought to reflect neural restructuring in the initial 
phase after a stroke.
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that of healthy individuals. Further, a negative correlation between motor outcome 
and the activity of task-related brain areas, such as the supplementary motor area, 
cingulate motor area, premotor cortex, posterior parietal cortex, and cerebellum, 
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investigate longitudinal changes in motor network activity during the recovery of 
motor function in the initial phase after stroke onset. The authors measured the 
motor function recovery score and brain activity during movement of the non-
paretic and paretic hands in stroke patients 2, 5, and 10 days after onset. The results 
demonstrated activity of the bilateral primary motor cortex, dorsal and ventral 
premotor area, and supplementary motor cortex during movement of the paretic 
hand in stroke patients (Figure 1B). Further, when the results were compared by 
level of motor function impairment, patients with mild impairment showed activity 
resembling that of healthy individuals at 2, 5, and 10 days, whereas patients with 
severe impairment showed increased bilateral activity over time (Figure 1C). As 
this bilateral activity demonstrated a positive correlation with motor function 
recovery (Figure 1D), it is thought to reflect neural restructuring in the initial 
phase after a stroke.
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3. Interhemispheric inhibition imbalance after brain injury
Interhemispheric inhibition refers to the phenomenon in which activation of one 
side of the cerebrum inhibits the activity of neurons in the opposite side of the brain 
[9]. In humans, sensory information from the right half of the body is normally 
conveyed to the neocortex of the left hemisphere, while sensory information from 
the left half of the body is conveyed to the neocortex of the right hemisphere. The 
left and right neocortices are connected via the corpus callosum. The inhibition of 
information exchange between the left and right hemispheres allows humans to 
move the bilateral upper and lower limbs dexterously. Recent research has revealed 
the mechanism of this neural network of interhemispheric inhibition. Palmer et al. 
Figure 1. 
Longitudinal changes in motor network activity in the initial phase after stroke onset [8]. (A) Brain activity 
during right/left hand movement in healthy adults. (B) Brain activity during non-paretic/paretic hand 
movement in stroke patients (2, 5, and 10 days after onset). Bilateral activation is expanded for the paretic 
hand. (C) Brain activity during paretic hand movement for mild and severe stroke patients (2, 5, and 10 days 
after onset). In patients with mild functional impairment, only the contralateral hemisphere is active, whereas 
the activity in both hemispheres expands for severe patients. (D) Map of brain regions involved in favorable 
motor function recovery.
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[10] explored neuronal activity in the left and right brain of conscious rats with foot 
stimulation in order to observe nerve activity in a more natural setting. This study 
revealed the following series of events: when information is conveyed to one side of 
the neocortex, excitatory information is conveyed to the other side via the corpus 
callosum, activating the inhibitory nerve cells that exist on its surface and releas-
ing gamma aminobutyric acid (GABA)—an inhibitory neurotransmitter—within 
the brain. GABA binds to GABAB receptors on the dendrites of pyramidal neurons 
within layer V of the neocortex, thereby inhibiting nerve activity.
However, this interhemispheric inhibition between the left and right brain 
becomes imbalanced after a brain injury, leading to various dysfunctions. Grefkes 
et al. [11] investigated the functional intrahemispheric and interhemispheric 
connections of motor-related areas during voluntary hand movement in healthy 
individuals and stroke patients using fMRI. Interhemispheric inhibition functioned 
normally as described above for healthy individuals; it was found that in the resting 
condition, the left and right brain inhibited one another, while motor-related 
areas within each hemisphere stimulated one another (Figure 2A). It was further 
found that when healthy individuals moved the right hand, inhibition from the 
right hemisphere to the left hemisphere ceased, and inhibition from the left hemi-
sphere to the right hemisphere was activated (Figure 2B). However, in contrast to 
healthy individuals, when stroke patients moved the paretic right hand, the right 
hemisphere (non-injured primary motor cortex) was found to inhibit the left 
hemisphere (injured primary motor cortex) (Figure 2C), such that the stronger 
the inhibition, the lower the motor performance in the paretic hand (Figure 2D). 
Use-dependent plasticity (use-dependent reorganization) is involved in this imbal-
ance in interhemispheric inhibition in stroke patients [12]. Stroke causes paresis 
of the upper and lower limbs resulting in reduced motor function. As such, stroke 
patients commonly disuse the paretic limbs while overusing the non-paretic limbs. 
This poststroke disuse of the paretic and overuse of the non-paretic limbs—in 
other words, imbalance in the frequency of use for paretic vs. non-paretic limbs—is 
believed to influence the balance of the left and right cerebrum.
How does the disuse of the paretic limbs and overuse of the non-paretic limbs 
influence the left and right cerebrum in reality? Avanzino et al. [13] established 
an environment resembling that of a hemiplegic patient to explore the effect of 
restraining one-sided upper limb use in healthy individuals on interhemispheric 
balance using transcranial magnetic stimulation (TMS). To examine cortical 
changes due to abnormal unequal use of the hands, two experimental groups were 
compared: a group in which one hand (right) was fixed in place but the loose hand 
(left) could be moved freely and a group in which use of the left hand was also 
restricted. Note that the upper limbs were restrained for a period of 10 min. Despite 
the short restraint period, disuse of the right upper limb was found to decrease 
excitation in the left primary motor cortex and reduce interhemispheric inhibition 
from the left hemisphere to the right for both groups. Further, the group that not 
only disused the right upper limb but also overused the left upper limb showed 
increased excitatory activity in the primary motor cortex of the right hemisphere 
and increased interhemispheric inhibition from the right hemisphere to the left. 
Thus, it was revealed that disuse of one upper limb and overuse of the other—that 
is, imbalance in usage frequency between both upper limbs—causes imbalance 
between the cerebral hemispheres.
The hypothesis regarding the imbalance in interhemispheric inhibition 
post-brain injury is called the abnormal interhemispheric inhibition hypothesis 
[14, 15]. It states that in cases of subcortical brain injury, an abnormal inhibi-
tory effect arises from the non-injured hemisphere, in which there is increased 
excitation, to the injured hemisphere. There are two conceivable strategies for 
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3. Interhemispheric inhibition imbalance after brain injury
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Figure 1. 
Longitudinal changes in motor network activity in the initial phase after stroke onset [8]. (A) Brain activity 
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the activity in both hemispheres expands for severe patients. (D) Map of brain regions involved in favorable 
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[10] explored neuronal activity in the left and right brain of conscious rats with foot 
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ing gamma aminobutyric acid (GABA)—an inhibitory neurotransmitter—within 
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within layer V of the neocortex, thereby inhibiting nerve activity.
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from the left hemisphere to the right for both groups. Further, the group that not 
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Thus, it was revealed that disuse of one upper limb and overuse of the other—that 
is, imbalance in usage frequency between both upper limbs—causes imbalance 
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The hypothesis regarding the imbalance in interhemispheric inhibition 
post-brain injury is called the abnormal interhemispheric inhibition hypothesis 
[14, 15]. It states that in cases of subcortical brain injury, an abnormal inhibi-
tory effect arises from the non-injured hemisphere, in which there is increased 
excitation, to the injured hemisphere. There are two conceivable strategies for 
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treatment interventions corresponding to this hypothesis: increasing corticomotor 
excitation in the injured hemisphere or decreasing excitation in the non-injured 
hemisphere. Approaches for these strategies are known as hypothesis-driven 
approaches (Figure 3) [16]. Specifically, proposed methods include (1) reduc-
ing non-paretic limb somatosensory input in order to decrease excitation of the 
non-injured hemisphere, (2) increasing paretic limb somatosensory input in order 
to increase excitation of the injured hemisphere, (3) increasing excitation in the 
injured hemisphere through a combination of movement training of the paretic 
hand and anesthesia of the paretic upper arm, (4) directly increasing excitation 
in the injured hemisphere, or (5) directly reducing excitation in the non-injured 
hemisphere. With regard to procedures to directly manipulate excitation in one 
hemisphere, as in methods (4) and (5), effects can be exerted through the use 
of noninvasive brain stimulation methods such as transcranial direct current 
stimulation (tDCS) or repetitive transcranial magnetic stimulation (rTMS). 
These methods of stimulation bring about changes that are similar to long-term 
potentiation or long-term depression, resulting in increased or reduced excitation, 
Figure 2. 
Differences in cortical connectivity between healthy adults and stroke patients [11]. Green arrows represent 
excitation and red arrows represent inhibition. (A) Intra-/interhemispheric functional connectivity in 
healthy adults at rest. (B) Intra-/interhemispheric functional connectivity in healthy adults during voluntary 
movement of the right hand. (C) Intra-/interhemispheric functional connectivity in stroke patients during 
voluntary movement of the paretic hand (right hand). (D) Correlation between interhemispheric inhibition 
of the primary motor cortex and motor performance for the paretic hand (right hand) in stroke patients. The 
stronger the inhibition from the non-injured hemisphere to the injured hemisphere, the more the paretic hand 
motor performance was reduced.
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respectively, at the stimulation site. Regarding the efficacy of these methods, Hsu 
et al. [17] performed a meta-analysis that showed that rTMS was effective in motor 
function recovery in stroke patients. It was also reported in the 2011 Cochrane 
Review [18] that tDCS improved ADL function poststroke. At present, it has been 
established that the effects of rTMS and tDCS work on cortical neuromodulation 
and do not cause direct recovery from paresis. In other words, these methods are 
used for preconditioning to create a more plastic state in the brain or to stabilize 
the activity of the cerebral cortex. It is thought that these effects can be demon-
strated with a combination of motor therapy, which is based on the process of 
motor learning. Constraint-induced movement therapy (CI therapy), established 
by Wolf et al. [19] and Taub et al. [20], is representative methods (1) and (2). In 
CI therapy, the non-paretic upper limb is first restrained in a sling or with a mitten 
to create a situation in which the patient is forced to use the paretic upper limb. 
Voluntary movement is then induced on the paretic side with intensive tasks of 
incremental difficulty levels leading to improvement in motor function. Regarding 
the results of this method, the 2009 Cochrane Review [21] confirmed the short-
term effects on the recovery of motor function in stroke patients directly after CI 
therapy intervention. A meta-analysis by Langhorne et al. [22] about the effects 
of various rehabilitation methods on upper limb paresis in stroke patients also 
found that CI therapy had better intervention effects than other methods and that 
there was little variation among such effects. In addition, recent studies have used 
randomized comparative experiments to study the effects of behavioral strategies 
for the utilization of function acquired through CI therapy in daily life (transfer 
Figure 3. 
Approach based on the abnormal interhemispheric inhibition hypothesis (hypothesis-driven approach) 
[16]. (1) Reducing non-paretic limb somatosensory input in order to decrease excitation in the non-injured 
hemisphere. (2) Increasing paretic limb somatosensory input in order to increase excitation in the injured 
hemisphere. (3) Increasing excitation in the injured hemisphere through a combination of movement training 
of the paretic hand and anesthesia of the paretic upper arm. (4) Directly increasing excitation in the injured 
hemisphere. (5) Directly reducing excitation in the non-injured hemisphere.
New Insight into Cerebrovascular Diseases - An Updated Comprehensive Review
304
treatment interventions corresponding to this hypothesis: increasing corticomotor 
excitation in the injured hemisphere or decreasing excitation in the non-injured 
hemisphere. Approaches for these strategies are known as hypothesis-driven 
approaches (Figure 3) [16]. Specifically, proposed methods include (1) reduc-
ing non-paretic limb somatosensory input in order to decrease excitation of the 
non-injured hemisphere, (2) increasing paretic limb somatosensory input in order 
to increase excitation of the injured hemisphere, (3) increasing excitation in the 
injured hemisphere through a combination of movement training of the paretic 
hand and anesthesia of the paretic upper arm, (4) directly increasing excitation 
in the injured hemisphere, or (5) directly reducing excitation in the non-injured 
hemisphere. With regard to procedures to directly manipulate excitation in one 
hemisphere, as in methods (4) and (5), effects can be exerted through the use 
of noninvasive brain stimulation methods such as transcranial direct current 
stimulation (tDCS) or repetitive transcranial magnetic stimulation (rTMS). 
These methods of stimulation bring about changes that are similar to long-term 
potentiation or long-term depression, resulting in increased or reduced excitation, 
Figure 2. 
Differences in cortical connectivity between healthy adults and stroke patients [11]. Green arrows represent 
excitation and red arrows represent inhibition. (A) Intra-/interhemispheric functional connectivity in 
healthy adults at rest. (B) Intra-/interhemispheric functional connectivity in healthy adults during voluntary 
movement of the right hand. (C) Intra-/interhemispheric functional connectivity in stroke patients during 
voluntary movement of the paretic hand (right hand). (D) Correlation between interhemispheric inhibition 
of the primary motor cortex and motor performance for the paretic hand (right hand) in stroke patients. The 
stronger the inhibition from the non-injured hemisphere to the injured hemisphere, the more the paretic hand 
motor performance was reduced.
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respectively, at the stimulation site. Regarding the efficacy of these methods, Hsu 
et al. [17] performed a meta-analysis that showed that rTMS was effective in motor 
function recovery in stroke patients. It was also reported in the 2011 Cochrane 
Review [18] that tDCS improved ADL function poststroke. At present, it has been 
established that the effects of rTMS and tDCS work on cortical neuromodulation 
and do not cause direct recovery from paresis. In other words, these methods are 
used for preconditioning to create a more plastic state in the brain or to stabilize 
the activity of the cerebral cortex. It is thought that these effects can be demon-
strated with a combination of motor therapy, which is based on the process of 
motor learning. Constraint-induced movement therapy (CI therapy), established 
by Wolf et al. [19] and Taub et al. [20], is representative methods (1) and (2). In 
CI therapy, the non-paretic upper limb is first restrained in a sling or with a mitten 
to create a situation in which the patient is forced to use the paretic upper limb. 
Voluntary movement is then induced on the paretic side with intensive tasks of 
incremental difficulty levels leading to improvement in motor function. Regarding 
the results of this method, the 2009 Cochrane Review [21] confirmed the short-
term effects on the recovery of motor function in stroke patients directly after CI 
therapy intervention. A meta-analysis by Langhorne et al. [22] about the effects 
of various rehabilitation methods on upper limb paresis in stroke patients also 
found that CI therapy had better intervention effects than other methods and that 
there was little variation among such effects. In addition, recent studies have used 
randomized comparative experiments to study the effects of behavioral strategies 
for the utilization of function acquired through CI therapy in daily life (transfer 
Figure 3. 
Approach based on the abnormal interhemispheric inhibition hypothesis (hypothesis-driven approach) 
[16]. (1) Reducing non-paretic limb somatosensory input in order to decrease excitation in the non-injured 
hemisphere. (2) Increasing paretic limb somatosensory input in order to increase excitation in the injured 
hemisphere. (3) Increasing excitation in the injured hemisphere through a combination of movement training 
of the paretic hand and anesthesia of the paretic upper arm. (4) Directly increasing excitation in the injured 
hemisphere. (5) Directly reducing excitation in the non-injured hemisphere.
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package) [23, 24], as well as research examining the effects of motor therapy, 
which combines CI therapy with the abovementioned rTMS and tDCS [25, 26]. In 
this way, it is essential that motor therapy in the rehabilitation of stroke patients 
be developed with sufficient consideration to the imbalance in interhemispheric 
inhibition between the left and right cerebrum.
4.  Rehabilitation strategies based on the functional characteristics  
of the brain and advances in clinical practice guidelines
Research by Geyer et al. [27] showed that the human primary motor cortex 
consists of two different regions: the anterior portion (IVa area) and the poste-
rior portion (IVp area). These two regions differ in cell structure and receptor 
density. The IVa area is located in the anterior (rostral) portion of the primary 
motor cortex. This area is phylogenetically ancient and is thus referred to as the 
old primary motor cortex (Old M1). Outputs from the Old M1 control physical 
movement via the corticospinal tract and spinal interneurons. Meanwhile, the 
IVp area is found in the posterior (caudal) portion of the primary motor cortex 
and, being a newer section of the motor cortex compared to the IVa, is known 
as the New M1. New M1 includes cortical motoneurons, which synapse directly 
with spinal motoneurons. These synaptic connections are not mediated by spinal 
interneurons and are involved in the execution of extremely masterful and 
complex movements [28].
In light of the neural network functional disparity between the IVa and IVp 
areas of the primary motor cortex, Sharma et al. [29] proposed the somatosensory 
feedback for the paretic limb as one factor influencing the recovery of motor func-
tion after stroke (Figure 4A). The authors suggested that increased neural activity 
in the IVp area due to somatosensory input is involved in the recovery of motor 
function. Loubinoux et al. [30] investigated brain areas involved in motor function 
recovery for stroke patients using fMRI. They found that stroke patients with high 
neural activity in the IVp area had favorable motor function recovery in the hand 
and that neural activity in the IVp area predicted motor performance 1 year later. 
This suggests that early poststroke stimulation of neural activity in the IVp area of 
the injured hemisphere is critical for rehabilitation. As described above, the IVa and 
IVp areas are structurally disparate, but they are also functionally different with 
respect to afferent somatosensory information processing. Strick et al. [31] investi-
gated differences in neural activity in the rostral (IVa) and caudal (IVp) areas of the 
primary motor cortex in monkeys using inputs from different sensory modalities. 
Their study found that the rostral primary motor cortex has plentiful cells that 
respond to the characteristic sensory input of muscles and joints, while the caudal 
area has an abundance of cells responding to cutaneous sensation input. Thus, it 
was suggested that providing cutaneous sensation to the paretic limb was important 
for increasing excitation in the IVp area. It was further found that neural activity 
in this IVp area was influenced by actively drawing attention. Binkofski et al. [32] 
examined the effect that directing attention to behavior had on neural activity in 
the IVa and IVp areas of the human primary motor cortex using fMRI. The authors 
found that the neural activity in the IVp area was affected by drawing attention to 
behavior, but this effect was not present in the IVa area. This suggested that apart 
from providing simple sensory stimulation, directing participants’ active attention 
would also be beneficial for increasing neural activity in the IVp area. To summa-
rize, for poststroke motor function recovery, it is considered important to increase 
the neural activity of the IVp area by providing somatosensory input to the paretic 
limb while capturing the patient’s active attention.
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Sharma et al. [29] proposed, as a second factor involved in poststroke recovery 
of motor function, activities preceding movement (Figure 4B). We know that the 
IVp area is excited in the same way by both the abovementioned somatosensory 
input and mental representations, such as motor imagery and preceding movement. 
Using fMRI and healthy adults, Sharma et al. [33] conducted a study of neural 
activity in the primary motor cortex (IVa and IVp areas) while the subjects imag-
ined movement. The results demonstrated that the relative involvement of imagin-
ing movement was larger in the IVp area than that in the IVa area. Sharma et al. 
[34] then explored the relationship between neural activity in the primary motor 
cortex (IVa and IVp areas) in stroke patients, while imagining movement and motor 
performance using fMRI. The authors found that, while imagining movement of 
the paretic hand, the neural activity in the injured side of the IVp area of stroke 
patients was positively correlated with motor performance. These studies suggest 
that the neural activity of the IVp area, when imagining movement, can be used as a 
tool to predict motor function in stroke patients and, further, that intervention with 
tasks involving motor imagery may increase excitation in the IVp area.
Figure 4. 
Three factors influencing motor function recovery after a stroke and the corresponding neural networks [29]. 
The injured hemisphere is shown in gray and the non-injured hemisphere in white. (A) Somatosensory 
feedback: This network can be accessed through somatosensory input such as peripheral nerve stimulation. (B) 
Processes preceding movement such as a movement plan: This network can be accessed through motor imagery 
or action observation. (C) Discharge via the corticospinal tract to produce movement: This network is involved 
in physical movement but predominantly through the combination of the other two (A and B).
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Sharma et al. [29] proposed, as a second factor involved in poststroke recovery 
of motor function, activities preceding movement (Figure 4B). We know that the 
IVp area is excited in the same way by both the abovementioned somatosensory 
input and mental representations, such as motor imagery and preceding movement. 
Using fMRI and healthy adults, Sharma et al. [33] conducted a study of neural 
activity in the primary motor cortex (IVa and IVp areas) while the subjects imag-
ined movement. The results demonstrated that the relative involvement of imagin-
ing movement was larger in the IVp area than that in the IVa area. Sharma et al. 
[34] then explored the relationship between neural activity in the primary motor 
cortex (IVa and IVp areas) in stroke patients, while imagining movement and motor 
performance using fMRI. The authors found that, while imagining movement of 
the paretic hand, the neural activity in the injured side of the IVp area of stroke 
patients was positively correlated with motor performance. These studies suggest 
that the neural activity of the IVp area, when imagining movement, can be used as a 
tool to predict motor function in stroke patients and, further, that intervention with 
tasks involving motor imagery may increase excitation in the IVp area.
Figure 4. 
Three factors influencing motor function recovery after a stroke and the corresponding neural networks [29]. 
The injured hemisphere is shown in gray and the non-injured hemisphere in white. (A) Somatosensory 
feedback: This network can be accessed through somatosensory input such as peripheral nerve stimulation. (B) 
Processes preceding movement such as a movement plan: This network can be accessed through motor imagery 
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A third factor influencing recovery of motor function after stroke suggested 
by Sharma et al. [29] is discharge via the corticospinal tract to produce movement 
(Figure 4C). This network is involved in all physical movement but predominantly 
through the combination of the other two. That is, this neural network for produc-
ing movement is predominantly utilized via the mutual involvement of the neural 
network based on somatosensory feedback and the neural network preceding 
movement. As a specific example, Nilsen et al. [35] and López et al. [36] conducted 
a systematic review and found that combining mental practice and the use of 
motor imagery with physical movement improved intervention effects. Further, a 
Cochrane Review [37] also reported that mental practice interventions combined 
with motor therapy, including physical movement, were more effective than mental 
practice alone. We also reported that neurofeedback-based motor imagery train-
ing combined with physical movement contributed to improving upper extrem-
ity function in stroke patients [38]. These findings indicate that somatosensory 
feedback accompanying physical movement promotes the effects of motor imagery 
interventions. In other words, the neural network preceding movement and that for 
somatosensory feedback may work together to enhance motor performance.
To summarize, the factors influencing motor function recovery accompanying 
the reorganization of the IVp area after a stroke are (1) somatosensory feedback to 
the paretic side; (2) movement-preceding activities, which utilize motor imagery 
and action observation; and (3) discharge via the corticospinal tract to produce 
movement. As (3) is ultimately effective through the combination of the neural net-
works involved in (1) and (2), information processing combined with somatosen-
sory input to the paretic limb should take priority in motor therapy for hemiparetic 
stroke patients exhibiting motor paresis. Next, treatment should precede mental 
practice interventions utilizing motor imagery induction, based on estimations 
from that information processing and from motor practice producing movement 
through an exercise program based on those movement-preceding activities. This 
step-by-step intervention strategy is considered vital.
Nevertheless, according to the Guidelines for the Management of Stroke [39], 
the following therapies are recommended for rehabilitation for upper limb dysfunc-
tion—for patients with mild paralysis, a therapy that suppresses the non-paralyzed 
upper limb and forces the use of the paralyzed upper limb in life is highly recom-
mended (grade A). For moderate paralytic muscles (such as wrist and finger exten-
sors), electrical stimulation is recommended (grade B). For patients with mild to 
moderate paralysis, training should be performed with repetition of certain move-
ments (reach movement of the upper limb on the paralyzed side, goal-oriented 
movement, repetitive movement of both upper limbs, mirror therapy, repetitive 
facilitation exercise, etc.) is recommended (grade B). rTMS and tDCS may be 
considered, but care must be taken in patient selection and safety (grade C1).
Moreover, the following therapies are recommended for rehabilitation for gait 
disorders—increasing the amount of limb training associated with walking or of 
walking itself is strongly recommended to improve walking ability (grade A). For 
stroke hemiplegic patients with equinovarus feet, it is recommended to use short 
leg braces to improve walking (grade B). Botulinum therapy and intramuscular 
nerve block to the tibial nerve or the lower leg muscle using 5% phenol is recom-
mended when the spastic equinovarus foot hinders walking and ADL (grade B). 
Tendon transfer may be considered for patients presenting with spastic equinus 
and abnormal gait (grade C1). Biofeedback using electromyogram and joint angle is 
also recommended to improve walking (grade B). Functional electrical stimulation 
is recommended for chronic stroke patients with drooping foot, but the duration 
of treatment effect is short (grade B). Treadmill training is recommended because 
it improves walking speed and endurance in ambulatory stroke patients (grade B). 
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Walking training using a walking assist robot is recommended for those who cannot 
walk within 3 months of onset (grade B).
Furthermore, the following therapies are recommended for rehabilitation in 
cases of movement disorders and ADL. For stroke sequelae, active rehabilitation 
from the early stage is strongly recommended to promote the recovery of dysfunc-
tion and disability (grade A). It is strongly recommended to increase the amount 
and frequency of training early after onset to promote more effective recovery of 
disability in patients (grade A). For lower limb function and ADL, repeated task 
training is recommended (grade B).
Based on the above guidelines, it is necessary to consider three points: (1) dose 
dependency, (2) task dependency, and (3) neuroplasticity, in order to promote 
effective functional recovery in stroke rehabilitation.
In clinical practice, it is important to perform optimal rehabilitation for stroke 
patients while keeping the functional characteristics of the brain and the existing 
guidelines in mind.
5. Final remarks
In this chapter, we outlined the neural mechanisms underlying motor function 
recovery after stroke-related brain injury. We have also outlined the corresponding 
rehabilitation strategies based on the functional characteristics of the brain and 
advances in clinical practice guidelines. We discussed how, considering the func-
tional characteristics of the primary motor area, it is important during the early 
stages after stroke to increase the somatosensory input to the paralyzed side and 
combine mental practices using motor imagery. The existing guidelines highlighted 
the importance of dose dependency, task dependency, and neuroplasticity, in 
promoting effective functional recovery in stroke rehabilitation. Understanding the 
rehabilitation strategies and key related mechanisms involved in stroke recovery is 
indispensable for the development of highly effective poststroke rehabilitation.
6. Future directions
Previous studies have shown that the recovery of motor function after stroke is 
acutely related to the functional replacement of damaged neuronal circuits and the 
interhemispheric imbalance model. Therefore, it is important to promote neuro-
plasticity related to motor function recovery in rehabilitation. In addition to the use 
of evidence-based clinical practice guidelines, rehabilitation strategies that take 
into account the functional characteristics of the brain may maximize the recovery 
of motor function in stroke patients. In the future, it is expected that improved 
intervention strategies will be widely applied in the clinical setting by accumulating 
knowledge about the pathology of relevant cases and brain areas.
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A third factor influencing recovery of motor function after stroke suggested 
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ing combined with physical movement contributed to improving upper extrem-
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practice interventions utilizing motor imagery induction, based on estimations 
from that information processing and from motor practice producing movement 
through an exercise program based on those movement-preceding activities. This 
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Nevertheless, according to the Guidelines for the Management of Stroke [39], 
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upper limb and forces the use of the paralyzed upper limb in life is highly recom-
mended (grade A). For moderate paralytic muscles (such as wrist and finger exten-
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considered, but care must be taken in patient selection and safety (grade C1).
Moreover, the following therapies are recommended for rehabilitation for gait 
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stroke hemiplegic patients with equinovarus feet, it is recommended to use short 
leg braces to improve walking (grade B). Botulinum therapy and intramuscular 
nerve block to the tibial nerve or the lower leg muscle using 5% phenol is recom-
mended when the spastic equinovarus foot hinders walking and ADL (grade B). 
Tendon transfer may be considered for patients presenting with spastic equinus 
and abnormal gait (grade C1). Biofeedback using electromyogram and joint angle is 
also recommended to improve walking (grade B). Functional electrical stimulation 
is recommended for chronic stroke patients with drooping foot, but the duration 
of treatment effect is short (grade B). Treadmill training is recommended because 
it improves walking speed and endurance in ambulatory stroke patients (grade B). 
309
Rehabilitation Strategies and Key Related Mechanisms Involved in Stroke Recovery
DOI: http://dx.doi.org/10.5772/intechopen.91025
Walking training using a walking assist robot is recommended for those who cannot 
walk within 3 months of onset (grade B).
Furthermore, the following therapies are recommended for rehabilitation in 
cases of movement disorders and ADL. For stroke sequelae, active rehabilitation 
from the early stage is strongly recommended to promote the recovery of dysfunc-
tion and disability (grade A). It is strongly recommended to increase the amount 
and frequency of training early after onset to promote more effective recovery of 
disability in patients (grade A). For lower limb function and ADL, repeated task 
training is recommended (grade B).
Based on the above guidelines, it is necessary to consider three points: (1) dose 
dependency, (2) task dependency, and (3) neuroplasticity, in order to promote 
effective functional recovery in stroke rehabilitation.
In clinical practice, it is important to perform optimal rehabilitation for stroke 
patients while keeping the functional characteristics of the brain and the existing 
guidelines in mind.
5. Final remarks
In this chapter, we outlined the neural mechanisms underlying motor function 
recovery after stroke-related brain injury. We have also outlined the corresponding 
rehabilitation strategies based on the functional characteristics of the brain and 
advances in clinical practice guidelines. We discussed how, considering the func-
tional characteristics of the primary motor area, it is important during the early 
stages after stroke to increase the somatosensory input to the paralyzed side and 
combine mental practices using motor imagery. The existing guidelines highlighted 
the importance of dose dependency, task dependency, and neuroplasticity, in 
promoting effective functional recovery in stroke rehabilitation. Understanding the 
rehabilitation strategies and key related mechanisms involved in stroke recovery is 
indispensable for the development of highly effective poststroke rehabilitation.
6. Future directions
Previous studies have shown that the recovery of motor function after stroke is 
acutely related to the functional replacement of damaged neuronal circuits and the 
interhemispheric imbalance model. Therefore, it is important to promote neuro-
plasticity related to motor function recovery in rehabilitation. In addition to the use 
of evidence-based clinical practice guidelines, rehabilitation strategies that take 
into account the functional characteristics of the brain may maximize the recovery 
of motor function in stroke patients. In the future, it is expected that improved 
intervention strategies will be widely applied in the clinical setting by accumulating 
knowledge about the pathology of relevant cases and brain areas.
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Abstract
Stroke occurs suddenly and has major impact on both the survivor and their 
caregiver. A third of stroke victims usually die from its direct effects or complica-
tions. The survivors usually have functional deficits resulting in the need for 
caregiver support. The caregivers may have inadequate knowledge of how to care 
for their affected relatives. The result is high caregiver burden and complications 
among the survivors. Once a person has stroke, it becomes important that their 
caregivers and their needs are determined so that they get the necessary support 
from the health professionals. Education of both the stroke survivors and the care-
givers, and follow-up to determine if their needs are being met may be the support 
required. This is important in low resource settings where the survivors and care-
givers may not always afford to go to stroke clinics for support visits and follow-up. 
Furthermore, stroke will result in reduced quality of life, poor functional outcomes, 
and poor community reintegration, which are important areas in life. Caregivers 
who look after the survivor for long periods may suffer burnout and have poor 
quality of life. Educating both the stroke survivor and their caregiver may result in 
better quality of life and survival rate.
Keywords: survivors of stroke, caregivers of stroke, low resource settings, outcomes 
of stroke, caregiver training
1. Introduction
Stroke is a common neurological problem and one of the leading causes of death 
in developing countries of the world [1]. It is one of the most disabling diseases and 
has great emotional impact on both the survivors of stroke and their relatives [2]. 
Stroke can affect virtually all human functions and unlike other disabling condi-
tions, the onset is sudden, leaving the survivor and family unprepared to deal with 
the consequences which can be clinical, social and economic [3]. In most develop-
ing countries, people affected by stroke present late to hospital and even then, are 
only kept in hospital for a short period until they are medically stable. They are 
then discharged home while still functionally dependent to the care of relatives 
who lack knowledge on what to do hence the need to be trained [3–5]. There are no 
institutions where they can get community support and the few that are available 
are beyond the reach of many. This puts the burden of care at home on the rela-
tives. This is the case in Zimbabwe, Rwanda, Tanzania and South Africa [5, 6]. The 
chapter therefore gives information on supporting informal caregivers in order to 
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1. Introduction
Stroke is a common neurological problem and one of the leading causes of death 
in developing countries of the world [1]. It is one of the most disabling diseases and 
has great emotional impact on both the survivors of stroke and their relatives [2]. 
Stroke can affect virtually all human functions and unlike other disabling condi-
tions, the onset is sudden, leaving the survivor and family unprepared to deal with 
the consequences which can be clinical, social and economic [3]. In most develop-
ing countries, people affected by stroke present late to hospital and even then, are 
only kept in hospital for a short period until they are medically stable. They are 
then discharged home while still functionally dependent to the care of relatives 
who lack knowledge on what to do hence the need to be trained [3–5]. There are no 
institutions where they can get community support and the few that are available 
are beyond the reach of many. This puts the burden of care at home on the rela-
tives. This is the case in Zimbabwe, Rwanda, Tanzania and South Africa [5, 6]. The 
chapter therefore gives information on supporting informal caregivers in order to 
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improve functional outcomes among survivors of stroke and quality of life among 
both the survivors and caregivers [7].
It also gives an overview of the extent and consequences of the stroke problem 
in low resource settings, length of hospital stay and the implications on stroke 
survivors and their caregivers, and the impact of stroke in terms of mortality 
and morbidity. Furthermore, the chapter looks at the rehabilitation of stroke 
patients, the impact of stroke on caregivers, and how patient and caregiver 
training can improve outcomes for both the patient and caregiver in low resource 
settings. In addition, it highlights the reason why supporting survivors of stroke 
and their caregivers are important in these settings considering that there are 
no consistent hospital-based services to support them. Finally, it outlines how 
a training programme for stroke patients and their caregivers can be developed 
using Kern’s six step model [8].
2. Epidemiology of stroke
Projected figures indicate that stroke is reaching epidemic proportions due to 
increased non-communicable diseases and HIV, and will be the number one killer 
by 2020 [9–11]. According to the Centre for Disease Control and Prevention, the 
incidence of stroke has increased by 100% in middle-to-low-income countries 
since 2002 [10, 12]. Although this increase is related to the increasing burden of 
cardiovascular risk factors and the ageing population, infectious causes of stroke 
are also thought to contribute. According to the World Health Organisation, 15 
million people suffer from a stroke worldwide each year, and of these, 5 million die, 
5 million fully recover and another 5 million are permanently disabled and need 
assistance with activities of daily living [13]. Low- and middle-income countries 
have 70% of strokes and 87% of both stroke-related deaths and disability-adjusted 
life years [14, 15] consequently making stroke the major cause of disability in Sub-
Saharan Africa [16].
The incidence of stroke varies by race and country [17]. In SSA, most cases of 
stroke occur in relatively young people (mean age < 60 years in most studies), some 
10–15 years younger than patients with stroke in developed countries [11, 17–21]. 
Earlier, Feigin and colleagues had found the mean ages for men and women to be 70 
and 75 years respectively [22]. In Chile, the mean age was reported to be 66.4 years 
[23]; while it was found it to be less than 50 years for sub Saharan Africa [24]. This 
was in line with findings in Malawi where the mean age was 54.2 ± 16.9 years [11]. 
A Gambian study found the mean age to be 58 years (10–15 years) younger than 
patients in developed countries [25]; as is the case with Brazil where the mean age 
was 64.1 years [26]. In Ghana the mean age of stroke patients is 63.68 years and the 
male to female ratio is 1:0.96 [27]. In Sudan the mean age was found to be 56.61 [28]. 
However in Zimbabwe there were more females than male [5, 20, 29].
It is hoped that improved post stroke care, through caregiver support and train-
ing would reduce morbidity and mortality among stroke survivors and improve 
caregiver outcomes in low income countries. Information on causes and prevention 
of subsequent strokes may be important to give during caregiver support so as to 
empower them and improve compliance with medications.
3. Length of hospital stay (LOS)
Generally, LOS in African hospitals and other developing countries is short 
and range from 2 to 30 days [20, 30–37]. Shorter LOS may be indicative of fewer 
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rehabilitation sessions and reduced impact on stroke survivor outcomes [6]. In 
2012, 6 ± 4 days were reported in South Africa [32]. This was however lower than 
the 14 days previously reported for public hospitals in the same country in 2002 
[34]. Other authors reported up to 30 days of hospital stay in South Africa [37]. LOS 
has a bearing on the state at which patients are discharged in terms of function. This 
may mean that the stroke survivor will still need care, and within 2 days, caregivers 
may not have been trained on care or even have met rehabilitation personnel to get 
information about their sick relative.
There are other reasons too. In most instances, survivors of stroke and their rela-
tives cannot afford long LOS as this means higher hospital bills [33–35]. Hospitals 
also need beds for other ill patients so once patient is stable, they are discharged 
home to the care of relatives more likely due to pressure for beds as survivors of 
stroke do not pay in the public hospitals in many developing countries [36, 38, 39]. 
Furthermore, most patients would have presented late to hospital due to several 
factors and the stroke would have progressed, and condition worsened [5, 40]. This 
is not unique to African countries as this was also the case in Jordan where 32% of 
the population was not covered by any health and social insurance, and also spent 
less time in hospital [41]. Short hospital stay also means that patients are discharged 
before they are fully functional [39, 42]. This may be an indication that patients 
are kept in hospital until they are medically stable but not for rehabilitation [6]. As 
in the Zimbabwean setting, there may be no community services available to cater 
for the stroke survivors and their caregivers in most instances. Even in developed 
countries, it was found that caregivers lack knowledge on how to care for their rela-
tives with stroke and are not trained to care [42].
Survivors do better with an organised, multidisciplinary approach to treatment 
in which they and the caregivers are a part, hence the need to offer support to 
caregivers [7, 43]. The ideal management of stroke involves several aspects although 
these are not uniform in different countries. These include rapid response systems 
to stroke where patients are seen within 3 hours and proper diagnosis is made which 
includes Computerised Tomography (CT) scans and Magnetic Resonance Imaging 
(MRI). Patients are also put in Stroke units for transition of care and given throm-
bolysis. Once stable they start rehabilitation treatment before being discharged 
home or to institutions. However, well-organised stroke services are virtually 
absent in the government sector in most developing countries [44]. For example, 
in Zimbabwe, current stroke management is hospital-based because most of the 
hospitals are acute care facilities and are not designed to provide rehabilitation in 
the wards beyond patient’s discharge from the acute ward. From experience, rapid 
response is not available as most patients are not able to present to hospital on time 
after stroke. Most survivors also cannot afford the diagnostic procedures hence 
physicians depend on clinical symptoms for diagnosis. This is also compounded 
by a high staff turn-over making it difficult for patients to get consistent care. 
Challenges may then occur with coordination, availability of health care profession-
als and finances [34, 45].
The short length of stay in most hospitals in developing countries, (on average, 
up to 2 weeks) may be too short considering the time required to restore function 
post stroke. After the survivors of stroke are stable in terms of blood pressure, they 
are discharged back into the community usually with a disability, to the care of 
their family who have to offer physical, emotional and psychological support. This 
is indicative of a situation where survivors are discharged home to families who 
may not be fully prepared to cope with the changes that have occurred in the stroke 
survivors. This scenario has been going on for a long time even in middle income 
countries like South Africa [32, 34, 46, 47]. It is therefore necessary to involve 
caregivers in the pre-discharge planning of stroke survivors as failure to do so may 
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improve functional outcomes among survivors of stroke and quality of life among 
both the survivors and caregivers [7].
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incidence of stroke has increased by 100% in middle-to-low-income countries 
since 2002 [10, 12]. Although this increase is related to the increasing burden of 
cardiovascular risk factors and the ageing population, infectious causes of stroke 
are also thought to contribute. According to the World Health Organisation, 15 
million people suffer from a stroke worldwide each year, and of these, 5 million die, 
5 million fully recover and another 5 million are permanently disabled and need 
assistance with activities of daily living [13]. Low- and middle-income countries 
have 70% of strokes and 87% of both stroke-related deaths and disability-adjusted 
life years [14, 15] consequently making stroke the major cause of disability in Sub-
Saharan Africa [16].
The incidence of stroke varies by race and country [17]. In SSA, most cases of 
stroke occur in relatively young people (mean age < 60 years in most studies), some 
10–15 years younger than patients with stroke in developed countries [11, 17–21]. 
Earlier, Feigin and colleagues had found the mean ages for men and women to be 70 
and 75 years respectively [22]. In Chile, the mean age was reported to be 66.4 years 
[23]; while it was found it to be less than 50 years for sub Saharan Africa [24]. This 
was in line with findings in Malawi where the mean age was 54.2 ± 16.9 years [11]. 
A Gambian study found the mean age to be 58 years (10–15 years) younger than 
patients in developed countries [25]; as is the case with Brazil where the mean age 
was 64.1 years [26]. In Ghana the mean age of stroke patients is 63.68 years and the 
male to female ratio is 1:0.96 [27]. In Sudan the mean age was found to be 56.61 [28]. 
However in Zimbabwe there were more females than male [5, 20, 29].
It is hoped that improved post stroke care, through caregiver support and train-
ing would reduce morbidity and mortality among stroke survivors and improve 
caregiver outcomes in low income countries. Information on causes and prevention 
of subsequent strokes may be important to give during caregiver support so as to 
empower them and improve compliance with medications.
3. Length of hospital stay (LOS)
Generally, LOS in African hospitals and other developing countries is short 
and range from 2 to 30 days [20, 30–37]. Shorter LOS may be indicative of fewer 
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rehabilitation sessions and reduced impact on stroke survivor outcomes [6]. In 
2012, 6 ± 4 days were reported in South Africa [32]. This was however lower than 
the 14 days previously reported for public hospitals in the same country in 2002 
[34]. Other authors reported up to 30 days of hospital stay in South Africa [37]. LOS 
has a bearing on the state at which patients are discharged in terms of function. This 
may mean that the stroke survivor will still need care, and within 2 days, caregivers 
may not have been trained on care or even have met rehabilitation personnel to get 
information about their sick relative.
There are other reasons too. In most instances, survivors of stroke and their rela-
tives cannot afford long LOS as this means higher hospital bills [33–35]. Hospitals 
also need beds for other ill patients so once patient is stable, they are discharged 
home to the care of relatives more likely due to pressure for beds as survivors of 
stroke do not pay in the public hospitals in many developing countries [36, 38, 39]. 
Furthermore, most patients would have presented late to hospital due to several 
factors and the stroke would have progressed, and condition worsened [5, 40]. This 
is not unique to African countries as this was also the case in Jordan where 32% of 
the population was not covered by any health and social insurance, and also spent 
less time in hospital [41]. Short hospital stay also means that patients are discharged 
before they are fully functional [39, 42]. This may be an indication that patients 
are kept in hospital until they are medically stable but not for rehabilitation [6]. As 
in the Zimbabwean setting, there may be no community services available to cater 
for the stroke survivors and their caregivers in most instances. Even in developed 
countries, it was found that caregivers lack knowledge on how to care for their rela-
tives with stroke and are not trained to care [42].
Survivors do better with an organised, multidisciplinary approach to treatment 
in which they and the caregivers are a part, hence the need to offer support to 
caregivers [7, 43]. The ideal management of stroke involves several aspects although 
these are not uniform in different countries. These include rapid response systems 
to stroke where patients are seen within 3 hours and proper diagnosis is made which 
includes Computerised Tomography (CT) scans and Magnetic Resonance Imaging 
(MRI). Patients are also put in Stroke units for transition of care and given throm-
bolysis. Once stable they start rehabilitation treatment before being discharged 
home or to institutions. However, well-organised stroke services are virtually 
absent in the government sector in most developing countries [44]. For example, 
in Zimbabwe, current stroke management is hospital-based because most of the 
hospitals are acute care facilities and are not designed to provide rehabilitation in 
the wards beyond patient’s discharge from the acute ward. From experience, rapid 
response is not available as most patients are not able to present to hospital on time 
after stroke. Most survivors also cannot afford the diagnostic procedures hence 
physicians depend on clinical symptoms for diagnosis. This is also compounded 
by a high staff turn-over making it difficult for patients to get consistent care. 
Challenges may then occur with coordination, availability of health care profession-
als and finances [34, 45].
The short length of stay in most hospitals in developing countries, (on average, 
up to 2 weeks) may be too short considering the time required to restore function 
post stroke. After the survivors of stroke are stable in terms of blood pressure, they 
are discharged back into the community usually with a disability, to the care of 
their family who have to offer physical, emotional and psychological support. This 
is indicative of a situation where survivors are discharged home to families who 
may not be fully prepared to cope with the changes that have occurred in the stroke 
survivors. This scenario has been going on for a long time even in middle income 
countries like South Africa [32, 34, 46, 47]. It is therefore necessary to involve 
caregivers in the pre-discharge planning of stroke survivors as failure to do so may 
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result in unsatisfactory care-giving as a result of higher caregiver burden and poor 
quality of life for both the stroke survivor and the caregiver.
It is not clear if during the hospitalisation period the rehabilitation personnel in 
developing countries meet with the caregivers of people who have survived a stroke 
to discuss ongoing progress and pre-discharge plans. Maybe this could facilitate 
caregivers’ access to information on stroke and its consequences, prevention and 
management options.
In Zimbabwe, management of survivors of stroke involves acute care in hospi-
tals and not much of the rapid response and thrombolytic therapy in government 
hospitals. Even in private hospitals the costs of thrombolytic therapies are prohibi-
tive. Most survivors cannot afford the CT scans and MRIs either. Once survivors 
are medically stable the rehabilitation professionals intervene whilst patients are 
still admitted. However, rehabilitation systems to support survivors of stroke have 
also not been fully developed. This means that hospital management of survivors 
of stroke is also deficient. Survivors are then discharged home with very minimal 
preparation and not notwithstanding the challenges of bringing them back for 
review. There are also no call centres in communities to assist, hence no support 
systems for caregivers in communities.
4. Outcome of stroke
Few studies have been done on the outcomes of stroke in Sub Saharan Africa 
(SSA) [11, 32, 48]. Initial stroke severity and in-hospital complications were found 
to be determinants of 28-day case fatality in Mozambique [48]; while in South 
Africa the case fatality was found to be associated with poor functional ability but 
not with age [32]. An important outcome post stroke is function which will be dis-
cussed in the next section. In Malawi mild stroke and the male gender were associ-
ated with favourable outcomes and being HIV positive did not worsen the outcomes 
of stroke [11]. In Zimbabwe, a 25% in hospital case fatality rate was reported [20]. 
Some of the patients who died had pneumonia, most probably from aspiration [20].
As mentioned before, a third of all patients with stroke will fully recover, a third 
will live with some disabilities and the other third will die [13]. Those who survive 
stroke and are disabled will require some form of care [7, 13, 49, 50]. Several factors 
affect prognosis post stroke. Some of these include demographic characteristics, 
type of stroke, severity and immediate and long-term post stroke care [51]. Factors 
that may contribute to a good prognosis after stroke are youth, mild deficit, speedy 
resolution of symptoms, no loss of consciousness, independent sitting balance, no 
cognitive impairment or urinary incontinence [52]. Medical complications are fre-
quent among individuals who have had a stroke, increasing the length of hospitali-
sation as well as the costs of care. These complications are a major cause of death in 
the acute and sub-acute stroke phases [53]. Some events, such as cardiac abnormali-
ties, dysphagia and pneumonia, are often apparent early after stroke onset whereas 
others, such as bed sores, venous thrombosis, and falls, can occur after several days 
[54, 55]. Potential cardiac complications such as atrial fibrillation and myocardial 
infarction are also common after stroke [54].
Neurological recovery in stroke occurs mainly within 1–3 months post stroke, 
whilst functional recovery occurs more fully at 4–6 months [56]. According to 
Doğan et al., 10% of stroke patients recover spontaneously within the first month, 
and 80% of patients are candidates for rehabilitation while the last 10% do not 
respond to treatment [57]. This is however different from the 2007 WHO report 
[13]. The neurological recovery of stroke often improves significantly within 3 
weeks and function may continue to improve up to 18 months [46].
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4.1 Mortality among people who suffer from stroke
Two-thirds of stroke deaths occur in people living in developing countries and 
40% of those with stroke aged less than 70 years [58]. The Inter-stroke phase 1 
study 2007–2009 reported that 5.7 million deaths in 2005 were due to stroke and the 
number is projected to rise to 7.8 million by 2030 and 87% of these will be in low or 
middle in-come countries. Similar findings were reported when it was estimated 
that approximately 80% of all deaths by stroke occur in developing countries [59]. 
However, age adjusted stroke mortality in adults in SSA seemed to be like developed 
countries [60]. This they attributed to lack of accuracy of longitudinal data collec-
tion in different regions.
In Africa, stroke accounts for 0.9–4% of hospital admissions and 2.8–4.5% of 
total deaths [61]. This is in line with findings elsewhere where it was reported that 
mortality due to stroke in low- and middle-income countries was the 5th leading 
cause of death in adults aged 15–59 years [62]. The same study found stroke to 
be the 7th leading cause of death in SSA with HIV/AIDS at the top. According to 
UNAIDS, HIV related deaths made up 16% in South Africa, 17% in Nigeria and 6% 
in Zimbabwe of total death [63]. This makes the need to support survivors of stroke 
more important so as to reduce mortality in communities.
This high stroke case fatality in Africa was found to be related to limited health-
care facilities and uncontrolled risk factors such as hypertension and diabetes which 
conditions and resultant death can be prevented [64]. Higher values have been 
found from community studies where deaths due to stroke contribute 5–10% of 
deaths in Tanzania [65]. Other studies in Africa have reported between 20 and 45% 
case fatality rates between admission and one-year post stroke [31, 32]. Stroke has 
been projected to be the 3rd leading cause of death in low income countries by 2030. 
Therefore, there is need for vigilance in prevention and care of patients with stroke 
as previously mentioned.
In South Africa based on an 11-disability adjusted number of life years lost per 
1000 of the population, stroke was declared a catastrophic illness as the prevalence 
of stroke in South Africa was reported to be 3000/100,000 people [66], much 
higher than the 500/100,000 people living with strokes in developed countries 
[67]. It may be safe to conclude that Sub-Saharan Africa has relatively low stroke 
incidence and prevalence but has high mortality rates [17]. This is may be attributed 
to high prevalence of smoking and other risk factors for stroke. Factors associated 
with mortality include severity of stroke, being a woman, haemorrhagic stroke, low 
level of consciousness upon admission and failing a swallow test, irreversible coma, 
stroke recurrence and other secondary infections and pressure sores, increased age, 
diabetes mellitus and stroke subtypes as independent predictors of 30-day case 
fatalities. Similarly, the relative risk of death from stroke was found to be higher for 
females in Ghana [68].
Ischaemic stroke patients with a National Institutes of Health Stroke Scale 
(NIHSS) score of less than 10 have a 60–70% chance of a favourable outcome 
at 1 year compared with only a 4–16% chance if the score is more than 20 [53]. 
However, ischaemic strokes have better prognosis, but less functional prognosis 
compared to haemorrhagic strokes [69]. Upon follow up, 23% of patients with 
ischaemic stroke had died while 65% of the survivors were functionally indepen-
dent at 1 year [69]. Meanwhile, among the patients with haemorrhagic strokes, 62% 
had died, and among the survivors, 68% were functionally independent at 1 year. 
Among those with subarachnoid haemorrhage, 48% were dead and 76% of the sur-
vivors were functionally independent. The differences in mortality during the acute 
phase between the two types of strokes are said to be due to the fact that haemor-
rhagic strokes are more severe at onset than ischaemic strokes. This results in 
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result in unsatisfactory care-giving as a result of higher caregiver burden and poor 
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systems for caregivers in communities.
4. Outcome of stroke
Few studies have been done on the outcomes of stroke in Sub Saharan Africa 
(SSA) [11, 32, 48]. Initial stroke severity and in-hospital complications were found 
to be determinants of 28-day case fatality in Mozambique [48]; while in South 
Africa the case fatality was found to be associated with poor functional ability but 
not with age [32]. An important outcome post stroke is function which will be dis-
cussed in the next section. In Malawi mild stroke and the male gender were associ-
ated with favourable outcomes and being HIV positive did not worsen the outcomes 
of stroke [11]. In Zimbabwe, a 25% in hospital case fatality rate was reported [20]. 
Some of the patients who died had pneumonia, most probably from aspiration [20].
As mentioned before, a third of all patients with stroke will fully recover, a third 
will live with some disabilities and the other third will die [13]. Those who survive 
stroke and are disabled will require some form of care [7, 13, 49, 50]. Several factors 
affect prognosis post stroke. Some of these include demographic characteristics, 
type of stroke, severity and immediate and long-term post stroke care [51]. Factors 
that may contribute to a good prognosis after stroke are youth, mild deficit, speedy 
resolution of symptoms, no loss of consciousness, independent sitting balance, no 
cognitive impairment or urinary incontinence [52]. Medical complications are fre-
quent among individuals who have had a stroke, increasing the length of hospitali-
sation as well as the costs of care. These complications are a major cause of death in 
the acute and sub-acute stroke phases [53]. Some events, such as cardiac abnormali-
ties, dysphagia and pneumonia, are often apparent early after stroke onset whereas 
others, such as bed sores, venous thrombosis, and falls, can occur after several days 
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4.1 Mortality among people who suffer from stroke
Two-thirds of stroke deaths occur in people living in developing countries and 
40% of those with stroke aged less than 70 years [58]. The Inter-stroke phase 1 
study 2007–2009 reported that 5.7 million deaths in 2005 were due to stroke and the 
number is projected to rise to 7.8 million by 2030 and 87% of these will be in low or 
middle in-come countries. Similar findings were reported when it was estimated 
that approximately 80% of all deaths by stroke occur in developing countries [59]. 
However, age adjusted stroke mortality in adults in SSA seemed to be like developed 
countries [60]. This they attributed to lack of accuracy of longitudinal data collec-
tion in different regions.
In Africa, stroke accounts for 0.9–4% of hospital admissions and 2.8–4.5% of 
total deaths [61]. This is in line with findings elsewhere where it was reported that 
mortality due to stroke in low- and middle-income countries was the 5th leading 
cause of death in adults aged 15–59 years [62]. The same study found stroke to 
be the 7th leading cause of death in SSA with HIV/AIDS at the top. According to 
UNAIDS, HIV related deaths made up 16% in South Africa, 17% in Nigeria and 6% 
in Zimbabwe of total death [63]. This makes the need to support survivors of stroke 
more important so as to reduce mortality in communities.
This high stroke case fatality in Africa was found to be related to limited health-
care facilities and uncontrolled risk factors such as hypertension and diabetes which 
conditions and resultant death can be prevented [64]. Higher values have been 
found from community studies where deaths due to stroke contribute 5–10% of 
deaths in Tanzania [65]. Other studies in Africa have reported between 20 and 45% 
case fatality rates between admission and one-year post stroke [31, 32]. Stroke has 
been projected to be the 3rd leading cause of death in low income countries by 2030. 
Therefore, there is need for vigilance in prevention and care of patients with stroke 
as previously mentioned.
In South Africa based on an 11-disability adjusted number of life years lost per 
1000 of the population, stroke was declared a catastrophic illness as the prevalence 
of stroke in South Africa was reported to be 3000/100,000 people [66], much 
higher than the 500/100,000 people living with strokes in developed countries 
[67]. It may be safe to conclude that Sub-Saharan Africa has relatively low stroke 
incidence and prevalence but has high mortality rates [17]. This is may be attributed 
to high prevalence of smoking and other risk factors for stroke. Factors associated 
with mortality include severity of stroke, being a woman, haemorrhagic stroke, low 
level of consciousness upon admission and failing a swallow test, irreversible coma, 
stroke recurrence and other secondary infections and pressure sores, increased age, 
diabetes mellitus and stroke subtypes as independent predictors of 30-day case 
fatalities. Similarly, the relative risk of death from stroke was found to be higher for 
females in Ghana [68].
Ischaemic stroke patients with a National Institutes of Health Stroke Scale 
(NIHSS) score of less than 10 have a 60–70% chance of a favourable outcome 
at 1 year compared with only a 4–16% chance if the score is more than 20 [53]. 
However, ischaemic strokes have better prognosis, but less functional prognosis 
compared to haemorrhagic strokes [69]. Upon follow up, 23% of patients with 
ischaemic stroke had died while 65% of the survivors were functionally indepen-
dent at 1 year [69]. Meanwhile, among the patients with haemorrhagic strokes, 62% 
had died, and among the survivors, 68% were functionally independent at 1 year. 
Among those with subarachnoid haemorrhage, 48% were dead and 76% of the sur-
vivors were functionally independent. The differences in mortality during the acute 
phase between the two types of strokes are said to be due to the fact that haemor-
rhagic strokes are more severe at onset than ischaemic strokes. This results in 
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increased pressure in the brain with mass shifting of brain which may be the reason 
for increased fatality. Later, as resolution occurs, swelling and pressure reduce with 
resultant reduction in mortality. Function is also better in Haemorrhagic strokes 
because there is less brain damage and once swelling and pressure have resolved, 
function is restored [70]. In Zimbabwe, not all patients with stroke can afford CT 
scans for diagnostic purposes, hence comparison is difficult. This also makes it dif-
ficult for typing the strokes although this is an important aspect of this study.
4.2 Functional outcomes in stroke
Poor functional recovery is associated with bowel and urinary incontinence, 
long time between stroke onset and hospital admission, more severe hemiparesis, 
visuospatial deficits and lower FIM scores [71, 72]. Functional recovery after stroke 
is also closely related to age, aetiology and severity of neurological deficit, nature 
of lesion and localization including integrity of collateral blood supply [52, 71]. 
The authors also reported that factors such as patient’s education, motivation and 
socio-economic level may be important in recovery. Psychosocial and cognitive 
impairments and other neurological and sociodemographic factors have been seen 
to affect the functional recovery of stroke survivors [73].
Functional prognosis is better among the patients with haemorrhagic stroke 
in the long term compared to patients with ischaemic stroke even when someone 
is caring for them [74–81]. This is however different from findings that report 
worse functional outcomes among haemorrhagic strokes [82]. In line with the 
study by Bamford et al. [69], Kelly et al., had comparable results when they used 
the Functional Independence Measure (FIM) and found that among 1064 patients 
with stroke, 871 had ischaemic stroke and these had better functional abilities at 
admission compared to those with haemorrhagic stroke [81]. However, at follow 
up, the patients with haemorrhagic stroke had better recovery in comparison 
to those with ischaemic stroke. However, the treatment they received was not 
standardised. Unfortunately there are not many studies where comparison of 
functional outcomes was done after training in Africa. In South Africa poor func-
tional outcomes were found to be associated with female gender, and more severe 
stroke and poor physical condition when patients were followed up at 6 weeks, 
6 months and 1 year [32]. This was also the case later in Malawi [31]. Stroke has 
both psychosocial and physical impact upon both the survivors of stroke and their 
caregivers and it is important to discuss this area. These are aspects that affect 
quality of life.
4.3 Participation
Participation restriction means that survivors are unable to take part in areas 
of life such as usual roles and hobbies. They are the challenges individuals would 
have ‘in involvement in life situations’ [83]. Achieving independent ambulation 
within the community post stroke is not easy [84]. This has an impact on com-
munity reintegration post stroke as the survivors may not be able to take part in 
their former activities and may become isolated [85]. It is therefore important 
to assess stroke survivor’s participation post stroke to get a complete picture of 
caregiver burden [86]. The relationship between participation and the environ-
ment was also highlighted elsewhere where the authors reported that perceptions 
of danger in the environment may make survivors increase speed for safety 
as seen when crossing roads [87]. In some cases, fear and the terrain may not 
be conducive for mobility. This is because there may be stones around and the 
terrain may be hilly thus reducing wheelchair mobility [6, 87]. Rehabilitation 
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professionals may face difficulties in trying to equip stroke survivors with the 
skills for community mobilisation in different terrains. Further, survivors may 
not be able to manoeuvre wheelchairs given for mobilisation as the environment 
plays a role in the outcome of rehabilitation and the patient’s recovery after 
stroke as it may act as a barrier [6, 87, 88]. This is more so because the objects, 
their position and orientation in the environment drives the motor pattern in an 
action as survivors try to move about [6].
Inability to ambulate within the community by survivors of stroke directly 
affects their community participation [87]. Reduced ambulation leads to poor 
accessibility of community facilities and this in turn causes poor social integration 
of survivors of stroke [89]. Once the survivors cannot access facilities, integration 
into community becomes poor, leading to non-compliance with medications [85]. 
This is further compounded by the fact that about 66% of community dwelling 
survivors of stroke will need help with at least one activity of daily living (ADL) 
[90]. Availability of support from family, acquaintances, peers, colleagues, neigh-
bours and personal care providers are facilitators to activity participation but these 
are not always available as they have other roles to play [91]. The impact of stroke 
on ADLs, emotions, cognition, and participation in social activities therefore 
significantly compromises survivor well-being and inevitably alters their and 
caregiver’s quality of life [67]. However, stroke survivors generally function better 
in activities of daily living than they do in social activities [92]. This is because 
stroke survivors are dependent on their caregivers for single and multiple tasks 
for up to one-year post stroke thus further compromising social integration [91]. 
Unfortunately, this need for help may cause dependency as they may continue to 
play the sick role.
5. Rehabilitation and caregiving of stroke survivors
The occurrence of stroke is devastating and overwhelming for both the survi-
vor who becomes disabled suddenly and the family who are not prepared for the 
changes brought about in their lives when managing the multiple problems of a 
patient post stroke [7]. This is because they may face financial worries and are not 
prepared for the long care-giving hours and emotional stress which are predomi-
nant factors in increasing caregiver stress when one is caring for stroke survivors 
[93]. Caregivers should therefore be involved early on in the rehabilitation phase 
so that they understand and deal with the problems and prepare for after discharge 
life. The quality of rehabilitation, timing of treatment and amount of time spent 
in hospital have a bearing on the functional outcomes of the patients [6, 94–96]. 
Success of rehabilitation is also determined by emotional and physical challenges 
that the patient faces post stroke [97]. It is therefore important to identify bar-
riers to an efficient rehabilitation service [6, 98, 99]. This is because availability 
of resources will affect the standard of stroke rehabilitation that patients receive 
[6, 100]. Effective rehabilitation initiated early after stroke can help enhance the 
recovery process and minimise functional disability which in turn improves quality 
of life of both the patient and the caregiver [42, 43, 97, 101–103]. Caregivers need to 
be well prepared for the emotional and physical challenges that the survivor faces as 
they may become barriers to care or even have a bearing on caregiver burden.
Moreover, organised respite care services that are available in developed coun-
tries may not be available in Zimbabwe to help with care of stroke survivors. This 
means that caregivers who have to look after survivors for long periods of time in 
most cases have no respite support. Disability benefits or allowances and voluntary 
support services to assist people living with disabilities and their caregivers may 
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within the community post stroke is not easy [84]. This has an impact on com-
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their former activities and may become isolated [85]. It is therefore important 
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caregiver burden [86]. The relationship between participation and the environ-
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professionals may face difficulties in trying to equip stroke survivors with the 
skills for community mobilisation in different terrains. Further, survivors may 
not be able to manoeuvre wheelchairs given for mobilisation as the environment 
plays a role in the outcome of rehabilitation and the patient’s recovery after 
stroke as it may act as a barrier [6, 87, 88]. This is more so because the objects, 
their position and orientation in the environment drives the motor pattern in an 
action as survivors try to move about [6].
Inability to ambulate within the community by survivors of stroke directly 
affects their community participation [87]. Reduced ambulation leads to poor 
accessibility of community facilities and this in turn causes poor social integration 
of survivors of stroke [89]. Once the survivors cannot access facilities, integration 
into community becomes poor, leading to non-compliance with medications [85]. 
This is further compounded by the fact that about 66% of community dwelling 
survivors of stroke will need help with at least one activity of daily living (ADL) 
[90]. Availability of support from family, acquaintances, peers, colleagues, neigh-
bours and personal care providers are facilitators to activity participation but these 
are not always available as they have other roles to play [91]. The impact of stroke 
on ADLs, emotions, cognition, and participation in social activities therefore 
significantly compromises survivor well-being and inevitably alters their and 
caregiver’s quality of life [67]. However, stroke survivors generally function better 
in activities of daily living than they do in social activities [92]. This is because 
stroke survivors are dependent on their caregivers for single and multiple tasks 
for up to one-year post stroke thus further compromising social integration [91]. 
Unfortunately, this need for help may cause dependency as they may continue to 
play the sick role.
5. Rehabilitation and caregiving of stroke survivors
The occurrence of stroke is devastating and overwhelming for both the survi-
vor who becomes disabled suddenly and the family who are not prepared for the 
changes brought about in their lives when managing the multiple problems of a 
patient post stroke [7]. This is because they may face financial worries and are not 
prepared for the long care-giving hours and emotional stress which are predomi-
nant factors in increasing caregiver stress when one is caring for stroke survivors 
[93]. Caregivers should therefore be involved early on in the rehabilitation phase 
so that they understand and deal with the problems and prepare for after discharge 
life. The quality of rehabilitation, timing of treatment and amount of time spent 
in hospital have a bearing on the functional outcomes of the patients [6, 94–96]. 
Success of rehabilitation is also determined by emotional and physical challenges 
that the patient faces post stroke [97]. It is therefore important to identify bar-
riers to an efficient rehabilitation service [6, 98, 99]. This is because availability 
of resources will affect the standard of stroke rehabilitation that patients receive 
[6, 100]. Effective rehabilitation initiated early after stroke can help enhance the 
recovery process and minimise functional disability which in turn improves quality 
of life of both the patient and the caregiver [42, 43, 97, 101–103]. Caregivers need to 
be well prepared for the emotional and physical challenges that the survivor faces as 
they may become barriers to care or even have a bearing on caregiver burden.
Moreover, organised respite care services that are available in developed coun-
tries may not be available in Zimbabwe to help with care of stroke survivors. This 
means that caregivers who have to look after survivors for long periods of time in 
most cases have no respite support. Disability benefits or allowances and voluntary 
support services to assist people living with disabilities and their caregivers may 
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not be available as is the case in Zimbabwe [104, 105]; yet the caregiver’s role in the 
health delivery system and support of stroke survivors is important. The global 
prevailing economic meltdown may also affect development of community services 
in most developing countries. This is despite home-based rehabilitation being con-
sidered an important complementary component of health-care to address stroke 
related disability as advocated by WHO in the case of HIV/AIDS. In South Africa, 
Hale et al. noted that stroke care leaves the caregiver who has no knowledge of what 
is going on in a predicament of what to do as information provided may not meet all 
their needs [33]. This results in increased caregiver strain as they may be the only 
source of rehabilitation available to the survivors of stroke as most cannot afford 
formal services due to poverty [34, 98]. There is therefore a missing link between 
hospital rehabilitation and survivors of stroke and their caregivers post discharge 
within the community.
The large numbers of people affected by stroke may also mean that the caregiver 
burden will increase and quality of life among many people will be affected. It is 
therefore important that caregivers of stroke survivors receive adequate caregiver 
support. When caregivers do not receive support, they may become strained 
resulting in inadequate support to survivors that will affect their quality of life. It 
is hoped that equipping caregivers by training them to look after stroke survivors 
may hopefully improve their outcomes and those of stroke survivors they care for. 
This is because elsewhere it has also been previously reported that disability affects 
quality of life and functional independence among survivors of stroke and increases 
burden of care among the caregivers [7].
6. Community management of stroke
Post stroke, many stroke survivors want to return to the roles they had prior to 
the stroke and integrate into their communities [46, 106]. However, the specific 
support systems required in helping stroke survivors and their caregivers remain 
unclear as the onset of stroke is sudden and patients and relatives are ill prepared 
to deal with the subsequent disability [7, 93, 107]. Survivors of stroke are primar-
ily rehabilitated as inpatients and are then discharged home once it is felt that the 
person and their primary caregivers can cope [108]. In most low-income countries 
community support for stroke survivors and their families remains fragmented and 
poorly coordinated [6, 42, 101, 107]. In rural areas this problem is further com-
pounded by physical geographical surroundings which are not conducive for mobil-
ity in any form [109, 110]. This results in patients receiving minimal therapeutic 
interventions to assist with recovery due to lack of access to rehabilitation services. 
In addition, this further strengthens the need for home-based rehabilitation [111, 
112]. Due to low numbers of rehabilitation personnel and inaccessibility of commu-
nities, family caregivers are important among survivors of stroke.
After experiencing a stroke, 60–74% of survivors need caregivers to take care 
of them since some recover with physical and cognitive limitations [7, 90, 113]. 
This is usually provided by informal caregivers [114]; who are mainly women  
[38, 115]; and may be children, spouses or other relatives of the stroke survivors 
[116, 117]. Due to shortage of resources in low resourced countries, support 
of caregivers to enable them to offer home rehabilitation may be the option of 
choice. Many caregivers end up suffering from emotional, physical and psycho-
logical burnout due to the burden of caring for stroke relatives over a long period 
[7, 116]. They are also left with little time for their own responsibilities. Financial 
constraints may limit visits to hospitals to get support and distances to health 
centres may be prohibitive [32]. The fate of stroke victims has been documented 
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elsewhere where many die or live with morbidities [13, 32, 93]. The challenges 
that caregivers face require that they get support from the health professionals to 
carry out the caregiving duties.
Earlier on, the importance of caregivers as part of the community support for 
survivors of stroke was highlighted [118]. Their involvement may help reduce stroke 
recurrence and complications associated with stroke, improve function and physi-
cal health as well as community reintegration [42, 47, 107, 119]. Caregiver involve-
ment may reduce disability and depression [120] which can occur due to increased 
caregiver burden [114, 121]; and improve quality of life [122]; among survivors of 
stroke. Women, younger caregivers and caregivers with poor physical health are at 
a higher risk of suffering caregiver burden [123]. Caregiver support programmes 
should focus on self-efficacy, social support and coping strategies among these 
caregivers. Financial constraints are the chief causes of burden in caring for stroke 
survivors post discharge and could be minimised by educating caregivers on basic 
stroke management principles to reduce the economic burden when accessing 
rehabilitation services [32].
After suffering a stroke, stroke survivors and relatives are faced with physical, 
emotional and mental problems and health care providers should educate them 
about basic care before the patient is discharged to adequately prepare for life at 
home [124, 125]. As previously mentioned, after experiencing a stroke, 66–78% 
of survivors world-wide need caregivers to help with activities of daily living since 
some recover with physical and cognitive limitations [7, 66, 67, 113]. Caring for a 
stroke survivor is a complex, stressful, life changing experience for both the survi-
vors and their family caregivers especially when one had not prepared for it [7, 117].
Caring for a stroke survivor requires both informal and formal caregivers. While 
formal caregivers are trained, the informal caregivers are not, and are also not paid 
for the services they offer yet play an important role in the survival of patient with 
stroke after discharge [38, 126, 127]. Most caregivers are therefore put into a carer 
role without any idea of what to do with the resultant increase in caregiver burden 
and poor quality of life [38, 42, 47, 100, 108]. As previously discussed, this lack of 
training can overwhelm caregivers who are ill prepared to care for someone with 
these limitations [7, 38, 42, 128–130]. The caregivers and survivors of stroke rarely 
receive information on the nature of stroke, its cause, management and prognosis 
[131]. In support of this finding other authors also noted that the specific caregiver 
needs were information on causes of stroke, stroke progression, prevention of 
recurrence, practical care, emotional care and guidelines on use of medicines as 
needed by people who have survived a stroke [42, 132, 133]. This further compli-
cates their lives as their duties will also involve administration of drugs, assisting 
with rehabilitation exercises and performing medical procedures for which they 
are not trained [90, 134]. Assisting with rehabilitation exercises make them play an 
important role in rehabilitation [127].
Stroke is also associated with many complications such as falls, pressure sores, 
urinary tract infections, chest infections and caregivers must deal with these too 
[135]. The amount of time needed to look after an individual varies depending 
on several factors which may include severity of the stroke and relationship of 
caregiver to stroke survivor [136, 137]. Caregivers were found to complain of long 
hours of caregiving which in turn leads to increased caregiver strain and reduced 
sleep [138]. Caregiver strain also increases over time [139, 140]. Length of care is 
determined by the severity of the stroke where the more severely affected stroke 
survivors need constant care thus more strain in the caregivers [141, 142]. In con-
trast, another in their study found no difference in strain between those who had 
looked after a survivor of stroke over a long time compared to those who had cared 
over a short period [123]. This is because the authors found that other factors such 
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with rehabilitation exercises and performing medical procedures for which they 
are not trained [90, 134]. Assisting with rehabilitation exercises make them play an 
important role in rehabilitation [127].
Stroke is also associated with many complications such as falls, pressure sores, 
urinary tract infections, chest infections and caregivers must deal with these too 
[135]. The amount of time needed to look after an individual varies depending 
on several factors which may include severity of the stroke and relationship of 
caregiver to stroke survivor [136, 137]. Caregivers were found to complain of long 
hours of caregiving which in turn leads to increased caregiver strain and reduced 
sleep [138]. Caregiver strain also increases over time [139, 140]. Length of care is 
determined by the severity of the stroke where the more severely affected stroke 
survivors need constant care thus more strain in the caregivers [141, 142]. In con-
trast, another in their study found no difference in strain between those who had 
looked after a survivor of stroke over a long time compared to those who had cared 
over a short period [123]. This is because the authors found that other factors such 
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as cognitive, emotional and behavioural changes in the survivor have a negative 
influence on caregiver strain. On the other hand, high confidence knowledge about 
efficacy, high satisfaction with social support and frequent use of coping strategy 
confronting all had a positive influence [123]. They therefore concluded that care-
giver support programs should include education about self-efficacy, stimulation of 
the use of the coping strategy confronting and training in mobilising social support 
in a way that is satisfactory to caregivers. Furthermore, support programs should 
be offered both to caregivers who recently started to take care of a survivor and to 
caregivers who have been taking care of a patient for a longer time [123].
The mean age of caregivers ranged from 36 to 70 years [100, 142]. The most 
common informal caregivers are spouses and adult children or other relatives most 
of whom are poor [100, 116, 121, 143, 144]. Most of the caregivers are females [32, 
100, 123, 142, 145]. In most cases there is no one else to carry out the caregiving 
task [146]. Female caregivers usually encounter more caregiving demands than 
male caregivers [147, 148]. This is because the female caregivers spend more time 
doing care giving tasks and other multiple family responsibilities [147, 149]. They 
are also the cornerstone for development and implementation of community care 
policies [141]. Further to this it was also found that 93% of men were cared for by 
women (their spouse in 73% of cases), while 55% of women were cared for by men 
[100]. Governments should make sure that poor people are educated on reduction 
of chronic diseases [150]. This is because they will end up caring for their sick 
relatives.
An attractive option is the use of formal caregivers, but they are expensive and 
for low resources settings like SSA, where accessibility to health settings is difficult 
[6, 109]. Home rehabilitation using informal caregivers is therefore the option 
of choice and if they receive support, may provide alternative cost-effective care 
compared to usual care [36, 151]. However, caregivers may end up giving up their 
jobs to care for the stroke survivor full time, give up their houses to stay with the 
stroke survivor and give up some social activities like going out with friends and 
going to church [38, 116, 138]. As discussed before, caregivers have not been made 
an integral part of the health care system [118], yet are responsible for the improve-
ment of quality of life and survival of stroke survivors post discharge and suffer 
burnout themselves [38, 122].
In most SSA countries, most of the caregivers are informal [36]. Due to the 
high HIV burden the occurrence of stroke in HIV positive patients causes a 
dual burden of care [10, 31, 32]. Lack of support systems in poor countries also 
pose challenges as most of those affected are poor and cannot afford outside 
support [6, 44]. It was further noted that caregivers in developing countries 
are usually family not educated about care and face challenges in dealing with 
patients’ problems [32]. At the same time, they are expected to help lower the 
risk of stroke recurrence, reduce stroke related complications, improve function 
and subsequently improve community integration [42, 46, 47]. There is need to 
address the perceived needs of caregivers of stroke survivors to improve quality 
of life and reduce caregiver burden which may arise from long term caregiving. 
Caregiver training may be the best choice as these are available and will not need 
payment.
7. Training of caregivers of survivors of stroke
To help support survivors of stroke, stroke rehabilitation services should address 
caregiver issues and include practical training in nursing skills and counselling 
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sessions, which will help in reducing the caregiver burden and improve stroke 
survivor recovery. Survivors of stroke spend most of their time with caregivers who 
therefore need to be trained and educated on how to take care of the survivor and 
on what to expect [42].
In high income countries, caregiver training consisting of basic skills of moving 
and handling, facilitation of activities of daily living and simple nursing tasks have 
been seen to reduce caregiver burden and improve quality of life [42, 101]; and was 
cost-effective [101]. Trained caregivers were also followed up over time in South 
Africa, and the structured caregiver training positively impacted on survivors’ 
quality of life post discharge [98]. They recommended an exploration of different 
caregiver education programs to determine those that would produce the best out-
comes in patients and caregivers so that they can be adopted regionally and inter-
nationally [98]. That education of caregivers reduce the burden of care and was also 
later reported in other studies on home-based care in HIV [32, 152]. The authors 
reported that those who received support from a nurse or community care worker 
had a lower caregiver burden and had more than twice the odds of wanting to care 
for another person living with HIV in the future [152]. Any training or educational 
program should start during the acute phase of rehabilitation to prepare patients 
and caregivers for the trajectory of problems they may face during the recovery 
period [153].
Education may benefit both the survivors of stroke and caregivers by preventing 
stroke. Education is defined as ‘a planned experience that uses a combination of 
methods such as teaching, counselling and behaviour modification techniques to 
influence knowledge and behaviour’ [154]. Various interventions have been devel-
oped and evaluated with the intention of supporting informal caregivers. However, 
there are conflicting reports on their effectiveness and even for those with posi-
tive outcomes, only modest effects are reported [155, 156]. Caregiver training is a 
non-pharmacological intervention to reduce the burden on informal caregivers and 
facilitate patient recovery after stroke [131, 157].
Caregivers should receive information regarding stroke survivor handling, 
positioning and how to communicate with the stroke survivor [42, 101, 158]. 
These findings were supported by authors who reported that caregivers’ training 
programs should mainly be focused on practical demonstrations on physical activi-
ties which they do whilst performing their roles to reduce physical strains among 
caregivers [158, 159].
Education should be given to family caregivers as this will benefit the community 
as they may relay the information to others for sustainability and improve quality of 
life of stroke survivors [42, 132]. They should be educated on how to look after the 
stroke survivor to prevent complications as well as recurrence [64, 160]. Training 
should cover self-efficacy and enable coping strategies like how to mobilise social 
support and also help the stroke survivor [123]. Training caregivers will also reduce 
adverse outcomes [145] However, the long-term impact of training on caregivers is 
not known in that they may end up thinking that the training is a qualification.
In Africa, about two thirds of caregivers of stroke survivors in rural areas receive 
no basic stroke education before discharge due to scarcity of rehabilitation services 
[6, 161]. On a positive note, educating the public and health care providers about 
prevention of stroke, warning signs and symptoms of the disease has been found 
to be useful when treating patients with hypertension [64, 162]. Lack of training is 
associated with high mortality among stroke survivors and severe forms of dis-
abilities which could be minimised if training is done prior to discharge [161, 163]. 
Comparing the effects of training on the outcomes of caregivers and stroke survi-
vors may highlight the importance of this aspect of care.
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going to church [38, 116, 138]. As discussed before, caregivers have not been made 
an integral part of the health care system [118], yet are responsible for the improve-
ment of quality of life and survival of stroke survivors post discharge and suffer 
burnout themselves [38, 122].
In most SSA countries, most of the caregivers are informal [36]. Due to the 
high HIV burden the occurrence of stroke in HIV positive patients causes a 
dual burden of care [10, 31, 32]. Lack of support systems in poor countries also 
pose challenges as most of those affected are poor and cannot afford outside 
support [6, 44]. It was further noted that caregivers in developing countries 
are usually family not educated about care and face challenges in dealing with 
patients’ problems [32]. At the same time, they are expected to help lower the 
risk of stroke recurrence, reduce stroke related complications, improve function 
and subsequently improve community integration [42, 46, 47]. There is need to 
address the perceived needs of caregivers of stroke survivors to improve quality 
of life and reduce caregiver burden which may arise from long term caregiving. 
Caregiver training may be the best choice as these are available and will not need 
payment.
7. Training of caregivers of survivors of stroke
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caregiver issues and include practical training in nursing skills and counselling 
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sessions, which will help in reducing the caregiver burden and improve stroke 
survivor recovery. Survivors of stroke spend most of their time with caregivers who 
therefore need to be trained and educated on how to take care of the survivor and 
on what to expect [42].
In high income countries, caregiver training consisting of basic skills of moving 
and handling, facilitation of activities of daily living and simple nursing tasks have 
been seen to reduce caregiver burden and improve quality of life [42, 101]; and was 
cost-effective [101]. Trained caregivers were also followed up over time in South 
Africa, and the structured caregiver training positively impacted on survivors’ 
quality of life post discharge [98]. They recommended an exploration of different 
caregiver education programs to determine those that would produce the best out-
comes in patients and caregivers so that they can be adopted regionally and inter-
nationally [98]. That education of caregivers reduce the burden of care and was also 
later reported in other studies on home-based care in HIV [32, 152]. The authors 
reported that those who received support from a nurse or community care worker 
had a lower caregiver burden and had more than twice the odds of wanting to care 
for another person living with HIV in the future [152]. Any training or educational 
program should start during the acute phase of rehabilitation to prepare patients 
and caregivers for the trajectory of problems they may face during the recovery 
period [153].
Education may benefit both the survivors of stroke and caregivers by preventing 
stroke. Education is defined as ‘a planned experience that uses a combination of 
methods such as teaching, counselling and behaviour modification techniques to 
influence knowledge and behaviour’ [154]. Various interventions have been devel-
oped and evaluated with the intention of supporting informal caregivers. However, 
there are conflicting reports on their effectiveness and even for those with posi-
tive outcomes, only modest effects are reported [155, 156]. Caregiver training is a 
non-pharmacological intervention to reduce the burden on informal caregivers and 
facilitate patient recovery after stroke [131, 157].
Caregivers should receive information regarding stroke survivor handling, 
positioning and how to communicate with the stroke survivor [42, 101, 158]. 
These findings were supported by authors who reported that caregivers’ training 
programs should mainly be focused on practical demonstrations on physical activi-
ties which they do whilst performing their roles to reduce physical strains among 
caregivers [158, 159].
Education should be given to family caregivers as this will benefit the community 
as they may relay the information to others for sustainability and improve quality of 
life of stroke survivors [42, 132]. They should be educated on how to look after the 
stroke survivor to prevent complications as well as recurrence [64, 160]. Training 
should cover self-efficacy and enable coping strategies like how to mobilise social 
support and also help the stroke survivor [123]. Training caregivers will also reduce 
adverse outcomes [145] However, the long-term impact of training on caregivers is 
not known in that they may end up thinking that the training is a qualification.
In Africa, about two thirds of caregivers of stroke survivors in rural areas receive 
no basic stroke education before discharge due to scarcity of rehabilitation services 
[6, 161]. On a positive note, educating the public and health care providers about 
prevention of stroke, warning signs and symptoms of the disease has been found 
to be useful when treating patients with hypertension [64, 162]. Lack of training is 
associated with high mortality among stroke survivors and severe forms of dis-
abilities which could be minimised if training is done prior to discharge [161, 163]. 
Comparing the effects of training on the outcomes of caregivers and stroke survi-
vors may highlight the importance of this aspect of care.
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The training should not be generic, but tailor made or individually adapted for 
clients and include written information for caregivers given during the training ses-
sion together with pictorial charts [156, 157, 164–166]. Stroke survivors should also 
be educated about their condition, treatment, prognosis and what they may need 
to do or not do and about hypertension as their knowledge was found to be subop-
timal [64, 154, 160]. This finding strengthened findings from South Africa, which 
reported that 79% of hypertension and 64% of strokes said they did not know 
about the risk of stroke [167]. Development of a caregiver training programme that 
can be adapted to individual needs is important as any caregiver may receive this 
mode of support.
Any assistive devices used during training should be offered to them to take 
home to prevent regression of the stroke survivors’ condition and difficulties in 
execution of the exercise programs [168]. Any training involving stroke survivors 
should be done after the acute phase, when they are less overwhelmed and able to 
comprehend the information [158, 169]. It is also important for stroke survivors 
and caregivers to be educated about the importance of incorporating the survivor 
back into the family [170]; although in some instances it may not result in improved 
perceived health status [171]. This is because education may improve carers’ knowl-
edge about stroke and its consequences but may fail to provide positive solutions 
to their problems hence lack of improvement in perceived health status [171]. It is 
therefore important for health workers to disseminate the training to other staff for 
sustenance of the training programme [172]. Training after the acute phase may be 
a challenge in situations where beds are required for other patients. In that case the 
caregivers may only receive training and later survivors of stroke may be included 
once they are ready.
8. Patient and caregiver outcomes after training
Several studies were carried out to determine effect of training on the out-
comes of survivors of stroke and their caregivers. Most of the studies compared 
intervention and control groups. Most studies that found better outcomes in 
the intervention group were from developed countries and looked at functional 
status of patients and physical/emotional health of family caregivers, quality 
of life, caregiver optimism, task difficulties and use of intervention [42, 101, 
173–176]. In some instances, 89% of the control group was functionally inde-
pendent at 3 months compared to 93% in the intervention group. At 6 months, 
this was 86 and 89% respectively. Similarly, Foster and colleagues found a 
significant difference in two of the satisfaction questions on satisfaction with 
hospital services [177].
The differences found between the intervention and control group were largely 
attributed to extended training time and longer call durations in the intervention 
group [175]. Effects of the intervention can persist over a long-term period as the 
intervention can sustain home care by reducing institutionalisation and mortality as 
well as improve clinical outcomes for caregivers [173, 175]. On the other hand, some 
findings showed no difference in outcomes between the control and intervention 
groups and in other cases are contrasting [42, 175, 177, 178]. These authors found 
no statistically significant difference between groups in functional Barthel Index 
score or functional independence at 6 months among patients. They did not give 
caregiver outcomes. No significant differences in patient activities of daily living or 
functioning or in caregiver emotional distress, anxiety, depression and strain were 
also reported [177]. On the other hand, the intervention group had more patients 
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referred for depression in one study [178]; although stroke recurrence was similar 
in both groups. It was therefore concluded that there was no evidence of a clini-
cally significant benefit of the intervention to both patients and caregivers [177]. 
However it is important to consider the differences in this study with those that 
found positive results.
Studies that involved caregivers only were carried out in other places [176, 178]. 
One study in the rural areas in the United States found that all caregivers were sat-
isfied with the intervention and were willing and able to use the intervention [178]. 
The intervention helped the caregivers make informed decisions about health care 
needs of stroke survivors thus reducing stress. This was further supported when 
the caregiver training program was found to have a positive impact on the func-
tional status, post stroke depression and caregivers’ knowledge and practices [179].
Caregivers were trained alone or in some instances together with the stroke 
survivor [42]. In other instances, both the caregivers and patients were trained [101, 
176]. However different findings were reported in that some found the intervention 
to improve quality of life in both caregivers and patients [42] On the other hand, 
improvement in quality of life among the caregivers was found but not in the other 
outcomes [101]. No significant differences in survivors’ activities of daily living or 
functioning or in caregiver emotional distress, anxiety, depression and strain were 
found in other studies [177]. On the other hand, in South Africa, improvement in 
quality of life, mobility and reduction in caregiver burden were found in the inter-
vention group [98]. When training caregivers it is important to take into account 
other factors that may confound the outcomes such as culture and level of education.
All the results point towards a trend for caregiver targeted interventions hav-
ing some value, but there is need for further research to confirm this and improve 
generalizability [155]. A caregiver training programme in low resource settings may 
be of value to offer support to stroke survivors and caregivers.
9. Developing a caregiver training programme
Education of caregivers is important [32, 42, 47, 101, 158]. However any devel-
oped training programme should be repeatable [8]. To come up with a training 
programme that is relevant, objective and feasible, it is important to consider the 
cultural and socio-economic context in which it will be used. The Kern model of 
curriculum development for medical education a six-step approach that links health 
needs to the education process was used to develop a caregiver training programme. 
The process does not usually proceed in sequence but is rather an interactive and 
dynamic one and can be adapted for low resource settings. According to Kern et al., 
the curriculum development is based on the following six steps [8]:
Step 1. Problem identification and general needs assessment
This begins with identification and analysis of health care needs. A general 
analysis of the current approach to address the identified needs is done. The differ-
ence between the ideal approach and the current approach represents a general needs 
assessment. This helps identify the gaps that exist in the care of stroke survivors. 
There is need to assess how other countries are dealing with training issues and 
compare outcomes of the stroke survivors and those in one’s country. In most cases 
key informant interviews are carried out and other training programmes are assessed 
for adaptability. The observed gaps help in coming up with a targeted needs analysis.
Step 2. Targeted needs analysis
This involves assessing the needs of the targeted group of caregivers 
and stroke survivors which may be different from their needs in general. A 
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sustenance of the training programme [172]. Training after the acute phase may be 
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The differences found between the intervention and control group were largely 
attributed to extended training time and longer call durations in the intervention 
group [175]. Effects of the intervention can persist over a long-term period as the 
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well as improve clinical outcomes for caregivers [173, 175]. On the other hand, some 
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groups and in other cases are contrasting [42, 175, 177, 178]. These authors found 
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functioning or in caregiver emotional distress, anxiety, depression and strain were 
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referred for depression in one study [178]; although stroke recurrence was similar 
in both groups. It was therefore concluded that there was no evidence of a clini-
cally significant benefit of the intervention to both patients and caregivers [177]. 
However it is important to consider the differences in this study with those that 
found positive results.
Studies that involved caregivers only were carried out in other places [176, 178]. 
One study in the rural areas in the United States found that all caregivers were sat-
isfied with the intervention and were willing and able to use the intervention [178]. 
The intervention helped the caregivers make informed decisions about health care 
needs of stroke survivors thus reducing stress. This was further supported when 
the caregiver training program was found to have a positive impact on the func-
tional status, post stroke depression and caregivers’ knowledge and practices [179].
Caregivers were trained alone or in some instances together with the stroke 
survivor [42]. In other instances, both the caregivers and patients were trained [101, 
176]. However different findings were reported in that some found the intervention 
to improve quality of life in both caregivers and patients [42] On the other hand, 
improvement in quality of life among the caregivers was found but not in the other 
outcomes [101]. No significant differences in survivors’ activities of daily living or 
functioning or in caregiver emotional distress, anxiety, depression and strain were 
found in other studies [177]. On the other hand, in South Africa, improvement in 
quality of life, mobility and reduction in caregiver burden were found in the inter-
vention group [98]. When training caregivers it is important to take into account 
other factors that may confound the outcomes such as culture and level of education.
All the results point towards a trend for caregiver targeted interventions hav-
ing some value, but there is need for further research to confirm this and improve 
generalizability [155]. A caregiver training programme in low resource settings may 
be of value to offer support to stroke survivors and caregivers.
9. Developing a caregiver training programme
Education of caregivers is important [32, 42, 47, 101, 158]. However any devel-
oped training programme should be repeatable [8]. To come up with a training 
programme that is relevant, objective and feasible, it is important to consider the 
cultural and socio-economic context in which it will be used. The Kern model of 
curriculum development for medical education a six-step approach that links health 
needs to the education process was used to develop a caregiver training programme. 
The process does not usually proceed in sequence but is rather an interactive and 
dynamic one and can be adapted for low resource settings. According to Kern et al., 
the curriculum development is based on the following six steps [8]:
Step 1. Problem identification and general needs assessment
This begins with identification and analysis of health care needs. A general 
analysis of the current approach to address the identified needs is done. The differ-
ence between the ideal approach and the current approach represents a general needs 
assessment. This helps identify the gaps that exist in the care of stroke survivors. 
There is need to assess how other countries are dealing with training issues and 
compare outcomes of the stroke survivors and those in one’s country. In most cases 
key informant interviews are carried out and other training programmes are assessed 
for adaptability. The observed gaps help in coming up with a targeted needs analysis.
Step 2. Targeted needs analysis
This involves assessing the needs of the targeted group of caregivers 
and stroke survivors which may be different from their needs in general. A 
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triangulation of methodologies is used to come up with their needs and chal-
lenges that they face. This should be done among those that are likely to have 
faced challenges, meaning that they have experienced the challenges for a certain 
length of time.
9.1 Syllabus
Based on the findings from the targeted needs assessment, the syllabus for 
the training programme includes information on the condition and presentation 
of stroke, physical changes, causes, complications and risk factors, and related 
Topic Notes to assist with topic development
The disease stroke What is stroke? What are the causes of stroke? How does stroke present? 
How is the diagnosis made? What is the prognosis?
Identifying stroke Use appropriate evaluation procedures to assess psychological and physical 
state of patients. Accurate identification of the patient’s immediate and 
potential problems
Problems that patients face These range from sudden change in body image, immobility, dependence 
on others for activities of daily living and care and personality changes. 
Also includes fears of loss of self-care and income and insecurities




Changes in motor and sensory problems. Secondary issues from immobility 
in cardio-respiratory and muscular skeletal systems. Issues with urinary 
system, particularly incontinence
Progression time frames Changes in status from flaccidity to spasticity, immobility to mobility and 
recovery of lost function.
Comorbidities Additional diseases that may be found in stroke patients such as HIV and 
other potential infections
Infection control Use of gloves and disinfectants to minimise exposure to HIV and other 
potential infections
Handling of stroke patients Handling and training for positioning, preventing shoulder-hand 
syndrome and shoulder subluxations
Lifting and transfers Different methods of lifting stroke patients. Use of one-man method as 
well as methods for patients who are completely dependent. Help with 
facilitation of mobility and transfers as well as correct application of lifting 
and transferring techniques for safety reasons.
Activities of daily living Teach feeding, bathing, toileting and alternatives to assist with dressing and 
any other personal activities of daily living
Treatment Devising a plan of care for treatment that includes an appropriate 
progression and post discharge program of management. Recognition 
of contraindications and precautions for treatment, delivery of effective 
treatment and progression based on regularly scheduled evaluation of the 
patient’s progress.
Communication Tailored to the needs of each individual with identification and referral to 
appropriate resource persons or sources within the hospital and community
Dealing with bereavement Explain the different stages of bereavement from shock, anger, denial, 
depression, acceptance and that the cycle may repeat.
Role of different 
departments and of the 
community in patient care
Establishment of appropriate relationships with the patient and other 
caregivers and members of the health care team.
Table 1. 
Notes to assist with topic development [166].
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diseases are also included. The syllabus also addresses the activity limitations, 
participation restrictions and treatment needs of the stroke survivors in a practical 
way. Table 1 presents the notes to assist with topic development for training.
Step 3. Developing goals and objectives
After identifying the needs of caregivers and the stroke survivors, goals and 
objectives for the training programme are developed. The objectives may include 
cognitive (knowledge), affective (attitudinal) and psychomotor (skill and behav-
iour) for the caregivers and stroke survivors. Objectives help determine the content 
of the training programme, learning methods/educational strategies and communi-
cate what the curriculum is about and provide the basis for evaluation.
Step 4. Developing educational strategies
Educational strategies are based on the objectives and the content of training 
programme. After the educational needs of caregivers and stroke survivors have 
been identified, it is decided on what has to be taught based on the needs and the 
methods of delivery that will be effective. The selected strategies are the ones most 
likely to achieve the educational objectives.
Step 5. Implementation
Implementation of the training programme includes getting buy-in from the 
people who will allow use of the training programme, and the identification of 
any barriers to the use of programme. Usually these are the health professionals 
who will do the training later on or even Directors of health who have to enforce 
the training of caregivers and stroke survivors. The programme is introduced and 
Resources Outputs Program outcomes Impact
Caregivers of stroke survivors
Stroke survivors
Training materials
Places where training will 
be held
Support from communities of 
interest.










looking after stroke 
survivors
Number of CGs 
who are satisfied 
with the training 
program
Number of CGs 
confident to look 
after SS after 
training




in caring for stroke 
survivors.
Caregivers of stroke 
survivors demonstrate 
competencies in the 
following areas:
Explaining the causes and 
symptoms of stroke
Explaining how to handle 
and lift a patient with 
stroke
Can handle, lift, mobilise 
and help a stroke survivor 
to perform activities of 
daily living.
CGs have confidence and 
good attitude in dealing 
with problems of stroke
Stroke survivors have 




health care that 
reduces the 
impact of stroke 
on caregivers and 
people who have 
survived a stroke.
Underlying Assumptions:
• The caregiver training program is fully implemented with fidelity to written goals and objectives.
• Government policies and resources are supportive
• The total health care system is improved to support the work of caregivers
Table 2. 
Logic model for the training programme implementation [166].
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triangulation of methodologies is used to come up with their needs and chal-
lenges that they face. This should be done among those that are likely to have 
faced challenges, meaning that they have experienced the challenges for a certain 
length of time.
9.1 Syllabus
Based on the findings from the targeted needs assessment, the syllabus for 
the training programme includes information on the condition and presentation 
of stroke, physical changes, causes, complications and risk factors, and related 
Topic Notes to assist with topic development
The disease stroke What is stroke? What are the causes of stroke? How does stroke present? 
How is the diagnosis made? What is the prognosis?
Identifying stroke Use appropriate evaluation procedures to assess psychological and physical 
state of patients. Accurate identification of the patient’s immediate and 
potential problems
Problems that patients face These range from sudden change in body image, immobility, dependence 
on others for activities of daily living and care and personality changes. 
Also includes fears of loss of self-care and income and insecurities




Changes in motor and sensory problems. Secondary issues from immobility 
in cardio-respiratory and muscular skeletal systems. Issues with urinary 
system, particularly incontinence
Progression time frames Changes in status from flaccidity to spasticity, immobility to mobility and 
recovery of lost function.
Comorbidities Additional diseases that may be found in stroke patients such as HIV and 
other potential infections
Infection control Use of gloves and disinfectants to minimise exposure to HIV and other 
potential infections
Handling of stroke patients Handling and training for positioning, preventing shoulder-hand 
syndrome and shoulder subluxations
Lifting and transfers Different methods of lifting stroke patients. Use of one-man method as 
well as methods for patients who are completely dependent. Help with 
facilitation of mobility and transfers as well as correct application of lifting 
and transferring techniques for safety reasons.
Activities of daily living Teach feeding, bathing, toileting and alternatives to assist with dressing and 
any other personal activities of daily living
Treatment Devising a plan of care for treatment that includes an appropriate 
progression and post discharge program of management. Recognition 
of contraindications and precautions for treatment, delivery of effective 
treatment and progression based on regularly scheduled evaluation of the 
patient’s progress.
Communication Tailored to the needs of each individual with identification and referral to 
appropriate resource persons or sources within the hospital and community
Dealing with bereavement Explain the different stages of bereavement from shock, anger, denial, 
depression, acceptance and that the cycle may repeat.
Role of different 
departments and of the 
community in patient care
Establishment of appropriate relationships with the patient and other 
caregivers and members of the health care team.
Table 1. 
Notes to assist with topic development [166].
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diseases are also included. The syllabus also addresses the activity limitations, 
participation restrictions and treatment needs of the stroke survivors in a practical 
way. Table 1 presents the notes to assist with topic development for training.
Step 3. Developing goals and objectives
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objectives for the training programme are developed. The objectives may include 
cognitive (knowledge), affective (attitudinal) and psychomotor (skill and behav-
iour) for the caregivers and stroke survivors. Objectives help determine the content 
of the training programme, learning methods/educational strategies and communi-
cate what the curriculum is about and provide the basis for evaluation.
Step 4. Developing educational strategies
Educational strategies are based on the objectives and the content of training 
programme. After the educational needs of caregivers and stroke survivors have 
been identified, it is decided on what has to be taught based on the needs and the 
methods of delivery that will be effective. The selected strategies are the ones most 
likely to achieve the educational objectives.
Step 5. Implementation
Implementation of the training programme includes getting buy-in from the 
people who will allow use of the training programme, and the identification of 
any barriers to the use of programme. Usually these are the health professionals 
who will do the training later on or even Directors of health who have to enforce 
the training of caregivers and stroke survivors. The programme is introduced and 
Resources Outputs Program outcomes Impact
Caregivers of stroke survivors
Stroke survivors
Training materials
Places where training will 
be held
Support from communities of 
interest.
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Number of CGs 
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survivors demonstrate 
competencies in the 
following areas:
Explaining the causes and 
symptoms of stroke
Explaining how to handle 
and lift a patient with 
stroke
Can handle, lift, mobilise 
and help a stroke survivor 
to perform activities of 
daily living.
CGs have confidence and 
good attitude in dealing 
with problems of stroke
Stroke survivors have 




health care that 
reduces the 
impact of stroke 
on caregivers and 
people who have 
survived a stroke.
Underlying Assumptions:
• The caregiver training program is fully implemented with fidelity to written goals and objectives.
• Government policies and resources are supportive
• The total health care system is improved to support the work of caregivers
Table 2. 
Logic model for the training programme implementation [166].
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administered. Implementation is critical for success of programme as it converts 
a mental exercise into reality [8]. A logic model (Table 2) is used to help with the 
implementation process as exemplified below.
Step 6. Evaluation and feedback
In this phase the caregivers and stroke survivors as well as the training pro-
gramme are evaluated. This may be either formative (at the beginning) or sum-
mative (at the end) [8]. Evaluation of the content and delivery of the programme 
to caregivers is important as it leads to its acceptance [42, 172]. Evaluation is also 
important for recognition of caregiver and stroke survivor needs during and after 
training leading to appropriate and timeous interventions which are perceived as 
beneficial by the caregivers and the survivors of stroke [180].
10. Conclusion
Stroke occurs suddenly and affects functional outcomes in stroke survivors 
and the quality of life of both the caregivers and the stroke survivors. Most of the 
survivors end up with disabilities and have to depend on caregivers to survive. 
Unfortunately, most of the caregivers are not knowledgeable about looking after 
stroke survivors and end up with high caregiver burden. This chapter explained 
how the caregivers can be assisted in supporting stroke survivors. It also outlined 
the steps that can be followed in developing a training programme that can be 
adapted for low resource settings, and for conditions that may also affect func-
tion and quality of life. This is because supporting survivors of stroke is best done 
through training their caregivers. The training programme should take into account 
the cultural issues surrounding the caregivers and the stroke survivors. It is worth 
noting that over and above training the caregivers, health departments should 
continue to offer support to the stroke survivors through provision of appropriate 
rehabilitation services so that they become functionally independent. The support 
and training should be ongoing.
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In this phase the caregivers and stroke survivors as well as the training pro-
gramme are evaluated. This may be either formative (at the beginning) or sum-
mative (at the end) [8]. Evaluation of the content and delivery of the programme 
to caregivers is important as it leads to its acceptance [42, 172]. Evaluation is also 
important for recognition of caregiver and stroke survivor needs during and after 
training leading to appropriate and timeous interventions which are perceived as 
beneficial by the caregivers and the survivors of stroke [180].
10. Conclusion
Stroke occurs suddenly and affects functional outcomes in stroke survivors 
and the quality of life of both the caregivers and the stroke survivors. Most of the 
survivors end up with disabilities and have to depend on caregivers to survive. 
Unfortunately, most of the caregivers are not knowledgeable about looking after 
stroke survivors and end up with high caregiver burden. This chapter explained 
how the caregivers can be assisted in supporting stroke survivors. It also outlined 
the steps that can be followed in developing a training programme that can be 
adapted for low resource settings, and for conditions that may also affect func-
tion and quality of life. This is because supporting survivors of stroke is best done 
through training their caregivers. The training programme should take into account 
the cultural issues surrounding the caregivers and the stroke survivors. It is worth 
noting that over and above training the caregivers, health departments should 
continue to offer support to the stroke survivors through provision of appropriate 
rehabilitation services so that they become functionally independent. The support 
and training should be ongoing.
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